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Abstract 
Due to the spread of antimicrobial drug resistance, typhoid fever has become 
increasingly difficult to treat. In Vietnam, more than 50% of S. Typhi isolates are 
multidrug resistant and 90% are quinolone resistant. 
This thesis examines three aspects of typhoid fever; treatment, genotyping of 
bacteria and the clinical development of an oral vaccine. 
We enrolled 358 children and adults with suspected typhoid fever into a randomised 
controlled trial to compare the efficacy and safety of gatifloxacin (10 mg/kglday) 
versus azithromycin (20 mg/kglday) for 7 days. In the blood culture confinned 
group, 145 patients received gatifloxacin and 142 patients received azithromycin. 
Overall treatment failure occurred in 13/145 (9%) patients in the gatitloxacin group 
and 13/140 (9.3%) patients in the azithromycin group (HR = 0.93; 95% CI 0.43 -
2.0; p = 0.854). 
We found a statistically significant relationship between drug exposure to 
gatifloxacin and clinical response. In patients with AUCo-24: MIC ratios of greater 
than 92.7, 93.5% of patients had a favourable response; whilst in patients with AUC 
0-24: MIC ratios equal or less than 92.7, only 75% had a favorable response (OR = 
4.81; 95% CI 1.23-18.9; P = 0.02). 
We investigated the genetic variability and relationship between the S. Typhi trial 
isolates by using a novel SNP genotyping array. The majority of isolates (98%) 
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belonged to the H58 haplotype, a quinolone resistant haplotype that has expanded 
globally. Within this group three main subgroups could be distinguished. 
We conducted a randomised placebo controlled trial to detennine the safety and 
immunogenicity of a novel oral typhoid vaccine (MO IZH09) with two 
independently-attenuating deletions (Ty2 aroC- ssa V -) in healthy 5 to 14 year old 
children in Vietnam. One hundred and fifty-one children were enrolled and followed 
up for 28 days. Twenty-six percent of MOIZH09 subjects and 22% of placebo 
subjects experienced an adverse event. There were no serious adverse events and no 
bacteraemia. 
Ninety-seven percent of the subjects showed a positive immune response. MOIZH09 
was immunogenic and had an appropriate safety and reactogenicity profile in 
children in an area with endemic typhoid fever. 
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1.1 Typhoid and paratyphoid fever 
Typhoid and paratyphoid fever are septicaemias caused by the Gram negative bacteria 
Salmonella enterica serovar Typhi (s. Typhi) and Salmonella enterica serovar 
Paratyphi (s. Paratyphi) A, Band C. Typhoid and paratyphoid fever are summarized 
as enteric fevers. Whilst S. Typhi and S. Paratyphi A and B infections are restricted to 
humans, S. Paratyphi C can affect a variety of mammals. 
1.2 Epidemiology 
Typhoid fever is endemic in Africa, Asia, Central and South America and is also 
found in parts of the Middle East, southern and eastern Europe (Parry et al., 2002). 
Improvement of infrastructure and sanitation has virtually eliminated typhoid fever in 
developed countries and infections seen in Europe, Australia, and North America are 
usually acquired abroad (mostly from the Indian subcontinent, South East Asia and 
South America) (Steinberg et al., 2004). Current estimates from the World Health 
Organization (WHO) suggest that the global burden of typhoid fever is approximately 
21 million cases annually with more than 210 000 deaths and that paratyphoid fever 
causes an additional 5 million cases (Crump et al., 2004). These numbers are based on 
extrapolating data from 22 studies that used blood culture, the gold standard for the 
diagnosis of typhoid fever (World Health Organization, 2003). Many institutions in 
endemic countries lack blood culture facilities, so the true extent of typhoid and 
paratyphoid fever is difficult to establish. It is likely that the proportion of disease 
caused by S. Paratyphi A particularly in Asia has been underestimated. 
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Figure J.1. Areas of typhoid fever endemicity and distribution of antimicrobial 
drug resistance to Salmonella enterica serotype Typhi, 1990 to 2005. 
Modified from (Bhan et al. 2005). 
Rec nt data how that the proportion of diagnosed enteric fevers cau ed by S. 
Paratyphi A wa 64% in China, 24% in India and 33% in Nepal (Maskey et aI. , 2006; 
Ochiai t af. 2005). 
Tran mi ion of typhoid fever occur vIa the faeco-oral route by inge ting 
contaminated wat r or food or through direct contact (person to person transmis ion 
through poor hygien ). Ri k factor for acquiring typhoid fever are eating food 
pr par out id the home drinking contaminated water eating shellfi h from 
polluted wat r getable that have been fertili ed with human waste, the non-u e of 
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soap and having a relative with a recent history of typhoid fever living in the same 
house (Luxemburger et al., 2001; Parry, 2004b). Chronic typhoid carriers involved in 
food handling are an important reservoir of infection. 
The incidence of typhoid fever varies considerably. In population based surveillance 
studies from Asia conducted between 2002 and 2004, the annual typhoid incidence 
(per 100 000 persons per year) among the 5 to 15 year olds was low (24 and 29, 
respectively) at sites in Vietnam and China and high at sites in Indonesia, Pakistan 
and India (180, 413 and 493, respectively) (Ochiai et aI., 2008). In endemic areas 
typhoid fever has been traditionally considered to be a disease of school children and 
young adults. However, recent data from community based studies emphasize that 
enteric fever is a common cause of morbidity in children between 1 and 5 years and 
that pre-school children experience similar or greater infection rates than school 
children (Lin et al., 2000; Ochiai et al., 2008; Sinha et al., 1999). 
1.3 The bacterium and identification 
The genus Salmonella belongs to the family of Enterobacteriaceae and is currently 
divided into two species. bongor; and enterica (Brenner et al., 2000). The species 
Salmonella enterica is divided into six subspecies (I, enterica; II, salamae; Ill, 
arizonae; IV, diarizonae; V, houtenae and VI, indica) and contains more than 2400 
serotypes based on the Kaufmann-White scheme (Grimont and Weill, 2007). Most of 
the Salmonella that cause disease in humans (including S. Typhi, S. Paratyphi and S. 
Typhimurium) are in the sub-species I (enterica). In contrast to other S. serovars, i.e. 
S. enteritidis and typhimurium, which show a wide host range, S. Typhi and S. 
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Paratyphi (with the exception of S. Paratyphi C) are highly adapted to humans and 
have no other known natural hosts. 
S. Typhi and S. Paratyphi are flagellated, non-spore bearing, facultative anaerobic 
Gram negative bacilli. They are non-lactose fermenters and are identified by a 
characteristic biochemical pattern on triple sugar iron (TSI) agar slants (acid butt 
without gas, an alkaline slant and a moderate amount of H2S production) (World 
Health Organization, Communicable Disease Surveillance & Response, 2003).The 
identification is confirmed by serological identification of their somatic 
lipopolysaccharide (0) and flagellar protein (H) antigens. S. Typhi and S. Paratyphi C 
sometimes possess a polysaccharide capsular Vi (virulence) antigen that coats the 0 
antigen and potentially masks it from antibodies. 
S. Typhi is 09, 12 (group D), Vi and Hd positive and S. Paratyphi A is identified as 
01,2,12; Ha [1,5] positive. Unique flagella types, Hj and Hz66 are present in S. Typhi 
from Indonesia (Baker et 01.,2007; Frankel et 01., 1989). 
1.4 The genome of S. Typhi eTt8 
The sequenced S. Typhi isolate CT18 (Parkhill et 01., 2001a) is multi drug resistant 
(resistant to all first line antibiotics) and was isolated in 1993 from a child with 
typhoid fever in the Mekong Delta region of Vietnam. The genome of S. Typhi CTl8 
is 4.8 million base pairs in length and encodes approximately 4600 genes (Parkhill et 
aI., 2001 a). S. Typhi CT 18 strain has several large insertions, believed to originate 
from bacteriophages or plasmids, termed the Salmonella pathogenicity islands that 
28 
encode genes that are important for survival in the host. Salmonella enterica has two 
type III secretion systems (TTSS), which are important virulence factors of Gram 
negative bacteria used to trans locate proteins into the cytoplasm of eukaryotic host 
cells and are encoded by Salmonella pathogenicity islands SPI-l and SPI-2. The 
invasion of epithelial cells is mediated by the SPI-l TTSS, which is active on contact 
and injects virulence proteins into the host cell, leading to macropinocytosis of the 
bacteria and cytoskeletal rearrangement of the host cell to allow translocation. SPI-2 
encoded TTSS is expressed after phagocytosis of bacteria by host cells and secretes 
effectors required for survival and replication in Salmonella-containing vesicles 
(SCV) inside phagocytes and epithelial cells (House et al., 2001; Miao and Miller, 
2000). 
Another important feature of S. Typhi is the presence of more than 200 pseudo genes. 
The majority of these pseudo genes (124 out of 204) have arisen from introduction ofa 
single frameshift or stop codon, some genes (45) have been inactivated by frameshifts 
that are due to changes in the length of homo polymeric tracts and some (27) genes are 
the remnants of insertion sequence (IS) transposases, integrases and genes of 
bacteriophage origin (Parkhill et al., 200Ia). The inactivation of these genes may 
explain the human host restriction of S. Typhi. CT18 harbours two plasmids, one large 
220 kbp conjugative multiple drug resistance incH I plasmid (pHCM I) which shows a 
high degree (more than 99%) of sequence identity with R27, an incHI plasmid first 
isolated in the 1960s from S. enterica (Sherburne et al., 2000) and a smaller 110 kbp 
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cryptic plasmid (pHCM2), which shows recent common ancestry with a virulence 
plasmid of Yersinia pestis (Kidgell et aI., 2002a; Prentice et al., 200 I). 
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1.5 Pathogenesis and pathology 
The best studied model of typhoid fever is the "typhoid-like" illness of mice infected 
by S. Typhimurium, but not all findings from this infection model can be extrapolated 
to humans (House et of., 2001). 
Volunteer studies have shown that the infective dose of S. Typhi is between 103 to 109 
bacteria (Hornick et 01., 1970). Gastric acidity destroys the organisms but gastric 
hypoacidity (following gastrectomy, intake of histamine-2 receptor antagonists or 
proton pump inhibitors) allows a greater number of organisms to enter the small 
intestine. In a study from India, Helicobocter pylori infection has been associated with 
an increased risk of typhoid fever (Bhan et 01.,2002). 
After the ingestion in water or food, S. Typhi bacteria reach the small intestine where 
they adhere to the mucosal epithelial cells. They penetrate the mucosal epithelium 
either via the M (membranous) cells, specialised cells overlying the Peyer's patches, 
enterocytes or via a paracellular route. S. Typhi bacteria arrive in the lamina propria 
where they elicit a local influx of macrophages. They are taken up by macrophages 
and multiply in the mononuclear phagocytic cells of the small intestine, are drained 
into mesenteric lymph nodes and it is believed that they reach the general circulation 
(causing an asymptomatic primary bacteraemia) by lymph drainage from the thoracic 
duct. The incubation period, which depends on the inoculum size and host defence 
factors, varies between 7 and 14 days. During this phase the bacteria reside and 
multiply within the organs of the reticuloendothelial system (spleen, liver, bone 
marrow and lymph nodes and especially the Peyer's patches of the terminal ileum). 
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Bacteria are then shed again into the blood stream, marking the onset of fever and 
symptomatic disease. During the symptomatic stage S. Typhi can be cultured from 
blood, although this may be difficult in low level bacteraemia. In a study that 
performed quantitative blood cultures in a large number (n = 369) of patients with 
typhoid fever, the median S. Typhi count in blood was I colony forming unit per ml 
(range, <0.3 to 387 CFU/ml), of which a mean of 63% (95% CI, 58 to 67%) were 
intracellular (Wain el al., 1998). If left untreated, the S. Typhi bacteraemia persists for 
several weeks. In this phase the organism disseminates widely to the organs of the 
reticuloendothelial system (House el al., 2001; Parry et ai., 2002; Wain et ai., 2002). 
S. Typhi infection produces hyperplasia of the Peyer's patches in the first week, 
which can resolve or progress to necrosis. Ulcers can lead to perforation and 
haemorrhage, usually in the third week, although these may occur earlier or later 
during the disease (Owen, 1994; Parry et ai., 2002). It has been hypothesized that the 
significant inflammation in the ileum causing necrosis and ulceration might be due to 
the re-exposure of Peyer's patches to S. Typhi via the gallbladder, a mechanism 
similar to the Shwartzman and Koch reactions (Everest et al., 2001). The majority of 
patients mount local and systemic humoral and cellular immune responses but these 
do not give complete protection against relapse or re-infection. The mortality of 
typhoid fever in the pre-antibiotic era used to be about 10 to 20% (Herzog, 1976). 
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1.6 Clinical presentation 
Typhoid fever typically presents with fever, headache, anorexia and abdominal 
discomfort with either diarrhoea or constipation. This can be accompanied by nausea, 
vomiting and a dry cough. Diarrhoea is more common in children, whereas 
constipation is more often found in adults. Profuse diarrhoea has been described in 
typhoid patients with HIV infection (Parry et at., 2002). On examination, abdominal 
tenderness, hepatomegaly (in 40 to 70% of patients) and splenomegaly are common. 
It is rare for patients with typhoid fever to not have any abdominal symptoms and 
normal bowel movement, however even then typhoid fever cannot be excluded. A 
small percentage of patients (less than 5%) show rose spots, small blanching 
erythematous maculopapular lesions of about 2 to 4 mm diameter on the trunk. 
Haemoglobin levels, white cell counts and platelet counts are normal or reduced. 
Liver enzymes (AST, ALT) are usually elevated two to three times the upper limit of 
normal and bilirubin is normal or slightly raised. Abdominal sonography may 
demonstrate enlargement of liver and spleen and prominent mesenteric lymph nodes. 
It has been frequently cited that S. Paratyphi causes a milder disease, however recent 
prospective clinical trials have reported that enteric fever caused by S. Typhi and S. 
Paratyphi A are clinically indistinguishable (Maskey et at., 2006; Vollaard et at., 
2005). S. Paratyphi A has also been described as the cause of severe enteric fever in 
Indonesia (Hoffman et at., 1984). 
33 
1.6.1 Complications and severe typhoid fever 
Complications of typhoid fever are more likely to occur in patients who have been 
sick for longer periods without receiving treatment and in patients infected with non 
susceptible S. Typhi who do not receive appropriate treatment. Complications may 
develop in up to 10% of hospitalised patients (World Health Organization, 2003). The 
development of septic shock and acute respiratory distress syndrome are serious 
complications when treatment is delayed. 
Gastrointestinal bleeding (occurs in approximately 10% of patients), intestinal 
perforation and typhoid encephalopathy are the most common complications. 
Gastrointestinal bleeding results from a necrotic Peyer's patch eroding the wall of an 
enteric blood vessel. Often the bleeding is slight and resolves without intervention, 
however in approximately 2% of cases the bleeding is significant and requires blood 
transfusion. Gastrointestinal perforation (usually at the terminal ileum) is the most 
serious complication, and occurs in up to 3% of hospitalised cases (Parry et al., 2002). 
It manifests as acute abdomen or as worsening of abdominal pain accompanied by 
shock. Perforation is associated with a high mortality (van Basten and 
Stockenbrugger, 1994) and needs urgent surgical intervention. 
A reduced level of consciousness or encephalopathy, often accompanied by shock, is 
a serious complication associated with a mortality of up to 50% (Hoffman et at., 
1984). Typhoid encephalopathy is a complex neuropsychiatric syndrome with a wide 
range of symptoms and signs ranging from agitation to delirium and coma. These 
34 
symptoms might be worsened by associated liver failure, haematogenic dissemination 
to the brain or other as yet unknown mechanisms. The incidence of this presentation 
varies between different countries; ranging from 10 to 40% of hospitalised cases in 
Indonesia, and Papua New Guinea but less than 2% in Pakistan and Vietnam. 
Figure 1.2 Gastrointestinal perforation, usually of the terminal ileum, is one of 
the most serious complications of typhoid fever. 
The picture show the intraoperative picture of a patient with perforated necrotic 
ulcer. Photo credit: Pukar Ma key Patan Hospital, Kathmandu. 
35 
This variation is unexplained (Parry et aI., 2002). Seizures have been described as 
frequent complication (up to 1O%) in hospitalised children under the age of 10 in 
Bangladesh (Butler et al., 1991). In patients with encephalopathy, cerebrospinal fluid 
should be obtained to exclude tuberculous meningitis, other bacterial meningitis and 
encephalitis. The prognosis of typhoid fever during pregnancy has improved with the 
use of antibiotics (Seoud et aI., 1988), although the optimal treatment for pregnant 
women remains unclear. Typhoid fever acquired through intrauterine infection can 
lead to neonatal typhoid fever, a severe sepsis with a mortality of up to 10% or to 
asymptomatic persistent secretion (Reed and Klugman, 1994). 
Abdominal 
Gastrointestinal bleeding 
Intestinal perforation and shock 
Hepatitis with/without jaundice 
Cholecystitis 
Cardiovascular 
Asymptomatic ECG changes 
Myocarditis 
Sudden death 
Haematological 
Anaemia 
Disseminated Intravascular Coagulation (DIC) 
Neuropsychiatric 
Encephalopathy- Reduced consciousness levels 
Meningitis 
Seizures 
Respiratory 
Pneumonia 
Bronchitis 
Genitourinary 
Retention of urine 
Glomerulonephritis 
Focal infections 
Abcesses of brain, liver, spleen 
Table 1-1. Important complications of typhoid fever. 
Modified from (Parry et aI., 2002) 
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1.6.2 Relapse 
The re-occurrence of symptoms within one month after the treatment has been 
completed and symptoms have been resolved is considered a relapse. Depending on 
the efficacy of the antibacterial treatment to clear the bacteria, relapse rates vary from 
0% to 10% in patients (Parry et al., 2002; Parry et al., 2007). 
1.6.3 Chronic Carriage 
One to five percent of patients with a history of enteric fever become chronic carriers, 
which means they harbour S. Typhi or S. Paratyphi A or B in their gall bladder and 
are shedding bacteria intermittently in their stools for at least one year after the illness 
(World Health Organization, 2003; Ristori et al., 1982). These carriers are an 
important reservoir of infection and are usually asymptomatic. Up to 25% of chronic 
carriers do not have a history of typhoid fever. The rate of carriers is higher among 
females and patients with cholelithiasis. An association between urinary carriage of S. 
Typhi and S. Paratyphi A and schistosomiasis has been described, caused by 
obstructive lesions of the urinary tract (Hathout et al., 1966). 
1.6.4 Case Fatality 
A WHO report has estimated the case fatality rate in typhoid fever at 1% (Crump et 
al., 2004). There seems to be considerable geographic variation. In Vietnam and 
Pakistan the case fatality rate among hospitalised patients is less than 2%, but in 
patients with severe typhoid fever in Papua New Guinea and Indonesia it can vary 
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between 30 and 50% (Parry et al., 2002). The most important contributor to a poor 
outcome is probably a delay in appropriate antibiotic treatment. 
1.6.5 Differential diagnosis 
Typhoid fever presents with nonspecific symptoms and this makes the diagnosis 
difficult. Other endemic illnesses, most importantly malaria have to be ruled out. 
Typhoid can occasionally present as gastroenteritis with vomiting and diarrhoea. The 
dfferential diagnosis is broad and varies geographically but includes leptospirosis, 
rickettsial disease (scrub and murine typhus (rickettsial disease), tuberculosis, 
brucellosis, other bacterial sepsis, encephalitis, amoebic liver abscesses, visceral 
leishmaniasis, viral diseases (dengue fever, infectious mononucleosis, hepatitis, 
influenza), lymphoproliferative disease and autoimmune diseases including systemic 
lupus erythematosus (SLE). 
1. 7 Diagnosis 
1.7.1 Blood culture and bone marrow culture 
The definitive diagnosis of enteric fever requires the isolation of S. Typhi or S. 
Paratyphi from blood, bone marrow or an anatomic lesion. Blood culture is the gold 
standard in the diagnosis of enteric fever. However, the low level of bacteraemia 
(between 1 and 10 bacteria per ml of blood) is a characteristic feature of typhoid fever 
and the sensitivity of blood culture is estimated to be only 50 to 60%. Therefore 
obtaining a large volume of blood is one of the most important factors in the 
successful isolation of S. Typhi. Ideally 10 to 15 ml of blood should be taken from 
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school children and adults and 2 to 4 ml for toddlers and pre-school children (World 
Health Organization, 2003; Wain et af., 1998). Bone marrow culture is more sensitive 
(up to 80%), because of the higher concentration of bacteria found in the bone 
marrow (Wain et al., 200 I). 
Antimicrobial susceptibility testing should be performed against a fluoroquinolone, 
nalidixic acid (the prototype quinolone; strains that are nalidixic acid resistant show 
reduced susceptibility to fluoroquinolones, even when still within the current 
breakpoints for fluoroquinolone susceptibility), a third generation cephalosporin, 
other drugs currently used for treatment and the previous first line antibiotics to which 
the strains could be resistant (chloramphenicol, ampicillin, 
trimethoprim-sulfamethoxazole, streptomycin and tetracycline) (World Health 
Organization, 2003). 
1.7.2 Serology 
The Widal test was first described more than 100 years ago. It is a tube dilution test 
based on the presence of agglutinating antibodies to the 0 and H antigens of 
Salmonella. It is usually performed in settings where culture facilities are not 
available. In the original format, paired sera (acute and reconvalescent) were required 
and a four fold increase in the antibody titre (to 0 and H antigens) provided support 
for the diagnosis of typhoid fever. However, the test is usually performed on acute 
serum only as a screening assessment and there is no consensus regarding the 
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interpretation of the test, standardisation of the reagents and it lacks sensitivity and 
specificity. 
One of the main problems with the interpretation of the Widal test is the wide 
variation in the antibody responses of individuals and populations. This is because not 
everybody mounts a detectable antibody response to S. Typhi, healthy populations in 
endemic areas and patients who received typhoid vaccine show high levels of 
antibodies and there is cross-reactivity to other Salmonella serotypes. For the accurate 
interpretation of results it is necessary to know the antibody levels of the 
"background" population in the area where the test is being applied. 
Rapid tests have been developed for the serological diagnosis of typhoid fever. The 
typhidot test (Malaysian Biodiagnostics Research Ltd, Malaysia) is an immunodot 
ELISA based on the detection of IgG and IgM antibodies specific for the 50 kD outer 
membrane protein of S. Typhi. The Tubex test (IDL Biotech, Sweden) is a 
semiquantitative colorimetric test which detects anti-Salmonella 09 antibodies from a 
patient's serum by the ability of these antibodies to inhibit the binding between an 
indicator antibody-bound particle and a magnetic antigen-bound particle. A recent 
prospective community based study in Kolkata examined more than 6000 blood 
samples from patients with fever for more than 3 days and compared the performance 
of the Widal test, Typhidot and Tubex test to the gold standard blood culture (Dutta et 
al., 2006). An anti-TO titer of 1/80 in the Widal test had a sensitivity, specificity, 
positive predictive value and negative predictive value of 58%, 85%, 69%, and 77%, 
respectively for the diagnosis of typhoid fever. The overall performance of sensitivity, 
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specificity, positive predictive value and negative predictive value of Typhidot and 
Tubex was found to be 47%, 83%, 85%, and 42% and 56%, 88%, 81 %, and 69%, 
respectively. 
1.7.3 Molecular diagnosis 
peR based assays have been developed to diagnose S. Typhi infection in blood 
samples. Most of these assays target the flagellin gene (/liC) of S. Typhi. Whilst peR 
assays which use Salmonella isolates show robust results and high sensitivity and 
specificity (Levy et al., 2008), the results of peR assays based on patient's blood 
samples are more variable. In a study by Massi et al. real-time peR based on the 
amplification of fliC was applied to detect S. Typhi in blood samples from patients 
with clinically diagnosed typhoid (Massi et al., 2005). The TaqMan assay detected 
more than 103 (range 1.01 x 103 - 4.35 X 104) copies/ml blood of S. Typhi in the blood 
culture positive samples and less than 103 copies/ml blood in the blood culture 
negative samples. Given the low bacterial loads in blood that are characteristic of 
typhoid fever (Wain et al., 1998), these high copy numbers are surprising. A recent 
study found that a real-time peR assay had less than 50% sensitivity when tested on 
DNA extracted from 2 ml of blood taken from patients with blood culture confirmed 
typhoid fever (Nga et al., 2010). 
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1.8 Antimicrobials for the treatment of typhoid and paratyphoid fever 
1.8.1 First-line antimicrobial agents for the treatment of enteric fever 
1.8.1.1 Chloramphenicol 
Chloramphenicol is a broad spectrum antibiotic that was developed in 1947 from the 
soil bacterium Streptomyces venezuelae (Ehrlich et al., 1947). Chloramphenicol is 
active against many Gram positive and Gram negative organisms (aerobes and 
anaerobes), rickettsiae, chlamydiae and mycoplasma. It demonstrates mostly 
bacteriostatic activity and binds to the bacterial 50S ribosomal subunit where it 
prevents the binding of aminoacyl-tRNA and terminates polypeptide chain synthesis. 
It was the first antibiotic to be manufactured synthetically on a large scale. It 
dramatically changed the management of typhoid fever (Woodward et al., 1948). 
Chloramphenicol treatment has reduced the typhoid fever mortality from 20% to less 
than I %, and the duration of fever from 2 to 4 weeks to four to five days (White, 
2002; Woodward et al., 1948; Woodward et al., 1954) and has been the first line drug 
for the treatment of typhoid fever. However, disadvantages of chloramphenicol are 
that it does not influence the relapse rate nor the typhoid carrier rate (Herzog, 1976) 
and the need for prolonged treatment durations of 14 to 21 days (Woodward and 
Smadel, 1964). 
Chloramphenicol is available in three forms, as base, palmitate ester and sodium 
succinate ester (Neuhauser and Pendland, 2005). Chloramphenicol base is well 
absorbed and produces serum peak levels within I to 2 hours. The palmitate ester is 
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more soluble and palatable and used as the paediatric formulation, whereas the 
succinate ester is used for parenteral administration. The esters must be hydrolysed to 
yield the microbiologically active chloramphenicol base and therefore serum levels 
achieved with oral base are higher than with the palmitate ester and succinate ester. 
Chloramphenicol has good penetration into most tissues and body fluids with the 
exception of bile. It readily crosses the blood-brain barrier and is still used for the 
treatment of bacterial meningitis in many parts of the world. 
The most important adverse effect of chloramphenicol is a dose related, reversible 
bone marrow depression that results from inhibition of mitochondrial protein synthesis 
(Yunis, 1989). This is relatively common and results in reversible (when the drug is 
stopped) reticulocytopenia, anaemia, leukopaenia, or thrombocytopaenia. In contrast, 
the chloramphenicol associated "idiosyncratic" aplastic anemia is very rare but is not 
dose related, non reversible and invariably fatal. Aplastic anemia is estimated to 
occur in 1 in 24500 to 40800 patients who receive the antibiotic, a risk that is about 13 
times greater than in the general population (Wallerstein et al., 1969). 
Resistance to chloramphenicol was first reported in the 1970s and has been widely 
spread (Herzog, 1976). The most common mechanism of resistance is the inactivation 
of the drug by the enzyme chloramphenicol acetyl transferase. The catl gene is 
usually carried on large incHIl plasmids (Parkhill et al., 2001a). Despite these 
limitations chloramphenicol remains an effective first line treatment for typhoid fever 
in many regions of the world where the bacteria remain sensitive (World Health 
Organization, 2003; Parry et al., 2002; Thaver et aI., 2009) 
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1.8.1.2 Ampicillin and amoxicillin 
The aminopenicillins ampicillin and amoxicillin have been evaluated for the treatment 
of typhoid fever in several clinical trials and have given similar or slightly inferior 
results to those obtained with chloramphenicol (Herzog, 1976; White, 2002). Fever 
clearance times are 1 to 3 days longer than with chloramphenicol and failure rates 
slightly higher (Herzog, 1976). Relapse and faecal carriage rates are similar to those 
achieved with chloramphenicol. Ampicillin and amoxicillin have been the treatment 
of choice in pregnancy and neonates. Resistance is widespread and generally due to 
the production of the bacterial enzyme ~-lactamase that opens the ~-lactam ring and 
causes inactivation of the antibiotic. The gene responsible for resistance in S. Typhi 
has been TEM-l and is plasmid encoded (White, 2002). 
1.8.1.3 Trimethoprim-Su/famethoxazole (cotrimoxazole) 
Trimethoprim-sulfamethoxazole has been widely used for the treatment of typhoid 
fever and has been show to be an effective alternative to chloramphenicol (Herzog, 
1976). Resistance in S. Typhi is mediated by the acqusition of a plasmid encoded 
sulfonamide resistant dihydropteroate synthase and trimethoprim resistant 
dihydrofolate reductase (Goldstein and Stein, 2005). 
1.8.2 Fluoroquinolones 
Nalidixic acid, the prototype 4-quinolone antibiotic was discovered in 1962 (Lesher et 
al., 1962), it is active against Gram negative bacteria and only achieves modest serum 
and tissue concentrations. 
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o 
COOH 
Figure 1.3 Structure of nalidixic acid, the prototype quinolone 
Almost 20 years later, the addition of a fluorine molecule at position C6 created the 
fluoroquinolones. The 6-fluoro substituent confers a greater spectrum of activity 
against Gram negative and Gram positive pathogens, possibly by improving tissue 
penetration and binding to the DNA gyrase enzyme. 
All quinolone derivatives have a dual ring structure with nitrogen at position 1, a 
carbonyl group at position 4 and a carboxyl group attached to the carbon at position 3 
of the first ring (Hooper, 1995). Several structural modifications have led to 
compounds with enhanced antibacterial activity. Addition of a piperazinyl group 
(norfioxacin, enoxacin), methyl-piperazinyl group (pefloxacin, ofloxacin, 
amifloxacin, lomefloxacin, flerofloxacin, temafloxacin), or dimethyl-piperazinyl 
group (sparfloxacin) at position 7 enhances activity against aerobic Gram negative 
bacteria. 
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Figure 1.4 Structure activity relationship of the fluoroquinolones. 
From (Domagala, 1994) 
Ciprofloxacin (a second generation fluoroquinolone) which was discovered in 1981 
possesses a cyclopropyl group on position 1 of the quinolone ring which confers 
excellent activity against Gram negative orgamsms (Enterobacteriaceae, 
Haemophilus influenza, Neissereia meningitides and Moraxella catarrhalis) and 
Pseudomonas aeruginosa (Davis et al., 2005). 
Ofloxacin (a second generation fluoroquinolone) received FDA approval in 1990 and 
possesses an additional ring structure bridging positions 1 and 8. Due to its 
availability and affordability, ofloxacin has been widely used for the treatment of 
typhoid fever in Vietnam. 
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F COOH 
Figure 1.5 Structure of otloxacin 
Gatifloxacin is a broad spectrum 8-methoxy fluoroquinolone with enhanced activity 
against Gram positive organisms, which has received U.S. Food and Drug 
Administration (FDA) approval in 1999. It features a cyclopropyl group at position 1 
similar to ciprofloxacin. The addition of a methoxy group at position 8 targets both 
topoisomerase II and IV and probably prevents (or delays) the development of 
quinolone resistance. 
o 0 
o 
Figure 1.6 Structure of gatifloxacin 
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1.B.2.1 Mode of action 
Fluoroquinolones are considered bactericidal agents and have excellent in vitro 
activity against a wide range of Gram negative and Gram positive organisms. The 
quinolones rapidly inhibit bacterial DNA synthesis, causing rapid cell death. The 
targets for the fluoroquinolones are the bacterial topoisomerase enzymes, DNA gyrase 
(topoisomerase II) and Topoisomerase IV. DNA gyrase supercoils strands of bacterial 
DNA into the bacterial cell and transiently nicks each chromosomal domain during 
supercoiling. When supercoiling is complete, DNA gyrase seals the nicked DNA. 
Topoisomerase IV separates the two linked daughter DNA molecules when 
replication is complete. These two enzymes are essential in DNA replication and cell 
partitioning of DNA molecules (Andriole, 2004). DNA gyrase is a tetramer composed 
of a Gyrase A dimer and Gyrase B dimer which are encoded by gyrA and gyrB genes, 
respectively. Topoisomerase IV is a tetramer composed of a Pare and ParE dimer, 
which are encoded by pare and parE genes, respectively. For many fluoroquinolones, 
DNA gyrase is the primary target in Gram negative bacteria and topoisomerase IV 
may be a secondary target (Piddock, 2002). In Gram positive bacteria, topoisomerase 
IV is the primary target. Recent microarray data identified an oxidative damage-
mediated cell death pathway, which involves reactive oxygen species (ROS) 
generation and a breakdown in iron regulatory dynamics following norfloxacin-
induced DNA damage (Kohanski et at., 2010). 
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1.8.2.2 Mechanism of resistance 
The main mechanism of quinolone resistance in S. Typhi is the accumulation of 
amino acid substitutions in the bacterial target enzyme DNA gyrase. The most 
commonly identified alteration has been a serine to phenylalanine substitution at 
position 83 of GyrA (Chau et al., 2007; Wain et aI., 1997). Amino acid changes at 
position 87 (aspartate to tyrosine, glycine or asparagine) of GyrA are less frequent. 
These mutations are focused around a region called the quinolone resistance 
determining region (QRDR). The QRDR ofGyrA is close to tyrosine at position 122, 
the active site of the enzyme, which is covalently linked to DNA during strand 
breakage (Drlica, 1999). Single point mutations in gyrA of S. Typhi lead to nalidixic 
aeid resistance (MIC ~ 32 J.1g/ml) and reduced susceptibility to the fluoroquinolones 
(typically eiprofloxacin MICs ranging from 0.125 J.1g/ml to 1.0 J.1g/ml, compared to 
the wild type MIC of 0.03 J.1g/ml or below). Single isolates of fully fluoroquinolone 
resistant S. Typhi and S. Paratyphi A have been reported from India (Parry and 
Threlfall, 2008). The high-level fluoroquinolone resistance seen in these S. Typhi 
(ciprofloxacin MIC ~ 4 mg/ml) isolates was conferred by dual mutations in gyrA and 
a single mutation in pare (Dutta et al., 2008; Gaind et al., 2006). 
Alteration in drug transport has been described as an additional mechanism of 
fluoroquinolone resistance in E. coli (Mazzariol et al., 2000) and recently In 
Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia, 
Klebsiella pneumonia and S. Typhimurium (Baucheron et al., 2002; Baucheron et aI., 
2004; Mazzariol et al., 2002). The expression of the AerAB-ToIC system, the major 
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multi drug efflux pump, is under the regulation of ramA, marA, soxS or rob. 
Constitutive over expression of AcrAB is present in most ciprofloxacin resistant 
E.coli and also occurs in ciprofloxacin resistant S. Typhimurium phage type DT204 
(Baucheron et al., 2002). The MarA global activator, which can be derepressed by 
tetracycline or chloramphenicol, simultaneously up-regulates the AcrAB-TolC 
transport complex and down-regulates the synthesis of the larger porin OmpF, a 
mechanism that synergistically blocks the drug penetration and accumulation in the 
cell (Parry, 2003). 
Plasmid mediated quinolone resistance was first described in 1998 in an isolate of 
Klebsiella pneumonia (Martinez-Martinez et al., 1998). Since then five major groups 
of quinolone resistance determinants, qnrA, qnrS, qnrB, qnrC and qnrD, have been 
identified (Strahilevitz et al., 2009). The qnr genes encode for a pentapeptide repeat 
protein that confers reduced susceptibility to the fluoroquinolones (typically with an 8 
to 64 fold increased quinolone MIC). Qnr proteins are able to protect DNA gyrase 
from the quinolones. Aquatic bacteria are thought to be the origin of plasmid encoded 
quinolone resistance genes. qnr genes have been found on plasmids of varying size 
and incompatibility groups. 
Recently additional plasmid mediated quinolone resistance genes have been 
described. aac(6 ,)-lb-cr encodes a variant aminoglycoside acetyltransferase, which 
confers resistance to tobramycin, amikacin and kanamycin (Robicsek et al., 2006b). 
This enzyme reduces the activity of ciprofloxacin by N-acetylation at the amino 
nitrogen on its piperazinyl substituent. AAC(6')-lb-cr is selective only for 
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ciprofloxacin and norfloxacin, which both have an unsubstituted piperazinyl nitrogen. 
AAC{6')-lb-cr confers only a modest increase in MIC (3 to 4 fold), but has shown to 
cause a dramatic increase in the mutant prevention concentration (Robicsek et al., 
2006a). The aac(6 ,)-Ib-cr gene is located in an integron cassette with an associated 
attC site. It is often found on incFll plasmids expressing CTX-M-15 that have spread 
rapidly and become the predominant ESBL in many countries worldwide (Strahilevitz 
et al., 2009). 
So far, qnr genes and aac(6,)-lb-cr have only been reported in non-Typhi Salmonella 
(Strahilevitz et al., 2009), with the exception of a multiple drug resistant S. Typhi 
strain isolated from an Iraqi traveler that was characterized by the blacTx-MI5, qnrB2 
and the GyrA Ser83Phe amino acid substitution (Pfeifer et al., 2009). 
1.8.2.3 Adverse events 
The frequency of adverse reactions to quinolones is between 6 and 11 % with less than 
I % of adverse events being recorded as serious (Andriole, 2004). The most frequent 
adverse effects reported are nausea, upper gastrointestinal discomfort and central 
nervous system effects such as headache, insomnia and dizziness. The adverse events 
are typically mild, self limited and mostly resolve when the drug is stopped. 
Some adverse effects do not seem to be related to specific modifications, whereas 
phototoxicity and CNS effects are linked to a specific structure. Each fluoroquinolone 
tends to produce a characteristic profile of adverse effects. 
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In their preclinical evaluation, all quinolones studied caused arthropathy in immature 
animals, especially in young beagle dogs and usually in the major weight bearing 
joints (Gough et al., 1979; Stahlmann et af., 1990). Histopathological examination 
showed localized blister formation and erosions in the joint cartilage (Schaad and 
Wedgwood, 1992). The concern that the fluoroquinolones might also cause cartilage 
damage in children, have led to cautious use in many countries. However, extensive 
experience with the fluoroquinolones in children suffering from cystic fibrosis, 
typhoid fever and bacillary dysentery has provided a body of evidence suggesting that 
the joint damage seen in young dogs does not occur in children and these antibiotics 
are safe in children (Bethell et al., 1996; Organization, 2003; Parry et al., 2002; 
Schaad et al., 1991; Schaad and Wedgwood, 1992). 
Fluoroquinolones have been associated with tendinitis and tendon rupture in adults, 
primarily affecting the Achilles tendon, risk factors were renal dysfunction and 
concomitant corticosteroid use (Owens and Ambrose, 2005). 
Severe neurotoxic reactions are rare. However, hallucinations, depression, and 
psychotic reaction have been reported. Some fluoroquinolones may inhibit 
transmission of gamma-aminobutyric acid (GABA) leading to eNS stimulation. 
These eNS effects may be potentiated by interactions with other medications such as 
theophyllin (Andriole, 2004; Davis et al., 2005). Thus the quinolones should be used 
with caution in patients with known eNS disorders (e.g., epilepsy) or conditions 
predisposing to seizures (Andriole, 2004; Davis et aI., 2005). 
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The most common skin reactions are non specific skin rashes, pruritis and urticaria. 
Phototoxicity is a rare dermatologic complication of quinolone therapy which is 
inextricably related to the chemical structure (Owens and Ambrose, 2005). 
The "double halogenated" quinolones which possess a halogen moiety (chlorine, 
fluorine) at position 8 together with the fluorination of position 6 have demonstrated 
significant phototoxic potential. Agents with these modifications are fleroxacin, 
lomefloxacin and sparfloxacin. Thrombocytopenia, leucopenia and anaemia are rare 
(Andriole, 2004). Recently the cardiovascular effects of the quinolones, especially of 
the newer agents have been closely evaluated. Dose related prolongation of the QTc 
interval and rare cases of significant arrhythmias including torsades de pointes were 
reported in patients treated with sparfloxacin and to a lesser extent with grepafloxacin, 
these two antibiotics were therefore withdrawn. 
A study based on post marketing surveillance data reported that the crude incidence 
rate (95% confidence interval, 95% CI) of cases of Torsades de Pointes (TdP) per 10 
million prescriptions in the United States was 0.3 (0.0-1.1) for ciprofloxacin, 2.1 (0.3-
7.6) for ofloxacin, 5.4 (2.9-9.3) for levofloxacin and 27 (12-53) for gatifloxacin 
(Frothingham, 2001). However questions regarding the validity of both the 
numerators and denominators used in these incidence calculations remain (Owens and 
Ambrose, 2002). Preclinical and clinical data indicate that levofloxacin, moxifloxacin, 
and gatifloxacin prolong the QTc interval. The potential for TdP to develop as a result 
of this is rare and is influenced by many independent variables, especially by 
concurrent administration of class IA and III antiarrhythmic agents, genetic 
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susceptibility, underlying cardiac disease, electrolyte imbalance and organ 
impairment. Therefore gatifloxacin, levofloxacin, moxifloxacin or gemifloxacin 
should not be used in patients with risk factors predisposing them to TdP (Owens and 
Ambrose, 2002). 
The quinolones as a class have demonstrated the ability to close K+-ATP channels in 
the ~ cells of the pancreas, resulting in the release of insulin and subsequent 
hypoglycaemia. However the mechanism for hyperglycaemia remains poorly 
understood and might be caused by overexposure (failure to adjust the dose in patients 
with renal failure) (Owens and Ambrose, 2002). Product labels for ciprofloxacin, 
gatifloxacin, levofloxacin, and moxifloxacin mention the possibility of 
hypoglycaemia and hyperglycaemia, whereas the product label for gemifloxacin 
mentions hyperglycaemia only. Although glucose disturbances appear to be a class 
effect, the odds of hypo- and hyperglycaemia appear to vary among the agents 
(Aspinall et at., 2009). A retrospective study in Texas reviewed records of 
dysglycaemia in hospitalised patients receiving gatifloxacin, levofloxacin, 
ciprofloxacin or ceftriaxone (Mohr et at., 2005). Dysglycaemic events were more 
likely to occur in patients receiving gatifloxacin (relative risk, 3.29; 95% CI, 2.33-
4.65) or levofloxacin (relative risk, 1.55; 95% CI, 1.29-1.88) versus ceftriaxone. 
In another study of elderly inpatients who received gatifloxacin or levofloxacin, 
gatifloxacin was independently associated with hypoglycaemia (OR, 2.4; 95% CI, 
1.1-5.6) and hyperglycaemia (OR, 2.5; 95% CI, 1.6-3.9) versus levofloxacin (Lodise 
et al., 2007). In diabetic patients treated with gatifloxacin, the overall incidence of 
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hypoglycaemia was 0.4%, 0.7%, and 1.6% for patients below 65 years, 65 to 69 years 
and 80 years and above, respectively. The corresponding incidences of 
hyperglycaemia were 1.0%, 1.6%, and 3.3%, respectively (Owens and Ambrose, 
2005). 
When exposure to gatifloxacin was simulated in patients with severe hyperglycaemia, 
AVC values were 2 to 3 times those observed in patients with normal renal function 
(Ambrose et al., 2003). Therefore the authors suggested to empirically adjust the 
dose of gatifloxacin to 200 mg daily for patients aged above 65 years with community 
acquired respiratory tract infections. A detailed discussion of the risk benefit ratio of 
gatifloxacin for the treatment of enteric fever is presented in Chapter 2. 
Only ciprofloxacin, clinafloxacin, enoxacin, grepafloxacin, pefloxacin, and 
tosufloxacin can inhibit the hepatic cytochrome P 450 isoform CYP 1 A4 isoenzymes. 
Few drugs are metabolized by these isoenzymes, but important drugs include the 
methylxanthines (theophylline and caffeine) and warfarin. 
1.8.3 Extended spectrum cepbalosporins 
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Figure 1.7 Basic structure of cepbalosporins 
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The basic structure of the cephalosporins consists of a four membered ~-lactam ring 
fused with a six-membered dihydrothiazine ring. Cephalosporins exert bactericidal 
activity by interfering with the later stages of the bacterial cell wall synthesis 
(Capitano and Kays, 2005). The target site of the ~-lactam antibiotics including the 
cephalosporins are the penicillin-binding proteins (PBPs). During the process of 
peptidoglycan synthesis, the cephalosporin ~-lactam ring becomes covalently bound 
to the PBPs, acting as a false substrate. This process inhibits the cross linking of the 
peptidoglycan structure and ultimately leads to bacterial cell lysis. 
Production of ~-lactamases is the most common mechanism of bacterial resistance. In 
the late 90s, non-Typhi Salmonella producing extended spectrum ~-lactamases 
(ESBL) have been reported in numerous countries. Resistance generally results from 
the production of Ambler class A or C (also known as AmpC ~-lactamases) ESBL. 
Class A enzymes such as TEM, SHY, OXA, PER and CTX-M are plasmid mediated 
and confer resistance against oxyimino-~-lactams such as cefotaxime, ceftazidime and 
aztreonam, but are not active against cephamycins and can be inactivated by 
clavulanic acid. Ambler class C enzymes are able to hydrolise all ~-lactams to some 
extent and are not inhibited by clavulanic acid. Over-expression confers resistance to 
all ~-lactam including the cephamycins, but not to cefpirome, cefipime and the 
carbapenems (Parry, 2003). 
Salmonella producing the ~-lactamase CMY -2 have been isolated from food 
producing animals in Northern America and Europe (Aarestrup et al., 2004; Allen and 
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Poppe, 2002) and from hospitalised patients in the USA and Taiwan (Parry, 2003). 
Recent studies in the US, Mexico and South Africa have shown a wider range of 
ESBL enzymes in non-Typhi Salmonella (Parry and Threlfall, 2008). However, 
prevalence of extended spectrum cephalosporin resistance (ESC) was low in human 
non-Typhi Salmonella isolates collected across 10 European countries in 2000 
(Threlfall et al., 2003). Only 0.6% of 27000 Salmonella isolates showed resistance to 
cefotaxime. 
Resistance to extended spectrum cephalosporins has been reported in single isolates 
of S. Typhi from Bangladesh and Italy and Paratyphi A from Pakistan and Nepal, 
however the mechanism was not described in these reports (Parry, 2003; Pokharel et 
al.,2006). In 2009, as. Typhi isolate with ESBL phenotype caused by blacTX-15 was 
described in a patient returning from Iraq (Pfeifer et al., 2009). 
The cephalosporins exhibit time dependent bactericidal activity, therefore the target 
for antimicrobial therapy is to optimise the duration of exposure (Time above the 
MIC, T > MIC). Cephalosporins penetrate well into most tissues and body fluids 
(Capitano and Kays, 2005). High concentrations of ceftriaxone have been 
demonstrated in human monocytes. Overall, the cephalosporins are a safe class of 
antibiotics, hypersensitivity reactions are the most common adverse events. 
Gastrointestinal reactions, including nausea, vomiting and diarrhoea are also reported 
frequentl y. 
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The third generation cephalosporins ceftriaxone and cefixime have been widely used 
for the treatment of MDR typhoid fever. The average fever clearance times in 
randomised trials using ceftriaxone have been 7 days and 5 to 10% of patients failed 
clinically. Relapse rates varied between 4% and 6% (Parry et al., 2002). A study in 
Pakistan evaluated either 7 or 14 days of ceftriaxone treatment in children with 
typhoid fever and found a relapse rate of 14% (4 out of 28 patients) in the 7 day 
treatment group compared to no relapse in the 14 day group (Bhutta et al., 2000). The 
disadvantage of ceftriaxone is the need for parenteral administration and the high cost, 
especially for prolonged treatment courses. 
Oral cefixime has been a popular choice for the treatment of typhoid fever in children. 
In randomised controlled trials in children the mean fever clearance times ranged 
from 5 to 8 days and clinical failure rates were reported to be below 3% (Bhutta et al., 
1994; Girgis et al., 1995; Memon et al., 1997). However, a typhoid treatment trial in 
Vietnam reported much higher failure rates of 23% (10 out of 44 patients) when 
cefixime was used in children (Cao et al., 1999). 
I.S.4 Azithromycin 
Azithromycin belongs to the macrolide class of antibiotics and is a derivative of 
erythromycin. Erythromycin was isolated in 1952 from a strain of Streptomyces 
erythreus obtained from soil from the Philippines. The structure of erythromycin is a 
14-membered lactone ring, substituted by two sugars, desosamine and cladinose 
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(Steigbigel, 1995). Erythromycin is unstable in acidic medium which causes poor and 
inconsistent bioavailability. 
Azithromycin has a I5-membered macrocycle and a methyl-substituted nitrogen, 
hence the name azalides has been given to this class. Azithromycin exhibits increased 
activity against Gram negative bacteria and a longer half life. 
Macrolides are inhibitors of protein synthesis by impairing the elongation of the 
peptidyl chain. The main interaction site is the domain V of the 23S rRNA, which lies 
at the center of the peptidyl transferase site (Mulazimoglu et al., 2005). The macrolide 
binding site is located at the exit tunnel of the growing peptide chain. The critical 
interaction occurs between the 2'-OH group of the desosamine and the adenosine 
residue 2058. The binding site of the macrolides on the 50S subunit of the ribosome 
overlaps with that of chloramphenicol and the lincosamides, leading to antagonism 
and cross-resistance between these classes. 
Acquired resistance in macrolides can involve three mechanisms; modification of the 
target, antibiotic inactivation or active efflux (Mulazimoglu et al., 2005). Methylation 
of the rRNA is currently the most prevalent mechanism of resistance in pathogenic 
bacteria. This is mediated by the acquisition of erm genes which encodes for 
methyltransferases. Methylation of the N(6) position of adenine 2058 in 23S rRNA 
results in inhibition of macrolide binding. Monomethylation confers high levels of 
resistance to lincosamides and streptogramins and low-level resistance to macrolides, 
whilst dimethylation causes high level resistance to all three drug classes, leading to 
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the MLSB phenotype. More than 30 erm genes have been described, which are located 
on conjugative and transferable transposons. The expression of the methylase is either 
constitutive or inducible. Inducers include the 14-, 15- and 16-membered macrolides, 
the lincosamides and the streptogramins, but not the ketolides. 
Another mechanism of resistance is the substitution of the adenine at position 2058 
with guanine, this has been described in Helicobacter pylori, Mycoplasma and 
Mycobacterium spp. (Mulazimoglu et aI., 2005). 
Erythromycin-inactivating enzymes have been reported in Enterobacteriaceae. These 
are phosphorylases or esterases (encoded by ereA and ereB) that confer resistance to 
all 14-, 15- and 16-membered macrolides. 
In Gram positive bacteria, exposure to the antibiotic can induce over-expression of 
efflux pumps conferring resistance. Examples of inducible efflux pumps are the 
Msr(A) pump in Staphylococci and the Mef efflux system in Streptocooci 
(Mulazimoglu et al., 2005). 
AS. Paratyphi A isolate with an azithromycin MIC (Etest) of 64 mg/L. was recently 
reported to have caused treatment failure in an enteric fever patient returning from 
Pakistan, who was treated with oral azithromycin (Molloy et al .. 2010). 
Azithromycin has a bioavailability of 30% to 50%. The serum peak level is typically 
reached after 2 hours. Azithromycin has a large volume of distribution which is 
related to the ability to accumulate inside eukaryotic cells. The ratio of tissue to serum 
concentration for azithromycin is 50 to 1150 (Mulazimoglu et al., 2005). The half life 
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is 35 to 40 hours, which allows a single daily dose and shortened treatment regimen (3 
to 5 days). 
Macrolides are primarily metabolised through cytochrome P450 and eliminated 
through the bile. Gastrointestinal adverse events are relatively frequent with 
macrolides. Macrolides have been associated with prolongation of the QT interval and 
should not be used in patients with concurrent administration of class IA and III anti-
arrhythmic agents and underlying cardiac disease. 
Azithromycin has become a popular treatment choice for the treatment of MDR 
typhoid fever. The MICs for S. Typhi to azithromycin range from 4 to 16 ~glml 
(Metchock, 1990). The peak serum level after a single dose of 500 mg of 
azithromycin is 0.4 mglL (Mulazimoglu et al., 2005). However, as azithromycin is 
concentrated more than 100-fold inside polymorphonuclear cells and macrophages 
(Panteix et al., 1993) and S. Typhi is primarily an intracellular pathogen (Wain et aI., 
1998), effective drug concentrations are considerably above the MIC. 
In randomized clinical trials, azithromycin has been used for the treatment of MDR 
typhoid fever in children and adults in Egypt, India and Vietnam (Butler et al., 1999; 
Chinh et al., 2000; Frenck et al., 2000; Frenck et al., 2004; Girgis et at., 1999). Cure 
rates were excellent and outcomes in patients infected with nalidixic acid resistant S. 
Typhi were satisfactory (Chinh et ai., 2000). 
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1.9 Antimicrobial drug resistance of S. Typhi and S. Paratyphi A 
In 1948 the introduction of chloramphenicol revolutionised the management of 
typhoid fever (Woodward et al., 1948). Chloramphenicol was effective for more than 
20 years, but in the 1970s outbreaks of chloramphenicol resistant typhoid fever took 
place in Mexico, India and Vietnam. In the late 1980s and early 1990s outbreaks of 
typhoid fever occurred that were resistant against all 'first line" antimicrobials 
(multidrug resistance (MDR) defined as resistance to chloramphenicol, ampicillin and 
trimethoprim-sulfamethoxazole) (Parry et al., 2002). These MDR S. Typhi isolates 
have been responsible for numerous outbreaks in countries in the Indian subcontinent, 
South East Asia and Africa (Bhan et al., 2005). All MDR strains so far examined, 
have been harbouring plasm ids of the incHIl incompatibility group. 
Consequently, the fluoroquinolones have become the treatment of choice for typhoid 
fever. The fluoroquinolones show excellent tissue penetration, accumulation in 
monocytes and macrophages and high drug levels in the gall bladder. However, there 
have been reports from Vietnam, India and Tajikistan of the emergence of S. Typhi 
isolates that respond less well to the fluoroquinolones (Bhan et al., 2005; Parry et al., 
2002). In 1997, a typhoid epidemics in Tajikistan caused by such isolates caused more 
than 10000 illnesses and 108 deaths (Mermin et al., 1999). Technically these isolates 
remain within the breakpoints set for fluoroquinolone susceptibility by the Clinical 
Laboratory Standard Institute (CLSI) ( Clinical Laboratory Standard Institute, 2007), 
but they are resistant to nalidixic acid (the prototype quinolone) and show higher 
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MICs to the fluoroquinolones. Patients infected with these isolates show a poor 
clinical response when treated with ciprofloxacin or ofloxacin. 
Nalidixic acid resistance is usually caused by single point mutations in the bacterial 
target enzyme GyrA, either at codon 83 or 87 (Chau et at., 2007). High-level 
ciprofloxacin resistant S. Typhi (Dutta et at., 2008; Gaind et at., 2006) and S. 
Paratyphi A (Gaind et at., 2006) with double mutations in gyrA and single mutation in 
pare have been described in the Indian subcontinent. Recently there have been 
reports of S. Typhi isolates with reduced susceptibility to the fluoroquinolones that 
test nalidixic acid sensitive (Cooke et at., 2007), suggesting another mechanism of 
resistance. There have been sporadic reports of ceftriaxone resistant S. Typhi, but 
these isolates still seem to be rare (Parry and Threlfall, 2008). A decreasing trend of 
chloramphenicol resistant S. Typhi has been reported in recent years from the Indian 
subcontinent (Dutta et at., 2005; Mohanty et ai., 2006). MDR as well as nalidixic acid 
resistant S. Paratyphi A is an emerging problem in the Indian subcontinent (Chandel 
et ai., 2000; Maskey et ai., 2006). 
1.10 Treatment of typhoid and paratyphoid fever 
Enteric fevers are systemic infections and appropriate antimicrobial treatment should 
be initiated early. It is important to provide supportive measures, such as oral and 
intravenous fluids, appropriate nutrition and antipyretics. More than 90% of patients 
are managed as outpatients, with oral antibiotics, reliable care and close medical 
follow up for complications or failure to respond to therapy. Patients with persistent 
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vomiting, severe diarrhoea and abdominal distension need admission to hospital 
(World Health Organization, 2003). 
The management of patients with enteric fever should include blood cultures and stool 
cultures after completion of treatment to check for failure to clear the bacteria in the 
blood and stools (convalescent stool carriage), as well as follow up for at least 6 
months to identify chronic faecal carriage. However in most endemic areas such 
follow up is not possible and therefore the management of the acute illness with 
effective drugs, that also prevent chronic carriage and relapse, are essential. 
1.10.1 Current recommendations of the World Health Organization for the 
treatment of typhoid fever 
The choice of treatment depends on the antimicrobial susceptibility of the isolates, but 
also on the cost, which is an important factor especially in endemic regions. Table 1-2 
shows the current recommendations of the World Health Organization (WHO) for the 
treatment of typhoid fever (World Health Organization, 2003). 
The fluoroquinolones are the most effective treatment for typhoid fever. In patients 
infected with nalidixic acid susceptible isolates, fever usually resolves within 4 days, 
cure is achieved in 96% of patients and rates for faecal carriage and relapse are below 
2% (Parry et at., 2002). 
The fluoroquinolones are also recommended for the treatment of children with 
typhoid fever. Extensive experience with the fluoroquinolones in children suffering 
from cystic fibrosis, typhoid fever and bacillary dysentery has provided a body of 
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evidence suggesting that the cartilage damage seen in young animals does not occur 
in children (Bethell et al., 1996; World Health Organization, 2003; Parry et al., 2002). 
Alternatives to the fluoroquinolones are third generation cephalosporins (cefixime or 
ceftriaxone) and azithromycin. For infections with nalidixic acid (quinolone) resistant 
S. Typhi, azithromycin, prolonged courses of high dose fluoroquinolones (e.g. 
ofloxacin at 20 mglkglday) and third generation cephalosporins (ceftriaxone) are 
recommended. Ceftriaxone should be used for 10 to 14 days. Ceftriaxone therapy for 
7 days was associated with a relapse rate of 14% (Bhutta et al., 2000; Frenck et al., 
2000). 
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OPTIMAL THERAPY ALTERNATIVE EFFECTIVE DRUGS 
Susceptibility Antibiotic Daily dose Days Antibiotic Daily dose Days (mglkg) 
(mglkg) 
Fully sensitive Fluoroquinolone 15 5_7a Chloramphenicol 50-75 14-21 
e.g. ofloxacin or Amoxycillin 
ciprofloxacina 75-100 14 
Trimethoprim-
sulfamethoxazole 8-40 14 
Multidrug resistance Fluoroquinolone 15 5-7 Azithromycin 8-10 7 
or cefixime 15-20 7-14 Cefixime 15-20 7-14 
Quinolone (nalidixic Azithromycin or 8-10 7 Cefixime 20 7-14 
acid) resistanceb ceftriaxone 75 10-14 
a Three day courses are also effective and are particularly so in epidemic containment. 
b The optimum treatment for quinolone resistant typhoid fever has not been determined. Azithromycin, the third generation cephalosporins, or a 
10-14 day course of high-dose fluoroquinolones is effective. Combinations of these are now being evaluated. 
Table 1-2. World Health Organization treatment recommendations for uncomplicated typhoid fever. 
From (World Health Organization, 2003) 
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There are few data on the treatment of typhoid fever in pregnancy (Seoud et at., 
1988). Ampicillin for fully susceptible isolates and ceftriaxone are considered safe for 
this indication (World Health Organization, 2003; Parry et aI., 2002). 
1.10.2 Management of severe typhoid fever 
Both, in- and out-patients should be closely monitored for the development of 
complications. The parenteral fluoroquinolones are probably the first choice for the 
treatment of severe typhoid fever (Dutta et at., 1993; World Health Organization, 
2003) but there have been no randomised trials to date. In severe typhoid fever, the 
fluoroquinolones should be given for a minimum of 10 days. For patients infected 
with nalidixic acid resistant isolates, ceftriaxone is effective (World Health 
Organization, 2003). 
A trial conducted in the 1980s showed a dramatic beneficial effect of high dose 
steroid treatment (dexamethasone at 3 mg/kg for the first dose given over 30 minutes 
and 1 mg/kg every 6 hours for 48 hours) in severely sick typhoid fever patients with 
encephalopathy and shock, given in addition to chloramphenicol. Dexamethasone 
adjunctive treatment reduced the mortality from 56% to 10% when compared to 
placebo (Hoffman et ai., 1984). Hydrocortisone at a lower dose was not effective 
(World Health Organization, 2003). 
Intestinal perforation is a surgical emergency. Early intervention is crucial, and 
mortality rates increase when surgery cannot be performed immediately and vary 
between 10% and 32% (van Basten and Stockenbrugger, 1994). Metronidazole should 
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be added to the antibiotic regimen to treat leakage of intestinal bacteria into the 
abdominal cavity. Patients with intestinal haemorrhage need intensive care, 
monitoring and blood transfusion. Intervention is needed if there is significant blood 
loss, then cross matched blood should be ready and the operating theatre should be 
prepared (Parry et af., 2002). 
In patients presenting with a relapse, cultures should be obtained and patients should 
be treated according to the susceptibility pattern of the infecting isolate. 
1.10.3 Typhoid carriers 
Chronic carriers play an important role in the transmission of typhoid and paratyphoid 
fever. S. Typhi and S. Paratyphi are only shed intermittently in the faeces. Therefore, 
stool samples need be obtained repeatedly to detect typhoid carriers. Long 
antimicrobial treatment courses of up to six weeks should be given according to the 
susceptibility of the isolates to eradicate carriage (World Health Organization, 2003). 
In susceptible isolates, clearance was achieved in up to 80% with the administration 
of 750 mg ciprofloxacin or 400 mg norfloxacin twice daily for 28 days (Ferreccio et 
al., 1988; Gotuzzo et al., 1988). If cholelithiasis is present the patient may require 
antibiotic therapy as well as cholecystectomy. In patients with chronic urinary 
carriage resulting from infection with Schistosoma haematobium, antiparasitic 
medication in addition to antibiotics is needed to achieve bacteriological cure (World 
Health Organization, 2003). 
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1.11 Control and prevention of typhoid fever 
Typhoid fever can be prevented by the provision of safe drinking water, good food 
hygiene and safe sewage disposal. Chronic carriers pose a special risk to the 
community, therefore programmes to detect and treat chronic carriers should be in 
place. 
There are two licensed, safe typhoid vaccines available, the parenteral (intramuscular 
injectable) Vi polysaccharide and the oral live attenuated Ty21 vaccine, both vaccines 
are based on the pathogenic S. Typhi strain Ty2 (Felix and Pitt, 1951).The oral Ty21 
vaccine (Vivotif, Bema) needs to be administered in three doses (day I, 3, 5) and is 
licensed for adults and children above 6 years. Field studies with the oral Ty21 
vaccine in the 1980s have shown a protective efficacy after 3 years of 96% in Egypt 
(Wahdan et al., 1982) and up to 77% in Chile when using the liquid formulation 
(Levine et al., 1990). The parenteral Vi vaccine is licensed for adults and children 
above 2 years. A single intramuscular injection confers a protective efficacy of 77% 
after 21 months in South Africa (Klugman et al., 1987). The WHO recommends that 
the immunization of school-age children should be undertaken wherever the control 
of the disease is a priority (World Health Organization, 2003). Unfortunately, these 
two vaccines are both underutilised in developing countries. 
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1.12 Vietnam 
1.12.1 Introduction 
The Socialist Republic of Vietnam is the second largest country in South East Asia. 
Vietnam borders to China, Laos and Cambodia and stretches 1650 km north to south. 
Vietnam's coastline along the South China Sea extends 3400 km. The country is 
divided in the Red River Delta in the north, the Central Highlands and the Mekong 
Delta in the south. Vietnam has an estimated population of 87 million with a median 
age of 27 years (Central Intelligence Agency, 2009). The capital is Hanoi. There are 
four other municipalities (Ho Chi Minh City, Danang, Can Tho and Hai Phong) and 
58 provinces. 
Economically, Vietnam is classified as a developing low income country by the 
World Bank. In 2008, the gross domestic product (GDP) was US$ 90 billion and the 
GNI (gross national income) per capita (Atlas method) was US$ 890 (World Bank, 
2009). Twelve % of the population are estimated to be below the poverty line (i.e. 
living on less than US$ 1 per day) (Central Intelligence Agency, 2009). The total 
expenditure on health care is 7.1 % of the GDP or US$ 58 per capita per annum. The 
government expenditure on healthcare is US$ 23 per capita or 39% of the total 
expenditure (World Health Organization, 2010). There are six doctors, eight nurses 
and three pharmaceutical personnel and 28 hospital beds per 10,000 population. The 
maternal mortality rate is 150 per 100000 live births and the mortality rate in children 
under 5 years was 14 per 1000 live births in 2007. Life expectancy at birth is currently 
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74 years and the adult literacy rate is 90% (Central Intelligence Agency, 2009). Adult 
HIV prevalence is estimated at 0.5%. 
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Figure 1.8. Map of Vietnam, showing the major cities. 
From (Central Intelligence Agency, 2009) 
1.12.2 The Hospital for Tropical Diseases, Ho Chi Minh City 
The Hospital for Tropical Oi ea e wa initially built in 1865 and is a 500 bed 
infectious disease ho pital in Ho hi Minh City Vietnam and was formerly known 
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as the Centre for Tropical Diseases and before that as Cho Quan Hospital. It serves 
the local community in Ho Chi Minh City and is a tertiary referral centre for 
infectious diseases for the southern provinces of the country. Randomised controlled 
trials for the treatment of typhoid fever have been conducted on the adult and 
paediatric wards since 1992. The Well come Trust Major Overseas Programme 
Vietnam, Oxford University Clinical Research Unit, Ho Chi Minh City is based 
within the Hospital for Tropical Diseases, in a state of the art modem research facility, 
allowing close collaborations between clinicians and researchers. The research 
undertaken in this PhD was based at the Oxford University Clinical Research Unit, 
The Hospital for Tropical Diseases, Ho Chi Minh City. 
1.12.3 Typhoid fever and antimicrobial drug resistance in Vietnam 
Typhoid fever has been endemic in Vietnam, especially in the densely populated 
Mekong Delta area. 
Chloramphenicol resistant typhoid fever was first described at the Hospital for 
Tropical Diseases in 1973 (Butler et ai., 1973). In 1993, during the initial outbreak of 
MDR S. Typhi in Kien Giang province in the south of Vietnam, the fluoroquinolone 
antibiotics were introduced as the first choice for the treatment of typhoid fever 
(Nguyen et al., 1993). Since 1993, the proportion ofMDR S. Typhi plateaued at high 
levels in southern Vietnam and there has been a dramatic increase in nalidixic acid 
resistance. In 2004, 50% (10 11202) of the S. Typhi isolates from southern Vietnam 
were MDR. In 1998, five years after ofloxacin and ciprofloxacin become widely used 
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to treat typhoid fever but also a broad range of other febrile illnesses, often purchased 
without prescription in an uncontrolled market, 87% of the S. Typhi isolates were 
resistant to nalidixic acid (Chau et aI., 2007). 
In 2004, 97% (196/201) of the S. Typhi isolates were resistant to nalidixic acid and 
showed reduced susceptibility to the older fluoroquinolones, such as ofloxacin. This 
combination of MDR and nalidixic acid resistance is a particular problem in Vietnam, 
leading to poor clinical response and high failure rates (up to 36% clinical failure 
rates) in typhoid fever patients treated with ofloxacin (Chinh et al., 2000; Parry et al., 
2006), and severely restricts the therapeutic options in patients with typhoid fever. 
Data from a cross-sectional study from eight Asian countries (Bangladesh, China, 
India, Indonesia, Laos, Nepal, Pakistan and Vietnam) underline that antimicrobial 
drug resistance in S. Typhi is a problem in Asia (Chau et al., 2007). In 2003 and 2004, 
the prevalence of chloramphenicol resistant S. Typhi remained high with 18% (9/50) 
of isolates in Laos, 19% (28/149) in Nepal, 26% (6123 and 9/34 isolates, respectively) 
in India and Pakistan and 40% (16/40) in Bangladesh. All countries in the region, with 
the exception of China and Laos, faced an additional problem of widespread nalidixic 
acid resistance. Again southern Vietnam was a particular hot spot with more than 90% 
of all S. Typhi resistant to nalidixic acid. Roumagnac et al recently suggested that 
fluoroquinolone use has stimulated the clonal expansion of a nalidixic acid resistant S. 
Typhi haplotype H58 in southeast Asia (Roumagnac et al., 2006). 
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Provinces 
2004 2005 2006 
Cases Deaths Cases Deaths Cases Deaths 
Ho Chi Minh City 106 0 75 0 42 0 
An Giang 483 0 724 0 545 0 
Dong Thap 700 1 557 0 413 0 
Southern Provinces 2707 1 3088 0 2173 0 
Whole country 4323 1 5030 5 3018 0 
Table 1-3. Reported cases of syndromic typhoid fever in Vietnam, 2004 to 2006. 
Table 1-3 summarises the reported cases of syndromic typhoid fever in Vietnam 
(blood culture confirmed and unconfirmed) between 2004 and 2006 shown for three 
selected provinces (Ho Chi Minh City, An Giang and Dong Thap province), the 
southern provinces and the whole country. Source: Statistics on Infectious Diseases, 
National Institute of Health and Epidemiology (NIHE), Ministry of Health, Vietnam 
Compared to the 1990s, the number of reported cases of typhoid fever has declined in 
Vietnam. In 1995, more than 700 S. Typhi strains were isolated from blood cultures 
from patients admitted at the Hospital for Tropical Diseases in Ho Chi Minh City 
(Parry, 2004a). In 2009, there were less than 50 blood culture confirmed cases of 
typhoid fever at this hospital. The reduction in the incidence of typhoid fever in 
Vietnam has been attributed to improvements in infrastructure that have accompanied 
the economic development and to better treatment. There have been limited targeted 
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vaccination campaigns, using the Vi vaccine (Lin et al., 2001), however the extent to 
which vaccination contributed to the reduction in incidence is not clear. 
1.13 Nepal 
Nepal is a landlocked country in Southern Asia that shares borders with the Republic 
of India in the south, west and east and with the Peoples Republic of China in the 
north. The total land area is about 140 000 km2, of which only 16% are arable land. 
Nepal is a very mountainous country with eight of the world's ten highest peaks on its 
territory. Mount Everest, the world's tallest mountain with a height of 8844 m is 
located on the Nepalese-Tibetian border. Kanchenjunga, the world's third tallest 
mountain (8586 m) is located on the Nepalese-Indian border. 
The Tarai plain, the northern rim of the Ganges plain, is situated at 300 m above sea 
level in the south of Nepal. Due to the diverse geography and enormous range of 
altitudes, the weather in Nepal varies from cool summers and extreme alpine winters 
in the north to sub tropic summers and mild winters in the south. 
Nepal has an estimated population of 29 million and is among the poorest and least 
developed countries in the world. Approximately 31 % of its population are living 
below the poverty line (less than 1 US$ per day). Agriculture provides an income for 
75% ofthe population and accounts for approximately one third of the GDP. 
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Figure 1.9. Map of Nepal showing the major cities. 
Source: Central Intelligence Agency, 2009 
After ten years of civil war (from 1996 to 2006) which was led by Maoist insurgents, 
nationwide election took plac in 2008 and the newly elected Constituent Assembly 
declared Nepal a Federal 0 mocratic Republic and abolished the 240 year old 
monarchy. 
The gross national income (G I) P r capita i 400 US$ (Central Intelligence Agency 
2009). The adult literacy rate (abov 15 years) is 57% and the life expectancy is 67 
years. The maternal mortality rate (adju ted) is one of the world 's highest with 830 
death per 100 000 live birth and the infant mortality rate is 41 deaths per lOOO live 
births (World Health Organization 20 10). The mortality rate in children under 5 year 
is 51 per 1000 live birth . to trained health care workers is a major problem in 
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this mountainous country, where travel is often by foot. There is a huge disparity in 
the quality of health care offered in urban and rural areas. In Kathmandu 10 doctors 
serve for every 10 000 people, whereas in rural Nepal 0.3 doctors serve 10 000 
inhabitants. Only 19% of pregnant women have access to a skilled medical 
professional (doctor, nurse or midwife) at delivery, in some rural areas this percentage 
tends to be as low as 3% (Unicef, 2009). 
1.13.1 Patan Hospital, Kathmandu 
Kathmandu, Nepal's capital, has approximately 1.5 million inhabitants and is situated 
at an elevation of 1300 m. Kathmandu has four seasons, cold winters (December to 
February), spring (March to May), hot monsoon summers (June to August) and 
autumn (September to November). Pat an Hospital is one of the three general hospitals 
serving the Kathmandu metropolitan area. The hospital has 450 beds and provides 
inpatient and outpatient medical, surgical, paediatric, gynaecology and obstetric 
services for approximately 300 000 outpatients and 16 000 inpatients per year. It 
serves as a primary and secondary health care facility. 
Part of the research presented in Chapter 3 of this thesis was conducted at Patan 
Hospital, Kathmandu. 
1.13.2 Enteric fever in Nepal 
Enteric fever is a major public health problem in Nepal. Data regarding the burden of 
disease are difficult to obtain, this is partially due to self medication which is 
purchased without prescription from local phannacies and the absence of diagnostic 
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facilities in rural areas. A recent study reported that S. Typhi and S. Paratyphi A 
accounted for 75% (9124 out of 12252) of all positive blood cultures that were 
performed at Patan Hospital from 1993 till 2003, during an 11 year period (Maskey et 
al., 2008). The proportion of enteric fever caused by S. Paratyphi A increased from 
18% in 1993 to 34% in 2003. 
Multidrug resistant (MDR) S. Typhi was first reported in Nepal in 1991 and 
ciprofloxacin replaced chloramphenicol as first line treatment in 1994, but increasing 
rates of treatment failure were noted since 2000 (Maskey et al., 2008). Faecal 
contamination of water sources is significant. In 2002, an outbreak of enteric fever in 
5936 people in 8haratpur was reported (Lewis et al., 2005). The source of the 
outbreak was the municipal water supply. 
Kathmandu is served by an antiquated water supply. The water frequently contains 
coliform bacteria due to possible cross connections between water supply and sewage 
system. Chlorination is often inadeaquate. Often inhabitants do not have access to 
piped water in their homes and collect their water from local water spouts (Figure 1. 
9) (Karkey et al., 2008). 
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Figure 1.10. Community water spout in Kathmandu, Nepal. 
Villagers, mostly women and children are seen collecting their daily water provision 
from the community's stone spouts. This water is usually not boiled. 
1.14 Aims of the thesis 
The work described in this thesi includes two clinical trials (Chapters 2 and 5) and 
two laboratory studies (Chapter 3 and 4) that examine different aspects of typhoid 
fever and aim to improve our under tanding of this disease. The work for this thesis 
was undertaken at the Ho pital for Tropical Oi esases in Ho Chi Minh City, Vietnam 
and partly (Chapter 3) at Patan Hospital, Kathmandu, Nepal , in collaboration with the 
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Wellcome Trust Sanger Institute, UK and the Institute for Clinical 
Pharmacodynamics, US. 
Chapter 2 describes a randomised controlled trial conducted in the Mekong Delta 
region of Vietnam with a high proportion of multi drug and nalidixic acid resistant S. 
Typhi strains. This chapter examines whether the newer fluoroquinolone gatifloxacin 
or azithromycin is the better treatment for uncomplicated typhoid fever in Vietnam. In 
the discussion the results of this trial are compared with two recent enteric fever trials 
using gatifloxacin, performed in Kathmandu, Nepal. 
Chapter 3 uses exisiting data (patients' weight, height, serum creatinine and drug 
doses) from the gatifloxacin treatment trial (Chapter 2) to model the patients' drug 
exposure and put this into context with their clinical response to gatifloxacin 
treatment. It also identifies evidence based S. Typhi gatifloxacin MIC breakpoints to 
predict treatment success or failure. 
The second section of Chapter 3 evaluates the pharmacokinetics of gatifloxacin in 
patients with typhoid fever. Blood samples were taken during a randomised trial of 
gatifloxacin versus chloramphenicol in Nepal and gatifloxacin plasma concentrations 
were measured. The pharmacokinetic profile of the Nepalese enteric fever patients is 
compared to North American adult subjects and paediatric patients with otitis media. 
Chapter 4 explores the question of why the Mekong Delta has continued to be a hot 
spot for typhoid fever infections, particularly multidrug and nalidixic acid resistant 
typhoid fever, whilst the incidence of typhoid fever has declined in the rest of 
80 
Vietnam. This chapter looks at the population structure of the S. Typhi population 
isolated in the Mekong delta region during the clinical trial described in Chapter 2 and 
attempts to determine whether typhoid infections in this area are due to a certain 
genotype of S. Typhi. 
Chapter 5 highlights possible mechanisms of prevention and describes a randomised 
controlled Phase II clinical trial of a novel oral typhoid fever vaccine in healthy 
Vietnamese children. The MOIZH09 (S. Typhi (Ty2 aroC ssaV) ZH9) vaccine has a 
well-defined dual mechanism of attenuation and is given in a single oral dose. This 
chapter describes the safety and immunogenicity of this vaccine in healthy children in 
an endemic area. 
In the conclusion the key findings of this thesis are summarised and other research, 
current developments and possible future directions are discussed. 
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Chapter 2 
A Multi-Center Randomised Controlled Trial of Gatifloxacin versus 
Azithromycin for the Treatment of Uncomplicated Typhoid Fever in 
Children and Adults in Vietnam 
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2.1 Introduction 
The emergence of antimicrobial drug resistance in S. Typhi is a major problem 
particularly in South East Asia and the Indian sub-continent (Bhan et al., 2005; 
Bhutta, 2006; Parry et al., 2002). There is a need for an efficacious, safe and 
affordable oral treatment, particularly in regions with a high proportion of both 
multidrug and nalidixic acid resistant S. Typhi. 
The World Health Organization (see Chapter I) recommends the fluoroquinolones or 
cefixime for the treatment of MDR typhoid fever and azithromycin, the third-
generation cephalosporins, or a 10-14 day course of high-dose older generation 
fluoroquinolones (e.g. ofloxacin or ciprofloxacin) for the treatment of nalidixic acid 
resistant typhoid fever (World Health Organization, 2003). 
A trial from southern Vietnam used ofloxacin at the maximum recommended dose of 
20 mglkg/day for 7 days for the treatment of MDR and nalidixic acid resistant typhoid 
fever and showed high clinical failure rates (36%), high immediate post-treatment 
faecal carriage (19%), which may lead to transmission in the community after 
discharge from hospital, and prolonged mean fever clearance times of 8.2 days (95% 
CI, 7.2-9.2 days) (Parry el al., 2007). These results underline that the older generation 
fluoroquinolones are clearly failing in the treatment of nalidixic acid resistant typhoid 
fever. 
Of the newer fluoroquinolones. gatifloxacin, a broad spectrum synthetic 8-
methoxyfluoroquinolone is available and affordable in South and South East Asia 
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including Vietnam. Of all the fluoroquinolones, gatifloxacin showed the lowest 
minimum inhibitory concentrations (MICs) for nalidixic acid resistant S. Typhi from 
Nepal (Maskey et al., 2006) and Vietnam and a rapid bactericidal effect in time-kill 
experiments involving S. Typhi isolates with single and double mutations in gyrA of 
S. Typhi (Chau et al., 2007). Gatifloxacin can be administered as a once daily oral 
dose. 
Gatifloxacin was shown to be safe and efficacious in a pilot study in patients with a 
median fever clearance time (FCT) of76 hours (unpublished data Dr. Nguyen Chinh). 
Azithromycin, an azalid antibiotic, has achieved excellent clinical results in the 
treatment of MDR and nalidixic acid resistant typhoid fever (Chinh et al., 2000; Parry 
et al., 2007). However azithromycin is expensive and often not available in 
developing countries. 
We conducted a randomised controlled trial comparing the efficacy of gatifloxacin to 
azithromycin in southern Vietnam, an area characterised by a very high proportion of 
MDR (88%) and nalidixic acid resistant (93%) S. Typhi isolates (Parry et al., 2007). 
2.2 Methods 
2.2.1 Study design and objectives 
The study was designed as a multicenter, open-label randomised controlled trial to 
compare the efficacy and safety of gatifloxacin versus azithromycin for the treatment 
of uncomplicated typhoid fever in children and adult in-patients in southern Vietnam. 
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The overall objective of the trial was to identify an efficacious, safe, available and 
affordable oral treatment for MDR and nalidixic acid resistant typhoid fever. 
2.2.2 Participants 
Patients were eligible to be included in the study if they had clinically suspected or 
culture confinned uncomplicated typhoid fever and if fully infonned written consent 
had been obtained. For children, consent was obtained from the parent. Exclusion 
criteria were pregnancy, age under 6 months, history of hypersensitivity to either of 
the trial drugs, any signs of severe typhoid fever (shock, deep jaundice, 
encephalopathy, convulsions, bleeding, suspicion or evidence of gut perforation), or 
previous reported treatment with a fluoroquinolone antibiotics, a third generation 
cephalosporin or macrolide antibiotics within one week prior to hospital admission. 
2.2.3 The study sites and ethical approval 
The study was conducted at three hospitals in the south of Vietnam (Figure 2.1.). 
Adult and paediatric patients were recruited at the Hospital for Tropical Diseases in 
Ho Chi Minh City, at the Dong Thap Provincial Hospital in Cao Lanh, Dong Thap 
province and at the An Giang Provincial Hospital in Long Xuyen in An Giang 
province. 
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Figure 2.1. Map of southern Vietnam. 
The trial was conducted as a multicenter trial in three hospitals in southern Vietnam. 
The study was approved by the Ethical and Scientific Committee of the Hospital for 
Tropical Diseases in Ho Chi Minh City and the Oxford University Tropical Research 
Ethics Committee (OXTREC), UK for all three study sites, The clinical and 
microbiological data from the first 40 patients recruited to each arm of the study were 
sent to the independent Data Safety and Monitoring Committee for their advice 
regarding the continuation of the study, The study was not stopped, The trial was 
registered at Current Controlled Trials (ISRCTN67946944), 
2.2.4 Intervention 
According to their randomi ation number patients were assigned to oral treatment 
with either 20 mg/kg azithromycin (Zithromax suspension Pfizer, USA; 200 mg/5 
mL or Zithromax tablets, Pfizer USA- 500 mg/tablet) or to mg/kg gatifloxacin 
(Tequin®, Bristol-Myer Squibb USA; 400 mg/tablet) once daily for 7 days. Tablets 
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were cut to obtain the appropriate study dosage and administered with water. 
Inevitably, the dose administered was an estimate of 10 mglkglday of gatifloxacin or 
20 mg/kglday of azithromycin (number of tablets or proportions of tablets were 
documented in the CRFs). Gatifloxacin was only available as tablets, which were cut 
to obtain the appropriate dosage and crushed if necessary for children. 
The maximum dose of azithromycin was I g per day. All drugs were purchased 
commercially. 
2.2.5 Procedures 
2.2.5.1 In-patient procedures 
On admission to the hospital the patient's full history was taken, a standard clinical 
examination was performed and axillary temperature, weight and height were 
measured. Before treatment, full blood counts including white blood differential 
counts, serum aspartate transaminase (AST), serum alanine transaminase (ALT) and 
bilirubin were checked and blood cultures were obtained. For adult patients, 
creatinine, blood urea nitrogen (BUN) and glucose levels were additionally measured. 
In some patients bone marrow cultures were obtained. Urines were checked with 
dipstick and pre-treatment stool cultures were obtained. Chest X-ray and abdominal 
ultrasound were performed and repeated as clinically indicated. Randomisation and 
initiation of therapy took place either immediately on admission to hospital or patients 
were observed until results of blood tests including blood cultures were available and 
then randomised. Vital signs including measurement of axillary temperatures were 
measured and recorded every 6 hours (at 6, 12, 18 and 24 hours) until discharge. 
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Patients were examined daily until discharge from hospital, with particular reference 
to clinical symptoms, FCT, side effects of the drug and any complication of the 
disease. Additionally laboratory tests were scheduled if clinically indicated. All 
adverse events were recorded. On day 7 to 9 after the start of treatment full blood 
counts, liver function tests, blood and stool cultures were checked. In case of 
insufficient response to therapy, development of complications or drug-associated 
adverse events, the initial treatment was suspended and parenteral ceftriaxone (2 g per 
day) in two divided doses was used as rescue treatment for to days. 
2.2.5.2 Follow-up procedures 
Out-patient follow-up appointments were scheduled at I month, 3 months and 6 
months after discharge from hospital to seek evidence for relapse (l month visit) and 
check for chronic typhoid carriage (all visits). At these appointments a full history 
was taken, relevant examinations performed and stool cultures obtained. Blood or 
bone marrow cultures were only obtained if clinical symptoms were indicative of 
acute infection. If patients did not attend their follow up appointment, they were 
reminded by letter or a member of the study team visited their home. If stool samples 
were not available, a rectal swab was obtained. 
Patients with convalescent stool carriage of S. Typhi or S. Paratyphi A were retreated 
according to the sensitivity of the isolate and were further followed up. Ultrasound 
was performed to exclude biliary or kidney stones if carriage was persistent. 
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2.2.6 Microbiology 
Five to 8 mL of blood was collected from adults and inoculated into Bactec Plus 
Aerobic Blood bottles, and 3 to 5 mL of blood from children was inoculated into 
Bactec Peds Plus culture bottles (Becton Dickinson, New Jersey, USA). The bottles 
were incubated at 37°C in the BACTEC 9050 automated analyser for 7 days and sub-
cultured according to standard methods when the machine indicated a positive signal, 
or incubated at 37°C in a standard laboratory incubator (An Giang hospital) and 
examined daily. 
Stool samples or rectal swabs were inoculated onto MacConkey agar and Xylose 
Lysine Decarboxylase (XLD) agar plates, and in 10 mL of selenite F broth. Plates and 
broth were incubated at 37°C overnight and the broth was sub-cultured on 
MacConkey and XLD agar plates the next morning. 
Isolates were screened using standard biochemical tests and S. Typhi and S. Paratyphi 
A were identified using API20E (BioMerieux, Paris, France) and slide agglutination 
with specific antiserum (Murex, Dartford, UK). 
Antimicrobial susceptibility testing was performed by disc diffusion according to 
Clinical Laboratory Standards Institute (CLSI) guidelines (CLSI, 2006), using CLSI 
breakpoints (CLSI, 2007). Antimicrobial agents tested were: ampicillin, 
chloramphenicol, trimethoprim-sulfamethoxazol, nalidixic acid, ofloxacin, 
ciprofloxacin and ceftriaxone (Oxoid, Basingstoke, UK). MICs for amoxicillin, 
chloramphenicol, nalidixic acid, ofloxacin, ciprofloxacin, gatifloxacin, ceftriaxone 
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and azithromycin were determined by E-test (AB Biodisk, Soma, Sweden). Multidrug 
resistance (MDR) of isolates was defined as resistance to chloramphenicol (MIC ~ 32 
J,lg/mL), ampicillin (MIC ~ 32 J,lglmL) and trimethoprim-sulfamethoxazole (MIC ~ 
8/152 Jlg/mL). Nalidixic acid resistance was defined as an MIC ~ 32 JlglmL. The 
CLSI breakpoints for ofloxacin and gatifloxacin were ~ 2 Jlg/mL susceptible and ~ 8 
J,lg/mL resistant, for ciprofloxacin ~ 1 JlglmL susceptible and ~ 4 JlglmL resistant and 
for ceftriaxone ~ 8 Jlg/mL susceptible and ~ 64 ~glmL resistant. There were no CLSI 
MIC breakpoints for azithromycin (CLSI, 2007). The control strains used for all 
susceptibility tests were E. coli A TCC 25922, Pseudomonas aeruginosa A TCC 
27853, Staphylococcus aureus ATCC 29213. 
All cultures, identification of S. Typhi and S. Paratyphi A and disc diffusion were 
performed at the three study sites. All isolates were sent to the Hospital for Tropical 
Diseases, Ho Chi Minh City, for confirmation of identity, susceptibility testing and 
MIC testing. 
2.2.7 Outcomes of the study 
The primary endpoint of the study was the resolution of fever (fever clearance time, 
FCT), which was defined as the time from the start of the antibiotic treatment to when 
the axillary temperature first fell ~ 37.5°C and remained there for at least 48 hours. 
Secondary endpoints were the overall failure to treatment, which was defined a priori 
as any of the following: clinical failure (persistence of fever and symptoms two days 
after the end of treatment, i.e. on day 10) or need for re-treatment due to insufficient 
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treatment response as judged by the treating physician; microbiological failure 
(positive blood culture on day 7 to 9 after the start of treatment); the development of 
typhoid fever-related complications during hospital-stay; the occurrence of relapse 
(symptoms and signs suggestive of typhoid fever) within 1 month after completion of 
treatment or the detection of faecal carriage of S. Typhi at the follow-up visits at 1, 3 
and 6 months (to exclude faecal carriage a minimum of two consecutive follow-up 
visits had to be attended). 
2.2.8 Sample Size 
The primary outcome measure for the study was the fever clearance time (FCT). 
Previous studies that used azithromycin to treat typhoid fever patients, reported a 
mean fever clearance time of 130 hours (Chinh et at., 2000) and 139 hours (Parry et 
at., 2007). For gatifloxacin, clinical observations from a small number of typhoid 
fever patients were available and indicated a mean FCT of 76 hours. We calculated 
that 139 patients with culture confirmed typhoid fever would be needed in each 
treatment arm to detect a Hazard Ratio of 1.40 with two-sided alpha of 0.05 and 
power of 0.80 (Machin et at., 1997). Therefore, assuming a median fever clearance 
time of 130 hours for azithromycin, the sample size of 140 patients with culture-
confirmed typhoid fever in each arm would give power of at least 0.80 to detect a 
difference between treatments if the fever clearance time in the gatifloxacin group 
was 92 hours or less. 
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2.2.9 Randomisation 
An administrator independent from the study generated the random number sequence 
in Excel using RAND function. These randomised codes were blocked in a size of 50. 
Treatment assignments were folded and kept in opaque, sealed, sequentially 
numbered envelopes at all three study sites. Due to logistic reasons randomisation was 
not stratified by centre. 
After all inclusion and exclusion criteria were checked, and informed consent given, 
the study doctor opened the envelope to determine which treatment the subject would 
receive. The sealed envelopes were opened in strict numeric sequence. This study was 
conducted as an open study. 
2.2.10 Statistical methods 
Binary outcomes (clinical failure, microbiological failure, typhoid fever-related 
complications) were compared between the two treatment groups using Fisher's exact 
test, assuming the worst case scenario (all lost to follow up treated as failures). The 
un-adjusted Odds Ratio (OR) and Cornfield's 95% Confidence Interval (Breslow and 
Day, 1980) were calculated to show the relative risk of developing individual 
secondary outcomes (clinical, microbiological failure, typhoid fever-related 
complications) in the gatifloxacin group compared to the azithromycin group. 
Fever clearance time, time to relapse and time to overall failure were analysed using 
survival methods. The time to overall failure equaled the earliest time individual 
failure was recorded. Kaplan-Meier estimates of probabilities of each event were 
92 
calculated at any time-point, and they were compared between the two treatment 
groups using the log-rank test. Data of patients who were lost to follow-up were 
censored at the time of the last recorded outcome. The Hazard Ratio was derived from 
Cox proportional hazard model (Collett, 2003). 
All patients with positive blood or bone marrow culture for S. Typhi and S. Paratyphi 
A (per protocol analysis) and separately all randomised patients (intention to treat 
analysis) were analysed. 
All data were recorded prospectively into individual Case Record Forms (CRF) and 
entered into an electronic database (Epi Info 2003, CDC, Atlanta, USA) and double-
checked. 
Analysis was performed using STAT A version 8.0 (Stata Corporation, Texas, USA) 
statistical software program. 
2.3 Results 
2.3.1 Participant flow and recruitment 
During the study period, 460 patients were assessed for eligibility (Figure 2.2). One 
hundred and two patients were ineligible; the main reason was the reported previous 
use of fluoroquinolone, macrolide or third generation cephalosporin antibiotics (41 
patients) in the week before hospitalisation. 
Between April 2004 and August 2005,358 patients with suspected typhoid fever were 
randomised to receive either gatifloxacin or azithromycin. Two hundred eighty-eight 
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of these patients had blood or bone marrow confirmed typhoid fever and 70 patients 
were culture negative for S. Typhi. One culture positive patient was excluded from the 
per protocol analysis (PP), because he had received ciprofloxacin before entry to the 
trial. The PP group consisted of 287 patients, 145 in the gatifloxacin group and 142 in 
the azithromycin group. All PP patients, except two in the azithromycin group, 
finished the full course of treatment. 
The total number of patients visiting the follow-up at 1 month was 275 out of 287 
(96%), at 3 months 268 out of287 (93%), at 6 months 128 out of287 (44%) patients. 
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Figure 2.2. Profile of the trial 
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All 358 randomised patients were analysed in the intention to treat (ITT) analysis. 
Two hundred and eighty-seven patients with culture confirmed typhoid fever, 145 
treated with gatifloxacin and 142 with azithromycin, were analysed in the pre-
specified PP analysis. 
2.3.2 Baseline Data 
The median age of patients recruited in this trial was 11 years (range 1-41) in the PP 
group. 
The baseline characteristics of the patients were similar in the two treatment groups 
and in the culture negative patients (Table 2-1) 
Patients with suspected and blood culture confirmed typhoid fever were eligible for 
this trial. In the PP group, the median delay in time between hospital admission and 
randomisation was 3 days (interquartile range 1-4) in the gatifloxacin group and 3 
days (interquartile range 2-4) in the azithromycin group. In the ITT group, the median 
delay in time between hospital admission and randomisation was 2 days (interquartile 
range 0-4) in the gatifloxacin group and 3 days (interquartile range 1-4) in the 
azithromycin group. 
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Characteristics Culture confirmed patients treated with Blood culture negative 
Gatifloxacin, n= 145 Azithromycin, n= 142 patients, n=70 
Median age in years (range) 11 (2-30) 11 (1-41) 9 (2-42) 
Number of children defined as age under 15 (%) 109 (75.2) 101 (71.1) 56 (80) 
Number of males (%) 71 (49) 76 (53.5) 29 (41) 
Median weight in kilograms (range) 25 (8.5-55) 24.5 (9.5-57) 19.5 (10.5-53) 
Median duration of fever before admission in days (range) 7 (2-30) 7 (2-30) 7 (3-30) 
Number of patients who received pretreatment (%) 21 (14.5) 18 (12.7) 16 (22.9) 
Median temperature at admission in °c (range) 39 (37-40.5) 39 (37.3-41) 38.75 (37-40) 
Hepatomegaly, number (%) 69 (47.6) 63 (44.4) 36 (51.4) 
Splenomegaly, number (%) 17 (11.7) 14 (9.8) 2 (2.9) 
Abdominal pain, number (%) 82 (56.5) 76 (53.5) 43 (61.4) 
Weight loss, numbers (%) 69 (47.6) 71 (50) 21 (30) 
Vomiting, number (%) 47 (32.4) 54 (38) 19 (27.1) 
Diarrhoea, number (%) 95 (65.5) 82 (57.7) 49 (70) 
Mild jaundice, number (%) 12 (8.3) 20 (14.1) 1 (1.4) 
Median haematocrit in % (range) 34.3 (19.2-54.3) 34.6 (20.7-60.5) 34.2 (24.6-46.7) 
Median white cell count, 109 IL (range) 6.9 (2-17.2) 7.05 (2.4-16.8) 7.25 (2.8-11.7) 
Median platelet count, 109/L (range) 172 (34-500) 172.5 (45-578) 208 (51-496) 
Median AST, U/L(range) 85 (16.9-773) 72 (17.6-1190) 50.1 (11-533) 
Median ALT, U/L (range) 67.4 (10.3-276) 59.4 (10.2-734) 44.1 (10-375) 
Numbers of S.TyphilS.Paratyphi A isolated from culture 144/1 138/4 0 
Positive pretreatment faecal cultures, numbers (%) 111124 (8.9) 6/118 (5.1) 0 
AST, Serum Aspartate Aminotransferase AST (normal range, 12-30 U/L) 
ALT, Serum Alanine Aminotransferase ALT (normal range, 13-40 U/L) 
Table 2-1. Baseline characteristics of culture confirmed (PP analysis) and culture negative typhoid fever patients 
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2.3.3 Protocol deviations 
At one study site, the An Giang Provincial Hospital, the follow-up visit at 6 months was 
not possible due to logistic reasons. It was therefore agreed to carry out two follow-up 
visits at 1 and 3 months and to schedule additional (cross-sectional) follow-up dates to 
invite as many patients as possible to a third follow-up visit. From the PP population, 
22 out of 91 patients in the gatifloxacin arm and 17 out of 87 patients in the 
azithromycin arm attended the third visit. 
2.3.4 Primary outcomes 
There was no significant difference in the resolution of fever (FCT) between the two 
treatment groups (Table 2-2). 
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Outcome 
Type 
Primary 
Secondary 
Outcomes Sub-Categories 
Fever Clearance Time in hours (95% CI) 
Overall Treatment Failure, numbers of patients (%) 
Did not complete full treatment course, n (%) 
Clinical failure, n (%) 
Microbiological failure, n (%) 
Typhoid-fever related complications, n (%) 
Gastrointestinal bleeding 
Pneumonia 
Liver dysfunction 
Relapse after discharge from hospital, n (%) 
Number of patients with faecal carriage& (%) 
Treatment group (n=287) 
Gatifloxacin Azithromycin 
n=145 n=142 
106 (94-118) 106 (88-112) 
13/145 (9) 13/140 (9.3)* 
0 2 
6/145 (4.3) 6/140 (4.2) 
2/145 (1.4) 3/140 (2.2) 
0/145 (0) 8/140 (5.7) 
0 4 
0 2 
0 2 
4/137 (2.9) 0/127 (0) 
11137 (0.7) 0/131 (0) 
p-Value 
0.984" 
0.854" 
1.000# 
0.680# 
0.003# 
0.052" 
Patients can fail in more than one subcategory. *In the worst case scenario: 15/142 (10.6%) showed overall treatment failure in the azithromycin 
group, p = 0.570. "The p value is based on the logrank test. #The p value is based on Fisher's exact test. &Evaluated in patients who attended at 
least two follow up visits. 
Table 2-2. Primary and secondary outcomes of culture confirmed patients (PP analysis) 
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By PP analysis, the median FCT was 106 hours in both treatment anns (95% 
Confidence Interval [CI] ; 94 to 118 hours for gatifloxacin versus 88 to 112 hours for 
azithromycin), (logrank test p = 0.984, HR = 1.0; 95% CI 0.80 to 1.26). The Kaplan-
Meier survival curve for the fever clearance time is shown in Figure 2.3. At day 7, fever 
clearance rate was 82.8% (95% CI; 76.2% to 88.4%) in the gatifloxacin group and 
80.5% (95% CI; 73.6 % to 86.6%) in the azithromycin group. 
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Figure 2.3 Proportion of culture confirmed patients still febrile. 
Kaplan- Meier survival curve showing the proportion of culture confinned patients (PP 
analysis) sti ll febrile through time by treatment group. 
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In the ITT population, the median FCT was 100 hours in both treatment anns (95% CI; 
92 to 106 hours for gatifloxacin versus 88 to 112 hours for azithromycin), (logrank test 
p = 0.914, HR = 1.01; 95% CI 0.82 to 1.25). At day 7, fever clearance rate was 84.2% 
(95% CI; 78.5% to 89%) in the gatifloxacin group and 82.6% (95% CI; 76.5% to 
87.9%) in the azithromycin group (Figure 2.4). 
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Figure 2.4. Proportion of aLI randomised patients still febrile. 
Kaplan-Meier survival curve showing the proportion of all randomised patients (ITT 
analysis) still febrile through time by treatment group. 
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2.4 Secondary outcomes 
There was no death in the study. There was no significant difference in overall failure 
to treatment between the two groups (Table 2-2). 
By PP analysis, the number of patients that showed overall failure to treatment was 
131145 (9%) in the gatifloxacin group and 13/140 (9.3%) in the azithromycin group 
(logrank test p = 0.854, HR = 0.93; 95% CI 0.43 to 2.0), or when assuming the worst 
case scenario, that all dropped-out patients were failures, 15/142 (10.6%) failures in the 
azithromycin group (logrank test p = 0.570, HR = 0.81; 95% CI 0.38 to 1.7). Figure 2.5 
shows the proportion of patients failing through time after the start of treatment. 
In the azithromycin arm, more than one failure event occurred in individual patients 
(Table 2-2). Clinical failure occurred in 6/145 (4.3%) patients in the gatifloxacin group 
and in 6/140 (4.2%) in the azithromycin group (p = 1.000, OR = 0.96; 95% CI 0.25 to 
3.7). Three patients in each study arm were re-treated with ceftriaxone, the other 
patients resolved their symptoms within 24 hours. 
Microbiological failure (defined as positive blood culture on day 8) was seen in 2 out of 
145 patients in the gatifloxacin arm (1.4%) and in 3 out of 140 (2.2%) in the 
azithromycin arm (p = 0.680, OR = 0.64; 95% CI 0.05 to 5.7). Two of the azithromycin 
recipients showed additionally signs of clinical failure. 
There were no typhoid fever-related complications in the 145 gatifloxacin patients 
compared to 8 out of 140 (5.7%) patients in the azithromycin arm (p = 0.003, OR = 0; 
95% CI 0 to 0.4). Two azithromycin recipients developed signs of liver dysfunction 
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(elevated AST and ALT, deepening of jaundice) in addition to signs of clinical failure. 
Study treatment was continued and symptoms resolved by the time of discharge. Four 
patients, three children and one adult, suffered from gastrointestinal bleeding on day 3, 
day 5 (2 cases) and day 7 of treatment respectively, three patients received blood 
transfusions. One of these patients developed shock but responded to intravenous fluids 
and supportive treatment. Treatment was discontinued immediately in all the patients 
and re-treatment with ceftriaxone was initiated. Two adult patients developed 
pneumonia during treatment. 
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Figure 2.5 Proportion of patients with overall failure in the culture 
confirmed population. 
Kaplan-Meier survival curve showing the proportion of patients with overall failure in 
the culture confirmed population (PP analysis) by treatment group. 
Relapse was evaluated only in patients that were initially categorised as successfully 
treated, patients with clinical failure, microbiological failure or complications were not 
evaluated. Four patients out of 137 (2.9%) relapsed in the gatifloxacin group compared 
to none out of 127 in the azithromycin group (logrank test p = 0.052, HR = not 
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estimable due to zero observations in one group), (Figure 2.6). These relapses with 
symptoms suggestive of typhoid fever occurred on day 7, 11, 13 and 15 respectively, 
after completion of treatment, three patients were confirmed culture positive for S. 
Typhi. One patient developed acute respiratory distress syndrome (ARDS) and needed 
ventilation. The patient was treated with ceftriaxone and pefloxacine and subsequently 
made a complete recovery. 
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Figure 2.6 Proportion of patients with relapse in the culture confirmed population. 
Kaplan-Meier survival curve showing the proportion of patients with relapse in the 
culture confirmed population (PP analysis) by treatment group. 
Chronic faecal carriage was evaluated in patients who attended at least two follow-up 
appointments, 137 in the gatifloxacin group and 131 in the azithromycin group. Only 
one patient with chronic faecal carriage was detected after 6 months (An Giang study 
site), the patient had received gatifloxacin. 
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In the ITT analysis (all 358 randomised patients), overall treatment failure was reported 
in 13 out of 185 (7%) in the gatifioxacin group compared to 14 out of 168 (8.4%) in the 
azithromycin group (logrank test p = 0.615, HR = 0.82; 95% CI 0.39 to 1.76). One 
culture negative patient in the azithromycin group had a positive blood culture on day 7 
after start of treatment. There were no clinical failures or typhoid fever-related 
complications in the culture negative patients. 
2.4.1 Adverse events 
Both treatments were well tolerated. One adverse event related to azithromycin was 
reported, a maculopapular rash that occurred after the first dose of treatment. 
Azithromycin was discontinued immediately and the patient was treated with 
ceftriaxone. 
Gastrointestinal side effects (change in consistency and frequency of stools) that were 
probably typhoid fever related were relatively frequent in both treatment arms at the 
start of treatment. In the gatifioxacin group, one patient experienced vomiting on day 2 
and day 3 and one patient experienced diarrhoea (4 episodesl day) on day 4 and day 5 
of treatment. These episodes were self-limiting and did not require the interruption of 
therapy. 
The median levels of serum AST and AL T fell in both groups after 7 days of therapy. 
In the PP group, the median post-treatment AST was 46.4 U/L (range 12.8 - 217.5) in 
the gatifloxacin arm and 45 U/L (range 5 - 358) in the azithromycin arm. The median 
post-treatment ALT fell to 46.8 U/L (range 7.4 - 278) and 49.9 (1.1 - 494), 
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respectively. In the culture-negative patients, the median post-treatment AST was 44.8 
U/L (range 12 - 654) and ALT was 40 U/L (range 10 - 424.4). 
2.4.2 Antimicrobial susceptibilities of S. Typhi and S. Paratyphi A isolates 
From the PP population, 282 (98%) S. Typhi and 5 (2%) S. Paratyphi A strains were 
isolated. Two hundred and sixty three S. Typhi and five S. Paratyphi A were received at 
the Hospital for Tropical Diseases for antimicrobial susceptibility testing. 
Fifty-eight percent of the S. Typhi isolates were MDR and 96% were nalidixic acid 
resistant and showed reduced susceptibility to the older generation fluoroquinolones 
(Table 2-3). However technically, using current CLSI breakpoints, all isolates remained 
susceptible in vitro to ciprofloxacin and ofloxacin. The MIC90 of gatifloxacin was the 
lowest of all the fluoroquinolones tested at 0.19 fJg/mL (range 0.004 - 0.5). All isolates 
were susceptible to ceftriaxone. 
The 5 S. Paratyphi A strains were fully susceptible to all the antimicrobials tested. 
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Treatment with 
All isolates Gatifloxacin Azithromycin 
n=263 n= 137 n= 126 
Mu1tidrug resistant, numbers (%) 153 (57) 87 (63) 66 (50.8) 
Nalidixic acid resistant, numbers (%) 254 (94.8) 132 (95.6) 121 (93) 
MIC50 >256 >256 >256 
Amoxicillin (J.lg/ml) MIC90 >256 >256 >256 
range 0.125 to >256 0.5 to >256 0.125 to >256 
MIC50 >256 >256 >256 
Chloramphenicol (J.lg/ml) MIC90 >256 >256 >256 
range 0.38 to >256 2 to >256 0.38 to >256 
MIC50 >256 >256 >256 
Nalidixic acid (J.lg/ml) MIC90 >256 >256 >256 
range 1.5 to >256 1.5 to >256 1.5 to >256 
MIC50 0,75 0,75 1 
Ofloxacin (J.lg/ml) MIC90 1,5 1,5 1,5 
range 0.23-2 0.32-2 0.23-2 
MIC50 0.38 0.38 0.38 
Ciprofloxacin (J.lg/ml) MIC90 0.5 0.5 0.5 
range 0.004-0.75 0.006-0.75 0.004-0.38 
MIC50 0.125 0.125 0.125 
Gatifloxacin (J.lg/ml) MIC90 0.19 0.19 0.19 
range 0.004-0.5 0.006-0.25 0.004-0.5 
MIC50 0.125 0.125 0.125 
Ceftriaxone (J.lg/ml) MIC90 0.125 0.125 0.19 
range 0.064-0.25 0.064-0.19 0.064-0.25 
MIC50 8 8 8 
Azithromycin (J.lg/ml) MIC90 12 12 12 
range 1.5-16 1.5-16 4-16 
Table 2-3 Antimicrobial susceptibilities and MICs of 263 S. Typhi isolates. 
MICso/9o, at which 50% and 90% of the organisms are inhibited respectively. MDR is 
defined as resistance to chloramphenicol, ampicillin and trimethoprim-
sulfamethoxazole. CLSI MIC breakpoints are as follows: for chloramphenicol, 
ampicillin and nalidixic acid resistance ~ 32 J.lg/mL; ofloxacin and gatifloxacin ~ 2 
J.lglmL susceptible and ~ 8 J.lglmL resistant; ciprofloxacin ~ 1 J.lg/mL susceptible and ~ 
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4 IlglmL resistant; ceftriaxone ~ 8 IlglmL susceptible and ~ 64 IlglmL resistant; there 
are none for azithromycin. 
2.S Discussion 
The results of this trial show that both antibiotics worked well for the treatment of 
MDR and nalidixic acid resistant typhoid fever in Vietnam. A seven day oral course of 
gatifloxacin had similar efficacy and safety as a seven day course of azithromycin, 
which is recommended for the treatment of MDR and nalidixic acid resistant typhoid 
fever (Chinh et al., 2000; World Health Organization, 2003). 
However, azithromycin is not available throughout much of the developing world and it 
is expensive. The costs of a 7-day treatment course of gatifloxacin (at 10 mglkg per 
day) for an adult patient in Vietnam were approximately 25 US$, the costs of 
azithromycin (at 20 mglkg per day) were more than 90 US$. 
The results for gatifloxacin in this trial are comparable to the excellent clinical 
outcomes achieved with ofloxacin in Vietnam in the early 1990s, when S. Typhi 
isolates were still nalidixic acid susceptible (Cao et al., 1999; Tran et at., 1995; Vinh et 
at., 1996). 
Gatifloxacin has a higher affinity to GyrA and is less inhibited by the common 
mutations in the gyrA gene (Lu et al., 1999). The gatiiloxacin MIC50 of the study 
isolates was 0.125 IlglmL compared to the ofloxacin MIC50 of 0.75 IlgimL. We would 
not recommend the continued use of the older generation fluoroquinolones (ofloxacin 
and ciprofloxacin) in regions with high rates of nalidixic acid resistant typhoid fever for 
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fear of selecting further mutations in gyrA (Tam et al., 2007). This could put at risk the 
potential clinical benefit of the newer fluoroquinolones, including gatifloxacin. 
There have been several case reports of gatifloxacin-associated dysglycaemia m 
patients with type II diabetes mellitus, overweight or with other comorbidity (Ambrose 
et al., 2003; Baker and Hangii, 2002; Frothingham, 2005). There have been concerns 
about the use of gatifloxacin, after a retrospective case-control study in 1.4 million 
individuals over the age of 66 years (mean age 77 years) in Canada was published 
((Park-Wyllie et al., 2006). Subsequently, the US FDA required a 'Black Box' warning 
to be added to the package insert information. Later, "Tequin" (gatifloxacin) was 
voluntarily withdrawn in the US, Canada and Japan. 
However, gatifloxacin remains approved in many countries where enteric fever is 
endemic and drug resistant strains are present, including India, Vietnam, Nepal, 
Bangladesh and China. It is also still available as an ophthalmic solution for eye 
infections in Canada and the US (OHiaro P., 2011). 
As our trial was completed before publication of this report (Park-Wyllie et al., 2006), 
we did not systematically monitor for hypo- and hyperglycaemia. Blood glucose levels 
taken as part of the routine care were normal. All patients were managed as in-patients 
and potential symptoms of hypo- and hyperglycaemia would have been noted by the 
study physicians. No dysglycaemia events were reported during the in-patient period or 
during the follow up period of 3 to 6 months. 
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The patients in our trial were healthy, young and non-obese individuals. In our setting 
and in our patient population gatifloxacin was highly effective despite very high rates of 
drug resistance and was well tolerated. 
A trial in 867 children with otitis media with glucose monitoring and a one year follow-
up (Pichichero et at., 2005), as well as two recent enteric (typhoid and paratyphoid) 
fever trial in Nepal used gatifloxacin and did not report any clinically relevant 
dysglycaemias (Arjyal et at., 2011; Pandit et at., 2007). Other newer generation 
fluoroquinolones, i.e. gemifloxacin and moxifloxacin have shown low MICs for 
nalidixic acid resistant S. Typhi and S. Paratyphi A (Maskey et at., 2006), unfortunately 
these drugs are not available in Vietnam and they are considerably more expensive. The 
in vitro results seen with these other newer generation fluoroquinolones should be 
evaluated in clinical trials. 
The emergence of nalidixic acid resistant S. Typhi and S. Paratyphi A with reduced 
susceptibility to the fluoroquinolones is a widespread problem throughout Asia and 
therefore our study is relevant to the whole region (Bhan et aI., 2005; Chau et aI., 
2007). Many case reports and some randomised controlled trials have described the 
worsening clinical response to ciprofloxacin and ofloxacin (Aarestrup et ai., 2003; 
Kadhiravan et at., 2005; Parry et aI., 2007). 
The search for effective antibiotics to treat typhoid fever is imperative. 
Typically trials in typhoid fever are limited by small sample sizes. A recent Cochrane 
review stressed the need for large well-designed trials in enteric fever (Thaver et al., 
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2005). The evidence from our trial is strengthened by a sample size of 287 patients with 
culture confirmed typhoid fever (358 patients randomised). Both antibiotics also 
worked well for the patients with negative blood cultures. This is an important finding 
because the sensitivity of blood culture for the diagnosis of typhoid fever is only 
approximately 50 to 80% (World Health Organization, 2003). 
One possible limitation of our trial was the low rate of stool cultures positive for S. 
Typhi. Faecal carriage is usually characterised by intermittent shedding and the stool 
culture for S. Typhi is not very sensitive. When comparing our data with other studies 
that demonstrate that azithromycin is highly efficacious for the treatment of typhoid 
fever, we find similar low rates of faecal carriage at follow-up (Chinh et al., 2000; 
Frenck et al., 2004). It could be hypothesized that antibiotics that show high 
intracellular concentrations and good tissue penetration like azithromycin and the 
fluoroquinolones, achieve rapid bacterial killing and elimination throughout the body, 
which reduces faecal carriage. 
The dose of gatitloxacin and azithromycin tablets was prepared by careful cutting of the 
tablets (proportions of the tablets administered were recorded in the CRFs). Inevitably, 
it was therefore an estimation of the exact dose. Hence we cannot guarantee that each 
patient received exactly 10 mglkglday of gatitloxacin or 20 mglkglday of azithromycin. 
A MEDLINE search for "azithromycin, clinical trial, typhoid/enteric fever" and the 
recent enteric fever Cochrane review (Thaver et al., 2008) identified 6 clinical trials in 
the literature. In total, 251 typhoid fever patients were treated with azithromycin. 
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Four trials, three from Egypt and one from India, used azithromycin to treat MDR 
typhoid fever (Butler et al., 1999; Frenck et al., 2000; Frenck et al., 2004; Girgis et al., 
1999). Azithromycin achieved cure rates between 88% and 100%, the mean FCT 
ranged from 3.8 to 4.5 days. Two trials performed in Vietnam used azithromycin at 20 
mglkglday (Chinh et al., 2000) and at 10 mglkglday (Parry et aI., 2007) for the 
treatment of MDR and nalidixic acid resistant typhoid fever. In total, 107 patients with 
culture confirmed typhoid fever were enrolled. The cure rate was 93% and 82% and the 
FCT was 5.6 and 5.8 days, respectively. Our results concur with these excellent data. 
Two recently completed trials conducted in Kathmandu, Nepal also used gatifloxacin at 
the same dose and duration for the treatment of nalidixic acid resistant typhoid and 
paratyphoid fever (Arjyal et al., 2011; Pandit et al., 2007). Both trials reported excellent 
results for patients treated with gatifloxacin. The first trial compared the efficacy of 
gatifloxacin versus cefixime (20 mglkg per day given in two divided doses for 7 days) 
(Pandit et al., 2007). Successful treatment in the gatifloxacin group was achieved in 
96.5% (85 out of 88) patients and the median FCT (95% CI) was 92 hours (84-114 
hours). This trial was stopped early by the independent Data and Safety Monitoring 
Committee as a result of the poor clinical response in the patients randomised to 
cefixime. In the cefixime group the overall failure rate was 37.6 % (26 out of 70 
patients) and the median FCT was 138 hours. 
The second trial compared the efficacy of gatifloxacin versus chloramphenicol (75 
mglkg per day in four divided doses for 14 days) (Arjyal et al., 2011). Treatment failure 
occurred in 12 out of 177 patients (6.8%) in the gatifloxacin arm compared to 14 out of 
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175 (8%) in the chloramphenicol ann (HR 0'86, 95% CI 0·40 to 1'86; p = 0'70). The 
median FCT was 3.9 days in both treatment groups. 
I believe on the basis of this and other recently published trials, that gatifloxacin or 
azithromycin are now the treatments of choice for enteric fever in areas of MDR and 
nalidixic acid resistance (Arjyal et al., 2011; Chinh et al., 2000; Pandit et al., 2007; 
Parry et al., 2007). However it is important to use these antimicrobial agents sparingly 
(i.e. at the recommended dose and duration) because indiscriminate use would 
inevitably encourage further drug resistance. 
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Chapter 3 
Population Pharmacodynamics and Population Pharmacokinetics of 
Gatifloxacin in Patients with Typhoid Fever 
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3.1 Introduction 
3.1.1 Pharmacokinetics 
Pharmacokinetics (PK) describes the changes of drug concentrations over time in the 
body. The concentration versus time is a result of the processes of adsorption, 
distribution, metabolism and elimination. 
The appropriate use of antimicrobial agents reqUlres an understanding of the 
characteristics of the drug, host factors and the pathogen. Pharmacokinetic studies 
describe parameters such as the peak serum concentration Cmax• the serum half life tl/2 
and the cumulative exposure to an agent by the area under the concentration time curve 
(AUC) for a 24 hour period (McKinnon and Davis, 2004). Severe disease and sepsis 
can significantly alter the pharmacokinetics of drugs, especially distribution and 
elimination. 
3.1.2 Pharmacodynamics 
Pharmacodynamics (PD) describes the relationship between the drug exposure in 
serum, tissues and body fluids and the pharmacological and toxicological effects of the 
drugs (Craig, 2007). For antimicrobials, the success of a given drug dose depends on a 
measure of drug exposure (such as the area under the concentration-time curve, the 
serum peak concentration and the duration of time the serum concentrations exceed a 
certain level) and a measure of the potency of the drug against the infecting organisms, 
e.g. the minimum inhibitory concentration (MIC) or the minimum bactericidal 
concentration (Craig, 200 I). The relationship between drug exposure and MIC of the 
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pathogen has been shown to be predictive of microbiological eradication, this is often 
summarised as exposure-response relationship (Craig, 2007). 
PKlPD indices that are used as surrogate markers for clinical and antimicrobial efficacy 
are the ratio of peak plasma concentration (Cmax) of the antimicrobial to MIC of the 
pathogen (Cmax/MIC), the ratio of the area under the concentration/time curve 0 to 24 
hours to the MIC (AUCo-24:MIC) and the time above MIC (T>MIC). 
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Figure 3.1 Concentration versus time with MIC superimposed and 
pharmacokinetic and pharmacodynamic markers. 
From (McKinnon and Davis, 2004). 
There is renewed interest in pharmacodynamic concepts as clinicians and scientists 
realise that our antimicrobial armamentarium is limited (Becker et aI., 2006) and only 
few new antibiotics are likely to be developed. 
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PO concepts can help to detennine how to best use current available antibiotics and 
how to prevent antibiotic resistance. Mathematical modelling and phannacodynamics 
have demonstrated that it is possible to delineate a drug exposure that would prevent the 
emergence of mutant subpopulations (Jumbe et al., 2003). 
3.1.3 Population pharmacokinetics and pharmacodynamics 
Population phannacokinetics and phannacodynamics has been developed in the late 
1980s and aims to quantify detenninants of drug concentration (PK) or response (PO) 
in a population of patients (Sheiner and Ludden, 1992). In general, population PK 
models provide precise estimates of the variance and covariance between PK 
parameters, this is useful for subsequent simulation experiments and the models are 
applicable to sparse sampling strategies (Rubino et al., 2007). Various software 
programmes are available, including NONMEM (non-linear mixed effects model) 
which was developed by Lewis Sheiner and Stuart Beal and S-AOAPT, which perfonns 
Monte Carlo Expectation Maximization (MCPEM) algorithm, as well as Bayesian 
estimation (Bauer et al., 2007). 
3.1.4 Patterns of antimicrobial killing 
Antimicrobials exhibit two primary patterns of microbial killing (Graig, 2007). The first 
pattern is characterised by concentration dependent killing which occurs over a wide 
range of concentrations and also shows moderate to prolonged persistent effects. Higher 
drug concentrations result in a greater rate and extent of microbial killing. This pattern 
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IS observed with the fluoroquinolones, aminoglycosides, daptomycin, ketolides, 
metronidazole and amphotericin B. 
The second pattern is the time dependent (or minimal concentration dependent) killing. 
The extent of the microbial killing is primarily dependent on the duration of the 
exposure. The killing rate is saturated at low multiples of the MIC, usually around four 
or five times the MIC. Higher drug concentrations do not kill microbes faster or more 
extensively. Time dependent killing with minimal to none persistent effects are 
observed with fl-Iactam antibiotics and flucytosine. Macrolides, clindamycin, 
glycopeptides, tetracyclines and linezolid exhibit a time dependent pattern with 
moderate to prolonged persistent effects that can prevent re-growth of bacteria during 
the dosing interval (Graig, 2007). 
3.1.5 The pharmacokinetics and pharmacodynamics of gatifloxacin 
Gatifloxacin (see Chapter 1) is a broad spectrum 8-methoxy fluoroquinolone with 
enhanced activity against Gram positive and Gram negative organisms, anaerobes and 
mycobacteria, which received U.S. Food and Drug Administration (FDA) approval in 
1999. In clinical trials, gatifloxacin was shown to be effective in the treatment of acute 
respiratory infections, including community-acquired pneumonia, acute exacerbation of 
chronic bronchitis, sinusitis and urinary tract infections in adults and otitis media in 
children (Capparelli et al., 2005). 
Gatifloxacin is readily absorbed from the gastrointestinal tract, with an absolute 
bioavailability of approximately 96% (LaCreta et al., 2000). Gatifloxacin has a large 
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volume of distribution (approximately 1.8 L/kg) , low protein binding (approximately 
20%), broad tissue distribution and is primarily (more than 80%) excreted unchanged in 
the urine (Grasela, 2000b; Nakashima et al., 1995). It has an elimination half life of 8 to 
10 hours, independently of the dose (Grasela, 2000b; Nakashima et al., 1995). 
In a single dose study, gatifloxacin concentrations in serum reached a peak between 1 
and 2 hours and the peak concentrations were 0.87, 1.71, 3.35, and 5.41 f.lg/ml at the 
doses of 100,200,400, and 600 mg, respectively (Nakashima et al., 1995). 
The PKlPD profile of the fluoroquinolones has been well characterized (Ambrose et a/., 
2007). For fluoroquinolones, the area under the concentration-time curve at 24 hours to 
MIC ratio (AUCo-24: MIC) has correlated most strongly with efficacy in animal and in 
vitro models and in patients with a variety of diseases (Ambrose et al., 2007). Studies 
by Forrest A. et al. evaluated intravenous ciprofloxacin for the treatment of pneumonia 
caused predominantly by Gram negative organisms and Pseudomonas aeruginosa in 
seriously ill patients (Forrest et al., 1993). At an AUCo-24: MIC above 125 the 
probability of therapeutic response, defined as clinical and microbiological cure was 
80%. 
In patients with hospital acquired pneumonia treated with levofloxacin, patients m 
whom AUCo-24: MIC ratios ~ 87 were attained had a 90% probability of a positive 
microbiological response, while those with lesser exposures had only a 43% favourable 
response to therapy (p = 0.01) (Drusano et al., 2004). 
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In vitro gatifloxacin PKlPD data against S. Typhi suggest that similar AUC: MIC ratios 
(approximately 105) correlate with bacterial eradication (Booker et al., 2005). 
However, no clinical PKlPD data exist for infections involving S. Typhi. This chapter 
describes the pharmacokinetics and pharmacodynamics of gatifloxacin and is divided 
into two sections. The first section uses data from a randomised controlled trial of 
gatifloxacin versus azithromycin (described in Chapter 2) for the treatment of typhoid 
fever in Vietnam, to model the relationship between drug exposure (AUCo-24: MIC) and 
therapeutic response in patients treated with gatifloxacin and to identify appropriate 
susceptibility breakpoints for gatifloxacin. The current CLSI breakpoints for 
Enterobacteriaceae (including Salmonella) for ofloxacin and gatifloxacin are ~ 2 mglL 
susceptible and 2: 8 mglL resistant, for ciprofloxacin ~ ImglL susceptible and 2: 4 mglL 
resistant (CLSI, 2007). The breakpoints for nalidixic acid are ~ 32 mglL (resistant) and 
~16 mg/L (susceptible). There has been discussion whether the current fluoroquinolone 
breakpoints are not too generous and therefore misleading clinicians (Aarestrup et at., 
2003; Crump et at., 2003). The CLSI guidelines (2007) on the "Performance Standards 
for Antimicrobial Susceptibility testing" have responded to this criticism and 
recommend that extraintestinal Salmonella isolates should be screened for nalidixic 
acid resistance, and that in case of nalidixic acid resistance the physician should be 
informed that the isolate may not be eradicated by fluoroquinolone treatment (Institute, 
2007). 
However some of the newer fluoroquinolones do remain effective against nalidixic acid 
resistant S. Typhi infection and therefore this recommendation is leading clinicians 
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towards less effective treatments. Therefore a review of the breakpoints for Salmonella 
is necessary but prospective clinical and pharmacological data are lacking. We also 
determined the positive and negative predictive value of the nalidixic acid screening 
test for the clinical efficacy of gatifloxacin treatment in the same patient population. 
The second section describes the pharmacokinetics of gatifloxacin in adult and 
paediatric patients with enteric fever in Nepal. Blood samples to measure gatifloxacin 
concentrations in Nepalese adults and children with enteric fever were obtained during 
a randomised trial of gatifloxacin versus chloramphenicol, described in the discussion 
of Chapter 2. The pharmacokinetics (PK) of gatifloxacin has been reported in healthy 
volunteers and in selected North American patient populations, who included adult 
patients with community-acquired respiratory tract infections and paediatric patients 
with acute or recurrent otitis media (Grasela, 2000a; Grasela et al., 1998; Rubino et al., 
2007). However, the PK of gatifloxacin in adult and paediatric patients with enteric 
fever is unknown. Such data will be useful to construct exposure-response relationships 
for the efficacy of gatifloxacin in this patient popUlation. 
3.2 Materials and Methods 
3.2.1 Section 1. Pharmacodynamics of gatifloxacin in adult and paediatric typhoid 
fever patients in Vietnam 
3.2.1.1 Patients and procedures 
Typhoid fever patients who were treated with an oral dose of 10 mg/kg/day of 
gatifloxacin (Tequin®, Bristol-Myers Squibb, USA; 400 mg/tablet) once daily for 7 
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days in a randomised clinical trial conducted in Vietnam were analysed (Trial 
registration: http://controlled-trials.comlISRCTN67946944). 
Patients, inclusion and exclusion criteria, procedures and outcomes have been described 
in detail in Chapter 2 of this thesis. In brief, favourable clinical response was defmed as 
the resolution of fever and symptoms within 48 hours of the end of therapy (i. e. on day 
10). Fever was evaluated every 6 hours. Relapse was defined as the recurrence of fever 
and symptoms and/or the isolation of S. Typhi from blood within 1 month after the 
completion of therapy. Patients were followed up at 1, 3 and 6 months, at these visits 
the recent history was obtained, physical examination carried out and stool cultures 
were performed to check for chronic faecal carriage of S. Typhi. 
3.2.1.2 Antimicrobial susceptibility testing olS. Typhi 
The antimicrobial susceptibility testing of S. Typhi has been described in chapter 2. 
Multidrug resistance was defined as resistance to ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole. 
3.2.1.3 Drug exposure determination 
For children under 16 years we used a previously validated population pharmacokinetic 
model to determine the drug exposure as expressed by the area under the concentration 
time curve at 24 hours (AUCO-24) (Rubino et al., 2007). The PK model used is a one-
compartment model with first order absorption and elimination, and linear relationships 
between body surface area (BSA) and apparent oral clearance (CLlF; where F is the 
oral bioavailability), and weight and apparent volume of distribution (VIF), 
respectively. We used patients' specific demographic and baseline information (age, 
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sex, weight, height and serum creatinine) to estimate individual patient drug exposures. 
Body surface area (BSA) was calculated according to the method of Gehan and George 
(Gehan and George, 1970). 
EQUATION 1: BSA (m2) = 0.0235 x Height (cm)O.42246 x Weight (kg)O.51456 
For patients below 16 years, clearance was estimated according to Rubino et al. 
(Rubino et al., 2007). 
EQUATION 2: Clearance «16 years) = 8.46· body surface area 
For patients above 16 years of age, creatinine clearance (CLer) was estimated according 
to the Cockcroft-Gault fonnula (Cockcroft and Gault, 1976), which estimates the 
glomerular filtration rate: 
EQUATION 3: estCLer= (140 - age) x weight (kg) /72 x serum creatinine (mg/dL)* 
*Multiply with factor 0.85 if female 
Clearance was estimated for patients above the age of 16 years according to Ambrose et 
al. (Ambrose et al., 2001). 
EQUATION 4: Clearance (>16 years) = 8.11 + 0.0629 (creatinine clearance - 75.0) 
The clearance estimates were then used in conjunction with dose to estimate 
gatifloxacin exposure AUCo-24 for each patient: 
EQUATION 5: AUCo-24 = dose/clearance 
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The ratio of drug exposure to MIC (AUCO-24: MIC ratio) was calculated by dividing the 
AUCO-24 by the MIC of the patient's infecting S. Typhi isolate: 
EQUATION 6: AUCO-24: MIC ratio = AUCo-2JMIC 
The analysis included all patients with sufficient data to estimate the AUCO-24, who 
were blood culture positive and for whom the gatifloxacin MICs of the infecting S. 
Typhi isolate was available. 
3.2.1.4 Pharmacodynamic analysis 
All statistical analyses were implemented In the statistical program SYSTAT 11, 
Richmond, CA. Univariate and multivariate logistic regression were used to evaluate 
the probability of clinical response. Multivariate logistic regression modelling was 
carried out using likelihood ratio testing and backwards stepping. Categorical 
breakpoint values for continuous variables, such as AUCO-24: MIC ratio, were 
determined by classification and regression tree (CART) analysis. Variables evaluated 
included age, sex, weight, multidrug resistance, AUCO-24, MIC, and AUCO-24: MIC ratio. 
Stratified Kaplan-Meier and Cox proportional hazards regression analyses were used to 
examine the relationship between independent variables of interest and the time to fever 
resolution. The time until fever resolution was defined as the first time the patient's 
axillary temperature was less than 37.5 °C and remained so for a minimum of 48 hours. 
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3.2.2 Section 2. Pharmacokinetics of gatifloxacin in paediatric and adult enteric 
fever patients in Nepal 
3.2.2.1 Patient population, ethical approval, inclusion and exclusion criteria 
Blood samples were collected during a randomised controlled trial comparing the 
efficacy and safety of an oral dose of 10 mglkglday of gatifloxacin (Broadband, Acme 
Formulation Private Limited, Solan, India; marketed by Novartis AG, Basel, 
Switzerland; 400 mgltablet) once daily for 7 days versus an oral dose of 75 mglkglday 
of chloramphenicol (Chloro, National Healthcare, Nepal) in four divided doses for 14 
days for the treatment of enteric fever. 
The trial was conducted at Patan Hospital, Kathmandu, Nepal. Patients aged 2 years to 
60 years with suspected enteric fever (more than 3 days of fever and clinically 
diagnosed typhoid fever) were invited to participate. The trial was approved by the 
Oxford University Tropical Research Ethics Committee and the Nepal Health Research 
Council. The trial registration number was ISRCTN53258327 (http://www.controlled-
trials.comlISRCTN53258327). 
Patients who lived in a pre-designated area of approximately 20 square kilometres in 
urban Lalitpur and who gave fully informed written consent were eligible for the study. 
Exclusion criteria were pregnancy or lactation, age under 2 years or weight less than 10 
kg, shock, jaundice, gastrointestinal bleeding or any other signs of severe typhoid fever, 
previous history of hypersensitivity to either of the trial drugs, known previous 
treatment with chloramphenicol, quinolone antibiotic or third generation cephalosporin 
or macrolide within one week of hospital admission. Patients who had received 
127 
amoxicillin or cotrimoxazole were included as long as they did not show evidence of 
clinical response. 
3.2.2.2 Procedures 
Patients were enrolled into the study by dedicated physicians at Patan hospital, who 
took a full history and carried out the clinical examination. Once the study physicians 
had enrolled the patient, they were managed as outpatients. Trained community medical 
auxiliaries (CMAs) visited each patient's house every 12 hours until the patient was 
cured, as described previously (Pandit et al., 2007). At each visit the CMAs recorded 
oral temperature, inquired about symptoms and directly observed each patient ingesting 
the single dose of gatifloxacin and the two doses of chloramphenicol coinciding with 
their daily visits. 
Patients were re-examined by the study physicians at Patan Hospital on day 8 and blood 
and stool cultures were collected if the initial blood culture was positive. Patients also 
visited the study physicians on day 15, and at one, three and six months. At these visits 
stool of blood culture positive patients was checked for faecal carriage. Also febrile 
illnesses in household members were inquired. Random plasma glucose was measured 
on day 1, days 2 to 7 (using finger prick testing using OneTouch SureStep, Johnson & 
Johnson, USA during the CMAs' evening visits), on day 8, day 15 and one month. 
Haemoglobin A I C was measured at three months. Full blood counts, liver enzymes and 
creatinine were studied on days 1,8, and 15. 
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3.2.2.3 Outcomes 
In brief, favourable clinical response was defined as the resolution of fever and 
symptoms within 48 hours of the end of therapy (i. e. on day 10). Fever was evaluated 
every 12 hours. Relapse was defined as the recurrence of fever and symptoms and/or 
the isolation of S. Typhi or S. Paratyphi A from blood within 1 month after the 
completion of therapy. At the 1, 3 and 6 months follow up visits, stool cultures were 
performed to check for chronic faecal carriage of S. Typhi or S. Paratyphi A. 
3.2.2.4 Blood samples and sparse plasma sampling schedule 
Blood sampling was performed in steady state concentrations. Steady state 
concentrations describe equilibrium between administration and elimination, which is 
usually reached after 5 drug half lives. For gatitloxacin with a half life of approximately 
8 hours, steady state is reached after administration of the second dose. 
Two ml of blood were collected into lithium heparin tubes using a sparse sampling 
scheme. The first of two samples was taken 3 to 6 hours after administration of the third 
or a later dose and the second sample was taken 12 to 24 hours after the third or a later 
dose. Blood tubes were inverted several times and immediately placed on ice. Samples 
were processed as soon as possible after collection. The samples were centrifuged for 
10 minutes at 100 x g in a centrifuge which cups have been chilled. The plasma layer 
was transferred to polypropylene screw-capped tubes and labelled with the study 
number, study day, date and the actual sampling time. Plasma and cell pellets were 
immediately stored at -80oe. Information about each blood sample (date, time), the 
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exact time and doses (in mg; all tablets were weighed before administration) of all 
previous gatifloxacin administrations were recorded in a spreadsheet. 
For children, one sample was taken 6 to 24 hours after the third dose. Sampling times 
were spread out to allow for the best possible validation using a single sample. 
3.2.2.5 Gatijloxacin assay 
Human plasma samples (50 f..ll) were deproteinated with 250 f..ll acetonitrile. The 
samples were centrifuged and an aliquot of the supernatant (50 f..ll) was transferred into 
an autosampler vial containing 1 ml of HPLC water. 
Samples were analyzed by high pressure liquid chromatography tandem mass 
spectrometry (LCIMS/MS). The LCIMSIMS system consists of a Shimadzu 
Prominence HPLC system and an Applied Biosystems/MDS Sciex API5000 
LCIMSIMS. 
Chromatographic separation was performed using a Phenomenex Luna Phenyl-Hexyl 
column, 5 f..lm, 150 x 3.0 mm column and a mobile phase consisting of 85% 0.1 % 
formic acid in water and 15% 0.1 % formic acid in acetonitrile, at a flow rate of 0.75 
mllmin. Gatifloxacin concentrations were obtained using LCIMSIMS monitoring the 
MSIMS transition mlz 376 - mlz 332. Analysis run time was 4.0 minutes. 
The assay was linear over a range of 0.050 to 10.0 Jlglml (r2 > 0.996). The inter-day 
precision (%CV) ranged from 2.61 to 9.69%, with an accuracy ranging from 106% to 
III % on quality control samples at three levels (0.10 Jlglml, 1.00 Jlglml, and 8.00 
Jlglml) in replicates of three at each level on each analysis day. 
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3.2.2.6 Development of a population pharmacokinetic model 
Population PK datasets were constructed using the exact dose and sampling times. The 
data were vetted for the presence of errors in dose and/or sampling times. Potential 
outlier concentrations were explored using accepted methodology. 
Separate population pharmacokinetic candidate models for adults (> 16 years of age) 
and paediatric patients (~16 years of age) were fit to the data using Monte-Carlo 
parametric expectation maximization (MCPEM) as implemented in the open-source 
software program S-ADAPT, which was written by Robert J. Bauer and is available at 
http://bmsr.usc.eduiSoftware/ADAPT/SADAPTsoftware.html (Bauer and Guzy, 2004). 
The program performs parametric population analysis, including maximum likelihood 
estimation, via the Expectation Maximization (EM) algorithm with sampling as 
implemented in the Monte Carlo Expectation Maximization (MCPEM) algorithm, as 
well as Bayesian estimation (University of South Carolina, 2009). 
Due to the sparse nature of the PK sampling scheme, the structure and covariate 
relationships from previous gatifloxacin adult and paediatric population PK models 
derived from North American patients were retained, but were revised to fit the data 
from this population (Grasela, 2000a; Grasela et al., 1998; Rubino et al., 2007). 
These PK models had the structure of one compartment models with first-order 
absorption and elimination. 
The equations and covariate relationships are provided below. 
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For the adult patients (> 16 years) the following equations were used to estimate total 
clearance (CLt) and central volume of distribution (Vc). Creatinine clearance (CLcr) 
was calculated using the method of Cock croft and Gault (Cockcrofi and Gault, 1976). 
CLt (LIhr) = CLt-intercept + CLt-slope x CLcr (mllminll.73m2) 
v c (L) = V c-slope x Body Weight (kg) 
The following equations were used for the paediatric patients (:::; 16 years) to estimate 
total clearance (CLt) and central volume of distribution (Vc). Body surface area (BSA) 
was estimated according to the Gehan and George method (Gehan and George, 1970). 
CLt (LIhr) = CLt-slope x BSA (m2) 
Vc (L) = Vc-slope x Body Weight (kg) 
3.3 Results 
3.3.1 Section 1. Pharmacodynamics of gatifloxacin in adult and paediatric typhoid 
fever patients in Vietnam 
3.3.1.1 Patient population and clinical data 
Of the 186 patients randomised to receive gatifloxacin therapy in this trial, 185 could be 
evaluated for this analysis. Of these, 144 patients were blood culture positive for S. 
Typhi and 124 patients had sufficient data to estimate gatifloxacin exposure. 
These 124 patients represent the population used in all pharmacodynamic analyses. 
Sixty three patients were male and 61 were female; their mean (standard deviation, SD) 
132 
age was 11.3 (5.48) years; their mean (SD) weight was 27.8 (12.4) kg; and their mean 
(SD) body surface area was 1.02 (0.299) m2• Nine of the 124 (7%) patients had positive 
bone marrow cultures for S. Typhi in addition to their positive blood cultures. Five 
(6/124) percent of patients were infected with nalidixic acid susceptible (MIC :::;; 16 
mglL) and 95% (118/124) with nalidixic acid resistant (MIC ~32 mglL) S. Typhi 
strains. Sixty one (76/124) percent of patients were infected with multi drug resistant S. 
Typhi strains. 
The median (range) gatifloxacin MIC of S. Typhi isolates was 0.018 (0.006-0.09) mglL 
for nalidixic acid susceptible isolates and 0.12 (0.06-0.25) mglL for nalidixic acid 
resistant isolates. The median (range) ciprofloxacin MIC value for nalidixic acid 
susceptible S. Typhi isolates was 0.014 (0.006-0.12) mglL and for nalidixic acid 
resistant isolates was 0.38 (0.12-0.75) mglL. 
3.3.1.2 Pharmacodynamic analysis 
Clearance estimates from previously validated adult and paediatric population 
pharmacokinetic models were used in conjunction with the dose to obtain an estimate 
for AVe (Ambrose et al., 2001; Rubino et al., 2007). 
In these typhoid fever patients, there was a statistically significant relationship between 
the intensity of the drug exposure to gatifloxacin and clinical response. 
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Risk Factor p value Risk Factor p value 
Age 0.206 MDR 0.867 
Sex 0.795 AUC I 0.519 
Weight 0.136 AUC2 0.0833 
S. Typhi in bone marrow 0.165 MIC I 0.0256 
MIC2 0.0716 
AUC:MIC I 0.0849 
AUC:MIC2 0.0243 
ITreated as a continuous variable 
2 Treated as a categorical variable 
Table 3-1 Univariate logistic regression analysis results. 
Risk factors were tested for association with clinical response in typhoid fever patients 
(n =124) using univariate logistic regression analysis. 
We could identify a significant dichotomous categorical breakpoint for AUCO-24: MIC 
ratio which was predictive of clinical success. Patients in whom an AUCO-24: MIC ratio 
of greater than 92.7 was obtained, had a favourable response to treatment in 93.5%, 
whilst in patients with AUCO-24: MIC ratios ~ 92.7 only 75% had a favourable response 
(Odds Ratio = 4.81,95% CI 1.23-18.9;p = 0.02) (Figure 3.2). 
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Figure 3.2 Relationship between gatifloxacin exposure and clinical response 
in typhoid fever patients. 
Univariate logi tic regre ion analy is with AVC: MIC as a continuous variable, 
for U : MIC br akpoint (92.7); p = 0.02. 
The mean time to fever re olution wa 113 hour in patients in whom AUCo-24 : MIC 
ratios greater than 92 .7 were attain d, compar d to 142 hour in those patients with 
lesser exposures (p = 0.0 ) (Figur 3.3). The proportion of patients who had a positive 
clinical respon e wa 91 % (11 1124) for all pati nt . All six patients infected with 
nalidixic acid su ceptible train had ucc ful clinical r pon e to therapy; while 91 % 
(107/118) of those patient infected with nalidixic acid re i tant trains had a po itive 
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therapeutic response (Fi her exact test p = 1.0). Similarly high cure rates of 91 % 
(69/76) were obtained among the patients infected with multidrug resistant S. Typhi. 
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Figure 3.3 Kaplan-Meier survival curve. 
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The Kaplan-Meier survival curv shows the proportion of culture confirmed patients 
still febrile through time tratifi d by AUC 0-24: MIC ratio breakpoint. The mean time to 
fever resolution tended to be horter in patients with AUCO-24: MIC > 92.7 (blue line) 
than those patient with AU 0-24: MIC ratios ~ 92.7 (red line). 
We could identify a borderline ignificant dichotomous categorical gatifloxacin MIC 
breakpoint for S. Typhi which wa predictive for clinical response. S. Typhi 
gatifloxacin MIC value ~ 0.19 mg/L were a ociat d with 83.8% of patients having a 
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positive clinical response, while patients with gatifloxacin MIC values less than 0.19 
mglL had in 94.3% positive response (p = 0.0716; odds ratio 3.17, 95% CI 0.93-11.2). 
The positive (predicts success) and negative (predicts failure) predictive value of the 
nalidixic acid screening test for gatifloxacin treatment was 100% and 9.3%, 
respectively. 
3.3.2 Section 2. Pharmacokinetics of gatifloxacin in paediatric and adult enteric 
fever patients in Nepal 
3.3.2.1 Patient population and blood samples 
Thirty six patients (aged 3 to 54 years) participated in the PK study and contributed 68 
plasma samples for the population pharmacokinetic analysis. The majority of patients 
(31 [86%] out of 36) contributed at least two samples. Seventeen adult patients 
contributed 31 PK samples and 19 paediatric patients contributed 37 PK samples. The 
median age of the 19 children was 10 years (range 5 to 16) and that of the 17 adult 
patients was 23 years (range 17 to 54 years), respectively. The following co-variables 
were analysed: age, sex, weight, height, body surface area (BSA), and serum creatinine 
concentrations. The demographic characteristics of the 36 patients are shown in Table 
3-2. 
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Variable Population N Mean (SD) Median Range 
Adults 17 27.4 (10.6) 23.0 17.0 - 54.0 
Age (years) 
Children 19 10.5 (3.01) 10.0 5.0 - 16.0 
Adults 17 56.6 (9.28) 53.0 44.0 -72.0 
Weight (kg) 
Children 19 26.9 (8.87) 25.0 15.0 - 50.0 
Adults 17 1.61 (0.152) 1.58 1.36 - 1.87 
BSA (m2) 
Children 19 0.999 (0.212) 0.955 0.665 -1.53 
CLer Adults
a 17 67.1 (12.2) 69.4 46.2 -93.0 
(mLlminll.73m2) Childrenb 19 79.6 (11.8) 79.8 56.7 -104 
n number of patients 
acalculated using the method of Cocker oft and Gault (Cockcroft and Gault, 1976) 
b calculated using the Schwartz equation (Schwartz et al., 1976) 
Table 3-2 Demographic characteristics of the adult and paediatric 
pharmacokinetic analysis population 
3.3.2.2 Pharmacokinetic analysis and population pharmakokinetic model 
Gatifloxacin pharmacokinetics was best fit by a linear one compartment model with 
first order absorption and elimination. Fits of data were excellent (R2 > 0.9 for 
paediatric and adult data); the inter-individual variability in pharmacokinetics was 
modest. None of the gatifloxacin concentrations were deemed to be significant outliers. 
Standard diagnostic goodness-of-fit and weighted residual plots were employed to 
establish whether the pharmacokinetic model was adequate for describing the data. 
Figure 3.4 shows the goodness-of-fit plots for the observed versus the individual fitted 
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gatifloxacin concentrations for the final adult (Panel A) and paediatric population 
(Panel B) PK model, respectively. Panels C and D are the plots of individual weighted 
residuals versus individual fitted gatifloxacin concentrations for the final adult and 
paediatric population PK models, respectively. 
Figure 3.5 shows a scatter plot of gatifloxacin concentrations (Ilg/ml) measured in 
blood versus the time since the previous dose was administered for adult and paediatric 
patients, respectively. Gatifloxacin steady state concentrations measured at 3 hours after 
the previous dose ranged from 4.5 Ilg/ml to 8.9 Ilg/ml in children and from 5 Ilg/ml to 
9.8 Ilg/ml in adults, respectively. 
Table 3-3 presents the final population pharmacokinetic parameter estimates for the 
adult and paediatric data. Given the relatively small size of the datasets and the 
sparseness of the sampling scheme, the precision of parameter estimates was 
acceptable. 
We compared the gatifloxacin PK parameter estimates between the previous PK 
models, developed from North American patients/subjects and those resulting from the 
application of this model to Nepalese patients with enteric fever (Table 3-4). Compared 
to the North American children with otitis media (Rubino et at., 2007), the Nepalese 
paediatric enteric fever patients had approximately 50% slower clearance (Table 3-4). 
The distributions of age and body surface area (BSA) were similar between the North 
American and Nepalese paediatric populations, but the Nepalese population had higher 
serum creatinine values, suggesting comparatively lower renal function (Figure 3.6). 
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Figure 3.4 Goodness-of-fit plots. 
Goodness-of-fit plots for the observed versus the individual fitted gatifloxacin 
concentrations for the final adult (Panel A) and paediatric popUlation (Panel B) PK 
model, respectively. Panels C and 0 are the plots of individual weighted residuals 
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versus individual fitted gatiflo acin concentrations fo r the final adult and paediatric 
population PK model re p cti ely. 
-
10 
..J • E 9 
""'" 
-. Age Group tl.O 
u 
E 8 • • Adult 
-c: 7 .t 0 • • Peds 
.-.., 
n:s 6 s... 
.., 
-
c: 5 cu 
u 
-c: 4 0 
u 
c: 3 
u 
• 
III 
n:s 2 -.-• 
.. 
x 
0 
~ 1 .., 
n:s (!) 0 
0 6 12 18 24 30 
Time Since last Dose (hr) 
Figure 3.5 Scatter plot of gatifloxacin concentrations versus time since the last 
do e tratified by population. 
Adult patient (r d quar ) ar d fin d a age above 16 years, 
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Adult Population PK Model- Pediatric Population PK Modelb 
Population Mean Magnitude of Interindividual Population Mean Magnitude of Interindividual Variability (%CV) Variability (%CV) 
Parameter Final %SEM Final %SEM Final %SEM Final %SEM Estimate Estimate Estimate Estimate 
Ka (llhr) 3.34 116 38.5 135 0.982 43.8 28.4 485 
Vc/F (L/kg) 1.28 17.7 4.57 493 1.21 13.8 6.33 119 
CUF, non-renal (Llhr) 2.91 21.9 72.3 57.4 
CUF, renal slopec 0.0629 (L/hr/mLimin) 
CUF(Uhr/m2) 4.42 5.65 15.0 101 
SDsl 0.250 17.2 0.229 41.7 
aMinimum value of the objective function = 6.34; bMinimum value ofthe objective function = -6.50; cThis parameter was not fit due to the 
narrow range of renal function in this population; Ka absorption rate constant; VelF central volume of distribution; CUF apparent oral clearance; 
SDsl standard deviation of the slope 
Table 3-3 Final PK parameter estimates and associated standard errors for the adult and paediatric population PK models 
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Patient Mean (%SEM) parameter estimates 
population PK parameter 
Previous models Current data 
CLiF (Llhlm2) 8.46 (3.50) 4.41 (5.65) 
Paediatric Vc (L/kg) 2.15 (3.30) 1.21(13.8) 
CLIF, nonrenal (LIh) 8.11(35.3) 2.91 (21.9) 
CLlF, renal-slope 0.0629 (37.8) 0.0629 (---) 
Adult (LlhlmLimin) 
Vc (L/kg) 1.45 (7.9) 1.28 (17.7) 
Vc central volume of distribution; CLiF apparent oral clearance 
Table 3-4 Comparison of gatifloxacin PK parameters. 
Comparison of gatifloxacin PK parameters between previous PK models (developed 
from North American patients/subjects) and the application of this model in the analysis 
of Nepalese patients with enteric fever (current data). 
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Figure 3.6 Box plots of age, serum creatinine (in mgldl) and body surface area 
(BSA) in paediatric patients. 
The data are stratified by population (Nepal = current analysis, US = model 
development population). The line inside the box represents the median, the upper and 
lower limits of the box are the 75th and 25th percentiles, respectively, and the upper 
and lower error bars indicate the values that are 1.5 times the inter-quartile range. 
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Individual points outside the error bars represent values that are > 1.5 times the inter-
quartile range (i.e., outliers). 
3.4 Discussion 
This chapter describes two studies that analyse the pharmacodynamic (section 1 of this 
chapter) and the pharmacokinetic profile (section 2) of gatifloxacin in patients infected 
with S. Typhi and S. Paratyphi A. 
The first study had two objectives, to examine the relationship between gatifloxacin 
exposure and clinical efficacy and to determine the positive and negative predictive 
value of the nalidixic acid screening test for the clinical efficacy of gatifloxacin in the 
same patient population. A relationship between exposure to gatifloxacin and clinical 
response was identified. In patients in whom an AUCO-24: MIC ratio of greater than 92.7 
was attained, 93.5% were classified as clinically cured, while in patients in whom AUC 
0-24: MIC ratios of less than or equal to 92.7 were achieved only 75% of patients had a 
favourable response (Odds Ratio = 4.81,95% CI 1.23 - 18.9; p = 0.02). These findings 
are supported by clinical (Drusano et at., 2004; Forrest et at., 1993) and non-clinical 
studies (Booker et at., 2005). A study in critically ill patients infected with Gram 
negative enteric pathogens and Pseudomonas aeruginosa (Forrest et at., 1993) treated 
with intravenous ciprofloxacin, concluded that achieving an AUCO-24: MIC ratio of 
greater than 125 was associated with improved clinical outcomes. Drusano et al. 
showed that an AUCO-24: MIC ratio of greater than 100 also prevented the emergence of 
bacterial resistance, particularly in the critically ill (Drusano et at., 2004). 
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In a one compartment in vitro phannacodynamic model of gatifloxacin and S. Typhi, a 
fAUCo-24: MIC ratio of 105 correlated with 90% bacterial eradication (Booker et al., 
2005). Importantly, the relationship between exposure and response based on this 
model did not differ for a strain that was gatifloxacin susceptible (MIC 0.5 mg/L) and 
one that was resistant (MIC 4.0 mg/L), despite the latter having two GyrA (Ser83~Tyr; 
Asp87~Gly) and two ParC (Thr 57~Ser; Ser80~Ile) mutations. This observation is 
supported by a neutropenic murine thigh infection model involving Salmonella and 
levofloxacin, where the AUCO-24: MIC ratios necessary for net bacterial stasis or a 90% 
reduction in bacterial burden did not differ by nalidixic acid susceptibility status (Craig 
et al., 2006). 
Patients in whom AUCO-24: MIC ratios greater than 92.7 were attained also tended 
towards a more rapid time (29 hours) to fever resolution (p = 0.08). Administering 
drugs in a manner that leads to clinical improvements, such as fever and symptom 
resolution or the more rapid eradication of faecal pathogens, may have profound public 
health implications. As large epidemics are often related to faecal contamination of 
food and water supplies, decreasing the duration of S. Typhi shedding may limit 
secondary infections «Luxemburger et al., 2001). Perhaps more importantly, it has 
been demonstrated that for fluoroquinolones and other Enterobacteriaceae and P. 
aeruginosa, it is possible to suppress the emergence of resistant subpopulations by 
administering high intensity (e.g. large AUCO-24: MIC ratio) regimens for shorter 
durations (Jumbe et al., 2003). 
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The predictive value of the nalidixic acid screening test for gatifloxacin in patients with 
typhoid fever was poor (p = 1.0). While all patients infected with nalidixic acid 
susceptible strains were treated successfully, so were 90.7% of patients infected with 
nalidixic acid resistant strains. 
This is not true for the older generation fluoroquinolones such as ofloxacin and 
ciprofloxacin for which the nalidixic acid screening test was highly predictive of 
clinical success in the treatment of typhoid fever (Parry, 2004a). This observation has 
important clinical implications, as current CLSI guidelines state that "Fluoroquinolone-
susceptible strains of Salmonella that test resistant to nalidixic acid may be associated 
with clinical failure or delayed response in fluoroquinolone-treated patients with extra-
intestinal Salmonellosis. Extra-intestinal isolates of Salmonella should also be tested for 
resistance to nalidixic acid. For isolates that test susceptible to fluoroquinolones and 
resistant to nalidixic acid, the physician should be informed that the isolate may not be 
eradicated by fluoroquinolone treatment" (CLSI, 2007). As fluoroquinolones are 
associated with higher cure rates and more rapid fever resolution than other agents 
(Parry et al., 2002), these CLSI guidelines may direct clinicians to use other suboptimal 
antimicrobial therapies. 
The explanation for the failure of the nalidixic acid screening test to predict gatifloxacin 
efficacy likely relates to the methoxy group at the 8-position of the quinolone bicyclic 
aromatic core of gatifloxacin. The C-8 methoxy group allows for dual enzymatic 
targeting of DNA gyrase and DNA topoisomerase IV in Escherichia coli, which results 
in a modest MIC increase in DNA gyrase mutants (Lu et al., 1999). This is exemplified 
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by the ratio of median MIC of nalidixic acid susceptible strains to the median MIC of 
resistant strains which was 7-fold for gatifloxacin compared to 27-fold for 
ciprofloxacin. 
This data represent, to our knowledge, the first clinical validation of the importance of 
this structure-activity relationship for Enterobacteriaceae and highlights that not all 
fluoroquinolones are the same. The poorer clinical responses to the older 
fluoroquinolones now reported for enteric fever should not be extrapolated to the latest 
generation of drugs from this class. 
Finally, these clinical data suggest gatifloxacin, and perhaps other 8-methoxy 
fluoroquinolone, specific susceptibility breakpoints. Gatifloxacin MIC values ~ 0.19 
mg/L were associated with 83.8% of patients having a positive clinical response, while 
patients with MIC values less than 0.19 mg/L had a 94.3% positive response (p = 
0.0716). This MIC breakpoint is similar to that derived from the aforementioned in 
vitro PKlPD S. Typhi infection model and Monte Carlo simulation (Booker et al., 
2005). Simulation results suggested susceptible breakpoint of 0.12 mg/L for 
gatifloxacin. Moreover, these data indicate that the nalidixic acid screening test does 
not predict gatifloxacin efficacy. Gatifloxacin attained high favourable clinical response 
rates regardless of nalidixic acid susceptibility or multidrug resistance status. Continued 
use of this screening test to predict gatifloxacin efficacy, and perhaps that of other 8-
methoxy fluoroquinolones, may drive clinical use away from effective treatment 
regimens to less effective regimens. One possible remedy is the use of S. Typhi specific 
susceptibility breakpoints, which to date have not been determined by the CLSI. 
148 
As drug clearance was markedly lower in Nepalese enteric fever patients compared to 
North American infected patients, these data demonstrate the importance of evaluating 
pharmacokinetics in different patient populations. The PK models described in this 
chapter will be used in future pharmacokinetics-pharmacodynamics analyses of efficacy 
in Asian populations with enteric fever. 
149 
Chapter 4 
High throughput genotyping of S. Typhi strains isolated in the Mekong 
Delta region of Vietnam 
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4.1 Introduction 
S. Typhi is a recently evolved and genetically monomorphic organism. S. Typhi is 
exceptional amongst the 2400 serovars of S. enteric a, as it doesn't have a promiscuous 
life style infecting a wide range of animals and has an ecologically adapted niche as a 
human invasive pathogen. This host restriction has been attributed to the acquisition of 
several Salmonella pathogenicity islands (SPIs) and the accumulation of pseudogenes 
(Achtman, 2008; Parkhill et aI., 2001a). 
The S. Typhi genome contains several large insertions, which encode virulence-
associated genes, the Salmonella pathogenicity islands (SPI) (Parkhill et al., 2001a). 
Bacterial pathogenicity islands often exhibit features of mobile genetic elements (Hou, 
1999) and are believed to be acquired through recent horizontal acquisition from other 
bacteria. Features of SPIs include a GC content that differs from that of the rest of the 
bacterial genomes, the presence of flanking direct repeats and insertion elements that 
are reminiscent of those of phages and plasmids and the ability to encode 'mobility 
genes', such as integrases, transposases and origins of plasmid replication (Hou, 1999). 
Often these elements overlap with tRNA genes suggesting that the 3' sites of transfer 
RNAs may serve as recombination site for pathogenicity islands (Hou, 1999). 
Two hundred and four pseudogenes have been described in the genome of S. Typhi 
strain CT 18 (Parkhill et al., 2001a). Most of these pseudogenes have been introduced 
by a single frameshift or stop codon and many of these pseudogenes are found in 
housekeeping genes and genes that are potentially involved in virulence (Parkhill et al., 
200la). 
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As a young and monophyletic organism, S. Typhi shows little DNA sequence variation. 
The analysis of a global collection of 334 S. Typhi isolates by multi locus enzyme 
electrophoresis (MLEE), which tested 24 conserved neutral cytoplasmic enzymes for 
variation in charge identified only two multi locus enzyme genotypes (Selander et al., 
1990). Multi Locus Sequence Typing (MLST) of seven S. Typhi housekeeping genes 
also demonstrated that genetic polymorphisms were rare in S. Typhi (Kidgell et al., 
2002b). Only three polymorphic sites were found when seven genes from a diverse 
collection of 26 S. Typhi isolates were sequenced. It was estimated that the last 
common ancestor of S. Typhi is approximately 50,000 years (Kidgell et at., 2002b). 
For epidemiological purposes to identify genetic relationship of isolates, especially in 
outbreak situations and to trace sources of infection, different typing schemes for S. 
Typhi have been deployed. These include Pulsed Field Gel Electrophoresis (PFGE) 
(Thong et al., 1994; Thong et al., 1995), Variable Number of Tandem Repeat (VNTR) 
analysis (Liu et al., 2003), IS200 typing (Threlfall et al., 1994) and ribotyping 
«Navarro et al., 1996). These typing schemes can identify multiple variants and can 
capture strain variation and properties, especially in outbreak situations. It has been 
shown that differences in PFGE and ribotype patterns of S. Typhi reflect the genomic 
rearrangement of the chromosome through recombination between rRNA loci (Ng et 
al., 1999). Also the modular nature and distribution of prophages can contribute 
significantly to strain variation (Hou, 1999). However, whilst these techniques capture 
variation, there are some disadvantages, as they are difficult to standardise within and in 
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between laboratories and they do not readily provide phylogenetic relationships 
(Achtman, 2008). 
Recently, Roumagnac et al. (Roumagnac et al., 2006) have developed a typing scheme 
based on Single Nucleotide Polymorphisms (SNP) for S. Typhi. Denatured High 
Performance Liquid Chromatography (dHPLC) was performed to analyse the diversity 
of 199 gene fragments of a global collection of 105 S. Typhi isolates. Fifty-five 
polymorphic gene fragments were analysed in an additional 350 isolates, which were 
isolated mostly in Southern Asia. Mutation discovery detected 97 bi-allelic 
Polymorphisms (BiPs). S. Typhi was resolved into a fully parsimonious phylogenetic 
tree defining 85 distinct haplotypes (H I-H85), which developed from a common root 
node, S. Typhi H45 (Figure 4.1) (Achtman, 2008; Roumagnac et al., 2006). 
This study revealed that S. Typhi has a neutral population structure, which is defined by 
the absence of strong selection in housekeeping genes and pathogenicity genes. 
However, on the backbone of this neutral population structure the clonal expansion of 
nalidixic acid (quinolone) resistant S. Typhi haplotype H58 emerged recently in South 
East Asia, presumably due to high antibiotic selective pressure. This clone has become 
the predominant S. Typhi haplotype in Vietnam. S. Typhi haplotype H58 IS more 
closely related to Ty2 than to CT 18 (Figure 4.1) (Roumagnac et al., 2006). 
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Figure 4.1 Minimal spanning tree of lOS global S. Typhi isolates. 
Minimal spanning tr e of 105 global S. Typhi isolates based on sequence 
polymorphisms in 199 gene fragments (88,739 base pairs). From (Rownagnac et ai. , 
2006). The tree shows 59 haplotype (nodes) based on 88 BiPs, the colour coding of the 
pie charts indicate the contin ntal ource of the S. Typhi strains. The numbers along 
some edges indicate th numb r of BiP) that eparate the nodes that they connect; 
unlabeled edges reflect ingl BiP . The g nome of the CT18 and Ty2 strains have 
been fully sequenced. z66 refer to a flagellar variant that i common in Indonesia. 
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Very recently, new technologies that allow high throughput parallel sequencing (454 
pyrosequencing technology, Roche Diagnostics and Solexa sequencing, Illumina) and 
high throughput genotyping (GoldenGate genotyping assay, Illumina) have been 
developed and have vastly increased the pace at which large datasets of genomic 
infonnation can be obtained and analysed (Fan et at., 2006). 
Nineteen S. Typhi isolates from central and radial haplotype groups of this phylogenetic 
tree (Figure 4.1) were chosen for whole genome sequencing using a combination of 454 
pyrosequencing (Roche Diagnostics) and Solexa sequencing (Illumina) (Holt et al., 
2008). Repetitive sequences (including Variable Number of Tandem Repeats, VNTRs) 
were excluded from the analysis. In total 1964 SNPs were identified in the S. Typhi 
genome. The SNPs traced the same phylogenetic tree as defined by Roumagnac 
(Roumagnac et al., 2006), but provided better resolution, especially of the H58 and H59 
haplotypes (Holt et al., 2008) (Figure 4.2). The study revealed that pseudogene 
formation has occurred independently in different lineages of S. Typhi and is ongoing. 
This supports the hypothesis that evolution in this human restricted pathogen is 
dominated by loss of gene function (Holt et al., 2008). Reduction in genome size and 
accumulation of large numbers of pseudo genes have been described as mechanisms of 
host restriction in other pathogens, including Yersinia pestis (Parkhill et al., 2001b) and 
Mycobacterium leprae (Vissa and Brennan, 2001). 
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Figure 4.2 Phylogenetic tree of S. Typhi based on SNP data from whole-genome 
equencing of 19 S. Typhi isolates. 
From (Holt el aI. , 200 ). Branch colour indicate different lineages of S. Typhi; branch 
lengths are mea ured in numb r of P (cale a indicated). Central small black circle 
indicates the ance tral root da h d lin r pre ent the Salmonella lineag . phage (ST) 
and SPIl5 insertion e nt ar hown along branche ; plasmid detected in each isolate 
are indicated by filled cir I (In HIl multidrug re i tance plasmid ), op n circles 
lin ar pIa mid carrying z66 flag lla variant). 
In this chapter we u d a Iden at (llIumina) a ay to type 1500 single nucleotid 
polymorphism ( and analy th g n tic ariation of S. Typhi i olated from 264 
typhoid fever pati ot during a rand mi d multic nter treatment trial (reported in 
Chapter 2) conduct d in th M k ng d Ita region of ietnam betwe n 2004 and 2005. 
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Nearly all S. Typhi isolates from these patients were resistant to nalidixic acid (96%) 
and 58% were multidrug resistant (Chapter 2). 
The incidence of typhoid fever has declined in Vietnam. Whilst between 1991 and 2001 
approximately 17,000 cases of typhoid fever (blood culture confirmed and syndromic 
cases) were reported annually through the Vietnamese national surveillance system 
(Kelly-Hope et al., 2007; Kelly-Hope et al., 2008), only 4,323 and 5,030 annual 
typhoid fever cases were reported in 2004 and 2005, respectively (Source: National 
Institute of Health and Epidemiology, Ministry of Health, Vietnam). However, 75% of 
these cases occurred in the Mekong delta (Kelly-Hope et al., 2007; Kelly-Hope et al., 
2008). 
4.2 Methods 
4.2.1 S. Typhi isolates 
s. Typhi isolates were collected during a multicenter clinical trial (described in Chapter 
2), conducted at the (a) the Hospital for Tropical Diseases in Ho Chi Minh City (n=IO), 
(b) Dong Thap Provincial Hospital, Cao Lanh, Dong Thap province (n=25) and (c) An 
Giang Provincial Hospital, Long Xuyen, An Giang province (n=232). Children (above 
6 months) and adults were eligible to be included in the study if they had clinically 
suspected or culture confirmed uncomplicated typhoid fever and if fully informed 
written consent had been obtained. 
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4.2.2 Bacterial isolation and DNA preparation 
After initial isolation, S. Typhi isolates were stored at -70°C in a 20% glycerol solution 
until required for further analysis and DNA extraction. To revive frozen organisms, 
MacConkey and Xylose Lysine Decarboxylase (XLD) agar plates were inoculated from 
the glycerol solution and incubated at 37°C overnight. To ensure correct identification, 
colonies were checked using slide agglutination with serotype specific antiserum (Vi, 
09) and an irrelevant antiserum as a negative control (04) (Murex, Dartford, United 
Kingdom). Two mL of nutrient broth were inoculated with single S. Typhi colonies and 
incubated overnight. Overnight cultures were centrifuged and S. Typhi DNA was 
extracted using Wizard Genomic DNA Purification kit (Promega, USA) as 
recommended by the manufacturer's guidelines. DNA was stored at -20°C and was 
quantified using the Quant-IT PicoGreen dsDNA Reagent and Kit (Invitrogen, UK). S. 
Typhi DNA concentrations were adjusted to 50 ng/mL and 250 ng of DNA were 
pipetted into 96-well plates. Each 96-well plate contained two isolates in duplicate and 
the sequenced S. Typhi isolate CT 18 as control for assay reproducibility. 
4.2.3 Selection of S. Typhi SNPs 
S. Typhi SNPs identified by dHPLC (Roumagnac et al., 2006) and by whole genome 
sequencing of 19 S. Typhi isolates (Holt et al., 2008), were used to design a custom 
GoldenGate assay (Figure 4.3). In total, 1485 chromosomal SNPs, (listed in (Holt et al.; 
Kariuki et al.) and 172 IncHIl plasmid haplotype SNPs (Kariuki et al.; Phan et al., 
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2009) including antibiotic resistance gene sequences were probed in sample S. Typhi 
using the GoldenGate assay. 
4.2.4 High throughput SNP genotyping 
The GoldenGate assay (Illumina) provides high throughput SNP genotyping platform. 
The assay was originally developed for high throughput SNP calling in complex human 
genetic linkage studies and is modified in this study for SNP identification in bacteria. 
The assay generates SNP specific PCR products that are subsequently hybridised to 
beads either on a solid matrix or in solution (Figure 4.3). Three oligonucleotides are 
synthesized for each SNP, two allele specific oligonucleotides that distinguish the SNP, 
and a locus specific sequence just downstream of the SNP. The allele specific and locus 
specific oligonucleotide sequences also contain target sequences for a set of universal 
primers (universal PCR sequences 1-3). Each locus specific oligonucleotide also 
contains a unique sequence (address or "illumicode") which is complementary to 
sequences attached to the 3 f..lM beads. The pooled oligonucleotides are hybridized 
simultaneously to genomic DNA in a single DNA sample per well reaction. Highly 
multiplexed allele specific oligonucleotide hybridization, ligation and extension assays 
are followed by universal PCR amplification, which reduces amplification bias to a 
minimum. The address sequences of the peR amplification products hybridize with its 
cognate sequences on the 3 f..lM beads in the 96-sample Sentrix Array Matrices (SAMs). 
The fluorescence on each bead is quantified. Each address sequence translates to a 
particular SNP locus and the presence of Cy3 and Cy5 indicates the allele. For the 
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GoldenGate array designed in this study it facilitated the interrogation of 1536 custom 
designed SNPs per sample. 
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Figure 4.3 Schematic repre entation of GoldenGate assay workflow 
(GoldenGate, Illumina). 
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enabled by an enzymatic di crimination t p. Modified from www.illumina.com. 
161 
4.2.S Genotype calling 
The raw data provided by the Illumina GoldenGate assay is, for each SNP in each 
sample, a fluorescence signal corresponding to each allele-specific fluorescent-labelled 
probe. Raw data was normalised using the proprietary Illumina BeadStudio software, 
but the mean normalised signal intensities and signal to noise ratios vary among SNPs. 
Thus turning allele-specific signals into genotype calls requires each SNP to be 
analysed individually, across a range of samples. This process is known as genotype 
clustering, and is essentially a two-dimensional clustering problem, where each allele-
specific probe contributes one dimension. Since each SNP needs to be clustered 
individually, manual genotype clustering is extremely time consuming and is 
considered to introduce bias into genotyping results. An automated clustering algorithm 
is implemented in the Illumina software (BeadStudio), but has been optimised for 
clustering genotypes in diploid samples, i.e. where three clusters are expected for each 
locus, corresponding to two homozygous and one heterozygous genotype (AA, BB or 
AB). However for the present study involving haploid bacterial genotyping, we expect 
no heterozygous genotype clusters but some 'no signal' genotype clusters. Illumina 
BeadStudio is proprietary software and unable to be modified, but third-party 
opensource genotype clustering algorithms are available. Among the best performing 
for the Illumina genotyping platform is Illuminus (Teo et al., 2007), whose author Y. 
Teo modified to search for a third 'no signal' cluster centred at the origin rather than a 
heterozygous cluster. This version, referred to hereafter as Illuminus-P, was applied to 
genotype clustering of all GoldenGate data presented in this thesis. 
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4.2.6 Phylogenetic analysis 
Alleles determined by genotype clustering with Illuminus-P as described above were 
analysed as follows. A Perl script was written to extract allele data from subsets of 
high-quality SNPs. The script outputs alignments of concatenated strings of SNP alleles 
in phylip format, suitable for analysis using phylogenetic methods. Chromosomal 
alleles from a global collection of 180 S. Typhi isolates plus 19 sequenced isolates were 
analysed in ModelTest (Posada and Crandall, 1998), a tool to select the best-fit model 
of nucleotide substitution (implemented In FindModel at 
http://www.hiv.lanl.gov/contentisequence/findmodeVfindmodel.html). The analysis 
suggested a general time reversible (GTR) model provided the most appropriate 
phylogenetic model for these data. Phylogenetic analysis was performed using 
maximum likelihood approaches to fit a GTR model, implemented in the software 
program RAxML (Stamatakis et al., 2005). SNP genotyping with the Illumina 
GoldenGate only provides genetic information at the specific assayed loci; in the case 
of chromosomal SNPs, these are mostly loci determined by whole genome comparison 
of 19 S. Typhi strains (Holt et al., 2008). Thus the genotyping analysis essentially 
places each S. Typhi isolate at the appropriate position along branches defining the 
phylogenetic tree of these 19 strains, and branch lengths reflect genetic divergence only 
at the assayed loci. Short branches separating very closely related clusters (e.g. within 
the H58 group) were verified by manually inspecting cluster plots for SNPs that 
differentiated within those clusters. 
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4.2.7 Statistical analysis 
Clinical data were deposited into an electronic database (Epi Info 2003, CDC, Atlanta, 
USA). For comparison of patient characteristics according to infecting S. Typhi 
haplotypes, Kruskal-Wallis tests were used for analysis of continuous variables (age, 
length of stay in hospital, fever clearance time) and X2 tests were used for categorical 
variables (presence of symptoms). Two-tailed p-values are reported; statistical analysis 
was performed using the R package (http://www.r-project.orgl). 
4.2.8 peR amplification and sequencing of gyrA gene in S. Typhi 
Oligonucleotide primers for the amplification of the quinolone resistance determining 
regions in gyrA gene in S. Typhi were as follows (Chau et at., 2007): GYRAlPl 5' 
TGTCCGAG ATGGCCTGAAGC and GYRAlP2 5' 
TACCGTCATAAGTTATCCACG. Predicted PCR amplicon size was 347 bp. PCR 
was performed under the following conditions; 30 cycles of: 92°C for 45 seconds, 45 -
62°C for 45 seconds and extension at 74°C for 1 minute, followed by a final extension 
step at 74°C for 2 minutes. PCR products were purified and directly sequenced using 
the CEQ DTCS - Quick Start Kit (Beckman Coulter, USA) and the CEQ 8000 capillary 
sequencer. The resulting DNA sequence was analyzed using CEQuence Investigator 
CEQ2000XL (Beckman Coulter, USA). All sequences were verified, aligned and 
manipulated using Bioedit software (http://www.mbio.ncsu.edulBioEditlbioedit.html) 
and compared to other gyrA sequences by BLASTn at NCB!. 
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4.2.9 Spatial data collection and analysis 
Patient addresses were recorded at the time of hospital admission. The latitude and 
longitude of the residences of typhoid fever patients (to the hamlet/village level) was 
assigned from the collected address data using 1150,000 scale maps (Source: 
Cartographic Publishing House and VinaREN, Ministry of Natural Resources and 
Environment, Vietnam) and cross-checked using the websites http://www.basao.com.vn 
and http://ciren.gov.vn. 
Location data was analysed using Quantum GIS version 1.4.0 (http://www.qgis.org/). 
Locations were colour coded according to S. Typhi haplotype and clustering of specific 
haplotypes was calculated using the nearest neighbour analysis function. Nearest 
neighbour analysis examines the distances between each point and the closest point to 
it, and then compares these to expected values for a random sample of points from a 
CSR (complete spatial randomness) pattern. Significant clustering was inferred by Z-
score value (standard normal variate) of less than 0; a positive score was interpreted as 
dispersion of locations. 
4.3 Results 
4.3.1 S. Typhi population structure 
A recently developed typing system, which is based on the simultaneous interrogation 
of 1,485 single nucleotide polyrnorphisms (SNPs) distributed in the S. Typhi 
chromosome using a custom Illumina GoldenGate array, was used' to analyse each of 
the S. Typhi isolates. This approach facilitates the unequivocal assignment of isolates to 
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haplotypes, allowing closely related strains to be distinguished phylogenetically based 
on single nucleotide changes (Holt et al., 2010; Kariuki et al., 2010). From the 287 
patients with culture confinned typhoid fever recruited between January 2004 and 
December 2005, 267 S. Typhi were available for SNP typing. This included 264 S. 
Typhi isolated from blood culture at admission (see clinical trial described in Chapter 
2), one relapse S. Typhi isolate and two S. Typhi faecal carriage isolates. A total of 261 
isolates (98%) were of the common H58 haplogroup. The remaining isolates were of 
haplotypes HI (n=3), H45, H50 and H52 (see Figure 4.4 and Table 4-1). 
The H58 S. Typhi isolates displayed variation at 10 SNP loci (detailed in (Holt et al., 
2010», which differentiated seven distinct sub-H58 haplotypes, shown in Figure 4.4. 
However, 242 (93%) of these isolates belonged to just three closely related H58 
haplotypes, designated C, E1 and E2 in Figure 4.4. The genome of S. Typhi strain AG3, 
isolated during the study (March 2004) from a typhoid fever patient living in An Giang 
province, was sequenced previously (Holt et al., 2008). AG3 belongs to the H58-E2 
haplotype, and the SNPs separating E2 from haplotypes Eland C were originally 
identified by analysis of the AG3 genome. Therefore, the ability to differentiate within 
the cluster of 242 S. Typhi isolates was dependant on the inclusion of strain AG3 in the 
initial SNP detection study (Holt et al., 2008). 
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Figure 4.4 Phylogenetic distribution of S. Typhi isolates from the Mekong delta 
region of Vietnam. 
From (Holt et ai., 2011). 
Grey nodes represent control isolates (labelled by isolate code and haplotype group), 
unfilled grey circle indicates tree root (H45 (Roumagnac et ai., 2006)), white nodes 
correspond to non-H58 S. Typhi isolated in this study (labelled with isolate code), black 
nodes show H58 isolates. Inset: Enlargement of the H58 haplogroup; grey nodes 
represent control isolates (lab lled by isolate code or haplotype code), unfilled grey 
circle indicates tree root· coloured circles indicate nodes corresponding to H58 S. Typhi 
isolated in this study, node label are a in the text node colours indicates the haplotype 
of the S. Typhi isolate, nod 1Z indicate the number of isolates on the scale as 
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E03-49S3 
(H59) 
indicated by numbered circles. The tree was rooted using alleles from other Salmonella 
serovars as outgroups. 
All 231 (out of 232) S. Typhi strains isolated from the blood culture of patients 
admitted to An Giang Provincial Hospital as well as the two faecal S. Typhi strains 
isolated from chronic carriers belonged to the S. Typhi H58 haplogroup. The remaining 
S. Typhi isolate was of the H45 haplotype and was isolated from a patient who was 
resident in neighbouring Can Tho province. One patient at An Giang Provincial 
Hospital relapsed with symptoms of typhoid fever and had S. Typhi isolated from blood 
culture 11 days after the initial treatment had been completed. The mother of the patient 
was found to be a chronic S. Typhi carrier. All three S. Typhi strains, the patient's 
admission and relapse blood culture isolates and the mother's faecal isolate belonged to 
the S. H58-E2 subtype. The patients' isolates were both MDR and carried the IncHIl 
ST6 plasmid (see below), whereas the mother's S. Typhi isolate was susceptible to all 
first line antimicrobials at the time of isolation. Patients were followed up at I, 3 and 6 
months to obtain stool samples. Chronic faecal carriage of S. Typhi was detected in 
only one trial patient. This was a MDR H58-C strain isolated from stool after 6 months 
of follow-up, which was indistinguishable in all SNP loci from the patient's original 
blood culture isolate. 
At Dong Thap Provincial Hospital, only 3 of the 25 S. Typhi isolates did not belong to 
the H58 haplogroup. Two H I isolates (8J63 and 8J64) were identical at all assayed 
SNP loci (Figure 4.4) and were isolated on consecutive days from two patients in Dong 
Thap. A third HI strain (8J 105; Figure 4.4) differed from 8J63 and 8J64 at 16 SNP 
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loci and was isolated in Dong Thap 14 months after these isolates. Two siblings (8175 
and 8176) from Dong Thap province were admitted on two consecutive days in 2004 
and were both infected with MDR S. Typhi of the haplotype H58-C. 
B 
N 
t 
200Km 
Figure 4.5 Location of the hospitals in the Mekong delta of Vietnam. 
The map shows the 8 Vietnamese regions. Highlighted in grey is Mekong delta region 
in the south, which covers 40,000 km2. The dotted box corresponds to the area 
magnified in Figure lb. Highlighted in Figure 1 B are An Giang province (green) and 
Dong Thap province (grey) and th provincial hospitals of An Giang province (x) and 
Dong Thap (y). The direct distance between the two hospitals is 22.5 km. 
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ProviDee 
AD Glaaa Doaan.p 80 Cbl Mia. City TotaIlhldy 
S. TypIli IIoIata Total a-232 a-25 .-10 .-267 
CII.raderistia n n n n (% orall isolates) 
H5IlIapiotypes Total 231 22 8 261 {98%} 
Total 95 17 6 118( .... %) 
nopiasmid 17 6 3 26 
H51_C ST6 78 \I 3 92 
MDR 86 12 4 \02 
NaR 9S 17 S 117 
MDR and NaR 86 12 4 102 
Total 12 2 1 15 (6·1e) 
no plasmid 0 0 0 0 
H51_EI ST6 12 2 IS 
MDR 12 2 IS 
NaR 12 2 IS 
MDRandNaR 12 2 IS 
Total 107 1 1 109(41%) 
no plasmid 91 0 I 92 
H51_E2 ST6 16 0 17 
MDR 20 0 21 
NaR 107 1 1 109 
MDRandNaR 20 1 0 21 
Total 17 2 0 19(7%) 
no plasmid 3 0 0 3 
0dMr H51HbIypeI ST6 14 2 0 16 
MDR 14 2 0 16 
NaR 14 2 0 16 
MDR and NaR 14 2 0 16 
N_ H511I • .....",. Total 1- 3- 2" 6(2%) 
no plasmid 1 3 2 6 
ST6 0 0 0 0 
MDR 0 0 0 0 
NaR 0 0 0 0 
MDR and NaR 0 0 0 0 
Table 4-1 S. Typhi haplotypes according to region. 
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S. Typhi haplotypes are listed according to the hospital (An Giang Provincial Hospital, 
An Giang; Dong Thap Provincial Hospital, Dong Thap and the Hospital for Tropical 
Diseases, Ho Chi Minh City) where they were isolated. 
*One S. Typhi H45 haplotype was isolated. &Three S. Typhi HI haplotypes were 
collected. I\One S. Typhi isolate of the H50 and one of the H52 haplotype were 
isolated.NaR nalidixic acid resistance. 
Of the ten S. Typhi strains isolated at the Hospital for Tropical Diseases in Ho Chi 
Minh City, eight were members of the H58 haplogroup, with patients reporting to be 
residents in Ho Chi Minh City (n=5), Long An (n=I), Kien Giang (n=2) and An Giang 
(n=l) provinces, reflecting the larger catchment area of the hospital. The remaining two 
S. Typhi were of haplotypes H52 (B13) and H50 (BJ9) and were isolated from patients 
living in Binh Hoa province (north of Ho Chi Minh City) and Ho Chi Minh City, 
respectively. There was no obvious association between S. Typhi haplotype and patient 
age, length of stay in hospital, fever clearance time or relapse (Table 4-2). However, 
upon admission, patients infected with S. Typhi haplotype H58-E2 tended to report 
lower frequencies of diarrhoea and headache and higher frequencies of constipation 
compared to patients infected with other haplotypes, including H58-C (see Table 4-2). 
171 
s. Typhi Non-H58- S. Typhi H58-E2 vs all other p-value H58-E2 E2 S. Typhi H58-C S. Typhi [95% Cll 
n=107 n=157 n=117 
Age (yrs) 11.9 12.2 12.7 Diff. -0.8 (-2.0,1.0) 0.83 
Time in 
hospital (days) 13.9 13.7 13.8 Diff. 0.2 (-1.0, l.0) 0.74 
Fever 
clearance (hrs) 116 115 121 Diff. 1 (-12,18) 0.70 
Constipation 13.6% 5.8% 6.0% OR2.6(1.1,6.1) 0.03 
Headache 55.7% 70.1% 70.1% OR 0.54 (0.32,0.90) 0.02 
Diarrhoea 55.1% 72.6% 73.5% OR 0.46 (0.28,0.78) 0.004 
Table 4-2 Selected characteristics of 264 typhoid fever patients, based on baseline 
presentation, history and outcomes. 
For continuous variables age, time in hospital and fever clearance, values shown are 
means and test statistic given is the difference in means (Diff.); other variables indicate 
frequency of constipation, headache or diarrhoea self-reported at time of admission, test 
statistic is odds ratio (OR); 95% confidence intervals are given in brackets. All 
comparisons shown are for patients infected with H58-E2 S. Typhi versus those 
infected with other S. Typhi haplotypes (including H58-C and others). 
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4.3.2 Plasmids and antimicrobial resistance 
The GoldenGate SNP assay incorporated probes targeting IncHI I plasmid sequences, 
allowing for detection of the presence of IncHI I plasmid within the S. Typhi genomic 
DNA. The SNP assay indicated that a total of 139 of the S. Typhi isolates harboured an 
IncHIl plasmid. All plasmids were of the IncHIl ST6 sequence type (Phan et al., 2009) 
and all plasmid-bearing isolates belonged to the S. Typhi H58 haplogroup (see Table 4-
I). The MDR IncHIl plasmid was more common among H58-C isolates than H58-E2 
isolates (86% vs 19%, see Table 4-1). Of the 139 S. Typhi isolates giving positive 
signals for IncHIl SNP loci, 137 (99%) were classified as MDR by antimicrobial 
susceptibility testing conducted at the time of isolation (see Chapter 2). One other 
IncHIl-positive isolate tested positive by GoldenGate SNP typing for the genes sull, 
sul2, dfrA7, tetACDR, strAB, bla and cat, like the MDR isolates, yet had low MICs for 
chloramphenicol, ampicillin and co-trimoxazole. An additional S. Typhi isolate, BJ5, 
was resistant to ampicillin and co-trimoxazole but sensitive to chloramphenicol. This 
was consistent with GoldenGate results, which gave positive signals for the repC 
replication initiation gene of IncH II , resistance genes strAB, bla, sull, sul2, dfrA7, but 
no signal for sequences from the cat gene which encodes chloramphenicol resistance. A 
further 17 S. Typhi isolates were recorded as MDR according to their antimicrobial 
susceptibility pattern at the time of isolation, but did not test positive for IncHIl 
plasmid SNPs. This likely reflects loss of the IncH I I plasmid during culture or in 
storage between the time of isolation and DNA extraction. 
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A total of 257 S. Typhi isolates were resistant to nalidixic acid. All of these isolates 
belonged to the H58 haplogroup and all were susceptible to gatifloxacin, ciprofloxacin 
and ofloxacin according to current CLSI guidelines (Clinical and Laboratory Standards 
Institute, 2007). S. Typhi haplotypes H58-C, H58-El and H58-E2 were uniformly 
resistant to nalidixic acid with the exception of a single H58-C isolate which had an 
intermediate MIC of 28 J.lglmL (resistance defined as MIC ~ 32 J.lglmL). The 
sequenced H58-E2 isolate AG3 harbours a mutation changing serine (TCC) to 
phenylalanine (TIC) at codon 83 in the gyrA gene (Holt et al., 2008), which is known 
to confer resistance to nalidixic acid (Hopkins et al., 2005). In the present study we 
sequenced the gyrA gene in 223 of the nalidixic acid resistant isolates (88%) and found 
the GyrA Ser83Phe amino acid substitution in all isolates tested. 
4.3.3 Spatial and temporal distribution 
Figure 4.6 shows the spatial distribution of the residences of 160 of the 267 typhoid 
patients (this information was not available for the remaining patients). At the time of 
the study prospective GPS mapping of patients' residences was not possible, however 
we used patients address data to allocate longitude and latitude. Of the patients admitted 
at An Giang Provincial Hospital and Dong Thap Provincial hospital, sufficient address 
detail to allow for assignment of latitude and longitude was provided in 61 % and 73% 
of cases, respectively. In An Giang, the patients' homes clustered around the An Giang 
Provincial Hospital, but also around the Song H~u branch of the Mekong river (arrow 
in Figure 4.6). Mainly S. Typhi of the H58-E2 haplotype were isolated from patients 
living near this point in An Giang province and this group demonstrated significant 
174 
clustering using nearest neighbour analysis (orange in Figure 4.6; n = 57, Z-score = -
14.145). In contrast, S. Typhi of the H58-C haplotype were isolated relatively 
frequently in neighbouring provinces and had a more sporadic, yet significant, 
clustering pattern (red in Figure 4 .6; n = 31 , Z-score = - 5.747) . 
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Figure 4.6 The spatial distribution of S. Typhi haplotypes surrounding An Giang 
provincial hospital in 2004 (a) and 2005 (b). 
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Each point corresponds to the residential location of a typhoid fever patient and the colour 
represents the haplotype of the S. Typhi isolate (with or without plasmid): dark orange, H58-E2 
with MDR plasmid; light orange, H58-E2 without MDR plasmid; dark red, H58-C with MDR 
plasmid; pink, H58-C with MDR plasmid; grey, other S. Typhi haplotypes. Locations of the 
hospitals are shown by a white cross on a red background. The pink circle corresponds to a 
range of 15 km from An Giang Provincial Hospital. The arrow distinguishes the Song H~u 
branch ofthe Mekong river. 
In 2004, S. Typhi H58-E2 (103 isolates) and H58-C (62 isolates) were both prevalent. 
In 2005, 55 S. Typhi H58-C isolates were observed, but only 4 H58-E2 Typhi. The 
decline of H58-E2 may be associated with selection for the IncHIl MDR plasmid, 
which was much more common in H58-C. As Figure 4.7 highlights, the majority of 
isolates collected during the second season were MDR and carried the IncHIl plasmid 
ST6. 
The temporal distribution of S. Typhi haplotypes over 2004 and 2005 is shown in 
Figure 4.7. Typhoid incidence peaked just prior to the onset of the wet season in each 
year (see monthly rainfall, solid line in Figure 4.7). 
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Figure 4.7 Monthly incidence of typhoid fever cases by haplotype 
in An Giang province 
Bar heights indicate the total number of S. Typhi isolated each month during the study, 
according to the scale given on the left-hand y-axis; colours indicate S. Typhi haplotype 
and presence of IncHIl plasmid as given in the legend. Solid black line = total rainfall 
each month recorded in An Giang, dashed line = maximum rainfall occurring in a 24 h 
period during each month in An Giang; scale given on right-hand y-axis. 
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4.4 Discussion 
We used high throughput SNP typing as tool to discriminate the population structure 
and genetic relationship of 267 S. Typhi strains which were isolated during a clinical 
treatment trial between 2004 and 2005 in the Mekong river delta region of Vietnam. 
The S. Typhi population in this study was very homogenous, with the vast majority of 
S. Typhi isolates (n = 261, 98%) belonging to the H58 haplogroup. Furthermore, 242 
(91%) belonged to a single sublineage of S. Typhi H58 (nodes C, EI, E2), 
demonstrating remarkable c10nality in the S. Typhi population in this location over the 
study period. The observed level of clonal dominance is greater than that observed in 
previous haplotyping studies of local S. Typhi populations. 
Among 54 S. Typhi isolates from Jakarta, Indonesia, a total of nine haplotypes were 
detected, with the dominant H59 haplotype accounting for 53% of isolates; the next 
most frequent haplotype was genetically distant from H59 and comprised 24% of 
isolates (Baker et al., 2008). In Kathmandu, Nepal, a collection of S. Typhi isolated 
from children hospitalised with typhoid fever was dominated by the H58-G haplotype 
(66%) but the distant H42 haplotype was also present at a significant frequency (19%) 
(Holt et af.). Among S. Typhi isolated between 2001 and 2008 in Nairobi, Kenya, 87% 
were H58, although two distinct lineages of this haplogroup (nodes B and J) were co-
circulating at high frequencies (>40% each) over the period between 2004 to 2008 
(Kariuki et af.). S. Typhi H58 nodes Band J (concomitant in Nairobi) represent distinct 
lineages, each acquiring unique SNPs since the last common ancestor of H58 (Figure 
4.2). H58 nodes C, Eland E2, which account for 91 % of isolates in this study in 
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Vietnam, are closely related and formed a tight clonal complex differentiated by just 
two SNPs (Figure 4.4). The overall level of clonality of the S. Typhi population 
analysed in this study was unexpectedly high. The clonal complex comprising H58-C, 
H58-El and -E2 was not detected in study populations in Nepal and Kenya where the 
same SNP typing method was used (Holt et at., 2010; Kariuki et at., 2010), suggesting 
it may have arisen locally in Vietnam. 
Despite the genetic homogeneity we observed, the availability of whole-genome 
sequence data for S. Typhi isolate AG3 (Holt et at., 2008), collected during the study, 
allowed us to differentiate closely related organisms within the H58 group. Just two 
SNPs identified in strain AG3 (haplotype H58-E2) subdivided the homogeneous group 
into three nodes (Figure 4.2), of which two, subgroup C and E2 were dominant (> 40% 
of isolates each). Isolates belonging to the H58-C node were present at a constant rate 
during the two years of the study (62 isolates in 2004 and 55 in 2005). However, 
isolates belonging to the H58-E2 node were common during 2004 (103 isolates), yet 
were virtually undetected in 2005 (3 isolates). This change in both haplotype 
distribution and total number of typhoid cases from 2004 to 2005 is striking, and 
suggests an outbreak caused by S. Typhi H58-E2 during 2004. This decline is also 
reflected in hospital data from the An Giang Provincial Hospital, where in 2004 193 
patients were admitted with blood culture confirmed typhoid fever, whereas in 2005 
only 91 patients had S. Typhi isolated from blood culture. 
It was additionally found that H58-C strains had a much stronger association with the 
ST6 IncHIl MDR plasmid than H58-E2 (Table 4-2). It is possible to speculate that the 
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persistence of H58-C strains and the corresponding disappearance of H58-E2 may be 
associated with a competitive phenotypic advantage conferred by the IncH II MDR 
plasmid. However, it is important to remember that node C is a precursor of node E2 
and we can only differentiate E2 from C because we had whole genome sequence data 
for an H58-E2 strain from which to identify SNPs (Holt et at., 2008). Thus the 
population of S. Typhi isolates assigned to node C by our SNP typing assay may be 
more diverse than that assigned to H58-E2. 
We identified two cases of chronic faecal carriage of S. Typhi during the course of the 
study, one in a patient's relative and one in a patient after 6 months of follow-up. This 
underlines the importance of screening procedures to identify carriers and effective 
treatment to eliminate carriage and reduce transmission. The faecal S. Typhi isolates 
were of the dominant H58-E2 and H58-C haplotypes, respectively. In a previous case-
control study performed in the Mekong delta, close contact with a patient with typhoid 
fever was significantly associated with developing the disease compared to hospital 
controls (adjusted odds ratio (OR) = 5.2; 95% CI 1.7-15.9) or community controls 
(adjusted OR = 11.9; 95% CI 2.3-60.7) (Luxemburger et at., 2001). This suggests that 
close contacts and faecal carriers play an important role in the transmission and 
persistence of these haplotypes in the community. 
We were able to collect residential location data from 160 typhoid patients (61 %); these 
provided roughly equal representation of patients infected with S. Typhi H58-C (65%) 
and H58-E2 (62%). Spatial clustering of S. Typhi H58-E2 was evident particularly 
around the Song H~u branch of the Mekong river, while other S. Typhi haplotypes were 
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more broadly distributed. The spatial clustering of H58-E2 S. Typhi further supports an 
outbreak in 2004 caused by these isolates. In contrast, the broader spatial and temporal 
distribution of S. Typhi H58-C during the study suggests it may be well established in 
the community and can persist over longer distances and time periods. 
We also observed that some symptoms of patients infected with H58-E2 S. Typhi 
differed from those infected with other S. Typhi haplotypes (Table 4.2). Infections 
associated with H58-E2 S. Typhi were less likely to be associated with diarrhoea and 
headache compared with other S. Typhi haplotypes (Odds Ratio 0.46; 95% CI 0.28-0.78 
and OR 0.54; 95% CI 0.32-0.9, respectively), but were more commonly associated with 
constipation (OR 2.6; 95% CI 1.1 - 6.1). This suggests there may be some differences 
between H58-E2 and other S. Typhi with respect to the disease phenotype, however 
these were post-hoc analyses, no adjustments were made for multiple comparisons and 
hence these associations should be interpreted with caution. However, if confirmed in 
subsequent prospective studies, it would be of interest to know whether these 
phenotypic characteristic were associated with specific mutations in the H58-E2 clone. 
The two SNPs differentiating the E2 node from Eland C are both synonymous 
mutations (C->T in melA (nt 315); G->A in rbsA (nt 576» and the phage insertions and 
large deletions detected in our earlier analysis of the AG3 strain sequence data were 
also detected in other sequenced H58 isolates (Holt et al., 2008). However, we were 
unable to verify if other single-base insertions or deletions were present, which may 
result in gene inactivation with corresponding phenotypic effects. 
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Patterns of antimicrobial resistance of S. Typhi tend to vary markedly between different 
typhoid endemic regions. In this present work, as in the recent study of Kenyan isolates 
(Kariuki et al., 2010), there were high rates of MDR associated with IncHIl ST6 
plasmids among strains of the S. Typhi H58 haplogroup. This suggests that the presence 
of the plasmid may contribute to the success of the dominant S. Typhi haplotypes, and 
the results of our study corroborate this hypothesis. The S. Typhi H58-E2 SUbtype 
(which was generally not associated with a plasmid) was only transient, while the H58-
C subtype (which was more commonly associated with the IncHIl MDR plasmid) was 
present in 2004 and 2005 in southern Vietnam. In a Kenyan study, almost all isolates of 
the dominant haplotypes carried the MDR plasmid, while the plasmid-free H58-G 
subtype was only detected twice (Kariuki et al., 2010). All the H58 isolates analysed in 
the present study were resistant to nalidixic acid, conferred by an identical mutation in 
gyrA. This is consistent with previous studies reporting strong associations between the 
nalidixic acid resistance phenotype and the H58 haplogroup of S. Typhi (Holt et al., 
2010; Kariuki et al., 2010; Roumagnac et al., 2006). The presence of the same mutation 
conferring nalidixic acid resistance in all isolates of H58-C, -El and -E2 suggests that 
this mutation may have arisen in the common ancestor of this clonal complex, perhaps 
in situ in the Mekong delta region, and its continued presence is likely maintained by 
selective pressure exerted by the administration of fluoroquinolones. 
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Chapter 5 
Safety and Immunogenicity of the Novel Single Oral Dose Live 
Typhoid Vaccine MOIZH09 in Healthy Vietnamese Children 
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5.1 Introduction 
The previous chapters of this thesis have highlighted the problem of antimicrobial drug 
resistance of S. Typhi. In industrialised countries typhoid fever has been essentially 
eliminated. The most potent measures to eliminate typhoid fever are improvements in 
infrastructure and sanitation. 
Typhoid vaccines are another effective strategy to prevent typhoid fever. Whole-cell 
typhoid fever vaccines have been introduced by Almroth E. Wright in England and by 
Richard Pfeiffer in Germany at the end of the 19th century. These vaccines were given 
to soldiers in developing and developed countries and were applied in mass vaccination 
campaigns in several countries in the 1960s (DeRoeck et al., 2008; Engels et al., 1998; 
Tarr et al., 1999). The three year cumulative efficacy of the whole-cell typhoid vaccine 
was 73% for two doses (based on seven trials), however fever after vaccination 
occurred in 15.7% of recipients (Engels et al., 1998). The high rates of adverse events 
necessitated the introduction of new generation vaccines. 
There are currently two licensed, safe typhoid vaccines available, the live oral Ty21a 
vaccine and the parenteral (intramuscular injectable) Vi polysaccharide. The World 
Health Organization recommends that countries should consider the programmatic use 
of these typhoid vaccines for controlling endemic diseases and that the immunization of 
school age and/or pre-school age children should be undertaken particularly in areas 
where antibiotic resistant Salmonella enterica serovar Typhi (s. Typhi) is prevalent 
(World Health Organization, 2008). 
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Ty21 a typhoid vaccine was developed in the 1970s by random chemical mutagenesis of 
the pathogenic S. Typhi strain Ty2. The mutations responsible for its attenuation 
include an inactivation of galE (which encodes UDP-galactose-4-epimerase, involved 
in synthesis of lipopolysaccharide), an inability to express Vi polysaccharide 
presumably through mutation and other mutations that are collectively responsible for 
the stable, highly attenuated phenotype (Germanier and Fuer, 1975; Kopecko et al., 
2009). 
Ty21 a vaccine is available in enteric-coated capsules or liquid formulation. It is 
administered in three doses (four doses in the US and Canada) two days apart and is 
licensed for adults and children above 6 years. Field studies with the oral Ty21 a vaccine 
in the 1980s have shown a protective efficacy between of 96% after 3 years in Egypt 
(Wahdan et al., 1982), 77% in Chile after 3 years when using the liquid formulation 
(Levine et al., 1999) and up to 53% in Indonesia after 2.5 years {Simanjuntak, 1991 
#920. Ty21 a cannot be used in immunocomprised patients and pregnant women, and 
antibiotics should be avoided seven days before and after immunisation. Revaccination 
is recommended every 5 years. 
The parenteral capsular polysaccharide Vi vaccine is given in a single dose (25 J.lg) and 
is licensed for individuals above 2 years. A single intramuscular injection conferred a 
protective efficacy of 77% after 21 months in South Africa {Klugman, 1987 #616}, 
72% after 17 months in Nepal (Acharya et aI., 1987) and 61 % after 2 years in India 
(Sur et al., 2009). Revaccination is recommended every three years. 
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Similar to other T -cell-independent polysaccharide vaccmes, Vi vaccine IS not 
immunogenic in children under 2 years of age and does not induce immunological 
memory. To overcome this limitation, a conjugate Vi vaccine bound to recombinant 
protein Pseudomonas aeruginosa exotoxin A (rEPA) was developed (Szu et al., 1 994). 
Two doses of the conjugate Vi-rEPA vaccine administered 6 weeks apart had a 
protective efficacy of 91.5% in children aged two to five years in Vietnam after 27 
months (Lin et al., 2001), but this vaccine is not yet commercially available. 
The major limitation of the Ty21a vaccine is the need to administer at least 3 doses. 
From a public health perspective, a single dose oral typhoid vaccine would have major 
advantages (Fraser et al., 2007; Levine, 2003). Modem genetic techniques allow the 
construction of oral one dose typhoid vaccines with defined attenuating mutations. 
These next generation typhoid vaccines include S. Typhi strain Ty800 (attenuated by a 
double deletion in the genes phoP and phoQ) (Hohmann et al., 1996), CVD908-htrA 
(attenuated by deletion mutations in aroC, aroD and htrA genes) (Tacket et al., 2000) 
and MOIZH09. 
MOIZH09 (S. Typhi (Ty2 aroC ssaV) ZH9} is a promising defined attenuated typhoid 
vaccine candidate, it has a well-defined dual mechanism of attenuation (Hindle et al., 
2002) and has been safe and immunogenic in a single dose in Western (Hindle et al., 
2002; Kirkpatrick et af., 2005b; Kirkpatrick et al., 2006) and Vietnamese adult 
volunteers (Hien TT, unpublished). 
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Historically, oral live vaccines often showed reduced immunogenicity in developing 
country populations compared to Western populations (Levine, 2006), therefore 
MOIZH09 was evaluated at an early stage of its development in children in an endemic 
country. 
This chapter describes the results of a randomised placebo controlled trial that 
evaluated the safety and immunogenicity of MOIZH09 in 151 healthy Vietnamese 
children aged between 5 and 14 years. 
5.2 Methods 
5.2.1 Study design and objectives 
The study was designed as a randomised placebo controlled single blind trial to 
evaluate the safety and immunogenicity of the novel oral single dose live typhoid 
vaccine MOIZH09 in Vietnamese children aged 5 to 14 years (inclusive). 
5.2.2 The study site and ethical approval 
The trial was conducted at the Hospital for Tropical Diseases in Ho Chi Minh City, 
Vietnam. Ethical approval for the trial and all trial related documents was obtained 
from the Oxford Tropical Research Ethics Committee (OXTREC) and the Institutional 
Review Board of the Ministry of Health, Hanoi, Vietnam. The trial was conducted in 
accordance with the Declaration of Helsinki and its amendments and according to Good 
Clinical Practice guidelines and was monitored by Matrix Contract Research Ltd., UK 
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(now Novella Clinical). The trial was also conducted under an US Investigational New 
Drug (IND) license. Trial registration: www.controlled-trials.comlISRCTN91111837. 
5.2.3 Investigator and sponsor roles 
The trial was sponsored by Emergent Product Development UK Ltd., UK and funded 
by a Strategic Translational Award from the Well come Trust, UK (grant code: 
B9RKYTO). 
The data were subject to a confidentiality agreement between the sponsor and 
investigator, which established full access to the study data. Prior to publication the 
manuscript was reviewed by the sponsor but there was no obligation on behalf of the 
academic authors to modify the publication. The data entry and analysis of data were 
managed by Statwood (now Quanticate), UK, an independent Clinical Research 
Organisation. 
5.2.4 Participants 
Healthy Vietnamese children aged 5 to 14 years (inclusive) were invited to participate 
in the trial. Recruitment was carried out by word of mouth and flyers. Families who 
were interested in the trial were invited to attend one of several information evenings at 
the Hospital for Tropical Diseases. At these meetings the study was presented by the 
principal investigator (TTH) and all questions could be discussed and answered. 
Families who remained interested in the trial were invited to attend the screening visit. 
Children were eligible if they were available during the trial period and at least one of 
their parents gave written informed consent for their child to participate after the trial 
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procedures and potential risks were carefully explained by the study investigators. All 
children were invited to give their assent to the study and written informed assent was 
obtained from subjects starting at the age of 6 years. After informed consent was 
obtained, screening tests were performed. Children were screened by history, physical 
examination (including height, weight and vital signs), blood tests (biochemistry, 
haematology and HIV test), urine dipsticks and pregnancy tests (for female subjects of 
II years and above). Stool cultures were performed to check for the presence of 
Salmonella species. 
Subjects with a history of typhoid fever, Ty21 a vaccination in the last 10 years or any 
other typhoid vaccine in the last 5 years, any clinically significant illness, abnormal 
blood test results, immune suppression, positive HIV or pregnancy test were excluded. 
Also excluded were subjects whose body weight was under 17 kg in the 5 to 10 year 
old group or under 27 kg in the 11 to 14 year old group and subjects who suffered from 
an acute febrile illness at the time of dosing. Only one child per family was allowed to 
participate in the trial. 
The results of the screening tests were reviewed and subjects who continued to meet the 
inclusion criteria were invited to continue in the trial. 
S.2.S The MOIZH09 vaccine and dose 
S. Typhi (Ty2 aroC ssa V) ZH9 was constructed using a rational genetic attenuation 
strategy. Two defined independently attenuating deletion mutations were introduced 
into S. Typhi Ty2. Deletion of aroC, encoding chorismate synthase, prevents the 
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biosynthesis of aromatic amino acids and deprives the live vaccine bacterium of 
essential nutrients. Deletion of ssaV, encoding a structural component of the Salmonella 
pathogenicity island-2 (SPI-2) type III secretion system, which prevents systemic 
spread of S. Typhi (Hindle et al., 2002). The vaccine was manufactured according to 
Good Manufacturing Practice protocols by Eurogentec S.A. and SynCo Bio Partners 
B.V; batch number M-STZH9-FI6 was shipped to Vietnam. The vaccine kits were 
stored at 2-8°C. 
Previous studies in adult volunteers demonstrated that a nominal dose of 5 x 109 CFU of 
the vaccine strain was immunogenic and safe (Hindle et al., 2002; Kirkpatrick et al., 
2005b; Kirkpatrick et af., 2006). The Ty21a oral typhoid vaccine capsules are licensed 
for adults and children above 6 years using the same dose and immunization schedule 
and large Ty21 a field trials in children used the same dose and regimen as in adults 
(Levine et af., 1987). It was therefore determined that the appropriate dose for the 
children's study was a nominal dose of 5 x 109 CFU of S. Typhi (Ty2 aroC ssaV) ZH9. 
The vaccine (containing 5 x 109 CFU of vaccine strain plus excipients) and the placebo 
(vaccine excipients only) were supplied as freeze-dried formulations in single dose 
vials, which were labeled identically, containing "MOIZH09 oral typhoid vaccine or 
placebo" but with a unique subject number corresponding to the randomisation list. The 
bicarbonate solution was prepared by dissolving one effervescent bicarbonate tablet 
(provided in the vaccine kit and containing 2.6 g sodium bicarbonate, 1.65 g ascorbic 
acid and 30 mg aspartame) in 150 ml of bottled drinking water (final concentration: 
1. 75% wtlvol sodium bicarbonate, 1.1 % wtlvol ascorbic acid, and 0.02% wtlvol 
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aspartame). The lyophilised vaccine or placebo was reconstituted in either 150 ml (for 
children above 10 years) or in 75 ml of the bicarbonate solution (the other 75 ml were 
discarded) for children below 10 years and was administered immediately. 
The study used two age group specific randomisation lists, one for the 11 to 14 year old 
and one for the 5 to 10 year old children to ensure at least 70% children were between 5 
to 10 years old. 
5.2.6 Intervention 
On the day of vaccination (day 0) which took place within 28 days of the screening, 
inclusion and exclusion (including history of antibiotic medication in the last 2 weeks) 
criteria were reviewed. Pregnancy tests (female subjects of 11 years and above only), 
urine dipstick test and stool cultures were performed. Blood samples for haematology, 
biochemistry, ELISA and ELlS POT assays (only in children 11 years and above) were 
obtained. After the subjects had fasted for at least 2 hours (with the exception of 
drinking water), the candidate typhoid vaccine or placebo was administered. 
Subjects were allocated the next age-group specific subject number and the medication 
pack bearing the same number was prepared and issued by the pharmacist, who was 
otherwise not involved in the trial. The subjects were randomly assigned to receive 
either MOIZH09, consisting of 5 x 109 CFU of S. Typhi (Ty2 aroC ssaV) ZH9 or the 
placebo reconstituted in bicarbonate solution as described above. 
Volunteers were observed for at least 90 minutes at the hospital. During this time pulse 
and blood pressure were recorded periodically and only drinking water was provided. 
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Diary cards were issued for all the volunteers and all subjects received a basic hygiene 
kit containing soap, gloves and spatulas for the collection of stool samples. The subjects 
and their parents were instructed to measure and record the oral temperature of the 
children twice daily (morning and evening) and to record any adverse events (including 
headache, fever, nausea, vomiting, abdominal pain, frequency and consistency of stools 
and any other symptoms) for 14 days. 
5.2.7 Follow up procedures and monitoring of adverse events 
Children were followed up daily from days 1 to 14 and again on day 28 after dosing. At 
these appointments diary cards were checked and adverse events and concomitant 
medication reviewed. A history of the last 24 hours with special emphasis on 
temperatures of 38.5°C and above and adverse events (diarrhoea, loss of appetite, 
vomiting, headache and chills) was obtained. Oral temperatures and vital signs were 
recorded and children were examined for signs of splenomegaly. Stool cultures were 
performed daily from day 1 to day 14. Blood samples for biochemistry and 
haematology were obtained on days 7, 14 and 28; for the LPS specific serum IgA 
ELISA on days 7 and 14; for the IgG ELISA on days 14 and 28 and for the LPS 
specific IgA antibody secreting cell (ASC) ELISPOT assay (only in subjects aged 11 
years and above) on day 7. The total amount of blood taken during this study was 
approximately 28 ml from the 5 to 10 years old and 44 ml from the 11 to 14 years old 
children. 
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5.2.8 Unscheduled visits 
Subjects and parents were instructed to make additional visits to the clinic, if the child 
felt unwell and/or had a fever of ~38.5°C. At these visits the subject was assessed and 
samples taken for culture as clinically indicated. Blood cultures to investigate for the 
presence of S. Typhi in blood would be obtained if a fever of ~39.0°C was recorded 
twice over a 48 hours period, or a severe fever of~39.5°C was recorded once. 
5.2.9 Definition and reporting of serious adverse events 
There was no Data Safety and Monitoring Committee for this trial. Data from all 
children were reviewed daily and there were a priori defined stopping rules which 
would trigger a suspension of the trial and a safety review. Serious adverse events were 
reported to AKOS Ltd (Hitchin, UK), a pharmacovigilance company within 24 hours. 
5.2.10 Detection of Salmonella in stool samples at the screening visit and day 0 
The detection of Salmonella species at the screening visit and on day 0 was performed 
according to microbiological standard procedures. In brief, stool samples were 
inoculated onto MacConkey agar and xylose lysine deoxycholate (XLD) agar plates, 
and in 10 ml of selenite F broth. Plates and broth were incubated at 37°C overnight and 
the broth was sub-cultured on MacConkey and XLD agar plates the next morning. 
Isolates were screened using standard biochemical tests and Salmonella were identified 
by slide agglutination with specific antisera (Oxoid Ltd., UK) and API20E profiling 
(bioMerieux, UK). 
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5.2.11 Detection of S. Typhi in stool samples 
Stool samples were collected daily between days 1 and 14. Stool samples were cultured 
directly on deoxycholate citrate agar (DCA) Hynes plates (direct method) and in 
selenite F broth (enriched method). Both media were supplemented with aromatic 
compounds (DCA-aro and selenite F-aro, respectively) to detect S. Typhi, including the 
auxotrophic vaccine strain, in stools. Following overnight incubation at 37°C, an 
aliquot of the inoculated selenite F-aro broth was sub-cultured on DCA-aro Hynes 
plates. Suspected S. Typhi colonies were inoculated on brain heart infusion agar plates 
supplemented with aromatic compounds (BHI-aro). Oxidase negative colonies were 
evaluated by agglutination with Hd, Vi and 09 anti-sera (Oxoid Ltd., UK) and API20E 
profiling (bioMerieux, UK). Stool samples containing isolates that were positive in at 
least 2 out of 3 agglutinations and identified as S. Typhi by API20E profiling were 
considered to be positive for S. Typhi. All isolates were stored in 10% (v/v) glycerol at 
-80°C. 
5.2.12 Detection of S. Typhi in blood samples 
Blood samples were collected into either Bactec Peds Plus/F culture bottles (1-3 ml 
blood; BD, USA) or Bactec Plus Aerobic/F culture bottles (4-10 ml blood; BD, USA) 
and supplemented with aromatic compounds. Blood cultures were incubated at 35°C in 
the Bactec detection system and monitored for up to 5 days. Gram stain was perfonned 
on all bottles triggering a positive reaction. Positive cultures and all cultures that were 
negative after 5 days of incubation were sub-cultured on XLD agar plates. Suspected S. 
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Typhi colonies were sub-cultured onto BHI-aro agar plates. Oxidase negative isolates 
were evaluated by agglutination and API20E profiling (bioMerieux, UK) as above. 
5.2.13 peR identification of S. Typhi isolates 
Genomic DNA was isolated from glycerol stocks of S. Typhi isolates using a DNeasy 
blood and tissue kit (Qiagen, UK). Multiplex PCRs were performed using a Taq PCR 
core kit (Qiagen, UK). Each reaction mixture contained 200 f..1M dNTPs, 0.4 f..1M ssaV4 
(5' ATCCCCACGACTTCAGCAAG 3') and ssaV7 (5' 
CTTTCTGGCTCATCATGAGG 3'), and 0.1 f..1M aroC.Zl (5' 
GACAACTCTTTCGCGTAACC 3') and aroC.Z3 (5' TTACATCCGCATTCTGTGCC 
3'), 10 ng genomic DNA and 1.25 u Taq DNA polymerase in a total volume of 50 f..11 
reaction buffer. PCRs were performed for 25 cycles as follows: 94°C for 30 sec, 57°C 
for 30 sec and 72°C for 2.5 min. The PCR products were visualised by ethidium 
bromide staining and UV transillumination after electrophoresis on a 0.8% (w/v) TAE 
agarose gel. The expected sizes of the PCR products were 1.04 kb (aroC) and 2.59 kb 
(ssaV) for S. Typhi wild-type strains and 0.45 kb (aroC) and 0.70 kb (ssaV) for S. Typhi 
(Ty2 aroC ssaV) ZH9. 
5.2.14 Detection of antibody secreting cells producing S. Typhi LPS specific IgA 
antibodies by ELlS POT assay 
ELISPOT assays to detect antibody secreting cells (ACS) producing S. Typhi LPS 
specific IgA antibodies were performed on days 0 and 7 as described previously 
(Kirkpatrick et ai., 2005a; Kirkpatrick et ai., 2006). In brief, whole blood was collected in 
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heparinised cell preparation tubes (Vacutainer CPT; BD, UK) and centrifuged. 
Peripheral blood mononuclear cells (PBMCs) were washed, resuspended in culture 
medium and adjusted to three cell concentrations (I x 107/ml, 5 x 106/ml and 2.5 x 
106/ml). One hundred microlitres of each concentration were added to LPS coated and 
uncoated wells (for subtraction of non-specific results) of nitrocellulose microtiter 
plates (Millipore, USA) and incubated overnight at 37°C in a 5% C02 incubator. 
PBMC collected from a healthy volunteer who had received three doses of Ty21a 
(Vivotif, Bema, Switzerland) were included as positive control and PBMC from a non-
vaccinated person as negative control. Plates were washed and an alkaline phosphatase-
conjugated anti-human IgA antibody (Immune Systems Ltd., UK) was added and 
incubated for one hour. Plates were washed and spots were visualised by the addition of 
5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIPINBT) substrate. 
Antibody secreting cell (ASC) spots were counted manually using an inverted 
microscope. If more than 100 spots per well were present, the result was described as 
"too many spots to be counted". A positive response in the ELISPOT assay on day 7 
was defined as ~ 4 IgA ASC specific for LPS per 106 PBMCs and a negative response 
as < 4 IgA ASC specific for LPS per 106 PBMCs. Subjects with a day 0 result of ~ 4 
ASC per 106 PBMC were excluded from the ELlS POT analysis. ELiSPOT assays were 
performed at the Hospital for Tropical Diseases. 
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5.2.15 Analysis of S. Typhi LPS specific serum IgG and IgA by ELISA and 
definition of a positive immune response 
Quantitative ELISA methods for measuring S. Typhi LPS specific serum IgG and IgA 
were developed and qualified by Emergent Product Development UK Ltd using serum 
samples from recipients of MOIZH09 who participated in prior clinical trials and who 
had given informed consent for retention and usage of their samples. For the IgG 
ELISA, serum which demonstrated more than 4-fold increase from pre-dose in a 
previously described end point titre assay (Kirkpatrick et al., 2005b) were pooled and 
used as reference standard. The LPS specific IgG concentration in the standard serum 
was set arbitrarily at 30,000 units/ml. For the IgA ELISA, serum from past recipients of 
MOIZH09 who demonstrated positive response in IgA ELISPOT were pooled and used 
as reference standard. The LPS specific IgA concentration in the standard serum was 
set arbitrarily at 100 units/ml. 
The standard error of measured sample means and the least significant difference (LSD) 
between two samples at the I % significance level were calculated using PRISM 
(PRISM Training & Consultancy Ltd, UK). This was used as the cut-off value for a 
positive result in the respective assay. A positive serum IgG response was defined as a 
70% increase (fold change of 1.7) as compared to the corresponding baseline sample, 
whereas a positive serum 19A response was defined as a 50% increase (fold change of 
1.5) as compared to baseline. 
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Serum samples for measurement were frozen at -20°C and shipped to Emergent Product 
Development UK Ltd for the ELISA analyses. For the IgG ELISA, microtiter plates 
were coated with s. Typhi LPS, washed and then blocked. Washing occurred between 
each step. Calibration standards and diluted test samples were added, and the plates 
were incubated. Bound IgG was detected using an anti-human IgG antibody conjugated 
to horseradish peroxidise (HRP) (Dako, Denmark) followed by the addition of 
3,3',5,5'-Tetramethylbenzidine (TMB) substrate. The plates were read at 450 nm within 
30 minutes of stopping the reactions with 0.3 mollL sulphuric acid. The standard curve 
was constructed by plotting the optical densities (ODs) of standards against 
concentrations and fitted by a 4-parameter logistic equation (SoftMax Pro 4.6, 
Molecular Devices, USA). The concentration of LPS specific IgG in each sample was 
determined from the standard curve. The 19A quantitative ELISA was performed in a 
similar manner, except using a double detection system of biotinylated anti-human IgA 
antibody (Southern Biotech, USA) followed by streptavidin-HRP conjugate (Dako, 
Denmark). 
5.2.16 Outcomes of the study 
5.2.16.1 Safety Outcomes 
The primary safety endpoint was the proportion of subjects with any adverse events 
attributed to MOIZH09. The secondary safety endpoint was the proportion of subjects 
with any serious related adverse events; any related or unrelated adverse events; 
persisting faecal shedding of S. Typhi (Ty2 aroC ssaV") ZH9 after day 7; and/or had a 
fever of 38.5°C or greater in the 14 days post vaccination, withdrew from the trial due 
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to adverse events, including bacteraemia, and/or had clinically significant changes in 
laboratory parameters related to the candidate vaccine. 
All subjects who received a dose of the vaccine or placebo were analysed in the safety 
population. Post-vaccination adverse events were categorised according to body 
system and preferred term using the Medical Dictionary for Regulatory Activities 
(MedORA, Version 9.1), allocated before unblinding. Adverse events were graded by 
severity (mild, moderate, severe) and judged for the relatedness to the study vaccine 
(unlikely, possibly, probably) by the investigator. Only possibly and probably related 
adverse events were attributed to the vaccine. Moderate fever was defined as an oral 
temperature of~ 38.5°C and severe fever as an oral temperature of~ 39.5°C. Moderate 
diarrhoea was defined as more than 4 unformed stools and severe diarrhoea as more 
than 6 unformed stools in a 24 hour period or evidence of significant dehydration. All 
adverse events were recorded in the CRFs and monitored until return to normal. 
The numbers and proportion of subjects reporting adverse events were listed by body 
system. A per subject analysis of adverse events was performed e.g., if a subject 
reported the same adverse event on three occasions that adverse event was only counted 
once. Subjects reporting more than one adverse event per body system were counted 
only once in that body system total. 
5.2.16.21mmunogenicity Outcomes 
The primary immunogenicity endpoint was the proportion of subjects who developed a 
positive immune response to S. Typhi LPS defined by an increase of 70% (1.7 fold 
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change) in LPS specific serum IgG on day 14 or 28 and/or an increase of 50% (1.5 fold 
change) in LPS specific serum IgA on day 7 or 14 compared to baseline. 
The secondary immunogenicity endpoints were defined as the proportion of subjects 
who developed a positive immune response in each of the following assessments: S. 
Typhi LPS specific IgA ELISA assay on days 7 or 14, S. Typhi LPS specific IgG 
ELISA assay on days 14 or 28 and S. Typhi LPS specific IgA ELISPOT on day 7. A 
positive ELISPOT was defined as ~ 4 IgA antibody secreting cells specific for S. Typhi 
LPS per 106 PBMCs. 
5.2.17 Sample Size 
The planned sample size was 150 subjects, of whom at least 70% should be aged 10 
years or younger, as this was the target age of the vaccine, randomised to MOIZH09 or 
placebo in a 2: I ratio. 
No formal sample size calculation was considered appropriate; it was aimed to include 
a sufficient sample size to assess safety and immunogenicity based on previous 
observations in adult studies and immunogenicity rates of licensed typhoid vaccines in 
children. 
5.2.18 Randomisation procedures 
Randomisation codes were computer generated in blocks of 9 by Statwood Ltd, UK. 
The vaccine and the placebo were labeled identically but with a unique subject number 
corresponding to the randomisation list. The study used two age group specific 
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randomisation lists, one for the 11 to 14 year old and one for the 5 to 10 year old 
children to ensure at least 70% children were between 5 to 10 years old. 
Subjects were allocated the next age-group specific subject number in strict numerical 
sequence from this list and the medication pack bearing the same number was prepared 
by the pharmacist. 
5.2.19 Blinding 
This study was formally a single blind study due to slight differences in taste and aroma 
between the treatment preparations but it was conducted under the principles of a 
double blind study. MOlZH09 and placebo were packaged and labeled identically but 
with a unique sequential number. Possible sources of unblinding could have been the 
preparation of the vaccine. Therefore the study pharmacist was otherwise not involved 
in the trial. The subjects were asked to not report the taste of the vaccine. Microbiology 
results were not reviewed by the investigators for at least 14 days after vaccination to 
avoid potential unblinding through shedding in stools. Immunology results were not 
reviewed by the investigators. The study site received code break envelopes in case an 
emergency made unblinding for a single subject necessary. No codes were broken 
during this study. The unblinding of treatment allocations took place after the trial had 
been completed and the whole database had been entered and locked. 
5.2.20 Data collection, data entry and statistical methods 
All data were recorded in Case Record Forms (CRFs). CRFs were reviewed and 
collected by the study monitor. Data entry, data management and statistical analysis 
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were conducted by Statwood, UK using SAS software (version 9.1). Data were double 
entered and analysed according to an a priori defined statistical analysis plan which 
included the definition of all subject populations and the trial endpoints. The safety 
population included all subjects who received the study medication. The intention to 
treat (ITT) population comprised all dosed subjects who had any post-dose 
immunogenicity data available. The per protocol (PP) population excluded major 
protocol violators (failure to meet the inclusion/exclusion criteria, to comply with the 
study medication or use of other vaccinations or antibiotics two weeks before until 2 
weeks after vaccination, or use of antacids or proton-pump inhibitors prior to 
vaccination and/or did not provide samples for the ELISAs). The protocol stated that a 
confirmatory analysis of the primary immunogenicity endpoint in the PP population 
was planned if more than 5% of subjects were excluded. 
The proportion of subjects who experienced post-dose adverse events was presented 
together with their two-sided 95% confidence intervals (95% CI). Post dose adverse 
events, adverse events considered to be related to the vaccine and adverse events that 
occurred in more than 10% of the trial population were tested using a two-sided 
Fisher's exact test to compare between the two groups. 
The proportion of subjects who developed a positive immune response was presented 
together with their two-sided 95% CI calculated by using an exact binomial 
distribution. The treatment difference and associated 95% CI were presented as above. 
All available data from withdrawn subjects was included in the analysis. 
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5.3 Results 
5.3.1 Participant flow and recruitment 
The trial was conducted between April and July 2007. In total, 205 healthy Vietnamese 
children between 5 and 14 years (inclusive) were screened for eligibility. Fifty-four 
children were not eligible (Figure 5.1), the most common reasons were unavailability 
for the whole study period (n = 10) and a positive stool culture for Salmonella species 
at screening (non-typhoid Salmonella, n = 22). No S. Typhi or S. Paratyphi A were 
detected in stools at the screening visits. 
One hundred and fifty-one children were randomised, 101 children received the 
candidate typhoid vaccine MOIZH09 and 50 children received placebo. All subjects 
fulfilled the inclusion and exclusion criteria at screening and dosing, however two 
subjects (both in the MOIZH09 group) had clinically significant elevated white blood 
counts (16.3 and 18.2 x 109fL respectively) on day 0, these results were only available 
after dosing. 
One subject in the MOIZH09 group vomited after taking approximately 50% of the 
required vaccine dose. The subject agreed to take another dose, but failed to retain it. 
Three subjects withdrew from the study, one placebo recipient withdrew due to non-
compliance (refused to provide stool samples) after day 2 and two vaccine recipients 
left the study after day 6 (one wished to withdraw, the second subject went on holiday). 
All three subjects attended the day 28 visit. The remaining subjects attended all study 
visits. Two subjects had unscheduled visits. One subject in the vaccine group attended 
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the clinic on day 16 because of fever of 38.1 °C and one subject in the placebo group 
returned on day 26 with a temperature of 38.0°C. Blood cultures were obtained from 
both subjects and both cultures were negative. One MOIZH09 recipient had 
unscheduled tests performed. The subject presented on day 10 with a temperature of 
38.6°C and reported diarrhoea, vomiting and fever on the previous day. The white 
blood count was elevated with 14.2 x 109/L and the blood culture result was negative. 
5.3.2 Numbers analysed 
All 151 children who were randomised and received either MOIZH09 (n=101) or 
placebo (n=50) constituted the intention to treat (ITT) population. Seven subjects, 4 in 
the vaccine group and 3 in the placebo group were protocol violators (see Figure 5.1) 
and were excluded from the per protocol (PP) population. The analysis of the primary 
endpoints in the PP population was planned if more than 5% of subjects were excluded 
from the ITT. The PP population comprised 95% (144/151) of subjects and therefore no 
per protocol analysis was conducted. 
All outcomes were evaluated for the ITT population. 
5.3.3 Baseline data 
The two groups did not differ significantly at enrolment in terms of sex, age and 
laboratory parameters (Table 5-1). One hundred and seven (71 %) children were aged 10 
years or younger. 
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Two subjects in the MO 1 ZH09 group had clinically significant elevated white blood 
counts on day 0 (see above). Twelve subjects in total, five in the placebo group and 
seven in the MOIZH09 group (this included the subject who vomited on the day of 
dosing) had a positive stool culture for non-typhoid Salmonella on day 0, these results 
were only available after dosing. 
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Healthy VIetnamese children aged S to 14 years (inclusive) were screened for eligibility, 
n =205 
Not eligible, n = 54 
Age under S years, n = 1 
Fever on day 0, n = 1 
Body weight below 27 kg (11-14 year 
old), n = 2 
'Mthdrawal !\"om the study, n = 4 ~ Abnonnallaboratory result, n = 6 
No stooIeampie provided, n = 8 
Not available for the duration of the 
atudy,n=10 
Stool sample positive for any S. species 
at screening. n :I: 22 
I 1 S1 children randomi_d I 
~---------- ________ -L 
101 children a88lgned to M01 ZH09 SO children assigned to placebo 
101 children received M01 ZH09 SO children received placebo 
1 Subject did not take the required dose 1 Subject withdraw after day 2 
of M01ZH09 
2 Subjects took antibiotics between day 
2 Subject8 withdrew after day 6 -14 and day 14 
1 Subjects took antibiotiCS between day 1 Subject had one unscheduled vlait on 
-14 and day 14 day 26 becauae of fever 
1 Subjects had one unecheduled visit on 
day 16 because of fever 
1 Subject had unacheduled blood teata 
on day 10 becau. of fever 
An 101 subjects attended the day 28 visit All SO aubjecta attended the day 28 visit 
An 101 IUbjects analysed in the ITT All 50 subjects analy8ed in the ITT 
analyais analysis 
Figure 5.1 Flow of patients 
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M01ZH09 group Placebo group Overall 
Characteristics (n = 101) (n = 50) (n = 151) 
Age in years 
Number of children under 10 years (%) 
Number of males (%) 
Weight in kilograms 
Height in cm 
Oral temperature in °C 
Haemoglobin, gldl· 
White cell count, 109/L /\ 
Lymphocytes, %/\ 
Neutrophils, %/\ 
Monocytes, %" 
8asophiles, %" 
Eosinophiles, %" 
Platelet count, 109/L & 
AST, U/L 
ALT, U/L 
Creatinine, mMlL 
Stool culture positive for Salmonella sp. 
9 (5-14) 
109 (75.2) 
54 (53) 
28 (17-53) 
132 (97-165) 
36.80 (36.1-37.5) 
13.3 (10.5-15.3) 
7.2 ( 5-18.2) 
39.6 (14.9-55.5) 
48.6 (29.2-70) 
5.3 (2.3-12.3) 
0.3 (0-0.7) 
4.0 (0.1-18.4) 
295 (190-503) 
27 (14-52) 
16 (6-58) 
0.47 (0.33-0.70) 
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9 (5-14) 
101 (71.1) 
27 (54) 
26.5 (17-66) 
130.50 (100-165) 
36.75 (35.1-37.4) 
13.4 (10.9-15.5) 
8.0 (4.9-10.7) 
39.9 (21.4-67.4) 
50.5 (19.5-73.8) 
5.0 (1.4-13.2) 
0.3 (0-0.7) 
3.0 (0.4-15.2) 
311 (190-467) 
26 (14-51) 
17 (5-43) 
0.47 (0.27-0.73) 
5 
Table 5-1 Baseline characteristics of the subjects on day 0 
(Intention to Treat popUlation). 
9 (5-14) 
56 (80) 
81 (54) 
27 (17-66) 
132 (97-165) 
36.80 (35.1-37.5) 
13.3 (10.5-15.5) 
7.4 (4.9-18.2) 
39.7 (14.9-67.4) 
49.9 (19.5-73.8) 
5.2 (1.4-13.2) 
0.3 (0-0.7) 
3.8 (0.1-18.4) 
300 (190-503) 
27 (14-52) 
16 (5-58) 
0.47 (0.27-0.73) 
12 
All data are presented as median (range) unless otherwise specified. Data from one·, two" and seven& subjects not available. 
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5.3.4 Protocol deviations 
The protocol stated that the primary safety endpoint would be the proportion of subjects 
reporting serious adverse events attributed to MOIZH09. Due to concerns that these 
numbers might be small and would not be sufficient to detect a difference in safety 
between the two groups, the primary endpoint was changed to the proportion of 
subjects with any related adverse event. This change was made after the completion of 
the clinical phase but prior to database lock and unblinding. 
5.3.5 Outcomes and estimation 
5.3.5.1 Safety Outcomes 
There were no serious adverse events, no bacteraemia and none of the subjects 
withdrew due to adverse events in this trial. 
Similar proportion of subjects reported adverse events in both treatment groups during 
the 28 days of follow up, but the total number of events was higher in the MOIZH09 
group. In the vaccine group, 26 (26%; 95% CI 18-35%) of 101 subjects reported 64 
adverse events compared to 11 (22%; 95% CI 12-36%) of 50 subjects in the placebo 
group who reported 17 adverse events (odds ratio (OR) = 1.23,95% CI 0.550-2.747; P 
= 0.691) (Table 5-2). Repeated occurrences of a particular adverse event in the same 
subject were included in the total number of 64 and 17 adverse events, respectively. Of 
the 64 adverse events reported by MOIZH09 recipients, 55 were mild (8 of these were 
considered to be related to the candidate vaccine), 8 moderate (one related) and one was 
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severe and related to MOIZH09 (Table 5-2). Of the 17 adverse events in the placebo 
group, 12 were mild, 5 moderate and none was related. 
Four (4%) MOIZH09 recipients experienced 10 adverse events that were related to the 
candidate vaccine compared to none in the placebo group (p = 0.302). Of these, 8 were 
mild, one moderate (diarrhoea) and one event of pyrexia was severe. The moderate and 
the severe related adverse events occurred in the same subject. This subject had a 
normal temperature on day 0, but the pre-dose blood test showed an elevated white 
blood cell count (16.3 x 109/L). The subject experienced five post vaccination adverse 
events occurring on day 0, including fever of 38.5 and 39.0°C, diarrhoea, headache, 
abdominal pain and anorexia. The subject received paracetamol and recovered. 
Similar proportions of subjects experienced fever post vaccination (Table 5-2), only one 
subject reported fever related to MOIZH09 (see above). 
Adverse events classified as gastrointestinal disorders, nervous system disorders and 
investigations were experienced by a higher proportion of MOIZH09 recipients (Table 
5-2). Twelve (12%) vaccine recipients experienced gastrointestinal disorders compared 
to 1 (2%) placebo recipient (p = 0.061). Nervous system disorders (headache) occurred 
in 9 (9%) vaccine recipients compared to 1 (2%) placebo recipient (p = 0.166) and 
investigations were reported by 4 (4%) vaccine recipients compared to none of the 
placebo recipients (p = 0.302). Cough was the most frequently reported adverse event, 
occurring in 6 (6%) MOIZH09 recipients versus 7 (14%) placebo recipients (p = 0.124). 
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On day 1 after vaccination, faecal shedding of S. Typhi occurred in 47 (49%) of 95 
vaccine recipients; shedding was detected by the direct method in 11 (12%) subjects 
and by the enriched method of culturing stools in 36 (38%) subjects. On day 2 after 
vaccination, faecal shedding was detected in 12 (12%) of97 subjects (in 1 (1%) subject 
by direct and in 11 (11%) subjects by enriched method). Only one (1%) of98 subjects 
experienced shedding on Day 3 (detected by enrichment method). In total, 51 (51 %; 
95% CI 41-61 %) of 100 MOIZH09 subjects experienced shedding on either days 1,2 or 
3 and no subjects experienced shedding on day 4 after vaccination or later. 
The presence of S. Typhi was detected in the stools of I (2%; 95% CI 0-11 %) of 50 
subjects in the placebo group. This occurred on day 2 and was detected using the 
enriched method. No fever or adverse events were recorded for this subject. The finding 
of a positive stool culture for S. Typhi in a placebo subject was only available after 
unblinding of the trial. All previous and all sequential stool cultures up to day 14 of this 
subject were negative. This isolate was identified as the vaccine strain S. Typhi (Ty2 
aroC ssaV) ZH9 by subsequent PCR analysis. 
Seven (7%) of 101 MOIZH09 recipients and 3 (6%) of 50 placebo recipients were 
detected to have a positive stool culture for non-typhoid Salmonella between day 1 and 
14 after vaccination. 
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Event MOIZH09 (n=lOl} Placebo (n=50} 
Number Percent Number Percent 
of of 
subjects (95% CI) subjects (95% CI) 
Any adverse event 26 26 (18-35) 11 22 (12-36) 
Gastrointestinal disorders (%) 12 12 (6-20) 1 2 (0-11) 
related to vaccine 3 3 0 0 
Abdominal pain (%) 8 8 0 0 
related to vaccine 2 2 0 0 
Constipation (%) 2 2 0 0 
Diarrhoea 5 5 1 2 
related to vaccine 3 3 0 0 
Nausea 3 3 0 0 
related to vaccine 1 1 0 0 
Vomiting 3 3 0 0 
General disorders and administration 
site conditions 
9 9 (4-16) 5 10 (3-22) 
Chills 2 
Fatigue 0 0 2 4 
Pyrexia 8 8 3 6 
related to vaccine and severe· 1 1 0 0 
Infections and infestations 1 1 (0-5) 0 0(0-7) 
Viral infection 1 0 0 
Investigations 4 4 (1-10) 0 0(0-7) 
Urine colour abnormal 2 2 0 0 
White blood cell count increased 2 2 0 0 
Metabolism and nutrition disorders 3 3 (1-8) 0 0(0-7) 
Anorexia 1 1 0 0 
related to vaccine 1 1 0 0 
Decreased appetite 2 2 0 0 
Nervous system disorders 9 9 (4-16) 1 2 (0-11) 
Headache 9 9 2 
related to vaccine 2 2 0 0 
Respiratory, thoracic and mediastinal 6 6 (2-12) 7 14 (6-27) 
disorders 
Cough 6 6 7 14 
Rhinorrhoea 1 0 0 
Skin and subcutaneous tissue disorders 1 1 (0-5) 1 2 (0-11) 
Rash 1 1 2 
Vascular disorders 1 1 (0-5) 0 0(0-7) 
Hypertension 1 1 0 0 
Table 5-2 Incidence of adverse events after vaccination during 28 days of follow up 
(Intention to Treat population) 
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Per-subject analysis of adverse events (unlikely, possibly and probably related to the vaccine) 
reported during 28 days of follow up. Subjects could experience more than one adverse event. 
Each adverse event was only counted once for each subject and system class. There were 56 
adverse events in the MOIZH09 group and 16 in the placebo group, when repeated occurrences 
of a particular event in the same patient were only counted once. Adverse events that were 
possibly or probably related to the vaccine are presented in italic. * One severe adverse event 
was reported. 
5.3.5.2 Immunogenicity Outcomes 
Ninety-eight (97%; 95% CI, 92-99%) of 101 subjects in the MOIZH09 group and 8 
(16.0%; 95% CI, 7-29%) of 50 subjects in the placebo group developed a positive 
immune response in either the S. Typhi LPS specific serum IgO or IgA ELISA, defined 
as the primary endpoint (Table 3). The difference in proportions of responders between 
the vaccine group and the placebo group was 81.0% (95% CI; 68-89%), the lower limit 
of the 95% CI of this difference was greater than 50% and fulfilled the a priori defined 
criterion for an acceptable immune response. 
Median baseline LPS specific antibody levels were comparable in both groups (Figure 
5.2). In the MOIZH09 group, median IgA antibody levels increased from 3 (IQR; 3-7.2) 
units/ml at baseline to 94 (lQR; 19.8-231.5) units/ml and 103 (lQR; 23.9-253.5) 
units/ml on days 7 and 14 respectively. On day 7, the 88 immune responders in the 
vaccine group (Table 5-3) displayed a median 16.4 (lQR 3.75-60.25) fold rise in serum 
IgA antibodies relative to baseline (Table 5-4). 
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In the vaccine group, median LPS specific IgO antibody levels were 66650 (IQR; 
31075-123900) units/ml and 55700 (IQR; 25450-106800) units/ml on day 14 and 28, 
respectively, compared to median baseline levels of 6300 (IQR 3620-16560) units/ml. 
On day 14, the 91 immune responders in the MOIZH09 group (Table 5-3) showed a 
median 8.18 (IQR; 3.57-20.68) fold increase in serum IgO antibodies relative to 
baseline. 
Forty-two out of 44 eligible subjects provided samples for the ELlS POT assay on day 
7. All baseline ELISPOT samples were negative (defined as < 4 ASC per 106 PBMC). 
On day 7, 28 (100%) of 28 MOIZH09 subjects who provided samples showed a 
positive ELISPOT response compared to none (0%) of the 14 evaluable subjects in the 
placebo group. Sixteen (57%) of 28 MO lZH09 recipients displayed results of > 100 
spots per 106 PBMC and among the remaining 12 vaccine subjects numbers of spots 
ranged from 8 to 128 per 106 PBMC. The median number of spots in the MOIZH09 
recipients was > 100 (IQR 46.5-> 1 00) spots per 106 PBMC, as counting stopped above 
100 spots, this was recorded as " too many spots to be counted". All 14 placebo 
recipients showed < 4 spots per 106 PBMC, this was recorded as "too few spots to be 
counted." 
There was strong correlation between the results of the IgA ELISA and the IgA 
ELISPOT assays on day 7. Twenty-eight (100%) of 28 MOIZH09 recipients showed a 
positive immune response and 14 (100%) of 14 placebo recipients showed a negative 
response in both assays. 
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MOIZH09 group n=101 Placebo group n=50 
Positive Immune Positive Immune 
reponse reponse 
No. No. (%) 95%CI No. No. (%) 95%CI 
Detected in IgA ELISA assay 
Day 7 99 88 (89) 81-94 49 1 (2) 0-11 
Day 14 99 92 (93) 86-97 49 1 (2) 0-11 
Day 7 or day 14 99 94 (95) 89-98 49 2 (4) 1-14 
Detected in IgG ELISA assay 
Day 14 99 91 (92) 85-97 49 6 (12) 5-25 
Day 28 101 90 (89) 81-94 50 6 (12) 5-24 
Day 14 or 28 101 93 (92) 85-97 50 8 (16) 7-29 
Detected in either IgA or IgG ELISA assay 
Day 7,14 or 28 101 98 (97) 92-99 50 8 (16) 7-29 
Detected in IgA ELlS POT 
Da!7 28 28 {100} 88-100 14 o {O} 0-23 
Table 5-3 Proportions of responders to the candidate typhoid vaccine MOIZH09 
(Intention to Treat population). 
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No., number of subjects who provided samples. 
A positive immune response in the ELISA assay was defined by an increase of 50% (1.5 fold 
change) in LPS specific serum 19A and/or an increase of 70% (1.7 fold change) in LPS specific 
serum IgG compared to baseline. 
*44 subjects aged 11 years and above (29 subjects in the MOlZH09 group and 15 subjects in 
the placebo group) were eligible for the EllS POT . 
A positive EllS POT result was defined as ~ 4 IgA antibody secreting cells specific for S. Typhi 
6 
LPS per 10 PBMCs. None of the subjects had a positive day 0 ELISPOT result. 
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Day 
MOIZH09 group 
n=101 
Median 
units/ml 
IQR 
Serum IgA antibody levels specific for LPS 
Day 0 
Day 7 
Day 14 
3 
94" 
103" 
3-7.2 
19.8-231.5 
23.9-253.5 
Serum IgG antibody levels specific for LPS 
Day 0 6300 3620-16560 
Day 14 66650" 31075-123900 
Day 28 55700 25450-106800 
Data from one* and two" subjects missing. 
IQR interquartile range 
Placebo group 
n=50 
Median 
units/ml 
4 
3.1 * 
3.4* 
6925 
7680* 
8175 
IQR 
3-7.9 
3-7.4 
3-7.4 
3950-10762.5 
4170-11500 
4402.5-12437.5 
Table 5-4 Serum IgA and IgG antibody levels specific for S. Typhi LPS (Intention 
to Treat population) 
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Figure 5.2 Time course of LPS specific serum IgA and IgG antibody levels. 
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Time course of LPS specific serum IgA (A) and IgG (B) antibody levels, according to 
vaccination groups (Intention to Treat population). 
Box and whisker plots showing the distribution of antibodies according to time point 
and vaccination groups. The horizontal line within each box represents the median, the 
top and bottom of each box represents the 75th and 25th percentiles, respectively, and 
the I bar represents the highest and lowest values within 1.5 times the interquartile 
range. Circles show outliers. 
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5.4 Discussion 
This is the first evaluation of a novel oral typhoid vaccine in school children in an 
endemic country. S. Typhi (Ty2 aroC ssaV) ZH9 (contained in MOIZH09) is 
characterised by two well defined deletion mutations, one in an aromatic amino acid 
biosynthesis pathway gene and the other in a functional gene of the SPI-2 type III 
secretion system (Hindle et al., 2002). A single dose of 5 x 109 CFU of the vaccine 
strain was well tolerated and had an acceptable safety profile. There were no serious 
adverse events, no withdrawals due to adverse events and none of the subjects 
experienced bacteraemia. 
In general, adverse events were mild. Similar proportions of subjects, 26% (26 of 101) 
in the candidate vaccine group and 22% (11 of 50) in the placebo group reported 
adverse events during the 28 day follow up period (p = 0.691). The overall number of 
adverse events tended to be higher in the MOIZH09 group, especially those classified 
as gastrointestinal disorders, nervous system disorders and investigations. 
There was one severe related adverse event in this trial, a high fever of 39.0°C which 
occurred on day 0 after vaccination in a subject who had a pre-dose elevated white 
blood count (18.2 x 109fL) and might have suffered from an underlying infection. One 
other subject vomited after drinking approximately half of the vaccine dose, this subject 
was found to have a positive stool culture for non-typhoid Salmonella on day O. 
S. Typhi was isolated from the stools of one placebo recipient on day 2 after 
vaccination which was later identified as S. Typhi (Ty2 aroC SSG V) ZH9 by PCR 
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analysis. The previous stool cultures and all following stool cultures of this subject up 
to day 14 were negative. After a thorough check, which included the randomisation 
codes and vaccination paperwork, the possibility that the subject received MO lZH09 by 
error was excluded. The subject also did not display any positive results in the 
immunogenicity assays. It was concluded that the most likely cause for isolating S. 
Typhi (Ty2 aroC ssa V) ZH9 in the stools of a placebo recipient was the mislabelling 
or mismatch of stool samples. 
The candidate vaccine elicited a positive immune response in 97% (98/10 1) of the 
MOIZH09 recipients by ELISA and in 100% (28/28) of MOIZH09 recipients who were 
evaluable by ELISPOT assay. In conclusion MOIZH09 was safe and immunogenic in 
Vietnamese children. 
The observed safety and immunogenicity profile of the candidate typhoid vaccine in 
children compares favourably to that seen in Western adult volunteers. MOIZH09 has 
been tested so far up to a nominal dose level of 5 x 109 CFU in nine UK volunteers 
(Hindle et af., 2002) and 80 US volunteers (Kirkpatrick et al., 2005b; Kirkpatrick et af., 
2006). Immunogenicity results from previously published MOIZH09 trials used a 4 fold 
or higher increase in LPS specific IgG antibody levels as definition of a positive 
immune response in the endpoint titre ELISA and seroconversion rates were 50% (8/16 
subjects) (Kirkpatrick et af., 2006) and 77.4% (24/31 subjects) (Kirkpatrick et a/., 
2005b). In this study, allowing for these different cut-offs, the magnitude of the 
immune response seen in the children was approximately 30 fold and 10 fold increase 
of median levels of LPS specific IgA and IgG antibodies, respectively. Furthermore. the 
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median number of ASCs producing LPS specific IgA antibodies, a measure for priming 
of the mucosal immune system, was greater than 100 per 106 PBMC in this trial, this 
compares favourably to an arithmetic mean of 118 ASC/l06 PBMC seen in a previous 
MOIZH09 trial in adults (Kirkpatrick et al., 2006) and a geometric mean of 119 
ASC/l06 PBMC (producing IgA and IgG) seen in American volunteers who received 4 
doses of the licensed Ty21 a typhoid vaccine at a dose of 2-6 x 109 CFU (Kantele et al., 
1998). 
This is encouraging as one major concern for the development of many oral vaccines 
has been their reduced immunogenicity when tested in developing country populations 
compared to Western volunteers (Dougan et al., 2002; Levine, 2006). For oral vaccines 
a brisk colonisation of the intestine is necessary to become immunogenic, it might be 
possible that drug resistant commensals, bacterial overgrowth, enteric viruses or 
helminths interfere with the colonisation of the new vaccine (Levine and Campbell, 
2004). In this study, 51% (511100) of vaccine recipients shed S. Typhi (Ty2 aroC ssaV 
) ZH9 in stools after vaccination, one subject excreted the vaccine strain on day 3, but 
no shedding was observed on day 4 and beyond. In Western adult volunteers shedding 
of S. Typhi in stools was reported for slightly longer durations and ranged from 1 to 6 
days and 1 to 7 days in a small number of volunteers, respectively (Hindle et aI., 2002; 
Kirkpatrick et al., 2005b). 
Typhoid fever is still a major health problem in developing countries, with high 
incidence (Crump et al., 2004; Ochiai et al., 2008) and high rates of antimicrobial drug 
resistance, especially in Asia (Chau et al., 2007; Ochiai et al., 2008). The WHO 
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recommends the immunisations of school and preschool children in endemic areas, 
especially where drug resistant typhoid fever is prevalent as well as in epidemic 
situations (World Health Organization, 2006, 2008). MOIZH09 is a promising novel 
oral one dose typhoid vaccine and large trials are necessary to evaluate vaccine 
efficacy. If protection from typhoid fever is demonstrated, MOIZH09 may facilitate 
large vaccination campaigns due to its simpler logistic and broader acceptance from 
children. 
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Chapter 6 
Conclusions 
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This thesis aims to evaluate different aspects of typhoid fever and to provide better 
understanding of this disease. This chapter will summarise key findings from the thesis 
and point at future avenues of research. 
Chapter 2 decribed a randomised clinical trial conducted in the Mekong Delta in 
Vietnam that compared gatifloxacin to azithromycin for the treatment of multi drug and 
nalidixic acid resistant typhoid fever. Two hundred and eighty-seven patients, both 
adults and children, with blood culture confirmed typhoid fever were enrolled, 145 
were treated with gatifloxacin and 142 patients with azithromycin. Both antibiotics 
showed an excellent efficacy and safety profile. The median FCT was 106 hours in both 
arms and overall treatment failure (defined as any of the following: persistence of fever 
till day 10, need for re-treatment, blood culture positive on day 7, development of 
complications, relapse or faecal carriage) occurred in approximately 9% of patients in 
both arms (13/145 patients in the gatifloxacin group and 13/140 patients in the 
azithromycin group, respectively). Ninety-six percent (254/263) of the S. Typhi isolates 
were resistant to nalidixic acid and 58% (153/263) were multidrug resistant. 
This trial was part of a series of clinical trials to evaluate the antibiotic regimen 
recommended for the treatment of typhoid fever by the WHO (World Health 
Organization, 2003). Particular attention was paid to the design of these trials, to 
respond to criticism made by the authors of a recent Cochrane review (Thaver et 01., 
2008). Typically clinical trials in typhoid fever have been small, outcomes have been 
defined at the discretion of the investigators, length of follow up varied, and they have 
often not included children, although this is the age group predominantly affected by 
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the disease (Thaver et al., 2008). The trial presented in this thesis and subsequent work 
(not included here) aimed to address these reasonable criticisms by designing large 
clinical trials using a standardised trial design with adequate sample sizes that include 
all age groups to facilitate subsequent meta-analyses. 
Blood culture, the gold standard for the diagnosis of typhoid fever is estimated to have 
only 40% to 60% sensitivity (World Health Organization, 2003; Parry et al., 2002). 
Therefore, a large proportion of patients in typhoid trials is blood culture negative for S. 
Typhi and only diagnosed clinically (World Health Organization, 2003), until now 
these patients have been excluded from the analysis. The trial described in Chapter 2 
reported an a priori defined "intention to treat" analysis including blood culture 
negative patients, as well as the "per protocol" analysis of those patients with blood 
culture confirmed typhoid fever. In my view this has addressed some of the criticisms 
from the Cochrane review (Thaver et al., 2008) and has helped establishing standard 
methods for the design of clinical trials in typhoid fever. 
These excellent results for gatifloxacin seen in this trial are supported by two 
subsequent trials conducted in Kathmandu, Nepal (Arjyal et al., 2011; Pandit et al., 
2007). In total, these two trials enrolled 265 patients with culture confirmed typhoid 
fever who were treated with gatifloxacin (Arjyal et al., 2011; Pandit et al., 2007), both 
trials also monitored daily blood glucose levels. There were no clinically relevant 
dysglycaemias in these young patients. 
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Gatifloxacin has also been used for the treatment of pulmonary tuberculosis. A 
randomised controlled trial evaluating gatifloxacin-containing short-course (4 months) 
regimen against standard regimen for the treatment of pulmonary tuberculosis has been 
conducted in 5 African countries (Benin, Guinea, Kenya, Senegal and South Africa) 
between 2005 and 2011 (Olliaro P., 2011). A total of 1836 patients have been recruited 
in this trial, 917 were randomised to the gatifloxacin arm. The incidence rates of 
dysglycaemic events were similar in the gatifloxacin and control arms (Olliaro P., 
2011). 
As outlined in the discussion of Chapter 2, gatifloxacin was withdrawn from the US 
and Canadian market following a report of increased risk of dysglycaemia in elderly 
Canadians (Park-Wyllie et al., 2006). A group of investigators including myself has 
recently submitted an application to WHO to include gatifloxacin in the Essential 
Medicines List (EML) for the indications typhoid fever and tuberculosis (Olliaro P., 
2011). Unfortunately, this has been rejected by the WHO committee in April 2011 on 
the basis, that there were alternative therapeutic options available. We are in the process 
of challenging the decision from the WHO committee and discussing options to try and 
ensure gatifloxacin remains available for specific populations and indications. 
There is clearly a different risklbenefit ratio of gatifloxacin in different populations. 
Whilst there have been side effects of hypo- and hyperglycaemia in multimorbid elderly 
patients, possibly because of age-related decreases in renal function (Ambrose et af., 
2003), these side effects have not been seen in young and otherwise healthy patients. 
We have few drugs available for the treatment of multi drug and nalidixic acid resistant 
226 
typhoid fever. The third generation cephalosporins are no real alternatives, as 
intravenous ceftriaxone shows slow fever clearance and clinical response (average FCT 
of one week) (Parry et al., 2002), and a clinical trial using oral cefixime had to be 
stopped early by the Data and Safety Monitoring Board due to poor performance 
(Pandit et al., 2007). 
From the evidence of these studies in predominantely young and otherwise healthy 
patients gatifloxacin is effective, safe and affordable. It would be a shame if 
gatifloxacin were not available for the treatment of typhoid fever and tubercolosis in 
young people due to adverse events in a different patient population, i.e.elderly multi-
morbid Canadians. Weare running out of antibiotics, we should be careful before we 
discard effective and safe drugs. 
A lot of thought and effort has been put into the development of protocols and the 
design of case record forms (CRFs) during these studies. These resources will be made 
available for other researchers on www.enterics.org, which will be linked with the e-
research hub, accessible via http://ght.globalhealthehub.orgl. 
The WHO guidelines (World Health Organization, 2003) which still recommend 
cefixime for the treatment of multi drug and nalidixic acid resistant S. Typhi, urgently 
need to be updated on the basis of clinical evidence. The Oxford University Clinical 
Research Unit Vietnam is involved in producing up-to-date guidelines in collaboration 
with the Coalition Against Typhoid. 
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Chapter 3 described the pharmacodynamic analysis of the gatifloxacin arm of the trial 
presented in Chapter 2. A dichotomous categorical breakpoint for AUCO.24: MIC ratio 
was identified. Patients in whom an AUCO-24: MIC ratio of greater than 92.7 was 
obtained, had a favourable response to treatment in 93.5%, whilst in patients with 
AUCO-24: MIC ratios ~ 92.7 only 75% had a favourable response. A borderline 
significant dichotomous categorical gatifloxacin MIC breakpoint for S. Typhi, 
predictive for clinical response, could be identified. S. Typhi gatifloxacin MIC values ~ 
0.19 mg/L were associated with 83.8% of patients having a positive clinical response, 
while patients with gatifloxacin MIC values less than 0.19 mg/L had in 94.3% positive 
response. In gatifloxacin treated patients infected with nalidixic acid susceptible (n=6) 
and nalidixic acid resistant (n=118) organisms, clinical success rates were 100% and 
91 %, respectively. Thus, based on the nalidixic acid screening test, nalidixic acid 
susceptibility predicts success 100% of the time (n=6/6), whereas nalidixic acid 
resistance predicts failure only 9.3% of the time (n=l 111 18). Therefore the nalidixic 
acid screening test is not suited to predict gatifloxacin failure. 
There has been criticism that the CLSI fluoroquinolone breakpoints for Salmonella 
were too generous. The MIC breakpoints for ciprofloxacin against extraintestinal 
Salmonella have been recently revised by CLSI and these new breakpoints will be 
published in 2012. In June 2011 the gatifloxacin breakpoints will be reviewed. The data 
presented in Chapter 3 has been made available to CLSI. 
Chapter 4 described the population structure of the S. Typhi strains isolated during the 
clinical trial. The S. Typhi isolates were very homogenous, the vast majority of S. Typhi 
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(n = 261, 98%) in the Mekong delta region belonged to the H58 haplogroup, which 
expanded and persisted under antibiotic pressure. 
Chapter 5 looked at novel and improved typhoid vaccines and described the safety and 
immunogenicity trial of a novel oral one dose typhoid vaccine in healthy Vietnames 
children. 
The adverse events were generally mild and the vaccme showed acceptable 
immunogenicity in these children. The next step would require an efficacy trial in an 
endemic region, however these trials are prohibitively expensive, at an estimated cost of 
1 Million US per 1000 subjects. Therefore the next phase for the MOIZH09 vaccine is a 
typhoid challenge study that is currently being performed at Oxford University, UK 
(Principal Investigator Professor Andrew Pollard). 
This thesis has addressed clinical issues, in particular aiming to establish a standard 
design for randomised clinical trials in typhoid fever and the use of pharmacokinetic 
and pharmacodynamic parameters, a better understanding of the population structure of 
S. Typhi in a region of high transmission and the assessment of a one dose oral typhoid 
vaccine. 
In 2011, it is the tenth anniversary of the publication of the genome sequence of S. 
Typhi CTI8, isolated in Vietnam (Parkhill et at., 200Ia). A lot has been accomplished 
in the last decade since this seminal publication, but much still remains to be done. 
We need to define the best treatment strategies and ensure we design trials in a way that 
permits more informative meta-analyses. There has been renewed interest in the 
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development of new vaccines for typhoid and paratyphoid fever and also for non-Typhi 
Salmonella. Although there are great challenges to the development of these vaccines, 
it should be possible. Perhaps a greater question is whether these vaccines can be fully 
developed and made available to low income countries. 
It is possible to consider the elimination or even eradication of typhoid fever. To do this 
a multidisciplinary approach would be required, including appropriate treatment of 
patients with effective antibiotics that cure the patient and also prevent secondary 
transmission and chronic carriage, the use of appropriate vaccines and the improvement 
of the infrastructure in low-income countries. 
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Lancet Infect Dis. 2011 Jun;1I(6):445-54. Epub 2011 Apr 29. 
2. Gatifloxacin for treating enteric fever. Submission to the 18th Expert Committee 
on the Selection and Use of Essential Medicines (2010). P. L. Olliaro, C. Do1ecek, 
J. Farrar, B. Basnyat, T. T. Hien, J. Horton, P. Gamer, P. G. Ambrose, N. 1. White, 
K. Fielding, C. Merle, C.Sismanidis. 
http://www.who.int/selection_medicines/committees/expertlI8/applications/Cochra 
ne_ Gatifloxacin.pdf 
3. Temporal fluctuation of multidrug resistant salmonella typhi haplotypes in the 
mekong river delta region of Vietnam. Holt KEA, Dolecek CA, Chau TT, Duy PT, 
La TT, Hoang NV, Nga TV, Campbell JI, Manh BH, Vinh Chau NV, Hien TT, 
Farrar J, Dougan G, Baker S. PLoS Negl Trop Dis. 2011 Jan 4;5(1):e929. AThese 
authors contributed equally. 
4. The burden and characteristics of enteric fever at a healthcare facility in a densely 
populated area of Kathmandu. Karkey A, Arjyal A, Anders KL, Boni MF, Dongol 
S, Koirala S, My PV, Nga TV, Clements AC, Holt KE, Duy PT, Day IN, Campbell 
11, Dougan G, Dolecek C, Farrar J, Basnyat B, Baker S. PLoS One. 2010 Nov 
15;5(11):e13988. 
5. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica 
serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Parry CM, 
Thuy CT, Dongol S, Karkey A, Vinh H, Chinh NT, Duy PT, Thieu Nga TV, 
Campbell 11, Van Minh Hoang N, Arjyal A, Bhutta ZA, Bhattacharya SK, Agtini 
MD, Dong B, Canh do G, Naheed A, Wain J, Tinh Hien T, Basnyat B, Ochiai L, 
231 
Clemens J, Farrar n, Dolecek C, Baker S. Antimicrob Agents Chemother. 2010 
Dec;54(12):520 1-8. 
6. A randomised trial evaluating the safety and immunogenicity of the novel single 
oral dose typhoid vaccine MOIZH09 in healthy Vietnamese children. Tran TH, 
Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, Tran TT, Cao TT, 
Pham VM, Nguyen TC, Tran TD, Pham VT, To SD, Campbell 11, Stockwell E, 
Schultsz C, Simmons CP, Glover C, Lam W, Marques F, May JP, Upton A, 
Budhram R, Dougan G, Farrar J, Nguyen VV, Dolecek C*. PLoS One. 2010 Jul 
26;5(7):e 11778. *Corresponding author. 
7. The sensitivity of real-time PCR amplification targeting invasive Salmonella 
serovars in biological specimens. Nga TV, Karkey A, Dongol S, Thuy HN, 
Dunstan S, Holt K, Tu Ie TP, Campbell 11, Chau TT, Chau NV, Arjyal A, Koirala 
S, Basnyat B, Dolecek C, Farrar J, Baker S. BMC Infect Dis. 2010 May 21;10:125. 
8. Typhoid fever and other enteric fevers. Christiane Dolecek. In: Infectious diseases. 
J. Cohen, W.G. Powderley (Eds.). 3rd Edition. Elsevier 
9. Transcriptional response in the peripheral blood of patients infected with 
Salmonella enterica serovar Typhi. Thompson LJ, Dunstan SJ, Dolecek C, Perkins 
T, House D, Dougan G, Nguyen TH, Tran TP, Doan CD, Le TP, Nguyen TD, Tran 
TH, Farrar n, Monack D, Lynn DJ, Popper SJ, Falkow S. Proc Natl Acad Sci U S 
A. 2009 Dec 29; 106(52):22433-8. 
10. Gallbladder carriage of Salmonella Paratyphi A may be an important factor in the 
increasing incidence of this infection in South Asia. Khatri NS, Maskey P, Poudel 
S, Jaiswal VK, Karkey A, Koirala S, Shakya N, Agrawal K, Arjyal A, Basnyat B, 
Day J, Farrar J, Dolecek C, Baker S. Ann Intern Med. 2009 Apr 21;150(8):567-8. 
11. Population Pharmacokinetics of Gatifloxacin in South East Asian Adult and 
Pediatric Patients with Typhoid Fever. Christiane Dolecek. Christopher M. Rubino, 
Alan Forrest, Sujata M. Bhavnani, S. Koirala, A. Arjyal, M. Sharma, S. Maharjan 
232 
Dangol, Buddha Basnyat, Tran Tinh Hien, Robert W. Kulawy, Jeremy Farrar, Paul 
G. Ambrose. Poster presentation at ICAAC 2008, Washington D. C. 
12. High-throughput sequencing provides insights into genome variation and evolution 
in Salmonella Typhi. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, 
Goodhead I, Rance R, Baker S, Maskell DJ, Wain J, Dolecek C, Achtman M, 
Dougan G.Nat Genet. 2008 Aug;40(8):987-93. 
13. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for 
the treatment of uncomplicated typhoid fever in children and adults in Vietnam. 
Dolecek C*, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, Doan CD, Nguyen 
TB, Duong TL, Luong BH, Nguyen TB, Nguyen TA, Pham ND, Mai NL, Phan 
VB, Vo AH, Nguyen VM, Tran TT, Tran TC, Schultsz C, Dunstan SJ, Stepniewska 
K, Campbell 11, To SD, Basnyat B, Nguyen W, Nguyen VS, Nguyen TC, Tran 
TH, Farrar 1. PLoS One. 2008 May 21;3(5):e2188.*Corresponding author. 
14. Antimicrobial drug resistance of Salmonella enterica serovar typhi in Asia and 
molecular mechanism of reduced susceptibility to the fluoroquinolones. Chau TT, 
Campbell 11, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, Van Vinh ehau 
N, Tuan PQ, Page AL, Ochiai RL, Schultsz C, Wain J, Bhutta ZA, Parry CM, 
Bhattacharya SK, Dutta S, Agtini M, Dong B, Honghui Y, Anh DD, Canh do G, 
Naheed A, Albert MJ, Phetsouvanh R, Newton PN, Basnyat B, Arjyal A, La TT, 
Rang NN, Phuong Ie T, Van Be Bay P, von Seidlein L, Dougan G, Clemens lD, 
Vinh H, Hien TT, ehinh NT, Acosta el, Farrar l, Dolecek e*. Antimicrob Agents 
Chemother. 2007 Dec;51(l2):4315-23. *Corresponding author. 
15. An open randomized comparison of gatifloxacin versus cefixime for the treatment 
of uncomplicated enteric fever. Pandit A, Arjyal A, Day IN, Paudyal B, Dangol S, 
Zimmerman MD, Yadav B, Stepniewska K, Campbell 11, Dolecek C, Farrar 11, 
Basnyat B. PLoS One. 2007 lun 27;2(6):e542. 
233 
16. Evolutionary history of Salmonella typhi. Roumagnac P, Weill FX, Dolecek C, 
Baker S, Brisse S, Chinh NT, Le TA, Acosta CJ, Farrar J, Dougan G, Achtman M. 
Science. 2006 Nov 24;314(5803):1301-4. 
234 
Relationship thesis-publications 
Chapter I of this thesis is in part based on the Review "Typhoid fever and other enteric 
fevers" written for "Infectious diseases. J. Cohen, W.G. Powderley (Eds.)". Parts of 
Chapter I have been used for the gatifloxacin EML application to WHO 
(http://www . who.int/selection _ medicines/committees/expertll8/applications/Cochrane_ 
Gatifloxacin.pdf). The results of the clinical trial reported in Chapter 2 have been 
published in PLoS One (Dolecek et al., 2008). The discussion has been updated to 
include more recent trials. Part of the results described in Chapter 3 of this thesis, have 
been reported at the Interscience Conference on Antimicrobial Agents and 
Chemotherapy (lCAAC) 2008, Washington D. C. Chapter 4 is based on a publication in 
PLoS Negl Trop Dis. 2011 (Holt et al.). The results described in Chapter 5 have been 
published in PLoS ONE 2010 (Tran et al.). 
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Gatifloxacin versus chloramphenicol for uncomplicated 
enteric fever: an open-label, randomised, controlled trial 
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Summary 
Articles I 
~ck9round w~ a im ed to Im'c tigate whether g,otl flolCl cin, a new gener2tion a nd affordable nuoroquinolonc, is better ,_,*.. 1011; 
thao chloramphenicol for the IrNtmtol of uncom pi ica led enleric fever io children aod adult , .... HoI 
Mothod. We did.n open.label r.ndomi ed superiori ly rrial.1 Pal. n Hos pil31, Kalhrnandu, Nepol, 10 invesliga le 
wheth .. g.tiflo:udn is more effcctJve Lh.n chloramphenicol for trealing uncompllcaled enlerlc fever. Children 
and .dults diniCllly di.gnosrd .. ith enrni f .... r recti>ed .ith er gJ litloudn (10 109/kg) on c. cL,y for 7 cL'ys, or 
chloramphenicol (75 me/kg per day) in four divided des .. fo, 14 days. Patients were nndemly .lIoared 
Ire.almcul (1 ;1) in blocks of SO, Wllhoul stratifiCllion. AIiOCItiom were placed in ' .. led enYelopes opened by Ihe 
study phyllician once. pod ent.... enrolled Into the trl.1. M:islcinll wo not po Ihl. beau.se of the different 
fonnuJ.tious .nd w.y of living Ih e two drugs . 11 .. P"III'ry outcome rne;lsure 1II'lI treatmenl funure, which 
consisted of .. ie.1s r one of the following; persistent fe,er at day 10, lleed for r l'SCUe Ire.llnenl, rnia blolOCIClI 
f. ill"", rcta~ until da 31 , .nd enteric·feve r·rclotled colllplica lions . 11te prirnar oulcome was .ssessed in all 
patieut! nndomly alloated tre.1m nl.od reporled sep.,r2 Ir1y for culture-positive patiellts aod for all patients. 
Secoud.uy outcome me ... UTe W"f ~ rr d euance ti nll~. I ... le rebt>~J uKl f3eal carriage. n.e trial is regi~~tred on 
cot1lrolled.tNls.com, numb .. I R 53258327. 
finding< 844 pari Of .... ifh a modun ace oft6 (IQR 9-22) yeo ,s .... e .. enrolled Inlh. trlol .nd r.ndomly a llocaled a 
trcolmeut. 352 patien bad blood-cullure-conlirm cd cnleri f<'Yer; 175 were Ir""ted with chlora"'phcnicol and 
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fever de ... nre ...... 1 · 95 da ys (95% CI1 · C\84·63) inlhrchlofOmph'flieol c.oup.nd 3 ·90 days (3·58-4 · 27) in Ihe 
g.titloxadn group (HR 1· 06, O· 6-1· 32, p.O · 59). All nlonlh ooly, Ihree of148 patients WNe slool·culture positive 
in the chloramphenicol group and none ill lh e galHloxado group. AI the end of 3 morrths only one person had a 
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gatinoD °11 grolil', 
Interpreta t io n Alti)ough 00 more effi dou. th;an chloramphenicol, g.tiAoudo should ~ lhe preferred trea tment 
for cnlPri f",. in d.-dopine cOlfntrie becauS<' of its harlPr Ir"" lm enl dllral ion .nd fewrr .dv.,SI' e .. nts. 
fund ing Wencom e nus\. 
Introduction 
Enle ric rev!.'r is a d ase tlul predominantly . ffe 
hUdr n and I dU ed by Ihe ~ I om tran. m lon' 
of Salmolldkl tnltrica er Iype Typhl (5 I~plll) and 
SalmoHllla lrIk",," Pdralyphl (5 purJI}pi1, ). Tit r 
a re.n tinlll ted 16 mJlllon Inr. Ion and er 
200000 dealhs c u.<Pd by Ihe di ~J .. .. orldwide I'd h 
year.' In pari or south i., Ihe indd.nL of enleri 
rever In chlIdren can high. 57 j cue per 
100 person years .' 
Ch loramph nl 01 w th undud t r atment r. r 
e nte ric fever from lhe 19505' " unUI 1l1c de>clopr nl 
.nd pread of ,m ,lt ldn'g r .. , .nt (MDR; d.fined as 
r Islan e to all first·line .ntibiotic ; chlol'lllllplwlli 01, 
1:00 Vol U ),In.:lOU 
amo i iIIin, and o- triolO"".ol.) S typhi nd panHyphi 
In Ihe early 19905. Sub equenlly. ftuoroqlllnoiones 
a~ firs t rhol e for the I",atment of enteric feve r. 
How c r, In rea ed r Isla n e to Ihe older g ' ner2tion 
/Iuoroqulnolone5 (clpronoxadn and oilo .. Inl bas 
eruer;: d. Thi redll Ihe opt ioDs for tre.tmenl, and 
raise Ilc . spec lr. o ff"il y r .. I IJ nl enteric fever." 
onflictiug report h ay erner~ed from ... ndomlS d 
onl rolled r.rI.lls with rel.thely smill •• mple sl.zes lhat 
sed older Auo roqlllnoi ones (cip r080~adn and 
ollox. in) v r lIS hi r mph n lcol for lh lreatme nt of 
enter! r. 'crY Additlon.lly, no trl.us have been done 10 
Inve t igale the elli <:y o f rhlorampheni 01 versus a 
new r fluoroquinolone, ouch a gatiAo a in, In the 
'ublt-.ilIdON .. w 
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treatment of enteric fever in chUdren,u R en t reports 
ugge t a general decline in the prevalence of M D R 
typhoid fewer in ia .... l1 and two recent studie of 
p.rlcnls wUh enleric feve r In Kalhmandu. N pal 
reported a low prevalence ofchloralllphenl 01 r sl tance 
In S typhi and S I"lrMyphi A Isolates: nine (1·7%) In 
512 .Irain. of Iyphi" and th rre 11.2%) of24hlrains of 
S jllJrat} phI A.X> 
GallO ado was e ffective ln lhe l rea tllle nt ofnalidixie· 
acld·reslsunt enteric fe,er in two previous r.ndolnlsed 
ldals done in epal" and ietO.1Jll.· The drug targ ts 
both D. A gyraseand lopolsomentse IV."''' and hence is 
less inhibi ted by Ihe onunon mlltal ions of the 
g}TA gene of S t)phi than are d pro llo aein o r oflooacin. 
We d Igned a raudomi<I'Il coutrolled 1f.,1 to .sses~ 
whether g>tiA cin h.d BUpt'rior efncacy comparPd 
~--------~~------~ J ... or 
with chloramphenicol in adults and children witll 
un ompJicated euteric rever in , epa!. 
Methods 
Patients 
The tudy physlc\:ln enrolled patients who pr cllted 
10 the Oul patient or emergency department of Patan 
lios pital, Lalltpur. Nepal fro m May 2. 2006. to August 30. 
2008. Patients witl, fever for more Ulan 3 dat'S who were 
clin lcaUy diagnosed to have enteric fever lund llTeren· 
lIated fever with no clear focus of infection on 
preliminary physL a.l exam and laboratory tests) whoo;e 
residen e was in a predesignated ore. of about 20 kml 
in urban laillpur and who gave fulJy infonned wrllten 
consent we", eligible for the tudy. Exclusion criteria 
were pregnancy or lactat ion. Oige undflr 2 ye..1rs orweigbt 
I \Iofo! So 
~ ~Jt ~>OuS 
..... " lA;."Itf~b\1'1tf $) 
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less than \0 kg, .h k, j.undice, go trolntestlnal 
bleedlng, or any other Igo of evere typhoid fever. 
previous history ofhypen;ensllivlty to eIther of the trial 
drugs. or koOWD previous lr t"",Dt with chlor· 
amphenicol. quinolooe aotlbloU, third gen r.tlon 
c phal05porin. or macrollJe within I '" k of hospital 
admission. Patients who tud recci"ed amoxi ilIin or co· 
tr lmoxazole were mduded as loog they did not how 
evidence of clinical ponse. [th! aJ .pprov.1 wa 
granted by both ~epal Health Research CouncU and 
Oxford Tropical Research Ethics Committee. 
Randomisation and maskin9 
Randomisation was done In blocks of 50 withou t 
st r:ltificat ion by an .dntlnl>1rator otherwise n llIvolwd 
In the lrial. The rand m lIocalions _r. placed in 
s a1ed opaque envelopes. wWch were k~'Pt In a I ed 
draw r and opened by the study physl ~n once ch 
patient ... " elUoUed Into U,e Inal aft r meeHn~ the 
In Ius Ion and exclusion cril eria. Patlcut "ere enrolled 
III the order they pr cuted;wd the s~.lt'<l "'1>(:101'" 
were opened in strict numerical equt'nce. MasklD!; W 
not possibll' because or the dUferenl formula t tons 31td 
ways ofgl,ID!! the two drugs . 
Procedure< 
Eadt em oUed patieut was ralldontiy • iglled to 
tre.,lment with elthergalll10raclD ubi IS 1400 ~ \O,~ 
per kg per day In a single oral d for 7 days or 
chloramphenicol capsule (250 n~ or r;oo mg) 75 ' og per 
kg per day in four dlVldcJ oral do fo r 14 d.~ . 
Gatifloacln tablets were cut and .. eighed and the 
p;<tlenlS'<iailyd w re prep"rNln 31edpiasII bags. 
The per.protocol pbnned duratloo of chlordmphenlcol 
IreatmeDt of 14 days was modified for blood·Cl~tur.,. 
neg,lIive patients, who rt'(~tved at If'ast day" of 
mloramphenicol and stopp<xl itber On <l..y or 5 d.~ 
aner ing.r. brtle . .. hichever came lat r. Gatiflox. In 
wa given for 7 days in all patleDts. 
After enrolmt'n~ patienl$ v. re lnanaBt'<l a OUI p:ltienls 
and seen by tnined ommunity n .... Ji al a,wli.ric 
(CMAs). as des ribed previously." Th MAs made a 
.ilIit '0 e. h p;<ti ... tl ' house <"Very t2 h r. r ellher to day 
(gatlno a III grollp), 14 da c ( hi ramphenl 01 ~roup). r 
UDtU the patient was cured . The C tA directly ob ervcd 
each p.ltient ingemln 1M in I d""e of gOlIAo acin nd 
two do cs of chi ora mph nicol. 11le phYSIcian re-
ex.1min II,e patients on daj and 15. nd al I, 1 nd 
6 month • . All exarmnatlOD! wert> t.'Iocbrd"ro lid 
enlt'red into a e " '(ord fon . 
Complete blood counts were done n <!dys 1. R, nd LS. 
D day 1. serum cre,llnlne, bilirubin, partate 
amin ran ferase lAST). and alanine amin ran fera e 
(AtJ') were al heeled. lUnd m pi ,TIl glu os wa 
nrasurcd on day 1. day . day IS. md I mooili . D 
d:ty 2 7. during Ole evening visH. Ole blood!!lu ose .. a · 
fTl('asured by fin ",.prick t tinll I n TOil h ureStep, 
Johnson nd Johnson, US ) by Ihe C~1 s. Ha moglobin 
was measured al 3 months. 
Blood cul tllre WAS dOlle as descnbed previousl in all 
p.lllents at adrnis lon, in the culture-positive patients 00 
day . and If symptoms and tgns suggested furthe r 
infi ction. 
t I (ull UJ"L-S were done 011 aum.ission in ... 11 patients, 
and In culture-positive patient after completion of 
treal menl aDd at the I month, 3 month, and 6 monili 
ylsits in \0 mL of elcnite P broth aDd Incubated at :rrc. 
AfterU,e overnJght incubation, Ule broth was subcultured 
onto Ma Conkey agar and xylose lysine decarboxylase 
agar ml"'ia . 
Isolates wete screened using sta ndard biochemical 
' ('SI$ . and S typh' and }"r.ltyphi wet(' identified using 
APll0E IBlo\ieriel.lx, Paris. r-r.nc~) and.lideasgiutination 
\ th speelf, antisera IMurexBlot h. Danford . UK). 
Mlnlmum inhibitory concentrations (M I ) were 
calo~aledr. ramoxi U1in.a7iUu omy in.chl rJrnpheoi 01. 
o-Irlmox.:lzoie. naJ ldlxlc add , oRoxadu. dpro(Joxacin. 
tetracycline, g.LlI10lCACin, and cellriaxone by E·tesl (AB 
Blo(1I k. Solo.. we<ien) . 
TIle primary endpoint of tltl. study was the omposlte 
odpoint oftrcalmcnl fuUure. which consisted orany ODe 
of the foUowlog: persistence offev r of more than Jl. S'c 
al day 10 oft"'" 1m."" 'he need for rescue tre.-tlment with 
Chl Ofanpftenlcot 
(no4l8) 
1 (8-22) 
261 (62 ...... ) 
42 (10-51) 
....... _,Ion II b<_ ..... """"(do~ ,(4-7) 
-~ ""'"."' ..... -rC) J8-'lS(l8.2-39-51 
t.. ]7;(89-1') 
.. "'..... 121(77-)" ) 
VbmlbOY 
tlI.omooo 
CotI'Jibp..tiou 
l\"twll)lIIef.J,11 
S,,",_1y 
I!«~m QQR) ""'"",lOCot!" 
Modan 11OR) lei.: CD .... (.10'/l) 
Mdon (lQR) p <DUn1 (.10 '11.) 
Mdon (IQI!) AST (lJJI~ 
IoIdon (1QR) AlT (IJIl) 
181(.(l· ) 
14504-h.) 
120(28-7'<) 
86(20-"') 
78(18-8,,) 
60(1404 ) 
47(1"''') 
6«15-)" ) 
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.... (5·0-81) 
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l2'O 
SO 
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f~ ",.M • ..,<t1I"'~t"' I'h~1 ·'I .. Mh4~QI!'IJ~labnOll t»)'8 \bf.t'don~t!ht(1~,l l f'St 
TtIbI.l: Summ.-y of prl"..., ... ucondMyOuttomH fo, cultur-.-poIllU.,. pMtWltl (pel'"p'Gmcgl .,lIIylll) 
cc/lri.a>oue or 00 n eill as juds xl by the lr.,.Ung 
physl Ian; microbiological faUure, d~fined as a posit ive 
blood cuJturp for ttphlor ,.oratyphi A on day ; rel. 1"'''. 
tJ .. t is ""ppo'ar'[l'''' of culture-confirmed (in Itlding 
mismatch of st'rotypcs I day 1 blood rultu!~ posJtlve 
for 5 Ilplu and mapse blood rulture positive fOT 
S pamtyplti r vi e v rsaD or S)'lldroonic enteric fever 
on or aft er day 11 to day 31 In patlenl who wcrc irtitlally 
cak ortsed:lS ucccssfulJy treoted: and curr<>nce of 
enten -fever-related mpl' alion ." Time to treatment 
faUure Yo ddilled. the time from tl,C fin,[ dose of 
treatment unill the date of the eadl t fa ilure evenl of 
tlul p.Ilient, and pallent without an !'Vent were en ored 
t the dale oftlleirl st fol low-up visll. 
Sl.'"Coucbry endpoints we fl.'"Ycr d arallcc time 
(reT: time from the fi r dose oftreatment given lIntil 
th£> tempt"rahlre W3S "j7· 5- :and the patient relmined 
.feb ril~ fi rat Ipast 48 hl: till'" lo relapse unt il day 31, 
day 62, OT month c, of follow-up; and faecal curtage ilt 
the follOW-li p visit at I, j, and G monlh • . The patient ' 
I'C1' w re a l ulat cle tronlcaUy on the b."i of 
twl e-d~i1y rc ord 1 mjX'r hl rcs_ Patients without 
r!.'Corded r. r dearanr or reJdPse werecensor datthe 
rute oft heir last foU -up visit . To redu e possible bias. 
an in> tlg~ to r nOl In,'olved In lhc rccn.il.ucnl of 
patienls deck! pall n!.s' 6nal out omes by use of a 
rna ked d.tab. e. 
sudstlc.aJ .nalysls 
The Ina! was d Igned • 3 ..... peri rity trial with 
the t..,pothesls lhat gat itloxacin was snperior to 
chloramphenicol in poUents WitJ, enteric fever, Th 
s. mple size was calculated to delect a diJference of 10% 
betwe n tl,e two grou I'" in the proportion of p. Uents 
reaching trf'lltment failu re at the two-sided 5% ignili-
cance level with 80% power. We assumed trealment 
failure rates of 15% in the chloramphenicol and 5% In 
the gaUUo,,"cln group, leadirtg lO • total required sample 
size of 160 patients with culturc-<onfi rmed enteric fever 
per grou 320 patients In total_ n tI", ba is of results 
fro m a previous "",dy,"'" we as umed that about 40')6 of 
patielll who were ra udornly assigned trealment had 
culturc-confi nned enleric fever. To ano fo r a loss to 
foUow-up rate of about 5%. a total of 53 patient with 
.usp<'Cled eoteric fever were recruited lo th trial. 
Tiul<.'S to ' re.tment failure, fever Icarance, and reb""e, 
were analysed by use of survival methods. The cumulabve 
Ineiden e of events was calcubtro with the IUpl.n-Meier 
melhod, and comp.risortl were based on Cox regr ion 
models with the tr<>ltmeDt group as the only covariate_ 
For the primary endpoint (treatment fail ure), we also 
ompared lhe .bsolute Ii k of treaLment faUure until 
day 31 on the basis of Kaplan-Nt r estirt1ates and 
st.udard errors accordln to Greenwood' fonnula ."' 
Addillonally, the time to treatment fa ilure was analy ed 
in the ubgroups d fined by culture rcsulJ , paUlOgen 
(5 I}phi or S JXlmtypiu A). and age (<16 years or '" 16 yeal'S). 
and heterosenelty of the treatment effect W11S tes ed with 
a Ox r res ion mode! lhat induded an irtteract!on 
bClWcc.n trcaltnenl and subgroup_ 
Thp per-protocol analysis population onsiste<i of al l 
patient with blood- ulture- onfinned enteri feve~ 
~ttw-l-vv:et.c.om/ln'Xtion Vol u Jun. 2011 
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We also analysed ill patients who were assigned 
treatment. with the e ceptioo of those patients who 
were mistakenly rnndornised or withdrew before the 
fi rst dose of study treatmeDt. for treatment f.Uurc 
and safety. 
All reported t IS we"" done at tht· two-sided 5% 
significanCt' I_I. and 95% Cis are reported. lIanalrs· 
were done with the statlsU al soflware R 10D 2.9.1." 
The trial Is registered on controDed·trials.com. number 
ISRCT 53258327. 
175 
177 
141 ~. JO I)S 167 161 
" 
IJ IT/ 17. lbJ 
Role ohhe funding source 
The spon or of the study had DO role in study design. 
data collection. data analysis. dab interpretation. or 
writing of the report . n.e corre:<ponding author Iud full 
access to aU the data In the study and had final 
responsibil ity for thp decision to submit ror publication. 
Results 
f 1151 patient! assessed. 53 were assigned treatment: 
8# were analysed. 418 assigned chloramphenicol and 
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be~ the two trt~tmlnt groups 
~26 gatifl oxa In (figure II . Th basclln chara I rlstla; of 
the p:lhenlll we", sunilar in the two treatment groups 
(tab I l). Th proponlon ofp:ll~n18 wllh In'atm~nl failure 
W4I i.rnihr in the two Lrc.ilt rneut y:l'Oupb' W ~l ieuls w ilh 
ruJture-posltive dis e (table 2). Of the five patients 
with p<'rsl51 nl r<-''P r on day 10 10 tl,.. gallJ10xanll grou p 
(I ablp 1). t",ob«' m,...f .. brUpon day lI.nd did nol r"qlll", 
resetl IrcatmtOl Tbe other three pallents were effectively 
tr ated 1lh mtravPOOlc eflmxonp SO mgfkg per day In 
lo(;le d for 7 dI . 111 6. p;!lleots In th 
chlor.unphenkol group who needed rescue lreatmenl 
re st fillly 11\';1100 with It a In 20 I'l:fl; per d y 
in tv.'QdlVlded dos .... po'rd yfor7 days. ln . 1I ases .rP!lCIIP 
trc~lmeot w lniWlcJ 00 either day to or day 11 . 
Two patients with mlcroblclogi.1 fallure In th 
g;atlB ~clD gr Ip also had persl tent fever. and 
re ponded wdl 10 nrUxoll SO nlr/l g fX'r dly In 2 
sln~ dlUydosc for7 da}'S. A11 relapse p.!tI DIS. consisting 
of ."",,0 (n"" of ",t,OI" Wf't'e culture confirmed) In the 
chloramphcni 01 Q JP and fc ur (IM'e of "hom were 
ChIo<unpII.,kol (n<418) C.dfloDcln' (n-426) 
Atb..lt,... 
Gr .. :let 2/411 (0.5_ 1/414(0.''') 
<'rJi.Je2 O'W(OOo) 21414(().5 J 
On cloy 8 
C..--... lel 4/41'] (1"''') 1 88(o~) 
(,rdJe2 1I4OJ ("7'1<) tn88 (o. ) 
0" cloy 1S 
(ir,net Ill, I (0.)') I 66(0-6 .. ) 
Gr ... '" 2 IlS' O,,) 0/166 ( ) 
OI1lUln )ofptl tMltt;U4CtodtlW"tb~("rwwqCWM 
",OOl)..l50o-.10·1..Gl1dt;"lCC«o-r:l~1999 t'f-A.,. ~;.,dt3Of4 
I«o.l( ~w~:O~~llp.h'J'llS'oIIhv ... ~ 1."'~ 
h~m~"''''9uteborHi .. )8~~diyt~ 
culture confirmed) ill /he gabfiolClcl n group, were also 
tre:ttcd with 000 In 20 mgfkg per day, and recovered. 
lbe second",), outcome m,,_sures. which in luded 
re.er clearance time (mt!dJan 3 ·95 da In Ibe 
ehloramphelllcol group and 3·90 in the g.tilloxacin 
group) and time to relapse until dly 31 or day 62 also 
h -ed no sign Uicant dJiferen e between the grOll ps 
(tabl 2). Only synd rolnic relapses wen' dOCUlTll'nted 
betw 0 day 62 ;lnd 6 months. Figure 2 sbows the 
Kaplan-Meier estimate for the time to treatment 
taillne. f""", ciearantl'. and rela pse . 
Stool samples . , baseline were posilive for S typhi or 
S p"ml}'p/>i A In 16 (10'~) of 157 p.!tienls in the 
cblorampbenlccl group and 14 (9%) of160 patients in the 
~a l iJl x.ein group. The proportion of JXlSlllve st I 
a mpl at ~ months of follow." p was low in both 
group': at I month . only Ihret! (2%) of 14 and none o f 
1)4 patients were stookulture-positive in Ihe chlor-
amph nl oJand gal iJIO><acln roups(p--O · U) . respectlveiy. 
N. th end of 3 mo nths. onl y one paLient (In the 
ch1orampberucol group) bad a po Itlve st I culture, aud 
at 6 months no p:tt~nt had posH I st I rullure. 
Table 3 shows the prinury .nd C oDdiry endpoin ts 
In all randornlsed patient . with the exception of 
patient who w(>fe mis taL;-enly r.tndornly allocated 
treAlme.nt or withdrew before the firs t d05 o f study 
treatment. There was a slightly greater risk oftreatment 
fa ilure In padent r e lvi ng chlorampbenlcol (p-()'(l9). 
Rerul tSl Il eI led uhgroups (t_ble 4) suggest thai this 
ls prinurily due to a h igher fa ilure ra le o f ehlor-
. mph nleol In Ihe culture-negallve popul4li n. 
e pt!rially a h iRher .,Ie of relaps. u ntil day 31 (n ine 
Ilhrccconfinncd .slxsyndroml lvs lwo{boihsyndroml I: 
HR of lime torela p e-0·ll.95'l6CIO ·0 1·01.p-O·05). 
TIle medldJl dmatlou of d~orHnphenicol Ireatmenl 
w. 9 d1ys(1 R U) In lhe rulture-neg31 I epopuJation. 
bul there was not a s;gnl fiGl nt usoclation between th 
duratio ll o frreah'l1Pnt and thetimt' 10 reiap;e (IIR ·93. 
9~% C I 0·66-1 · 30. 0·66). 
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C1t1o,ompktnkol GMI"OXIIcn p"' .... 
(0-418) (0 -416) 
~)'<uml .. t'~. 21 
.. ~ 11414 ("") 21422(0 1 00 
Ond.oyl""', 7 . 251-107 (6 1 ) 42'414 (I 1 ) 
-Ond.oy8 014"'(0 .. ) 1I4'lO(O J ) "SIl 
Onday I , 2/)66(0 )00) Ofj,I(IJ") 1·00 
Onmonlh t 7) (0) .'383(0"') "<;0 
HypO!h<.,.. ... grad.2Otw.,.S 
At"""" 4/4 t.1 (L 4'421(1 1-00 
On<k'Jl tD~/7% 11401 (") ) 114J4 ("") 1.(10 
Ondoy8 2/40' ("") 2"100(0 0;1» 1·00 
On day I, 66(1· 1 I 11351(0- ) 1-00 
Comanlh 1 1131> (0 I .nBl(I"") 1 00 
_.-6 
Onmond, '2/))1 «(.j ) , I]S9 (~6t.) 0.8 
TIlere w .... no Indicllion of Ire.lmeol efltrt hot ro-
gcueity in UIC ubgroups defined by p;lUlq;en or age 
(!.able,,). 
\lost ad""!8e .... enls were mid (grade 1 . nd 2; table S). 
Adverse """nts we", ~lightly more common in the rultu ..... 
positlv~ patients than th~ culturc!-negaU,-c p;llJents. In the 
cblorarnphenJcol group. 4-1 (2S%l of 115 a.dlure-posltlve 
patients experien ed at ~I one adve rse evCllt (81 ""enls 
In tOCal). In ll1egati/lo<lcln rou p. 30 (16·9%) of177 rullUr'C-
positive pallt'nts c.rpcricnced .1 I ast onl' .(herse I?Y ul 
(38 e><>nts In local). Thrfto patients in the rhioramphelll-
01 group had • ",hil{~b100d-('f~ 1 (OUtit be II 
1500 and 1999x.1()6 ccIIs per L on day . and had thcir 
cblontnpbenlcol opped. 0 ~de 3 or 41"'1 openL1 
" 'forded (tabl 6).' ~ hYJlOllIy emias were 
rccordt.'I1 (",hie 7) . and there w<>'" no Ilf.,.Utrc.to!wlIg 
complications of enteric fever in this cohort. 
fall th.. lrain of /'''''typhi'' and typhi lSoIat"". 
2S1 (73%) of W; were "alidon( a id ~i.lant • .tnd two 
(<1\\'.) were multJdrug resistant (table ). 80th MDR stratns 
were t)-fohi isolated [rom pabenls U1 th .. gatUiOlCl in 
group. Two S p"mtypi:i isol;ot wen:: "",istl nt to 
hloramphenl ol.oncof .. hJ h.. • oIatoHrom a patl nt 
in the gaUn l ei" group and on~ of ",tum" s isol. ted 
from a patient In Ihe chlonmphenKol CTOllp. 
In a.t1turC-JXl6illve p;ltlt'nts , tWldlxk Ii resl ~nce waJ 
signifi anUy led with.!! rnleofre roonn e 
(IIR 0·57. 95% CI O·~· I, .(02) r patients on 
gall/loxacln. bul there .. no ~nlficlnt dlffl'rCll e In 
spocd of f~ dcaran bet" patients ,,1U, nalldbdc-
.dd-reru1ant slTalM and tho e without in Ihe 
chloramphenicol roup 10· . 0 · 5&-1·14, P 0 ·21). 
Articles I 
S ..... ""'.""'ctyplllA Solm ..... 'YJlIoI p",.u. 
(n.l 03) (n-249) 
OlIor.""...>«.OI 
'IJ( 10 ( ..... t) SIlO 4-00 
,~(go (!.qIonl) \200 a.oo ..0.0001 
"'-9' 1.00-64·00 1 S6to.l)6.00 
AntOltldlin 
'~(SOW .. l) J.O • 0,", 
... OC!lO fIml 2.t)O 1 00 -.<).0001 
.....,. 
<>5'>-3"" "'" 10 >2;(>00 (0 .. _ 
MI( SO{jJglnlt) <>12 "'3 
All( .. flq.nl) <>J~ 0.06 .;).0001 
Roo'll ()'()20l8 O-O l lO"12.o0 
feu-.II()dne: 
MK. SO 6.g'''11 ) t .S<) 1·00 
MI(9OWent) 2.go 100 ~·OOOI 
R.1t.~ 1).50-8.00 <>J8to.251>oo 
........ 
MlCSOflo<i .. l) 1>19 <> 11 
MI(go font) 0-15 0 1 .... 0001 
RanI)" ""-<>}8 ... 2S 
AlIttw.m}':ln 
All 5O(jo<}'nct) 12.()Q 1>00 
MIt 90 (jqml) 16.00 12.(10 -.<).0001 
RMV 1-0<>-4&00 <>311-24·00 
NooUllK.Jd 
AI SIl~'!I"·t) .,\6.00 ,'SfoOO 
MIt 'lDfIo<jml) .2;1>00 ,'SfoOO ..0.0001 
RM>;/> ]·.:;0 .... 21)600 ().18to.lljb.OO 
c.;...:.~ 
MI( 50 UIr}''''I.) 0 50 02:; 
MI(90(l9'ml) 1).75 <>38 .... 0001 
.... )0 C).021.,o <>00-1.00 
Ofto><lcln 
'"t \0 (jo<}'''1.) 1<;0 0)8 
100 OS<> .... 0001 
"""'''00 0-02-400 
·In 
Mit 5O(jo<}'nct) I).S<) <>ll 
M,e 90 (Jq.nl) 1).<;0 1>19 ..0.0001 
R.uy. 1).()2-l-';O <>OO-1'lO 
~.ft!Slsv.ntllObtu .(0 ) 2 (0.3"') 1·00 
N;alr:bJ(.i:"'~t"'lI us 92(90-"') 1~9(~J ) 
"lC 2St)ft'J. rtd 141SP'I'lJ#)fhlA " 011 \11 be or M)C l~l~ MIC')O/'9O-«.or(t11I.~~.twt*h SO'l/.nj ~o 
"tht ""'-..ms. ~r\ltIY. lI '" nhtJ 1:><1 M,Jr w:inJ9 1{' 1 ~,J"(t ' 1t'ii'W'd lS,"!J~ l'\(t to(ho~ ",phIon4coI. 
~,"" .. lIl f'1 . looclI,tnlT'lCl'/( :oI 1!.Co~·I'iOr'I~'lfbllstdo,, 'W k1fIcc l'\ lt!J f"'r tOfl lln~d;t1l1!'1df (s m C! ltst 
'\.I (.le~nuld6tt 
r.Wd. kt tlrT"ACfOOlai JUlftptll>ll ty,.,.,.ts: minltnumlnhibltory concentr.dons (MI{.tt atd mrt1nc:. 
pofM 01 s.o-..II. PO"OYpl>l A;wId 5 I)IpIIIl.oIol. 
Disrussion 
Both chIoramph nlcol. which is a readUy avaUable drug 
in many ",""urce-poor ettinl}'!.and gati.fl OlClCIIl. "f, lch i. 
• n", er generation fIuoroquinololle, had (dlent ·fli cacy 
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In th~ IrNtment of culture-p<lOltl>e ent ne fe-er. and both 
c1n1 had a f.!sollr.lble idt"effi pro6lp. GatlHo.adn did 
well~. but ",as not superl r to. dllor.unphewcol Ul an 
area ",·Ith a hi h proponlon (73'!6) of lldlldlx! -add· 
r ot 'l'J'hl and l""'lIj-p/u raills. but almost 00 
chlorampben I 01 r lsU nee. 
With 84<1 ""llcnts allaly:ted (figure I). this i: 10 our 
knowledge the largest r.lndomlsed controlled trial 10 
enleri fevf~ .nd thP bl~ Irlal omparln 
chIoramphcnlcolwlth. OuoroqllJnolone. This is also the 
firsl trW to comp .... e chIorampbeol 01 to a fllloroqll lo· 
oIone in a predominantly paedJalric populatl.oll (table I) . 
We.1 .. d Ihl~IO ou r knowle<lt,.e--Iargesl 
popublion of blood·culturc-nC\l.lIve palienls witll 
""I .... ,C r. ver. III p.1I1I'D who h.d blood ultur .... neg:all"'· 
syndrom enleri r...... h drugs we ... effeclive. bill 
ga iOo. 10 wolj more Ifectl> .. In reduang yndroml ' 
clJnlc.u relapse. 
TI, .... rellnd.rlYlDg I hniral IS. II"'; for typhoid .nd 
enl rl f", .. r Ire Im<'DI trials. Onl' of the central 
Iimitllloo is ti ,e low .w Ilivity of the blood culture 
technique. whldt is estimated "" between 40% and 
SO;(,.U n I nlO6t patients will) etHeric feve r are 
c.tegorlsed a syndromlc. and trealed empi rically 
without a definIU\'C diOlgll Is for enterl fewr. is 
Iherefo.... n lIrprlslng. ror Ih ume r •• son. 
syndromi rcl.psew •• in 11Ide<l ... n outcome" DI in 
the a·prlorl d fined an.lysl pla n In this ludy. 
nle aDtlb1 Ie u. ed in thl Irlal how difrerenl 
pmrrm 01 !leal propprtlps. G'II~ Xllcln has Impomllll 
fNI .. rcs Illely 10 help will. tre Imenl adhercoce 
compared with chlor.unphenl 01: gatllloxadn only 
need 10 bt- t. en on I' a d.y fo r 7 <I;oy •• whereas 
hloramph nl 01 rrqlll~ r. r cs perd.1y for 14ci1y" 
TItete W~ no dlffereoce b{ofWt"{"O tlK· t dnl in terrTII 
of tre Im.,,1 fd,lurp 2nd f,,'t' r d. ranee hme In the 
cullure-po51l",e \;fOUp: h e- r. Ih" adwrse eRects 
profile hOYoed that anorexl •. naW! a. diarrhoea. and 
du:dn . " r. sl~lfi "l11 ly .... " e in Ibe clllor· 
.mph ni olg up It hie 5). 
We monltorcJ bl gl os I""", 10 dy In both 
treatment flJ'Oups chiefly be-c W!e of a re-cellt Canadian. 
ret pP<'1IVf' <I' ont I study of t · 4 mill ' II elderly 
Indl"dlUl In ... n .j;e 77) Ih.. h w.d Ihal caliOoxa ill 
was orbt tI with drs ycaemla.. ~ Aft r lhis r port. 
g,h8exacin .... Withdrawn from Ih U and nadlan 
nut\. . In our tri.l . bcl"cco <by 2 nd day7. Ule pro-
portion of pallent.! with a high (grade 2; 161 250 ~dL) 
nOIl·f. log bl III e 00 6n r·tkk t tln~ was 
higher In Ih. GJlifloXlclll group ,'t'I'1I< Ule d, leralll-
pllt'DI group. II 1r. Olere "d no dlfferen e on 
d.1ys IS and d.1) 30. lmilarly. at the end of 3 monlhs. 
Hb concenlnllon we .... nol dltferent m the ...... 0 
roups It ble 7). Addillon.Jly. prrvlous Siudl u Ing 
gaUfioxado In younger popul lion h.ve nol reported 
chni .lIy r .. I .... nl drs lye.emu. rlll.llly. 10 anoth.r 
study mparin ,.IIAaxa In "Uh olio,," In for tile 
Panfl, Reworch In (onltxt 
SysttmMlc rrvltw 
w~ S&1l h.>d ~b". forthet"",,, ·g .. tftOXol""". 
• hiolamphenicor. 'dink>! lri.oI".;utd ' Iyphoid/enl..ri< f"" .... 
W~ .Iso idenuf,od rel<!vanl .. , Itit-s flOm a nunl Cochran .. 
, .... It"..,! WHO Iypho,d !JU1do~nc<. U and a r""",1 meta an.1ly<l5 
o(OuoroqUlno~'h.'lf"SIJS h.:-r Jnt Dot KS tnth@trNtment 
oflyphoidf"'''' ... n-v. .... lentrio -,nil .. 
n "ta al"'lysis that (ompalod fluoroq,,,"olonESWllh 
(hlorampheno< I. Mokkhlig resl!!On st,.ms_ 
~nt 10 ~a but Qn~ t I iill,· Mld n .. ridlXK tlcid lesist~'l(~ Wlb 
only 'ipOrted in one tlial"ln .. hi<h lher were no n.tlidiJo< 
.l(KI f\'~~tant nr.un .. The "leb ~1ys1S condud~ that 
f1vo<oqulnolon",,,,.re not ''901liuntlyddr.,en f,om 
(hio'lII-.phd1i<ol fo<dulk.>J falkJreor miClClblOiol)'ColI ldilure 
In an aduk population. HOW\!Yef. the sampk! ,;zcs d lhe tnats 
InckJdl?d In the aNlysls W8'e SOlai. and there was a p.avoty 
of.,....tl .. ri< .... t .. Th..'f_w ... onlylwopr viouslriais 
of qat ifl""adn fOI the 1 ..... lmenl <I uncompliutod enl eric 
1i'V\'f: ""from Nepal andonefromV' t""m"" 
Inttrptetatlon 
G .. tftoxacm w not ttt'r I han (hloramp/>eNC.ol on (hlld"," 
.",llwl in Nop.IW1lh enteric 10_. Bothg.oliflou"n 
.. nd chlol amphcnkol show...'<ISlmlla, effic.lC)' "' lhe 
Ite"lme<ltofblood-(jJ~u posr!l ... enteric !<'WI' Ina setting 
w(h ,"a",,0(5 rwl' .odS prwtyphi A fully """"tilli! 
to ,hIo .. mph.."'i<ol..,d ,,,,i;t.nl to nalidixic ",id. Q,r t,iol 
show<"d that both In the adolt .nd pO<.>diahlc poput.llon 
'l"tt/lo'd(m wa, not b.>lt.,than dtI"","",*",nir:ol I low.".,. 
in dd",doplllCJ-<OUnlry SOIl'ng t,ke N.,p.I,Il.young 
popuiM Ion wI1ero thiS dISease ",edomlnJles. g. 1ft oc'n 
<hor ,1d b<othe ",i'fi'f'''''' <hoKe txor:auseof ~s.t-rr:>rt", 
lredlnl~ldUfOilion.f W<.',.J rse,-~h • .oJ.lowl.!f'l 
in th llrc.llmcnt of entl ... i<:rev~ 
trealment of enterk rever that we are doing 
II R N(3006567) . we have n I recordc<i any dys· 
glt'CacmiJI. 'i1lC gaIUloGcin-.ssoclated dysgl)' eml. in 
the Canadian study might be attributed to an e·rel.ted 
oeereas .. In r.n.1 fU IIChoD in eJd rly patient receiving 
Ilali no~. III, and Ihere mighl "ell b<o a pha rlll. okinetl 
or Fltamucodynamlc rationale for a potential a 
relaled dose reduction!' Trealmenl options fer enter' 
r. vcr ar d rly limited. GatiBoxacin is an elfi aclous 
drug for Ihe tre tment of enl rk fever In young and 
Ih,·",";se healthy pall nl:<. and hould be ava~ahle for 
Ind ' lioD In U,I nl'\ll~ed dise. e. It would be pllIdenl 
not to e allne.arin in p;1lielllS over 5O)eus of'lle. 
or In tienlS with comorblditl uch as di.lbet or 
rt'lla l faUu re. 
M l ent rI f<. .. erl rill a re dOD in a n inp;1tirnl etllng. 
which docs not re8 ct reality In dc-'eloplng countn s. 
wl .... re rn<lf'I ullcompli . ted enteric rever Ir •• tment ;, 
done In n aUlpali tit etling.u r trial was ompleted 
tbl Vol 11 junt 20U 
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In ao OUlpatlent n ing wllh !he help of \1A , a 
d cribe<! In our earlier trial.- TIlls model I more 
appuclIblc to d doping counlri"" 
A very allnctive fealu ",. especially for r ource- poor 
seltin . I the Inexpensl n of the :mtlblotl 
stuelled he re. The a\enge prl e for a l+day treal· 
lnelll ou rsI' with chior.mphulilol w SS7. The 
average pd e for a 7-<iay treatment with If~h.llo eln 
wa U $1·5. 
A recent Cochrane r lew (p.tncl) ofOuoroqulnoloncs 
for the trNlrnent of enteri fever polnled oul the 
wt akn .... "" of typhoid fever tre .. tlDent Irl.JS that !J;,ve 
smal l sample i7 , illad''qllale rdndomL~d l io ll and 
concealment. In omplete foil ,up, and a lad: of 
p:1edlatrk pal l nl and landard ist'<l pnd lil t .' w~ 
Irit'd 10 addr Ihe.., crili<Iom; by n'Cnuting a la'll" 
sample of patients, by per is Iy d fining our cndpolllls , 
and by alt mp.ing to reduct bl<ls WIthin the limits of an 
open trial. 
T",o othcrtrlaJ used gatlfl ad n forth treat01"n l of 
enle ric fe_er (panel) . >oJ' The frnt trill omparcd 
gatl80lGlcio to cefudme, and enrolled cb.Udren and dult 
outpatll'lIl in Nepal ." Th In I Iud 10 be pr rrulturdy 
stopped on the advice of !he Independent data safety 
monltoring cormnlttee beeau e ofth. poor performance 
of e fUlme. Thu w. a high rale of o\-er II II eatm'''" t 
fallure (pcrsiste DI fc'" r.t day 7. rcbpsc and dc.,l,) with 
29 (3 %) of 70 patients (.Ulng In the rcfixlme group 
co mparl'd Wllh Ihn><' (3% ) of poltlent III th~ 
gali fl oxacin group (II R 0 ·0 . O·OJ 0 ·28, (><0 . I) . 
There wa.s ODe death In the ccfixlmc roup. 
The second trial compared atl80xadn ""lth 
eon1VruoflntlAR 
BS.IF •• o,JCO. IUPf naJi Q r p" ·1\l'InfOtb<- HOESU!Qd~ 
W on .. UnIErJ") 11'lI4'PC'f': d Ca.nfo:'x:s.:f"jor,lT.I. "' '' lI'nc/tvcr, 
~.,...,"'. '" u.. l!llh &pm ... /h. Sder_ nd U".f 
bstntW lttf~W!'JMs. All ()Ib~ u!hon d~dJrei DO couBku of Ic'eren. 
Ac:lcnowWtnWIti 
\\. ttc.t .~y rbmiC l:t r eomttlllUtJ maG;c.aI.JU»I;.ny "CTkm-
NIJli~ly, Sl,l.. .. ttl(~t. SbrC21bi Ilr.uit'tp Tunnhr. NI~"'l'"" Rtpl, 
EWm'...lw:.~ Ntupule. md t\J~:n Adhiltut ~tlb .:'0 to) 
~drl Bn.l tor )oc.king aft:er the:xffice .dmlDtl"tr.lhOO We ll'O'Jld 
.:.0 ~h l.ub.nk: Kn.bD1 hol'''F.'t, '1.1 S"'lrKbrYI. "' 01~....a, O.bi., 
.td 6~ben from tbe l.bc.rat..ry.l' P.t.m Ho.q:-ttal We . regu ld'ul 
1, 8h .. nt raJ .. " .. lld hbll".rn ,f J )tt(1r'11 })I'oahb 1.."tilO". Iud nuuu:g 
t'tiltr 1 PAU !I. HOI"pml ~mH'S""'l7~nd Outpanent C it' __ Wilt ' lid 
.1'0 It ... Ii) th .. nlc ~hl" diJla ~ I ,1 ... {"!TY rnc'DI1OMng l.fu r'"e-· n01ro~11. 
zYl~f libutta, Phun!! Tu.uJ. " ith P ut)'IYiOlO, uy n .... :.ut ... r..loo 
B j P .. wJy l FlluHy. ., . ,uueu' . <1 toom POll' ,=CUJ.OO I lj~,r 
{jrtl1hl"' ft!'I"D Ll:u'pur W~ '1wnt ~ Wtr. ,. TN ~fCr"n ar~lo 
hr fun.i -!l.8 1~" m.tdy 
.'~(e" 
t F n)'CM"Hu~IlTT. Oeu;;.a .Wbt"jO~1.Fm·.TJr~i::.~dtn-et. 
II r.;1J M!>4 1<7 1 
Il 
?:JF:,ti f~,lrlo ~:tt ED,i;':.tt' b",d .. oC,>!,l>Jii (e. ... 
OeM,t Pl.Atn.uCI.o.rr roH,lhdorlolC, ... , A ty 
typbud fem- 10 five A..101Q «OUlllnes;. dai.eue lr • ...,jC"c _nd 
tm~a Olu<r.u for .:-cDtto ... Bit. ~ Hurd. Orp.n](x, 86: 1(.()...(...a.. 
Slun hi t Baht R. 6lurn~M s. Typhoid md pau ryp'brrtd r~ 
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1 Summary statement of the proposal for Inclusion 
Entertc fever (Salmonella typhl and S. paratyphl) aHects 26 million mostly young people In 
resource limited setting annually (conservative estimates). Resistance has developed and 
spread widely acalnst all the tradltlonal treatments and there are few therapeutic options 
that treat the patient effectively and prevent lonl term carriage. No antibiotics have ever 
been developed specifically for the treatment of enteric fever. Very few countries use 
typhoid vac:dnes and ther Is no vaccine for paratyphoid. 
Multldruc resistance (MOR • resistance to chloramphenlcDI, ampicillin and 
trlmethoprlm/sulfamethoxazole) and nalidixic acid resistance (reducing the sensitivity to 
the classical fluoroqulnolones otIoxacln and clprofloxacln) Is widespread. Resistance 
causes higher failure rates and prolonged carrla,e, lnereasln, the risk of compllcatlons In 
an Indhlldual and Increasln, the potential for contInued transmission to the community. 
There Is Coad evidence from a series of randomlsed controlled trials that ,atltloxaeln can 
be applied universally In all endemiC areas, Irrespective of SQlmonella susceptlbilfty 
profiles. There Is also pre<lInlcal and clinical pharmacokinetlc/pharmaccxtynamlc (PIC/PO) 
Information to support the proposed ,atlfloxadn treatment. 
A once-iHlay ,atlfloxacln 7-day regimen Is effective and safe against both sensitive, MOR 
and nalidixic acid resistant strains of Salmonella typhl and S. paratyphl. No susceptibility 
screening Is required. It Is the least expensive treatment currently avanable. 
1.1 Rationale for this submission 
The claim is supported by 
o In·vitro, cUnical (randomised controlled trials, ROTs and meta-analysis) and 
pharmacoloaical (PIC/PO) evidence thatgalifloxacln Is errective for the treatment of 
enteric feve r, indudlna multl-drug resistant and nalldbclc acid resistant strains. 
o Safety In formation based on ROTs of enteric feve r and longer e~posure for the 
treatment of tuberculosis. 
o CDst and cost-errectlveness data - gatifloxacln Is the least expensive option for treating 
enteric feve r. 
The product Is widely available across disease-endemic countries as a generic product; wl1ile 
approved as a general antibiotic it Is not specifICally Indicated at present for the treatment of 
enteric fever. However, gatifloxacin has been approved for treating urinary tract infections 
Involving non·So/moneila Enterobacteriaceae. such as Escherichia call, which is genetically 
closely related to So/monello. 
2 Focal point in WHO submitting the application 
Plel'O L Oillaro, MD, phD 
leader - Drug development and evaluation for helminths and other neglected tropical 
diseases 
UNICEF/UNOP/World Bank/WHO SpeCial Programme on Research & Training In Tropical 
Diseases (TOR), World Health Organization, 20 avenue Appla, CH·1211, Geneva 27, 
Switzerland 
Tel. no. +41 227913734 ; Mobile:+41 794726135; Fax no. + 4122 7914n4 
Email : olliarop@who,int 
4 
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3 Organizations consulted and supporting the application 
o Oxford University Clinical Research Unit . Hospital for Tropical Diseases 190 Ben Ham Tu. 
District S. Ho Chi Minh City, Viet Nam - Chrtstlane Dolecek <cdolecek@oucru.org> 
Jeremy Farrar <jfarrar@oucru ,orc>. 
o Patan Hospital Kathmandu Nepal -Buddha Basnyat <rlshlbas@wllnk.com.np> 
o Hospital for Tropical Diseases 190 Ben Ham Tu. District 5 Ho Chi Minh City. Viet Nam -
Tran TInt. Him <nientt@oucru ,org> 
o Tropical Projects. The Paddock. Hitchin. SG49EF. UK - John Horton 
< hedge plgs@aol.com> 
o Liverpool School of Tropical Medicine. Liverpool l3 SOA. UK - Paul Gamer 
<pgarner@liv.ac.uk> 
o Inst itute for Clinical Pha rmacodynamics. Inc. 43 Brit ish American Blvd. latham. NY 12110 
USA - Paul G. Ambrose <pambrose@lcpd ,com> 
o Centre for Tropical Medicine. Nuffield Department of Medicine. University of Oxford. 
Churchill Hospital. Oxford OX37U. UK - Nicholas White <nickw@tropmedres.ac>. 
Jeremy filrrar. Plero Olllaro, CI.-btlane Dolecek 
o London School of Hygiene and Tropical Medicine Keppel St. Camden. London WC1E 7HT 
- Katherine Reldl", <Kat erlne.Fielding@ lshtm.ilc.uk>. Corinne Merle 
<Corlnne.Merle@lshtm.ac.uk>.CharalambosSlsmanldls (current ly with t he World 
Health Organizat ion <slsmanldlsc@who,lnt» 
4 International Nonproprietary Name (INN, generic name) of 
the medicine 
INN: Gatlfloxacln 
Chemical name: (tl-1-cyclopropyl-f>.fluoro-1,4-dli1ydro-8-methoxy-7-{3-methyl-1-
piperazlnyl)-4-oxo-3-quinollnecarboxytic IICld sesqullwdrate 
Molecular formula: ClIH" FN,O •• 11/2H,O ",402 ,4 
CAS: 160736-57-8 (anhydrous gatlfloxacln); 180200-66-2 (gatif loxacln sesqulhydrate) 
ATC code: JOIMA16; SOlAX21 
Chemical structure: 
5 Formulation proposed for inclusion 
Solid oral forms (200mgand 400mgtablets and capsules) are available, 
No specific paediatric formu lation currently exists. 
s 
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5.1 Prospective formulation Improvements 
W2fVS or stimulating manufacturers to optimize gatlfloxacin formulation will be sought. 
The enteric fel/er patient populaLion is generally young and small and dosing Is based on 
body weisht. While tablet crushing is customary. and a practical dosing schedule is proposed 
here. smaller (lower strength) bblets. scored tablets or a suspension willimprol/e dosing 
accuracy. 
An oral suspension was developed and used In Phase 3 clinkal trials as part of the 
Bristol·Myers Squibb Company gaUnoxacln paediatric New Drug ApplicaLion. Additionally. a 
50 mg paediatric tablet was also studied. Formulation details will be sought from the Bristol-
Myers Squibb Company (Princeton, New Jersey. USA) for possible technology transfer. 
Scored 200mg and 400mg tablets could be developed easily. 
6 Intornatlonal availability 
Several generic products are on the market. 
6.1 Patent status 
The patent situation for gatinoxacin is publicly available in "Drugs in Focus January '10" (1), 
(details In Appendix 1). In addition WHO/TDR commissioned a search to Withers & Rogers In 
2009. 
Of the four patent families reported by the Key Patent Indicator (KPI). only the nrst 
family (claims to its chemical formula) Is relevant to the use of aatifloxacin products for 
enteric fever. All expired In 2010 or eal'lier, except: (i) 2012 In Germany and Austria 
(through extension of patent ) and (III 2011 In Germany. France and UK (data exclusillity 
expiry) bot (a) extension In Australia and Germany were granted for brand name Tequin· 
which is discontinued and (b) no marketing authOrization exists for gatinoxacln in Australia, 
~rance or UK. The latest patent to expire Is In canada although the product was voluntarily 
discontinued. There Is no patent in the dlsease-endemlc countries. 
6.2 Production 
Gatlfloxacln Is currently manufactured and sold by generic companies In India and China and 
freely available for export. 
In India. the principal manufacturer of Approved Pharmaceutical Ingredient (API) Is 
OPlA Pharmac~t\ca15 or Mumbal, who manufacture gallnoxacln sequihydrate as bulk. 
material for export (2) and use by other companies In India (3) . 
CIPlA also manufacture gatlfloxadn as tablets under the trade name Gatlquin as 200 
and 400 mg bblets (4). There are at least 80 generic manufacturers currently supplying 
gatHloxacln formulated material In India. The Individual presentations of generic gatlnoxacin 
in India are in Appendix 2. 
In China, there aTe a number of producers of API recorded. several of which produce 
to GMP standards. although the status of formulated gatiOoxacin in the China market is 
more dlmrult to determine. Gatlfloxadn Is also available In Nepal, Vietnam, Pakistan and 
other countries In the region. Availability In other countries with endemic enteric fever Is 
dlmcult to determine. 
7 Listing Is roquestod as an Individual modlclne 
Individual medlcin~ - gatiOoxacin 
Reasons are: reslstanc~ to nrst-generatlon fluoroqulnolones; speclre effic3CV. safety data 
and supportive pharmacoklnellc/pharmacodvnamic nd in vitro data; spedroe cost of 
product. 
6 
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8 Information supporting the public health relevance 
Enteric rever is widespread; conservalive estimates have 26 million cases per year between 
S. typl!l and S. poratyphi. 
Multidrug resistance (MOR " resistance to chloramphenicol, ampicillin and 
trimethoprim/sulfamethoxazole) and nalidixic acid resistance (NAR" reducing the sensitivity 
to the classlc .. 1 Ouoroqulnolones onoxacin and clproOoxacln) is widespread. 
Where MOR and NAR are common azlthromycln and gatinoxacJn are now the best options 
for treatment and can additionally treat other pathogens which may cause a clinical 
syndrome similar to enteric rever. 
B. 1 Epidemiology 
Typhoid fever and paratyphoid fever are septicaemlas caused bV the Gram negative bacteria 
SaimorW!/lo enttrico serovar Typhl (5. typl!tl and Salmonella enterico serovar Paratyphl (5. 
porotyph,) A, Band C. Typhoid and paratyphoid fever are summarized as enteric fevers. 
Whast s. typhl and S. PDrotyphl A and B Infections are restricted to humans, S. paratyphi C 
can arrect a variety or animals. 
Enteric rever Is endemic In Africa, Asia, Central and South America and found In 
parts or the Middle East. southern and eastern Europe (5). Improvement or infrastructure 
and sanitation has vlrtuany eliminated typhoid fever In developed countries and Infections 
seen In Europe, Australia, and North America are usually acquired abroad (mostly rrom the 
Indian SUbcontinent. South East Asia and South America) (6) . Cummt estimates rrom the 
World Health Oraanlzatlon (WHO) suasest that the global burden of typhoid rever Is 
approximately 21 million cases annually with more than 210000 deaths and that 
paratyphoid fever causes an additional 5 million cases (7). These numbers are based on 
extrapolatin8 data rrom 22 studies that used blood culture, th 801d standard for the 
diasnosls or typhoid rever. Many institutions In endemic countries lack blood culture 
facilities and the sensitivity of blood culture is less than 509(. and so the true magnitude of 
the problem is undoubtedlV areater. Transmission or typhoid fever occurs via the raeco-oral 
route by ingesting contaminated water or rood or through direct contact Chronic typhoid 
carriers involved In food handling are an Important reservoir or Inrectlon. In endemic areas 
enteric rever Is a disease of youn8 school children through to young adults. 
A WHO report has estimated the case ratality rate In enteric fever at 1" (7). The 
most Important contributor to a poor outcome Is a delay In appropriate antibiotic treatment 
made more likely by the presence or drug resistant strains In the community. 
The geo&riphlcal distribution or S. typhi and areas or mulU-dNg and nalidlx acid 
resistance are In Fiaure 1. 
7 
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Figure 1 Are05 of typhoid fever endemicity and distribution of arltlmlcroblal drug 
resistance ta Salmonella enterlcu serotype ryphl, 1990 to 2005. Modified from (8). MRD = 
Multldrug Rfilsran«; NAR . Nalldl. lc Ad d R~ISfan«. 
_ Typhoid ondomlc, MOR In<! NAR_1td 
8.2 Currenllrealment options and antibiotic resistance 
.1. 1 Cllluromphenicl} / 
Chlo, mph .colls ~d spectrum nliblotlc with bacte,iostatlc activity. It was developed 
In 1947. ChlonlT'phclllcol and was the first antlbiotk to be used In the treatment or typhoid 
feve,(9). 
Chlorllmph4!noeol treatment reduced typhoid rever mortality rrom 20% to 
PP'OllilT'ltely 1". nd the duration o( rever from 2-4 weeks to 4-5 days (9-11). The most 
Imporunt advene rfect of chlonmphcnlcol Is a dose related. reversible bone marrow 
depr4!sslOl1 tNt results rrom InhlblUon o( mitochondrial protein synthesis. This Is relatively 
common nd Is r4M'rsl when th dl\Jll Is stopped. In contrast. the chloramphenicol 
associated Idiosyncr IIc' plastiC anemia Is \I ry 'are but Is not dose related. non r verslble 
nd Inllana Iy fatal. ApbslIC anemia Is estimated to occur In 1 I 24.500 to 40.800 exposed 
(12 . R~Ha"ce to cillo, mphen.col was forst reported in the 19705 and has spread widely 
(13 OllorarrphtniCol rfOrmin of u e lor enteriC lever In regions of the world where the 
bactena are fully s nSltN (. 14. lS~ Howeve,. dlsadvant:lges of chlo,amphenicol Indude 
the need (or knowledi or the local sensitiVity pattern, hillher relapse and typhoid carrier 
,a tes (13) plu t tl n ed fo, tre tment fou, times a day fo, 14-21 days (16) which reduces 
adherence. 
(. . mplci{(in and amoxki/lin 
The amln~n.clIUns ampicillin nd mo.kiliin have been evaluated ro, the tr atment of 
typhood rewr In ~~ ral (hnkal tmb proved Inf rior to chloramphenicol (10, 13). Resistance 
IS wid p<' <Id nd Cene, Ily du. to the production of the bacterial enzyme JHactamase. 
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8.2.3 TrimetJ/Oprinr-SlIl/amell/Oxawle (colrinroxawle) 
Trimt>thoprim·sulfamethoxazole was widely used for the treatment of typhoid fever but With 
widespread resistance and an Inferior elficlacy it Is rarely used loday (13). 
8.2.,/ Extended lpectrunr cepholosporim; 
Cephalospoc'lnes exert bactericidal activity by Interfering with t he laler stages of the 
bacterial cea wall synthesis (17). The target site of the ~Iactam antibiotics including the 
cephalosporines are the penicllfin·bindlns proteins (P8Ps). Production of ~Iactamases is the 
most common mechanism o( bacterial resistance. In the late 90s, non-Typhl Solmon~lIa 
produdng extended spectrum ~Iactamases (ESBL) have been reported In numerous 
countries. Resistance to extended spectrum cephalosporlns has been reported In Isolates of 
S. Iyphl from Bangladesh and Italy and S. paratyphl A from Pakistan and Nepal (18, 19). In 
2009, a S. Iyph/ Isolate with ESBl phenotype caused by blac;rx IS has been described In a 
pati@nt retumins (rom Iraq (20). The cephalosporlnes exhibit time dependent bactericidal 
activity. 
OVeran, the cephalosporlnes are a safe class of antibiotics, hypersensltMty reactions 
are the most common adverse events. Gastrointestinal reactions, Including nausea, vomiting 
and diarrhoea are also reported frequently. The third generation cephalosporlnes 
ceftriaxone and cefbdme have been used for the treatment of MDR typhoid fever. The fever 
ciearance times In randomlsed trials using Intravenous ceftrlaxone have been 7·10 days and 
10')(. of patients failed clinically. Relapse rates varied between 4% and 6% (5). A study In 
Pakistan evaluated either 7 or 14 days of cefut·axone treatment In children with enteric fever 
and found a relapse rate of 14% (4 out of 28 patients) In the 7 day treatment group 
compared to no relapse In the 14 day group (21). The major disadvantage of ceftrlaxone Is 
the need for parenteral administration, the high cost, especially for what Is often a 
prolonged treatment course. 
Oral ceOJClme was a popular choice for the treatment of typhoid fever In children. In 
randomlsed controlled trials in children the mean Fever Clearance TImes ranged from 5 to 8 
days and clinical failure rates were reported to be below 3%.(22-24). However, a typhoid 
treatment trial In Vietnam reported much higher (allure rates o( 23% (10 out o( 44 patients) 
when cefbdme wa.s used In children (25) and a recent trial In Nepal usiOG Cenxlme was 
stopped by the Independent Data and Safety Monitoring Committee because of an 
unacceptably high failure and relapse rate In those receiving cerlldme. The overall treatment 
failure In this trial (acute treatment failure, relapsed patients plus one death) was 
delermined to be (95% conf1d nee Interval) 37.6 % (27.14%-50.2%) In the eefixlme group 
(26). Both S. typhl and S. paratyphl are predominantly Intracellular organisms and the 
cephalosporlnes do not penetrate wellintracellularly . This may explain the prolonged fever 
dearance times, hlSh r relapse and carr\ase rates seen when these drugs are used. 
8.2.S Azilhromydn 
Adthromycin belongs to the macrolide dass of antibiotics. Macrolldes are Inhibitors of 
protein synthesis by impairing the elongation of the peplidVI chain. Azlthromycln resistance 
has not vet be n reported In S. TVPhi. Azithromycln has a bloavallability of 30')(. to 50%. The 
serum peak level Is typically reached after 2 hours. Alithromycin has a large volume of 
dlstnbutlon which Is r lated to the ability to accumulate nslde eukaryotlc cells. The ratio of 
tissue to serum concentration (or uithromycln is 50 to U50 (27). The half li fe Is 35 to 40 
hours, which allows a single dally dose and shortened treatment regimen (3 to 5 days). 
Macrolidl!S are primarily metabolised throuah cytochrome P450 and IImlnated through the 
bile. 
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Gastrointestinal adverse events are frequent with macrolides. Macrolldes have been 
associated with prolona~tlon of the aT interval and should not be used in pa tients with 
concurrent administration of class IA and III antiarrhythmic agents and undertying cardiac 
disease. Azithromycin has become a treatment option for the treatment of MDR typhoid 
fever. The MlCs for S. I)Iphlto azithromycin ~nae from 4to 161l81ml (28). The peak serum 
level after a single dose of 500 ma of azithromycln is 0.4 mg/L (27). However, as 
arlthromvcin is concent~ted more than 100 fold Inside polymorphnuclear ceUs and 
macrophages (29) and S. I)Iph/iS primarily an Intracellular pathogen (30), effective drug 
concent~tions are considerably above the MIC. In randomized clinical trials, azithrornydn 
has been used for the treatment of MDR typhoid fever In children and adults In Egypt, India 
and Vietnam (31·35). Cure ~tes were good and outcomes in patients Infected with nalidixic 
acid resistant S. Typhl were satisfactory (321 • 
8.2.6 Plfloroqr/in%nes 
Nalidixic acid. the prototype 4-qulnolone antibiotic was discovered in 1962 (36), it is active 
against Gram negative bacteria and onl'{ achieves modest serum and tissue concentrations. 
Almost 20 years later. the addition of a fluorine molecule at position C6 created the 
nuoroquinolones. The 6-rtuoro substituent confers a greater spectrum of activity against 
G~m negative and Gram positive pathogens, possibly by improving tissue penetration and 
binding to the DNA gy~se enzyme. 
Clprofloxacln and Ofloxacin (second generation fluoroqulnolones) have excellent 
activity against Gram negative organisms (37). Due to Its avaiiabiUty and affordabifity, 
onoxacln has been widely used for the treatment of typhoid fever. However over the last 
few years strains resistant to nalidixic <ldd have appeared and spread widely. These strains 
are much less susceptible to both clprofloxacln and onoxacln with patients suffering from 
prolonged fever clearance times, clinical failures and prolonged carriage. Therefore the 
effectiveness of both of these drugs has declined leaving few options for treatment In 
regions with both multI-drug and nillldhdc acid resistance. 
Gatlfloxadn Is a broad spectrum 8·metho>cy nuoroqulnolone with enhanced activity 
aplnst Gram positive organisms, which has received U.S. Food and Drug Administration 
(FDA) approval In 1999. It features II cyclopropyl group at pOSition 1 similar to clprofloxacin. 
The addition of a methoxy aroup at position 8 targets both toplsome~5e II and IV and 
probabl'( prevents (or delays) the developmet1t of qulnolone resistance. 
Auoroqulnolones are considered bactericidal aaents and have excellent in vitro 
activity ..gainst a wide ~nge of Gram negative and Gram positive organisms. The 
qulnolones rapidly Inhibit bacterial DNA synthesis, causing rapid ceU death. The targets for 
the fluoroquinolones are the bacterial top isomerase enzymes. DNA gyrase (topolsomerase 
II) and topoisornerase IV. 
The main mechanism of qulnolone resist;ance In S. Typhl is the accumulation of 
amino acid substitutions In the bacterial target enzyme DNA gy~se. The most commonly 
Identified alte~tion has been a serine to phenylalanine substitution at position 83 of gyrA 
(3g, 39). These mutations are focused around a region called the qulnolone resistance 
determining realon (QRDR). The QRDR of gyrA is dose to tyrosine at posillon 122, the active 
site of the enzyme, which is covalentlv linked to DNA during strand breakage (40). Single 
point mutations In gyrA of S. l'fphl leads to nalidixic acid resistance (MIC 2: 32 Il8fml) and 
reduced susceptlbl6ty to the older generation nuoroqulnolones. Single Isolates of fully 
nuoroqUlflolone resistant S. Typhi nd S. Paratyphl A have been reported from India (41). 
The hlgh·level fluoroqulnolone resistance seen In these S. Typhl (clprofloxacln MIC 2: 4 
malml) Isolates was conferred by dual mutations In gyrA and a single mutation In porC (42. 
43). Galifloxacin binds with areater affinity to the QRDR and is less susceptible to these 
mutations remaining errectlve galnst these strains. 
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TIle frequency or adverse reactions to qulnolones Is between 6 and 11% or the 
subjects exposed with less than 1% or adverse events being recorded as serious (44). TIle 
most rrequent adverse errects reported are nausea, upper gastrointestinal dlscomrort and 
central nervous system errects such as headache, insomnia and dinlness. TIle adverse 
events are typically mild. self limited and mosLly resolve when the drug Is stopped. Some 
adverse errects do not seem to be related to specific modifications. whereas phototoxicity 
and CNS errects are linked to a specific structure. Each Ouoroquinolone tends to produce a 
characteristic profile or adverse errects. 
In their preclinical evaluation. all qulnolones studied caused arthropathy In 
Immature animals. especially In young beagle dogs and usually In the major weight bearing 
Joints (45. 46). TIle concem tha t the nuoroqulnolones might also cause cartilage damage in 
children has led to cautious use in many countries. However. extensive experience with the 
nuoroquinolones. especially cipronoxacln and ievorloxaein. in children surrering rrom cystic 
fibrosis. enteric rever and bacillary dysentery has provided a body of evidence suggesting 
that the Joint damage seen In young dogs does not occur In children and these antibiotics 
are sare In children (5.14,47-49). 
Fluoroqulnolones have been associated Wilh tendinitis and tendon rupture In adults. 
primarily afrecting the Achilles tendon; risk ractors were renal dysfunction and concomitant 
corticosteroid use (50). Severe neurotoxic reactions are rare. However. hallucinations, 
depression. and psychotic reaction have been reported. TIle quinolones should be used with 
caution In patients with known CNS disorders (e .... epilepsy) or conditions predisposing to 
sel2ures (37, 44) . The most common skin reactions are non·speclflc skin rashes. pruritus and 
urticaria. Phototo~lcity is a rare dermaloloalc complication or qulnolone therapy which is 
Inextricably related to the chemical structure, a halogen grouping at position C8 (SO) . 
A study based on post marketing surveUlance data reported that the crude incidence 
rate (95% confidence interval) of cases of Torsades de Poinles (TdP) per 10 miltion 
prescriptions In the United States was 0.3 (0.()'1.1) ror ciprofloxacin, 2.1 (0.3-7.6) ror 
oOoxacin, 5.4 (2.9,9.3) ror levofioxacln and 27 (12·53) for gatlfloxacln (51). However 
questions regarding the validity or both the numerators and denominators used In these 
Incidence calculations remain (521. Preclinical and clinical data Indicate that levofioxacln, 
moxirloxacin, and aaUfJoxacJn prolong the QTc interval. TIle potential ror TdP to develop as a 
result or this Is rare ;and Is influenced by many Independent variables, especially by 
concurrent administration of class IA and III antiarrhythmic agents. genetic susceptibility. 
underlying cardiac disease, electrolyte Imbalance and organ impairment. TIlererore 
gatifloxacln. levorloxacln. moxirloxacln or gemlfloxaeln should not be used In patients with 
risk factors predisposing them to TdP (521 . 
TIle quinolones as a class have demonstrated the ability to close K··ATP channels in 
the p cells or the pancreas. resulting in the release of insulin and subsequent hypoglycaemia. 
However the mechanism ror hypergtycaemia remains poorly understood and might be 
caused by overexposure (failure to adjust the dose In patients with renal failure) (52). 
Product labels for clpronoxacin. gatlfloxacin. levofloxacin. and moxirloxacin mention the 
possibility or hypoglycaemla and hyperglycaemia. Although glucose disturbances appear to 
be a dass efrect. the odds or hvpo- and hvperglycaem a appear to vary among the agents 
(53). A retrospective study In TexiS re'Jlewed records of dvsalvcaemia In hospitalised 
patients recelvlns gatlnoxacln. levonoxacln. clprofloxacln or ceftrlaxone (54). Oysglycemlc 
events were mOl'e likely to occur in patients receiving g Ufloxacin (relative risk. 3.29; 95% a . 
2.33--4.65) or levonoxacin (r I Uve risk, 1.55; 95% CI. 1.29-1.88) versus certriaxone. 
In another study or elderly in-patlents who received aat/noxaein or IevorloxilCln, 
gatlfloxacin was Independently associated with hypoglycaemia (OR. 2.4; 95% a. 1.1-5.6) and 
hyperglycaem~ (011, 2.5; 95% a . 1.6-3.9) versus levofloxacln (55). In diabetic patients 
treated with gatlnoxacln. the overall Incidence or hypogtycaemla was 0.4%. 0 .7%. and 1.6% 
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for patients below 65 yeall, 65 to 69 years and 80 years and above, respectively. The 
cOfrespondina Incidences of hyperglycaemla were 1.00(" 1 .6%. and 3.3%. respectively (SO). 
When exposure to gatlnoxacin was simulated In patients with severe hyperglycemia. 
who were often al.so oider Type-2 diabetics with renal dysfunction, AUC values were 2 to 3 
Umes those observed in patients with normal renal function (56). Therefore the authors 
suUested to empirically adjust the dose of gatinoxacin to 200 mg daily for patients aged 
above 65 years with community acquired respiratory tract infeetlons. Only cipronoxacin. 
clinanoxacin, enoxacin. grepafloxacin. penoxacln. and tosunoxacln can inhibit the hepatic 
cytochrome P..., i.soform cyp 1A4 Isoenzymes. Fi!W drugs are metabolized by these 
I.soenzymes, but ImPOflant drugs Include the melhyiKanthlnes (theophylline and caffeine) 
and warfarin. 
8.27 ummary o/rreatmell' opt/OIlS 
In regions of the world wh re MDR and Nalidbcic Acid strains of S. typhl and S. parotyphi are 
(()(Omon adthromydn and g tlfloxadn are now arguably the best options for treatmenL 
Intravenous antibiotJcs are not approprlale In most settings where patients are lreated as 
out-patients. In most parts of the wortd where enteric fever Is common the sensitivity of the 
strains Is not known as microbiological confirmation of lhe Infection Is lac kina and formal 
testing of sensitivities Is not undertaken. Hence most patients are treated empirically. In 
such drrumstances a 7-day regimen of azilhromycin Of gatifloxacin are excenent choices for 
all strains of S. typhi and S. parotyphi. The added value of these antibiotics is lhat they are 
effeetlve apinst other pathoaens which may cause a clinical syndrome similar to enteric 
fever. (see Section 9.2) 
9 Treatment details 
9.1 Dosage regimen and duration 
The d<lta presented In th s application support the use of gatifloxacln at 10 mg/kgld for 7 
days (nolto ~c~d 600 mgld y.) 
This Section presents the pharmacoloalcal basis ror this regimen. Efficacy results from 
randomlsed controlled studies are in Section 10) 
We also present In this Section practical dosing schedules with existing fOfmulatrons 
and prospective dosing with Improved formulations. 
9.2 Current clinical guidelines 
There have been no formal WHO Guidelines published on the specific treatment for Enteric 
Fever. In 2003 the WHO Department of Vaccines lind Biologicals produced an expert 
committee report "Background docum~nt: T1l~ diagnoSiS, treatment ond prevention of 
typhoid /eVf!r" (14)ln which the following recommendations were made: 
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Table L WHO rrc;ommcndations from 2003 on optimal and aitunatlve trratments for 
typhoid Jl!Vf!r (NOTE: this labk prr~ates the updated Cochrane Rel/lews and r/!Cent trials) 
OPTafAL THERAPY AL E EFFECTIVE DRUGS 
o.Ilydo_ o.I'ydo. 
SlJC'«PIIbJlI Antibiotic (m Ie ) AntibiotIc (mg," ~ 
ChlorampheniCol 50-75 
Fuly ...... 11 
FluoroqUIFlOIone 
IS 5--'«> Amoxycilim 75-100 
• 00 nor Trimethoprim-
clproflo In slifMlethoxtlZole 8-40 
FluoroqulnoioM 15 5-7 Azithromycm 8-10 
orcellxlm. t5-20 7-14 Celixlme '5-20 
8-10 7 Cefixlme 20 
75 10-14 
9.3 Summ:JrY target product profile 
9.4 Pharmacological basis of gatif/oxacfn treatment 
regImen for enteric fever 
14--21 
14 
14 
7 
7-1 4 
7-14 
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9.4.1 Summary of antimicrobial drllg resista"ce 
tn the tate 1980s and early 19905 outbreaks of typhoid fever occurred that were resistant 
against all " first tine' anUmiCroblals (mutUdrug resistance (MOR) defined as resistance to 
chloramphenicol. ampicillin and trimethoprlm-sulfamethoxazole) (5). These MOR S. Typhi 
isolates have been responsible for numerous outbreaks In countries In the Indian 
subcontinent. southeast Asia and Africa (8). All MOR strains so far examined have plasmlds 
of the incHll incompatibility group. 
Consequently. the nuoroquinolones have become the treatment of choice for typhoid fever 
especlany In areas of the world with MOR strains. The fluoroqulnolones show excellent 
tissue penetration. accumulation In monocytes and macrophages and high drug levels In the 
gall bladder. However. there have been reports from Vietnam. India and Tajikistan of the 
emergence of S. Typhllsolates that respond less well to the nuoroqulnolones (5. 8). In 1997. 
a typhoid epidemics In Tajikistan caused by such Isolates caused more than 10000 illnesses 
and 108 deaths (58). Technkally these isolates remain within the breakpoints set for 
nuoroqulnolone susceptibility by the Olnlcal Laboratory Standard Institute (WI) (59). but 
they are resistant to nalidixic add (the prototype qulnolone) and show higher MICs to the 
nuoroqulnolones. Patients Infected with these Isolates show a poor dinlcal response when 
treated with cipronoxacln or ofloxadn. Of all the fluoroquinolones assessed. gatifioxacin 
showed the lowest minimum Inhibitory concentrations (MICs) for nalidixic acid resistant S. 
typhi from Nepal (60) and Vietnam (381. In vitro time-kiU experiments showed a reduction In 
the errlCaCY of orloxacln alia nst strains harbouring a single amino acid substitution at codon 
83 or 87 of GyrA. this errect was more marted against a strain with a double substitution. 
The 8-methoxy nuoroquinolone gatifiolCacln showed rapid killing of S. Iyphi harbouring both 
the single and double amino acid substitutions (38). 
9.4.2 Pharmacodynamic and Pharmacokinelics of gatifloxacjn in 
patients will, enteric fever 
Pre-dinkal PIVPO models have long served as a basiS for dose regimen selection in early 
drull development and. subsequently. Pt</PO analyses of clinical data have served to 
confirm or renne pre-cllnlcal PIVPO model predictions (61). The pre-clinlcill and clinical 
PK/PO of nuoroqulnolone are better understood than perhaps any other class of 
antibacterial agents. The PK-PO relationship between exposure and response are 
understood in a wide ranae of indications. Induding community-acquired pneumonia. acute 
exacerbationS of chronic bronchitis. acute maxillary sinusitis. urinary traclinfectlons. 
hospital-acquired pneumonia and typhoid feve r (61). 
Flaure 2 pres nts the PIVPO Indices that are US d as surrogate markl!rs fordinlcal 
and antimicrobial efficacy are the ratio of peak plasma concentration (c.. .. ) of the 
antimicrobial to the minimum inhibitory concentration (MIC) of the pathogen (c....JMIC). 
the ratio of the area under the concentration time curve 0 to 24 hours to the M IC 
(AUOMIC) and the time above MIC (T>MIC). For the fluoroquinolones family in general 
antibacterial activity depends on the c..../MIC and the AUOMIC. 
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Figure 2. Concentration versus time curve wfth m/n/mllm InhlbltOlY concentration 
SIIperimposed and pharmacoklnetic and phannacadynamic markers. 
C~IC 
MIC 
Time 
PharmOlCodynamla of .atllloxacin In patients wtth typhoid fever (see Appendix 3 ) 
Olnlcal data from patients Crandomlsed controlled trial of galif\oxacin versus 
azithromycln; see Section 10.4.) with typhoid fever were used to invest~ate the 
exposure-response relationship of gatlfloxacln and the positive· and negative· 
predictive value of the naHdlx1c acid screening test. There are few non·cllnlcal PK·PO 
data available and essentially no cliniCal PIC·PO data for nuoroquinolones and S. typhi 
among patients with typhoid fever. If available, such data could be used to evaluate 
the adequacy of dosing reslmens and In vitro susceptibility breakpoints. In an effort to 
clarify these Issues, gatifloxacin exposure-rl!sponsl! relationships were modelled for 
patients with enteric fever. 
Abstract 
Background. The pharmacodynamics of sallfloxacln In patients with typhoid fever and 
the positive· (predicts clinical cure ) and negative· (predicts clinical failure) predictive 
value of the nalidixic acid screening test were evaluated In a randomized clinical trial 
Methods. Gatlfloxadn· treated (10 mg/kg/day 8lven orally for 7 days) patients with 
typhoid fever were analyzed. Previously vaUdated population phanmacoklnetic models 
were used in conjunctlon with patient·specinc demographics to estimate Individual 
patient drug exposures, as measured by the area under the concentratlon· tlme curve 
at 24 hours (AU Co 24 ). Analyses Included all patients with sufficient data to estimate 
AUCo l' and who had a defined minimum Inhibitory concentration (MIC) value (N = 
124). Fever was evaluated every 6 hours. Favourable Clinical response was denned as 
the resolution of fever and symptoms within 48 hours of the end of therapy. Relapse 
was defined as the recurrence of fever and symptoms and/or the isolation of S. typhi 
from blood after completion of therapy and discharge from hospital. A medical 
history, physical examination and stool cultures to determine chronic faecal carriage 
were performed at 1, 3 and 6 months after the end of therapy. 
Findings. StatisLical1y significant relationships between dnug e~posure intensity and 
cUnical response were detected. In patients with a AUe. ,. :MIC ratios of greater than 
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92.7, 93.5% hada favourable response; while for those with AU~.~. :MIC ra tios S 92.7, 
only 75% had a favourable response (odds ratio = 4.81, 95% CI 1.B , 18.9; P = 0.02). 
The positlve- (predicts cure) and negatlve- (predicts failure) predictive value of the 
nalidiXIc acid screening test was 100.0% and 9 .3%, respectively. 
Interpretation. The e.posure-response relationships identlned provide a paradigm for 
dose regimen evaluation of existing and new fluoroqulnolones for the treatment of 
typhoid fever. The results of this study also indicate that the nalidixic acid screening 
test was not predictive of clinical failure for galifloxadn and Salmonellae-specific 
susceptibili ty breakpoint s may be warranted. 
Population pharmacokinetics of catlfloxacln In south east Aslen adult and paediatric 
patients wltll typllold fever (see Appendix 4) 
Bacqround: An understanding of patient pharmacokinetics (PK) Is critical for the 
rational use of antibiotics. This is especially true for pathogens such as Salmonella 
typhi in South Eas t Asian countries where the development of multl·drug resistance is 
an increasing concern. Gatlfloxacln Is a commonly used treatment In South East Asia 
for typhoid fever. We Investigated gatinoKacin PK in paediatric patients and adult 
patients from Nepal with uncomplicat ed typhoid fever. 
Methods: PK data were collected during routine dinical care. Each patient had s 3 
plasma samples for PK drawn after 3 - 6 days of oral gatlfloxacln therapy. Separate 
candidate models for adults and children were fit to the data usinG Monte Carlo 
parametric expectation maximization with $-ADAPT. Due to the sparse nature of the 
PI( sampling. the structure and covariate relationships from previous gatlflOKacin adult 
and paediatric population PK models derived from Infected North American patients 
were retained but were revised to nt the data from this population. 
Results: 68 PI( samples from 36 patients (aged 3 · 54 years) were analyzed. 
gatlfloxadn PI( were best fit by a linear l<ompartment model. Fits of data were 
exci!lIent (r' > 0.9 for children and adult data); Interlndivldual "ariabUlty in PI< was 
modest. Compared to North American paedia tric pat ients, the Nepalese paediatric 
patient population had ~509(, slower clearance (Table 2). 
Conclusrons: As drug clearance was markedly lower in South East Asian typhoid fever 
lIS Infected North American patlents, these data demonstrate the Importance of 
evaluating PI( In varying patient populations. The PK models deSCribed herein win be 
used In future pNrmacoldnetlcs-pharmacodynamlcs (PK-PD) analyses of efficacy in 
South East Asian populations with typhoid fever. 
Table Z. Moln part/mders 01 (lm/fIDKocln derived from population kindles 01 AsICIn enlerlc 
lev.r pDt/ents 
PIC "",.".", 
Pediatric 
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9.5 Proposed dosing regimens 
Gatinoxacin is currently formulated as 200mg and 400mg strength non scored 
tablets. Table t fractionation is custom both in clinical practice and cl inical trials. 
We present here proposed practical dosing regimens using the current 
formulations and prospected improved formulations. The target dose was set at 
10mg/kg and the therapeutic window at 7-13.5mg/kg/d not to exceed 6oomg/d. This 
range is cons istent with how gati noxacin was originally developed by Bristol·Meyers 
Squibb and with the pharmacokinetic/pharmacodynamic data and safety margins in 
children and adults. 
The objective was to administer whole tablets and minimize tablet crushing. 
We also wanted to predict what proportion of the typical enteric fever 
patient population will be receiving which dose. The proportions of the overall 
population In the tables below re fe r to the weight frequencies found in the Nepal 
plus Vietnam database of 120B enteric fever patients (weight distribution in Figure 3 
below.) 
Figure 3. Weight distribution of Asian enteric fever patients 
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Option 1 uses the current non scored 200mg and 400mg tablets. It was not possible 
to give whole tablets for patients under 15kg body weight (.) for whom tablet 
crushing remains the only option. Patients weighing 29kg taking one 200mg tablet 
will be rece iving 6.9mglkg instead of the 7mg/kg. Because of the 600mg maximum 
dose patients weighing =>B7kg wi ll received <7mglkg. 
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Tab//! 3. Practical dosing of gat/floxacln with C\I~nt non scor~d 200mg and 400mll tablets 
nNMI min max 
34.20/. 200 9.5 6.9 13.3 
29.6% 400 10.4 8.2 13.3 
26.5% 600 8.8 6.7 12.0 
Option 2 refers to the possibility that manufacturers will accept to develop 200mg 
and 400mg tablets scored in half (or 400mg tablets scored to give four loomg units). 
(oJ patients weighing less than lSkg the dosing range displayed is for the weight 
range 8.Skg to <lSkg, below which tablet crushing Is required to avoid overdosing. 
Because of the 600mg maximum dose, patients weighing =>87kg will received 
<7mg/kg. 
Tab//!" Practical dosing of gatlftoxacln with scored 200m1l and 4OO1JIf1 tablets 
9.8'!1. 100 9 .4 7.1 12.5 
27.1% 200 10.5 8.3 13.3 
12.0% 300 10.3 8.8 12.0 
35 to 49 24.6% 400 9 .6 8.2 11.4 
-SO 26.5% 800 8 .8 87 12.0 
10 Summary of comparatlva effectiveness 
10.1 Identification of clinical evidence 
The current COchrane review (57) Is being updated. We completed a comprehensive search 
in October 2010 ~nd have screened this and retrieved full text articles. The Inclusion criteria 
remain the same as the curr nt pubUshed Cochrilne review. 
In the updating of this review, we wUI use the COchrane new risk of bias assessment 
We will use GRADE to summarize the results. This will be uslnc relative risk with confidence 
Intervals ilCross metraNllysis of comparisons for standard outcomes where this Is 
appropriate. (the updated review will be submitted at a later stage as Appendbc 5 .) 
10.2 Recent randomlsed comparative clinical trials 
Recent cl inical trials compared gatinoxacin to : 
A1Ilhromyci n: 
A multl-center randomlsed controlled trial of ,atlfloxadn versus allthromycln for ttle 
treatment of uncomplicated typhoId fever In children and adults In VIetnam. 
Oolecek C, Tran TP, Ngu~n NR, le TP, Ha V, Phung QT, Doan CD, Nguyen TB, Duong 
n. luong BH, Nguy n TB, Nguyen TA, Pham NO, Mal Nt, Phan VB, Vo AH, Nguyen VM, 
Tran TT, Tran Te, Schultsz C. Dunstan SJ, Stepnlewskil K, Campben JI, To SO, Basnyat B, 
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Nauyen VV, Nguyen VS, Nguyen TC, Tran TH, Farrar J. PtoS ONE. 2008 May 
21;3(S):e21B8. PMID: 18493)12.) 
Back(round: Drug resistant typhoid (ever is a major clinical problem globally. Many of 
the first line antibiotics, Including the older generation nuoroqulnolones, ciprofloxacin 
and ofloxacin, are falling. 
Objectives: We performed a randomlsed controlled trial to compare the efficacy and 
safety of gatlfloxacln (10 mg/kaJday) versus azithromycln (20 mg/kg/day) as a once 
dally oral dose for 7 days (or the treatment of uncomplicated typhoid feller in children 
(above 6 months) and adults In Vietnam. 
Methods: An open-label multi-centre randomised trial with pre-specified per protocol 
analysis and Intention to treat analysis was conducted. The primary outcome was 
fever clearance time, the secondary outcome was OIIeralitreatment failure (clinical or 
microbiological (ailure, delll!lopment of typhoid fever-related complications, relapse or 
faecal carriage of S. typh/). Patients were followed up at 1,3 and 6 months. 
Principal f1ndlncs : We enrolled 358 children and adults with suspected typhoid fever, 
186 patients were treated with latlflolfacln and 172 with azlthromydn. There was no 
death in the study. 287 patients had blood culture confirmed typhoid fever, 145 
pat ients received gatifloxacln and 142 patients received azlthromycln. The median FCT 
was 106 hours In both treatment arms (95% Confidence Interval [a]; 94-118 hours for 
galifloxacln versus 8a...112 hours for azlthromycln), (Iogrank test p = 0.984, HR [95% CI] 
= 1.0 [0.~1.26]). 
OVerall treatment (allure occurred In 13/145 (9%) patients In the gatlfloxacln group 
and 13/140 (9.3%) patients In the nithromycln group, (Iogrank test p = 0.854, HR (95% 
a] = 0.93 (0.43-2.0]). 96% (254/263) of the Salmonl!/lo enlerico serOliar Typhi isolates 
were resistant to nalidixic acid and 58% (153/263) were multidrug resistant. 
Condus/ons: Both anlibiot.ics showed an excellent efficacy and safety profile. Both 
gatifloxacin and azlt hromycin can be recommended for the treatment of typhoid fever 
particularly In regions with high rates of mullidrug and nalidixic acid resistance. The 
cost of a 7-day treatment course of gatifloxacln Is approximately one third of the cost 
of azithromycin In Vietnam. 
Trial rellstratlon: Current Controlled Trials ISRCTN 67946944 
tefl.llne: 
This trial was stapped early by the Independent Data Safety and Monltorl". Board 
due to the Inferior performance of cefl_llne. An open randomized comparison of 
aatlfloxacln versus wl.lme for the treatment of uncompllc.1ted enteric fever. 
Pandit A. Arjyal A, Day IN, paudyal B, Dangol S, Zimmerman MD, Yadav B, Stepnlewska 
K, Campbell ll, Dolecek C, Farrar lJ, Basnvat B. PloS One. 2007 Jun 27;2(6):e542 
Objective. To assess the efficacy 0( gatlfloxacln versus ceflxlme in the treatment of 
uncomprocated culture positive enteric fever. 
Destin. A randomized, open·label, actNe control trial With two paraliel arms. Setting. 
Emergency Room and Outpatl nt Oinics In POllan Hospital. lalil pur, Nepal. 
Participants. Pali nts (aged two to slxtv- flve years) with clinically diagnosed 
uncompRcated enteric fever meeting the Inclusion criteria. Interventions. Patients 
were allocated to r ceive one of two drugs, Gatlfloxacin or Cefbclme. The dosages used 
were Gatlfloxacln 10 maJka, gillen once daily for 7 days, or Cefixlme 20 maika/day 
given in two diVIded doses for 7 days. 
Outcome Me;uures. The primary outcome measure was (ever clearance lime. The 
second ry outcome measure was overall treatment failure (acute treatment failure 
ilnd relapse). Patients were followed up for 6 months. 
Results. Randomization was carried out in 390 patients before enrollment was 
suspended on the advice of the Independent data safety monitoring board due to 
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significant differences In both primary and secondary outcome measures In the two 
arms and the attainment of a priori denned endpoints. 
Among all randomized patients, 187 patIents were asslaned to receive cell.lme 
and 203 to ,atlllo.ac:ln. 77 patients assigned to receive cenxlme were blood culture 
positive for enteric fever wIliist 92 of those assigned to receive aatmoxacin were 
culture positive. 
Median (95" confidence interval) fever clearance times were 92 hours (84-114 hours) 
for g1Itlfloxacin recipients and l38 hours (105-164 hours) for cenxime-treated patients 
(Hazard Ratlo[9S~IJ = 2.171 [1.545-3.051J, p,O.OOOl). 19 out of 70 (27%) patients 
wIlo completed the 7 day trial had acute clinical failure In the cenxlme group as 
compared to 1 out of 88 patients (1%) In gatifloxacin sroup (Odds Ralio [95%OJ = 
0.031 [0.004 - 0.237J, p,0.OO1). Overall treatment failure pat ients (relapsed patients 
plus acute treatment failure patients plus death) numbered 29. They were determined 
to be (95" conndence Interval) 37.6 % (27.14%-50.29(,) In the ceflxlme group and 3.5" 
(2 .2%-11.5%) In the gatlfloxacln group (HR[95"CI] = 0.084 [0.025-0.280], p,0.OOO1). 
There was one death In the cenxlme group. This trial was stopped early by the 
Independent Data Safety and Monltorlns Board due to the Inferior performance of 
oefllclme. 
Conduslons. 80lsed on this study. gatlfloxaeln Is a better treatment for uncomplicated 
enteric fever than cenxlme. 
Trial Realstratlon. Cur",nt Controlled Trials ISRCTN75784180 
Chloramphenicol (Appendl. 4): 
A randomlsed controlled trial of .atlflo.adn versus chloramphenicol for the 
treatment of uncomplicated enteric fever In Nepalese children and adults: 
8olckground: It Is unclear whether chloramphenicol is a reliable therapy for enteric 
fever or whether gatifloxacin, a newer generation and affordable nuoroquinolone, 
would be the beller choice. 
ObJectives: To determine the effICaCY of chloramphenicol versus Ilallfloxacln in the 
treatment of uncomplica ted enteric fever. 
Participants: Patients (aged two to sixty-fIVe years) from Patan Hospital. Kathmandu, 
Nepal with clinically dlallOosed with enteric fever wIlo met the InclUSion criteria . 
Intervention: Patlenu received either gatinoxacln (10 mg/kg) once a day for 7 days or 
chloramphenicol (75 mg/kg/day) In four divided doses for 14 days. 
Outcome musures: The primary outcome measure was treatment failure which 
comprised of persistent fever at day 10, need for rescue treatment, microbiological 
failure, relapse until day 31. and enteric fever related comp~cations. The secondary 
outcome measure was fever c.learance time. late relapse, ilnd faecal carriage. Patients 
were followed up for 6 months. 
Results: One thousand one hundred and nfty one patients were ilssessed for eligibility 
of whlc.h 853 were randomized and 844 wene analyzed. Of these 418 were In the 
chloramphenicol anm and 426 were In the gatltlo.atln arm. Out of the 844 patients, 
352 patients had blood culture confirmed enteric fever, 175 in the chloramphenicol 
arm and 177 In the gatifloxacin arm. There were 14 treatment failure patients In the 
chloramphenicol anm and 12 In the gatifloxadn anm (Hazard Ratio [95" el)= 0.86 [0.40 
to 1.86], p=O.70). Major side effecu for chloramphenicol (bone marrow suppression) 
or galiOoxadn (dysglycemla) were not encountered althoullh, nausea, dlnlness, and 
dlanrheil were worsf! In th chloramphenicol group. Only 0.5" (2/352) of the isolates 
were mulUdrug neslstant (MOO). but 71 % (251/352) were na&dixic acid resistant. 
Conduslon: This large clinical trial of culture coo firmed eoterlc fever showed that both 
chloramphenicol and gilUfioxacln had an excellent efficacy in this young populat iOl1, in 
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a region with full sensitMty to chloramphenicol and over 70% resistance to nalidixic 
acid. Treatment duration, ease of administration, decreased side effects and expense 
favours the usage of gatinexacin. 
Trial Regist ration. Current Controlled Trials ISRcrn 53258327. Funding: Wellcome 
Trust. 
otIoxacln: 
An open randomlsed comparison of ,atltloxadn versus ofloxacln for the treatment 
of uncomplicated enteric fever; ISRCTN63006567). This Is In on",oln, trial. As of 
November 2010 approximately 500 patients have been enrolled. 
10.3 Meta·analysls of the above ReTs of gatlfloxacln for 
enterIc fever 
Two of the above ReTs (gatiOoxadn vs. azithromycin and vs. celixime' were already included 
In the previous Cochrane systematic review. A third study (vs. chloramphenicoll Is belng 
submitted for publication and will be Included In the updated systematic review. These 
studies total 414 gatifloxadn and 394 active control patients. 
This preliminary meta·analysis is based on averaU failures (primary faaure and 
relapse). No difference Is found between gaUfioxacln and azlthromycin and between 
gatiOoxacin and chloramphenicol ; gaUOoxacln is significantly more effective than cefbdme. 
The latter comparison explains the heterogeneity found on aggregate (I-square = 87",. 
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11 summary of comparative evidence on safety 
The class and product-specific safely liabilities are known 
The safely prome presented here Is derived from RCTs or enteric fever and 
pulmonary tuberculosis 
There Is no evidence from studies at the target dose in the target population that 
patients on gatinoxacln will be at a particular risk of dysglycaemla. This Is further 
connrmed by data from tuberculosis patients exposed to -25 times the total dose 
used for enteric fever. 
The drug Is well-tolerated In patients with enteric fever; the gatlfloxadn safety 
profile is similar to that of the comparator drugs. 
11.1 Class and product-specific safety liabilitIes 
Gatlfloxacin is a fourth-generation fluoroqulnolone antibiotic that, like other members of 
that family, Inhibits the bacterial enzymes DNA Byrase and topolsomerase IV. Gatinoxadn is 
generally well tolerated. In common with all broad-spectrum antibiotics, gastrointestinal 
disturbances may be encountered. The rtuoroqulnolones are also known to have a number 
of adverse effects that are considered to be common to the class, although the severity of 
these varies considerably between compounds. These Include effects on cardiac conduction, 
collagen formation (e.g. tenelon rupture), photosensitivity, and dysglycaemia. While another 
4'· generation nuoroqulnolone, moxlfloxacin, has significant effects on cardiac repolarisaUon 
(proloneatlon of QT Interval), this appears to be absent with gatlnoxacin. In contrast, 
dysglycaemic errects (hypoglycaemla at the beginning of treatment, followed later by 
hyperglycaemla) are most commonly reported with gaUOoxacin. (see also Section 8_2.6) 
Hints of galiOoxacin- sodated effects on glucose homeostasis were nrst noted 
during prednlcal development. Preclinical studies Which administered up to 19 Umes the 
400 mg dose for up to 6 monlhs demonstrated a dose related decrease in insulin release in 
pancreatic Ikells in all species studied (62). Shortly after gatinoxadn was Introduced, case 
reports of effects on glucose homeostasis began to emerge. Patients Identified as "at risk" 
included those with non-insulin-dependent diabetes on therapy and elderlv patients with 
age-related decreases In renal function (56). 
In summary, these data demonstrate 
a mechanism of gatlOoxacln-associated dYsalycemla that Is 
dose- (exposure) dependent, 
patients especiallv at risk include non-Insulin-dependent dlabelics treated with oral 
hYP<l8tycemlc medic tlons, and 
elderly patl nlS with age-related changes In renal function. 
GaUOoxacln-assoclated dvsglycaemia was not noted during the course of the 
paediatric development proaramme and a large trial In children with otitis media followed 
for one year demonstrated no dysglycaemia adverse effects (63). The concerns of 
dysglycaemla in elderly Canadian patients were further heightened with the retrospective 
report In 2006 In the NElM, concerning older, severely ill In-patients with a history of 
diabetes (641. That study received worldwide publicity leading to the drug being withdrawn 
In many countries.. 
Subsequent wor!( (far less publicized) quesUoned whether these effects were any 
more severe or common comp red to other nuoroqulnolones and comparable antibiotics In 
an out patient setting (65). In addition, patients with enteric fever are typically children and 
young adults and thus are very rarely non·insulln-dependent diabetics and have good kJdney 
function. Oearly In these two very different populations gaUOoxacin's dysglycaemla adverse 
effect pronle Is very different. 
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Between Nepal and Vietnam In recent years In registered clinical tria ls almost 1500 
young patients suffenna from enteric fever, shiRel losis and TB meningitis were treated with 
gatiOoxacin with no problems noted in glucose control. Of these, over 600 patients were 
followed up for six months and no episodes of dysslycaemla have been seen (26, 66) and 
ISRCTN53258327 (An open randomised study to assess the efficaey of ga tinoxacln versus 
chloramphenicol for the t reatment of uncomplicated typhoid fever In Kathmandu, Nepal; 
manuscript submitted as appendix) and ISRCTN63006S67 (An open randomlsed comparison 
of gatlfloxadn versus onoxaeln for the treatment of uncomplicated enteric fever; ongoing). 
In addition, dysglycaemia has not emerged as a side effect attributable to gatiOoxaeln In 917 
patients receiving gatifloxacin daily for four months as part of a drug combination regimen 
for the treatment of pulmonary tuberculosis In a multicenlre ACT in Africa (Senegal, Benin, 
GUinea, Kenya and South Africa). Blood glucose analysis from the above studies In presented 
below. 
As compared to the elderly Canadian patients, the prome of the enteric fever 
patients as deri ed from 1211 patients with age recorded enrolled In two ACTs in Nepal and 
Vietnam is that of a younger population (overall: median age 13 year, interquartile range 8-
2l years; median welsht 36k&. InterquartJle range 195-SOkg). 
TO.ble s. Afle{n: 8S3} and weigltt{n:8SO) prof/Ie of enteric/ever patients from two RCTs in 
Nepal and Vietnam. 
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11.2 Analysis of blood glucose In RCTs of enteric fever and 
pulmonary tuberculosis 
We pres nt here an nalysls of blood glucose as dysslycaemia has been Identified as a 
particular safety liability for thiS compound (see above.) We have detailed data from 
randomised controlled trials (RTCs) on enteric fever (-lOmg/kgfd x 7d, n=422 gatinoxacin-
treated p.Jtlents) and tuberculosis (400m&'d 6 days a week In combination with rifampicin, 
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isoniazid and pyrazinamide (or Initial 2 months and In combination with rifampicin and 
isoniazid for the followl~ 2 months, n=917 galinoxacin-lreated patientsl. 
11.2.1 Blood gillcose leveL~ in elltuic/erer 
Blood &Jucase levels wen! monitored durina the trial of gallnoxacin versus chloramphenicol 
In Nepalese children (above 2 ~ars) and adults (ISRCTN63258327). Random blood glucose 
(RBG) was measured dally on clays 1 to 8, on day 15 and at one month. On days 2 to 7, 
durinathe evenina visit, the blood alucose was measured by Onger-prick testing (OneTouc:h 
SUreStep" ', Johnson & Johnson. USA) by the Community Medical Assistants. HbAlc was 
measured at3 months_ 
For the analysis and llrading of adverse events includinll blood glucose. the NIH 
Dil/ison or AIDS Table for Grading the Severity of Adult and Pediatric Adverse E\lents ('DAIDS 
AE arlldire table"1 was used. 
Tabk 6. I'ImJnmers used In lite analysis 0/ ~~Iy 0/ dlsglyCTlf:mia 
The (ollowina Information reaardlng RBG and HbA1c was summarized: 
ENTIAlLY 
LIFE-
Median (IQR) levels for each visit (e.lI. daUy until day 8. day 15. and month 1 for 
random alucose and at day 90 for HbA1c) 
Worst hy~ralycemla grade overall. during days 1-8, at day 15. or at month 1 
(contingency tab'-s of frequencies by treatment arm) 
Worst hyposlycemla grade o~rail. dlJrinC days 1-8. at day 15, or at month 1 
(contingency tables of frequencies by treatment arm) 
Median (1QIt) levels of HbA1c at month 3. 
Proportion of patients with HbA1c >6%at month 3. 
Table 7 shows the numbers of hy~. and hypoglycaemias in both treatment arms 
and Table 8 shows the median random alucose lev Is. There were more non-fasllnggrade 2 
h~rglycumlas (160-250 ma/dl) In patients In the aatlfloxacln group wit h 42/414 (10.14%) 
compared to 25/407 (6.14"1 In the chloramphenicol group (p=O.04) durina treatment (day 2 
to day 7). There w re no non-rastlna hyperalycaemla events noted on day 15. The 
proportion of paUents with an elevated alycosylated Haemoglobin (HbA1Cj level between 6 
and 7.5% at 3 months was s mlbr In the two grolJps. 
Medl n glucose levels (Table 8) tended to be higher on days 2 to 7 during treatment 
In both rms. M4!dian aiuco le'oIels on days 4 to 8 were sll&hUy. 001 signlOcantiy. higher in 
the latlfloxadn anm compared to the chloramphenicol arm. 
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Tab~ 7 DIsglycaemla. Patients with abnormal non-fasting blood glucose. Numbers with 
f" of those t~s t~d) 
Comparison 
ChlonlmpMnicoi 
H;P;rlllycemi. , Gr. a; u 
a.tilfoJUJCin (p-tflllue) 
At Baseline 1/414 (024) 2/422 (0 47) 
On Day2 to Dayr 25/407 (6 14) 42/4 14 (10 14) 004 
On Day8 01402 (0) 1/400 (0 25) 05 
On DaylS 1/366 (0 27) 0/351 (0) 1 
On Month 1 1/375 (0 27) 0/383 (0) 0.50 
Hypoglycemia, Grllde 2@ or wo,.. 
At B3Seline 414 (0 97) 4/426 (0 95) 
On Day2 to Dayr 1/4Q7 (0 25) 11414(024) 
On Day8 2/4Q2 (0 SO) 2/400 (0 SO) 1.00 
On DaylS 31366 (0 82) 31351 (085) 1.00 
On Monthl 31375 (0 80) 383 (\.04) 
HbA1c >S 
On Month3 22 (6.27) 20 (5 57) 0.75 
• On Days 2 to 7 all patJents were monitored with nngerstJck glucose testJng. 
II Hyperglycemia grade 2 denned as non-fasting plasma glucose level belween 161 and2S0 
mg/dL No grade 3 hyperglycaemlas were observed. 
fj)Hypoglyaemla grade 2 deHned as non-fasting plasma glucose between 40 and 54 mg/dl 
Tab~ 8 Median doily random blood glucose ~I In enteric feW!r patients treated with 
chloramphenicol 01 gatlfl0Jtadn. Medlon glucose levels In mg/dL n z Number of pat/enu. 
Comporlsons b~d on Wilcoxon test. 
All,.".",. QIJotatrrplr«l1col o.tlfloxacin 
GNco. GIU_ GlIc:oat 
lOR lOR toR 
n III VIIIw 
Day 1 836 0 581 
Oa 2 805 0092 
Day 3 784 01 
Oay4 ns <0.001 
DayS 767 <0001 
Day 6 769 105 96·119 380 10295·1 14 389 109 98-122 <0.001 
Day 7 754 106 96- 117 379 10293· 11 4 375 11099- 121 <0.001 
Oay8 802 84 74·95 402 837325-92 400 86 75-98 000 
Day IS 717 8173·91 366 8173-92 351 8172-90 0 4 12 
Day 30 758 83 74·93 375 837450-92 383 8474-94.50 051 
J 1.2.2 Blood glllco II levels ill pllifl/(Jllary (lIbercJllo is (Appendix 7) 
Context 
The data analysed are from a randomlsed open-label controlled trial of a 4 month 
gatlOoxacin-conlainlng regimen versus standard 6 month regimen for the treatment of adult 
p loenLS with pulmon ry tuberculo is. i lri I has been conducted in 5 countries in Africa 
(Benin, Guine~, K nya, Senegal and Soul h Africa) . The recruitment started in January 2005 
~nd the study WIll end In Apri l 2011. 
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Method 
Male or female patients, aged 18 to 65 years, currently suffering from reCl!ntly diagnosed 
microscopically proven pulmonary tubenculosls and providing Informed consent were 
eligible for inclusion In the study. In the Galifloxacln arm, patients took GaUnoxacin at the 
dose of 400mg daily (6 days per weekI, irrespective of weight, for 4 months; in association 
with Rifampicin, isoniazid and Pyrazinamide during the ftrst 2 months of Ttl treatment and 
Rifampicin, Isoniazid for the last 2 months. 
Initially blood glucose measurements were taken at baseline (pre-randomisation; 
visit 11, week 4 (visit 3), 8 (visit 4) and end of treatment visits (either visit 6 or 8 depending 
on treatment arml, by nnger-prick or full blood tests. Ourlng the study recruitment period 
additional sampling Umes were incorporated based on the recommendation from the Oata 
Monitoring Committee. These were : 4 hours following first treatment dose, day 7, 14 and 
week 12 (visit 5) from randomisation. The measurement taken 4 hours after first dose was 
not taken when fasting as patients were allowed to eat 30 minutes after ftrst drug Intake. 
This report provides a summary, by treatment arm, of the (I) frequency of 
hypoglycaemlc (less than or equal to 3.5 mmol/L), normal (3.51-6.39 mmol/Ll and 
hyperglycaemic (greater than or equal to 6.4 mmol/ll events, (Ii) severity of these events, 
and (fill incidence rates of hyperglycaemic events. 
Results and conclusion 
A total of 1,836 patients have been recruited In this trial of whom 917 were randomlsed to 
the GaUfioxacln arm. In the Gatifloxacln arm the approximate mean age and weight were 30 
years and 55 kg, respectively. Based on the data analysed, the Incidence rates of 
dysglycaemk events were Similar in the GaUnoxacin and control arms. 
11.3 Summary of comparative safety against comparators In 
ReTs of enteric fever 
In randomized controlled trials comparing gatifloxacin to azlthromycin (66), cefbdme (26) 
and chloramphenicol; lIatifloxacln was extremely well tolerated. 
Gatlfioxacin versus atlthromycln 
Both treatments were well tolerated. One adverse event related to arlthromycln was 
reported, a maculopapular rash tha t occurred afler the first dose of treatment. Azithromycin 
was discontinued Immediately and the patient was treated with ceftrlaxone. 
Gastrointestinal side-effects (change in consistency and frequency of stools) that were 
probably Iyphoid fever related were relativelv frequent In both treatment arms at the start 
of treatment. In the gatinoxacin group, one patient experienced vomiting on day 2 and day 3 
and one patient had diarrhoea (4 episodes/ day) on day 4 and day 5 of treatment. These 
episodes were self-limiting and did not require the Interruption of therapy. 
The median levels of serum A5T and ALT fell In both Qroups after 7 days of therapy. In the 
culture positive group, the median pos t-treatment ASTwas 46.35 U/L (range 12.8 - 217.5) In 
the gallno)C3cin arm and 4S u/l (range S- 3581 In the azithromycin arm. 
Gatlfloxacln versus ceflxlme 
There was one death in the ceflxime ,roup. This might have been due to the development of 
disease-related compDc:ations during treatment The 16 year oid patient was enrolled on the 
foorteenth day of his ianess. On day 6 of treatment the patient complained of reddish stool 
and petechiae and was Immediately admitted to hospital where he developed severe 
thrombocytopenia and &astrolntestlnal bleeding. He developed acute respiratory distress 
syndrome and was mechanically venUlated. He developed disseminated Intravascular 
coagulation and succumbed to his Illness on day 21 of entry Into the trial. His pretreatment 
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blood culture grew S. Paratyphl A which was sensitive to cefbclme with an MIC of 0.38 
malmL One patient developed erythematous skin r.JSh which needed two doses of oral 
antihistamine. 
Among all patients who neceived gaUfloxacln there were 2 paUen ts with excessive vomiting, 
which reQuired Inlr.Jvenous anti-emetics and nuids and observation In the hospital 
emergency room for up to 6 hours. There was an additional 23 patients who complained of 
excessive nausea and occaSional vomiting after Ingestion of the drug. Of these, two needed 
oral antiemetics; in the remaining 21 patients no Intervention was required. 
Gatlfloxac:ln versus chloramphenicol 
A comparison of adverse events in the two randomized anns is shown in Table 9. Adverse 
events were mild (grades 1 and 2). Anorexia, diarrhoea, nausea and dlulness were 
significantly more common in the Chloramphenicol arm of the study. Three patients In the 
chloramphenkol arm who had a white cell count between lSOO-1999/mm' on day 5 to 8 and 
had their chloramphenicol stopped. The fever had already defervesced when the drug was 
stopped and they did not relapse for 6 months. There were no life-threatening complications 
of enteric fever in this study. 
Tab~ 9. Adt/ene ellents In enrerlc ~r patletlU trrlated with chloramphenicol 01' 
gatl/loltocln. 
12 Summary of available data on comparative cost and cost-
effectiveness within the pharmacological class or 
therapeutic group 
A variety of generic products is on the market, all generally cheap. We retrieved infonmatlon 
and compared costs with alternative treatment options. We also used enteric fever patient 
data to produce specific estimates of cost of drug when enteric fever Is treated with 
gatiOoxacin. Other direct costs and Indirect costs could not be quantified for the moment. 
The cost of Illness of enteric fever is poorly characterised. 
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This section shows that: 
Gatinoxacin is the cheapest of an treatments of enteric fever. Azithromvcin (the only 
altemative that could be used In areas of MRO and NARlls 2-5 limes as expensive. 
Treallng 1000 patients with the current products (200 and 400mg tablets) will cost 
4150$. 
12.1 Economic burden of enteric fever 
There have been very few studies of the economic burden of illness In regions where enteric 
fever is endemic. In 2004 from India the estimated direct and indirect costs to the family of 
an episode of enteric rever ranged between lS0US$ - SSOUS$ depending on whether the 
patient was treated as an out-patient or required admission to hospital (671. Neither or 
these estimates included the costs incurred during relapses or the costs associated with 
patients who develop long term carriage and pass on the infection to others In their 
communlty_ 
12.2 Direct costs: comparison of drug costs for treatment of 
enteric fever with gatlfloxacln vs, other options 
Cost of treatment 0( enteric fever with catifloxacin and several other antibiotics was 
estimated using data obtained from an on·llne pharmacy database In India 
<hltp://chemistparadlse.com>. Gener.llly accepted dosage regimens for adults of 50 kg and 
75 kg body weight, and children of 15 kg and 25 kg body weight were used to estimate the 
overall cost of treatment for these different classes. For galifloxacln, the maximum daily 
dose was set at 600mg. 
Tab~ 10. OMe and dUf'tltlon 01 therapy 01 enteric lewr wffh gatlf/Oxadn and other 
r~lmens. Examples 01 totaf dose /or a 15k" and 15k" child and a SO/(g and 7Skg adult are 
prollided. 
All gatlfloxacln products avall"ble In India on 1" November 2010 were identified, and per 
tablet costs obtained In U5$. Similartv, the costs of Chloramphenicol. ceftrioxane, 
ciprofloxacln, ofloxacin, and azithromycin were obtained. These were wholesale costs to 
pharmacy or single packs or, in aeneral. 10 t"blets. Since there were a larse number of 
products available, with a wide price ranae, the mean cort was obtained for each compound 
and strength. Only solid dosage forms (capsule/tablet) were considered, althOUgh 
examination or the costs of specifIC paediatric formulations and parenter.ll formulations, 
where available, showed Similar price structures. The mean single tablet costs were 
estimated, and applied to the different dosaae regimens to alve per treatment costs, USing 
the most appropriate dose sizes for the different weight classes. The derived data (in U5$) 
are tabulated below. 
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Tab~ 11. Cast 01 t~atJnQ chlld~n and adulu w ith t!ntmc 1t!Vt!f w i th Qatl/loxacln and otht!r 
ft!glmt!ns 
all oxacln ~ 00 -1.00 2 44 
C,prof\oxacin sao o ()9.() 81 S S $ $ $ 326 
AZI.hromycin 250 009-328 S $ $ 1847 S $ 1240 
OIIoxx in 400 00&-0.99 $ 0 .62 $ $ 1400 $ $ 5.00 
Chloramphenicol 500 o 17-073 $ 038 $ $ 38.48 $ 19.74 $ 1184 
Ceftriaxone 200 065 $ 065 $ 13734 $ 9156 $ 91 .56 $ 5600 
Cefixime 200 00&-408 $ 1.56 $ 163 50 $ 109 00 $ 54.50 $ 5000 
• usuallv half strength tablets/capsules used for these estimates 
Gatifloxacin appears to be cheapest option. The next least expensive drug is ciprofloxacin, 
which is 13%-69% more expensive. Onoxacln is l .83-2.05 and azlthromycin is 3-5 tines as 
expensive. Chloramphenicol is 5-9 times a.s expensive. The most costly options are 
ceftrla one (17-24) and cefixime (l4-16) times as expensive. 
FIQu~ 4. Comparatillt! costs 01 trt!atlnt!nt with Qatlftaxacin \/s. otht!f ~Imt!ns 10f t!ntt!r/c 
levt!f (In lilt! Tobit!: f t!latlllt! costs, Gati/lOxacill = 1) 
1.00 1.00 1.00 100 
2.0& I.s:! 1.13 131 
213 352 UI 5.01 
3.30 2.87 1.83 2~ 
U. 7.33 5. 15 4.15 
21.80 1744 23.111 22.15 
25" 20." ,.23 2082 
So $£0 $40 $00 $00 $100 $120 SI«l $160 $180 
D C41t:r75kQAU . Costtr 5a<gAOJr 0 C41t:r25 KgCtil· 0 C4ttJ 15K9C11~ 
A very large number of products (often In excess of lOO alternatives for each dose 
formulation) re av liable, with wid Iy differing costs, except for ceftriaxone where ontv a 
single product was listed. Costs for the beuer-known manufacturers were In general higher, 
but not always so. Although product costs have been estimated for treatments, this is a 
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basic analysis, and no attempt ha.s been made to assess quality of product, which would be a 
significant factor In determlnins true cost and efficacy of treatment While single tablet 
costs of other products are often lower than gaUfioxacln, cost of treatment Is determined by 
the regimen used, and when this is consklered, the cost of gatlOoxacln treatment, using 
Indian derived material, Is lower than with other accepted lreatments. Some limited data 
are available for other countries and roughly follows that of the Indian data (much of the 
material used is of Indian origin, especially In the sub-conUnent), but detailed Information on 
costs of all products within a country are not available to allow a Similar analysis. 
12.3 Direct costs of trBBtment of enteric fever with 
gatlfloxacln practical dosing 
Using the anthropometric database of Nepalese and Vietnamese patients, and applying the 
pracLicai dosing schedule with the current 200mg and 400mg tablets, we calculated the 
cos IS of treating 1.000 cases or enteric fever. These amoun t to 4.150 $. 
Using the Vietnamese patients' profile, the projected cost of dryg for treating all estimated 
~4500 cases occurriOB in one year In Vietnam will cost ~15.8QOS . 
Table U . CDst of drlJf1 for trNt/ng lOOO enteric ~ver patients with gat/floxadn using the 
pf'Gctlcal dosing scltedule wltlt tlte current nOlHcared 200mg ond 400mg tablns 
$25802 
151029 $909.72 
3010411 
When appiyll'\8 these calculations to Vietnam, the total costs of treaUng all the -4500 cases 
per annum of the entire country wi. be - 15,800$ for drug costs . 
Table 13. CDst of drlJf1 to treat all CGSes occurrlfIIJ In one yeor In ~/IGIII 
teqUIred 
< 
15 to 29 49% 7 X 200mg $5,817.82 
30 to 411 25% 7X~Omg $4,59302 
>-50 12% 7 X 600mg 
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12.4 Total direct and Indirect costs 
We are not In a position ilt present to submit a complete cost-i!ITectiveness analysis. Cost of 
inness has not been entirely quantified for enteric fever. To account for all direct costs, we 
are collecting Information on cost of care in Nepal and Vietnam. We are also attempting to 
collect more anthropometric datil on enteric fever patients from different settings to 
generate more complete projections of the ilppllcilbillty of the practical dosing ilnd costs of 
drug. 
USing gatiOoxacin will also mean that an antlbiogram is not needed - this cost should 
also be factored In. 
13 Summary of regulatory status of the modlclne 
Gatifloxacin was originally granted licences In the USA (Bristol·Myers Squibb) and Japan 
(Kyorin) In 1999. The Indications Included general In fections sensitive to fluoroqulnolones 
and community acquired pneumonia. In 2002, there were Indications that some patients 
might suffer dvsglycaemla, and warnings were added to the spc. Followin& publication of a 
review of dysglycaemla related deaths (64) and an editorial (68) in March 2006 in NElM, 
the US FDA required a 'Black Box' wamingl to be added to the SPC. Subsequently, In May 
2006, Bristol-Mvers Squibb stopped manufacture of Tequln·. 51mbr action was taken in 
2008 In Japan. In addition, The US FDA in September 2008 decided that. since "Tequin 
(gatlnoxacln) Tablets, Injections and Oral Suspensions were withdrawn from sales for 
reasons of safety or effectiveness· giltlfloxacln had become Ineligible t o the abbreviated 
new drug application (ANDA) should a new submission be filed for any of the previously 
approved dosage forms and indications of Tequln·(69). 
Although the licence for oral products has not been renewed or has been voluntary 
withdrawn In countries such as the USA and Japan, t he product remains approved In many 
countries where enteric fever Is endemic and drug resistant strains are present - including 
India, Vietnam, Nepal, Bangladesh and China. It also remains widely available as an 
ophthalmic solution for eve Infections 
14 Availability of pharmacopoeial standards (British 
Pharmacopoeia, International Pharmacopoeia, Unltod 
States Pharmacopoeia) 
A 'Pendill8 USP Standard' wa.s approved May 23 2008 (70). API and analytical standards exist 
in the Indian and Chinese Pharmacopoeias. 
15 Proposed (new) text for the WHO Model Formulary 
Gatlfloxacln 
Tobler, 2oomg, 400 mg (as sesqlhydrote) 
General informat ion 
Gat lnoxacln Is a synthetic nuoroqulnofone that acts as a specific Inhibitor or bacterial DNA 
gyrase and topoisomerase IV. It has a broad spectrum of efficacy against both Gram-
I The U Food QIId DNa Admtnlstratioo requjrcs IIulr • wben serious adwrse events 4re identifl d by 
me agency bema of PllrtU:Wllt con ern - tb dru '$ printed rruueriills c:ltT}' a 111'= 8 3bow those 
d",,", . fCec ... urrounded by a printed bluck x - rh\l$ the ":unc. an "" "1'1e. ince July 200S 
fluoraqumol ... family = ~qulfed 10 have bl.:l L: bo~ \\ aming for lendon nlplUfe 
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negative and Gram-positive aerobic bacteria. Transfer of lenes containing DNA coding for 
antimicrobial resistance has been reported but as vet is of little clinical significance. 
jGatifiolCaCln Is rapidly absorbed from the gastrointestinal tract. Peak plasma levels occur 1-2 
hours after dosing. It is widely distributed in body tissues and concentrated In the bile. It has 
a plasma half-life of approximately 8 hours and Is excreted in the urine mainly as unchanged 
drug. rRmlnatlon half-life 7-14 hours, with more than 70% of a given dose being excreted In 
/48 hours. Bioavallablllty 96%; protein binding 20%. 
Clinical Information 
Uses 
Treatment of typhoid and paratyphoid fever and Infectious enteritis due to Salmonella 
enleritldls. 
DosaBe and admln~tratlon 
Children and adults : lOmg/kg orallv (maximum 6OOmg/dl every 24 hours for 7 days. 
A practical dosing with 200mg and 400mg strength tablets win be as follows: 
weight band 
< 15 kg 
!Skg to 29kg 
301q: t049kg 
>=5Okg 
Contralndlcatlons 
daily dose 
lOmg/kg 
200mg 
400mg 
600mg 
Hypersensitivity to any qulnolone antibiotic. 
• Diabetes melltus. 
• Pregnancy and lactation 
Preclutlons 
DISTURBANCES OF BLOOD GLUCOSE. INCLUDING SYMPTOMATIC HYPOGLYCEMIA AND 
HYPERGLYCEMIA, HAVE BEEN REPOmD WITH GATIFLOXAClN. USUAllY IN DIABETIC 
PATIENTS. HOWEVER, HYPOGLYCEMIA AND PAR11CULARLY HYPERGLYCEMIA HAVE 
OCOJRRED IN PATIENTS WfrHOUT A HISTORY OF DIABETES. IN ADDITION TO DLABETES. 
OTHER RISK FACTORS ASSOOATED WITH DVSGLYCEMIA WHILE TAKING GATIFLOXACIN 
INCLUDE OLDER AGE, RENAL INSUFFIOENCV AND CONCOMITANT GLUCOSE-AlTERING 
MEDICATIONS (PARTICULARLY HYPOGLYCEMIC MEDICATIONS). PATIENTS WITH THESE RISK 
FACTORS SHOULD BE CLOSELY MONITORED FOR GLUCOSE DISTURBANCES. IF SIGNS AND 
SYMPTOMS OFEITHER HYPOGLYCEMIA OR HYPERGLYCEMIA OCCUR IN ANY PATIENT BEING 
TREATED WITH TEQUIN. APPROPRIATE THERAPY MUST BE INITIATED IMMEDIATELY AND 
GAnFLOXACIN SHOULD 8E DISCONTINUED. 
Reduced cIosiijle should be considered In pat ients with hepatic or renal impainment. 
Gatlnoxcln has the pot nlialto prolong the QTc Interval of the el ctrocardlogram In some 
Individuals, with an Increased risk of ventricular arrhythmias. Care should be taken In 
individuals taking Oass lA or Class 3 anti-arrhythmic iijlenLS. 
GatJnoxacln has been rarely assodated with tendon nupture, usually In elderly patients and 
those receiYinll corticosteroids. 
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GaLinoxacin should be administered cautiously to patients with epilepsy or raiSed 
intracranial pressure since seizures have been reported with other drugs of this class. 
Use In preBNncy lind early chlldllood 
Gatilloxacin should not be used durina pregnancy or during lactation. Use in chadren is 
controversial, since qulnolones have been shown to induce arthropathy in t he weightbearlns 
joints of youns animals. Although damage to growing cartilage has not been demonstrated 
In humans, use of qulnolones is not generally recommended In children and adolescents. 
However, In severe Infections such as enteric fever the benellts are considered to outweigh 
the riSk. 
Adverse effects 
Gatinoxacin Is generally weU tolerated. The most frequently reported adverse effects are 
nausea, diarrhoea, vomiting. dyspepsia, abdominal pain, headache, restlessness, t remor, 
confusion, rash, dizziness and pruritus. 
Myalgia, tendinitis, and hepatic lind renal disturbances have also been reported. Rapid 
heartbeat, mental confusion, hallucinations, agitation, nightmares, depression; 
photophobia; tendon rupture; insomnia, chills, fever; back pain; constipation, inflammation 
of the tongue, mouth sores; abnormal vision, ringing In the ears occur occaslonany. 
Hyperosmolar non ketotic hvpergiycaemic coma, diabetic ketoaddosls, and hypoglycaemlc 
coma have been reported and are potentially fatal If untreated. 
Drullnteractlons 
Systemic exposure to gatilioxacin Is Increased with concomitant administration of probenicld 
and reduced wfth concomitant administration of oral iron compounds and antacids 
containing aluminium or magnesium salts. Significant Interactions are not seen as a result of 
afrects on major cytochrome P4S0 enzymes (3A, lA2, 2C9, 2C19, and 206). 
OVerdo5a(le 
Gastric lavage Is of value if performed promptly. Electrolyte balance must be maintained and 
cardiac function monitored. Serum concentrations of gatilloxacin may be lowered by 
dialysis. 
Stora,e 
Tablets should be stored in well-<Iosed containers. 
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APPENDICES 
Ap pendlx 1. Patent status 
AppendIx 2. Indrvrdual presentatIons of lenerlc ptlfloxacln In IndIa 
AppendIx 3. ACCESS RESTRICTED TO REVIEWERS UNTIL PUBLISHED - Phannacodynamlcs of 
latifloxacln In patIents wrth typhoId fever 
AppendIx 4. ACCESS RESTRICTED TO REVIEWERS UNnL PUBUSHED - PopulatIon 
phannacoklnetlcs of catlfloxacln In south east AsIan adult and pediatric patients w Ith 
typhoid fever 
AppendIx 5. Updated Cochrane systematIc revIew and meta-analysis of f1uoroqulnolones 
for enteric fever- will be submItted later 
AppendIx 6. ACCESS RESTRICTED TO REVIEWERS UNTIL PUBLISHED - A randomlsed 
controlled trial of ,atlfloxacln venus chloramphenIcol for the treatment of uncomplicated 
enteric fever In Nepalese chndren and adults 
AppendIx 7. ACCESS RESTRICTED TO REVIEWERS UNTIL PUBLISHED - Blood Clucose levels In 
pulmonary tuberculosis patients treated with latlfloxadn 
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Abstract 
8.tckground: Typhood fever ",mains a public hea~h problf!f11 In Vietnam, With a sig nificant burden in the Mekong River de~ 
rcgion. Typhoid fever Is caused by the bactcrial patl1o<;lcn Sdmonfrlla mrmea scrovar Typhll5. TyphO, which is frequently 
muh::trug rI>5I,toInt with reduced su>ccpt1biloty to fluoroquinolone-ba>Cd drugs. me first chOICe for mc treatment of typhoid 
fever. We used • GoldenGate (Iliumind) .'>ay to type 1,500 Single nucleotide polymorphISm, CSNPs) and analyse the genetIC 
variJrion of S. Typhl olated from 267 typhoid fever patients In mc Mekong dclt.1 region participating In a randomizod t rial 
conducted belween 2004 and 200s. 
PrincipM Finding.s:The population of S. Typhi circulating dun"g the >rudy was highly clonal, with 91 of isola tcs belonging 
to a .ingle clon.>l comp of the S. Typhi HS8 h.plogroup. The pancrns of di,.,aliC WCn! cOnliinent with me presence of an 
.nd.mIC hoplotypC! HS8< nd a Iocaised outb~ak of S. Typhi haplotype H58-E2 In 2004 H58.£2-•• .ociated typhood fev.r 
CMe> exhil><ted evidenc of sign,"",nt geo-.patlal clustering along m. Song H4U bronch of thl! Mekong River, Mult,drug 
n!slsranICC was common In the cstabllshed clone HS8·C but not In t he outbreak done H5S-E2, however all HS8 S. Typhl were 
"al.dillic acid r(f~Jstant and CArried it r83Phe ammo acid substItution In the gyrA gene. 
SignlRanc~: The HS8 tlaplogroup dominates S. Typl-u populations In other endemic a,ea , but the population de>eribed 
her. was mo~ homogeneous than prevlou>ly examined populations. and the dominant clonal complex (H58<. ·fl • .£.2) 
ob Ned in this nudy ha, not n tectcd outside Vi nam. IncH11 plasmid·bearlng S. Typhl HS8-C wa, endemIC during 
me study period whi lst HSS-E2. ",hlCh rarely earned the plasmid, was only tra nSient, suggesting a selectille advanti!gc for 
mc pb>mld. T se dau add Insight Into me outbrcak dyromlcs and loca l molecular epidemiology of S. Typhl in soumem 
Vietnam. 
O ...... :_I(I'.DoI ~<;Qo rt . I)o.jyPI.I .. IlP .... QOl1lr __ fMtual QfI, .. J\odrut~.~" _1IIb1)1Jho H..,...,..,.,on ......... g", ... 
OtJw AlgI c:I \M:r PloS MGt hup [)(, S('t e429. dOl: o.llTl~ "' .. ~td.0000929 
Ecf;'or. 0iI'¥Id Jos4'!pt'I I!mf!fl. ftlf CI • \V,y. .... 10fI VAIoff"\lty t!dia l ~~ llrtt!KI f'S 01 Atn@flC.a 
.... _..-I ;.Jy 2 20'0; "<COP'''' ~o_lG, 20'0; P.bIi.,.d hnuory " lOll 
Introduct ion rc~io" [ I 1, wid. " meow incidence of -80 CL>< pee 100,000 
people p"r .... [1.!!,3,1,. "",,,,,,{I. T)1)lu \ . T)-phi:, ,he 
Imng t)pho:d th-rr, is tnlmm:tI d humlln-to..num3l1 
In rt with r s~ nir..u:oo . 
1 he f.nt mull.Jru n: : lanl WR; dd:ned rt1 ., 10 
dolorampnel1ico1, ""'p.cl1.11 ."d c,,"U'.lIlOl<uok l)opbrul ,1:nu. 
in "'- tnam lIrrrd in Kkn Gon In the: (OOn.g n r (kll3 in 
1 1 l~ , 3M m\Ct' then rh c: Ouoroqu-nolonts have Ixcomc the 
Ii ... , <hoin: tor ,il< tTe.,antn, of tvphold f...... IDR r yphi is 
lbuoll) '>tOO with cIf· traruf',=bIe In Hli pl:wmdt anym 
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Author Summary 
Typhoid fever remains 3 scnous public he.kh issue In 
some parts of Vietnam, including the M""oog delta region. 
Typhoid is uused by the bacterium Salmonella Typhi, 
which is frequently multidnug reSistant and shows reduced 
susceptlbl~ty to fluoroqUinolone-bdsed dnugs. We as~ 
singlc nucJcotide VarIAtion in Ihe genome, of S. Typhi 
organisms Isolated from 267 patients With typho d fever In 
the Mekong delta between 2004 and 2005, .nd identil1ed 
genetl",lIy dIStinct S. Typhl strains. We .Iso detected the 
presence cI genes or mutations that confer drug resistance 
In Ihose strain .. W. found that the va" majority of typ hoid 
cases were ",used by one of two subgroups of HS8 S. 
Typnl, referred to as HSS< and HS8-U_ The HSI1-E2 group 
appeJred to c~use an outbreak 1M 2004, affecting patienb 
Iivlnq ,n a small zone nc.r the Melconq River. The other 
group. HS8<' WJS present throughout the study perIOd 
and arrected patients IivKlIl in a bro"".r area o( the 
Mekonq River delta. Most of the HS8< strains were 
reslsunt 10 mUkiple drugs and earned a plasmid encoding 
multiple resistance genes Howe",r very (cw HSlI-E2 
>trains were multidrug resl'tan~ whICh may expbin why 
the strain did not persist after the ink ... 1 ovtbreak. 
mulnplr: rf' 1&tancr gt"nu l:n~l \-\1rhln moh!k nt': ltc t itltW'n 
( ,7,B 10] 8.,,, ... IQCj I tn IQQS, 0'" RO of Typlu l!':lln, 
i>lJlat<d '" tilt r,kon! ddr.a "giro w ... ''J'On<d 1(1 bt MDR 
( II" and d«un<d 10 .ppmxim:t .. ly!>O • bttwan 2 nd I 
A 
N 
f 
5. -Y""l ln tho Mekong ""itA 
r~,II,121. Th. " "'lint m,y haye Ix .. c tal ""d by tht chang< in 
II~alm~nt. policy Ilnd the widl""ipt ead U»C ofllooroquinolones uch 
d pl-olloxacm and ofloucin), 'Whi"h a~ dfecl ~\le agam t J\lDR 
II,.,ins [I3, I4j 
\'\bile h:gn·lcvd re~jt:lnCc. to fluoroquinolomt rema.iru m.com· 
mon in ietnarn and other mdc:mlc ryphoid regiel , there: h 
~c.n a $h. . trp UlCrQ4t in the proportion of Typhi isolatts th21 
...... is tant I n;lIidixic acid (l l] ' altdLW acid (Pal i, • 
qulnolone anhmicrobiai (Ih p cu~or of Il uoroquinolooa) and 
the main nl«ron: u f 'IaJ rt isl n« in oS: Typru j mutl lioo cL 
Ihe D:-l.'\ !\yr. c KCllC , OTtJ [ 1,15]. Typhi .. mit w'.th ' al 
r btance-cunft:ning munoo( in the. ",A gene wualJ h:.tH 
ekvllfed minimum inhih:l.()1)' ntrnOOns iJCl to f&.aOl'"oqu:n· 
olone nllu',' t' such ' ciproi ""cin (MI ;"O.l~ ~~/ml' [ 6]. 
lIo~e'\- er, lb~c: o r-glLu ' 111:1 & nOi ret~\l cording to C I 
guidclinrs, which a~ currrntl d efine '" by i\fTC _4 ~g/ml to 
riprofi.oxacin (17 , E" en though Ih~t ! tnlMJ an nOI cbsJlfied 
rt';(f1tnl , l~y are of d :nial !mpolT3J\ct: sinct: t)'pho:d pan n n 
infttttd with Ic h train. rt::!pond Ie ,,\d 10 Ouoroqmnolont. 
tht"'I'Y [ 1 4 , 1~, 1 8,1 ~. 11th p,, :.n lr.qu.n~y My. protnlCttd 
rll! er and an in reued ralt: of rtbl'St, compued I It t. lJlftctro 
with strains that do nO( h \.e 3n e.levated MI to Ouoroquinol e 
,,.\ \lC < O.US ~ Iml to 'pt flo ' n . nd < 0 2~ ~ 1m! to 
olloxacin\ (l~,18,1 91. Rtuta= to , a! is d.trtfOl't oficu u td 
tl tn,lIker 10 predict how".,~ a. pa.cienl will r pond to Ihel":lpy 
with 0 I oquinol 
Thr incicknre: typhoid fl!v" has ckdinf"d in l~tnam 
B""".,n 1"'11 .nd ' 001 .ppro im.1tdy 17,000 r35<! of 'yph",d 
ft\'t. r /blood ruitUrf: C n6.rmt:d and syndmmlC cases' were rrpo"~ 
Rvu'. 1. Loatlon of hoopltal. ln th. _ ""9 ,tv.- d .... of Vie", . .... (A) Map ,hawing the 8 VIot",m.", ~ns str .. chlng from the People, 
RI'p>Jb1ic d CII, ... In the north to tho .blng I. I d In tho ,outl\. Highftghtfd in oroy b Mekong m",r delta (l.J<ing BAng S<lng Gr u Long) reg"'o, 
which Is the ""ItI .. ",m(»1 o(tht ol\1ht reglo", and co .... " oW.OOO km' . e dotted box Ct)'""ponds 10 the .... magnofjed in (JI)- (SI M"P ,how<nO' 
- :u.ooo ' of the eIc_ ,......, dr .. ; htghlog""'d are An Giang ptOYIn<l! (green) and Dong ThaI' ptov",ce (grey) . Also htghlighted are the 
ploylndol holllUls of /In Giang PfOYII"'C and Dong -hap (y). di<ect distance between the two hospbb b 115 km. 
dotlo. t371~ ... ""lpnttLOOO09 .0001 
' . 
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annually 1hrough Ihe It.hlametr nanon..11 ,urYt.iD:tnce syste.m 
(1 .2), while only 4,323 and 5.030 annual typhoid f.v.rasos w .... 
reporl,ed in 2004. nd 2005. 1-etp"Clivcly ( n:t': I' lalln~ titule 
of ~I ealrh and Epidemiology. M ini.try of II Ith. ;"m m). 
Ii wov<r. 15% ofLl__ CUlTed in the t k"",ddta [1.21. 
likely ""ciated widl high popobtioo cleruity . nd 'he prop"tUity 
of lhe land to bccoru. rura ... .! with IIoodwat . In lhi. rqion, 
the occumna: of . )'Phi isolates that at<: LOR and aI resisoans 
sev<rcly limi" ""atOlCtlI optiorlt. More than 95% of oS: T yphi 
isolat<:d in ,he Mdwn della an: now re,i5cLnL to a1, placing. 
considel'1lble pre rc: n the .neroYe rue of fiuoroquinolotle. 
(11 .12). To compare a1"",.tive thenpit. for typhoid fever 
potienss infected with .tr.tiru lial .... ~LOR and al .... is:tlllI. a 
randomized controUed trill comparin prifloxadn (a nr.'A.'t.r 8 a 
_thoxy Ou()l'O(Jllinolone) nd u ilhromycin ( tn3crolidt 
conducted durin, 200 .. 200~ in It.. !\Ioko", della rtKion (20). 
T)'Phoid patients (adul .. and children) ....... recruired inlo It.. 
srudy at thre. ho<piClIJ in 'he south of .. rrwn (d.tail. in 
Malt rials . nd l\Ittho • loeaM ..... highlighl. d in r>gu" 18~ 
II ...... we used a hi II-,hroughput singl. nodeorlde pol)morphitm 
( NT') typing .... y 'a in"t"i ,. the popul rion lin lurt 0( oS: 
T)'Phi collected during L1", IlUdy (20) . nd 10 d<lmnmt lhe 
generic methan"m. f dru rtsisr:ance in thi, ypbl population. 
Materials and Methods 
Ethics slatemenl 
The study wu conduclcd accardin \0 the principle. cxprtlo1ed 
in lhe Declaration of Il<.lsinki and .pprOved b the Institu tionAl 
Reyiew Boord of Ihe lI"",il..! for T.'Opit:al Di:Je •• and tt.. 
Oxford Tropical Research £ulia Commitl e (OA1RE . All 
paricnss provided ",rillen illfoewed COrueD' for the eollectioD of 
aampks and .ulmquenl ~)'5is (writ .... infonn con .. nt .. 
provided by tl", parmts or gu;udlan .f children uncler 18 Y"~n of 
ago 
Patient recruilmenl 
. Typhi "u!aIC' wcre oollccu:d durin muhictnl. r t;Iinjc,.) 
lrial (20) tondococd be"""'January 2004 and D<ctmber 200~ at 
(. ) the H pilal lOr rop:a.l DiKutJ in Ho Chi Minh City 
(n - 10), I Don Thap Provincial HOIJlilai. ao wh, D Ollg 
Thap provina (n - 2" and (e) An Ciang Pl'OYinci.al H ""Pita!, 
Long . uren.An Ciangp""';.nce (n - 232). Locali o((b) and (e) 
at.. own in f'tgure l B. Adul.. nd children 0 r 6 months of age 
...... til 'ble 10 be induded in Ihe IlUdy if Ihey had dinic:illy 
.wp<C1ed "" eoln. rt-confln:ned uneomplicaocd typhoid fevcr nd if 
fully ",formed wril"n (on<tn' h:t<\ be~n obI ned. ""ntnts wert 
I I.d foe I}phoid (tri. (vi., stool calMe) rluring follow ... p 
appoinrou:n lJ 3.1 I. 3 and monlhs an.r discharge from h Ita!. 
The 267 isd .... ' pn!~n .. d In Ihis study ounitu neatl) the fuD 
campl.mtnl f 237 yphi ioolued from cult"r... tf"!TIed 
l)'Phoid p .. tiLn .. eDroII<d in II", trial; thc recruirmenl fiow for 
whk h ' d 'bed in dtr:ill In (20) 
Antlmiaobial susceptibility lesting 
All miC1' i.'I '"OC.pnb~lIY retrin was ""rfonnw . , the limc of 
inl ·oJ i§Obcon by d:.c <iiII'll 'nn tordin t bnk lll LAboro,ory 
·mnd.reb ' ",riMe ( &,lidd"", [I . n"microblal 
I d were: ampicill:n. chlonunphe",col. 'rimethoprUn-sulfame,h-
o.arol. (Co-lrimo",.., • nalidixic add, cin, ci fi . llt 
t ud cel\riaxone (Oxoid, ill " . K). MInimum Inhibilor), 
oncentntiom U t) for amoxicillin, hloramphenic.oa, nalidixic 
acid, oOoxacin . cipro x.0l. gatiO.QXIcin, edtri one and 
azithrom)'cin .. ~rt d.:t rmu>ed by £-It I (AB Biotl' . ~ 
S. Typhlln the Mtlk.ng Deb 
wedtn) ,(uh:idrug fr. i tan e DR) of isola ltl Will detintd 
r~i5ta_nce to chloramphenicol ile 32 llg/ lnL), arnpicW:n 
Ie ~32 ~glI)1L) a nd Inrocdlopn..U- linunrlhOJalW.e If 
"'8/ 152 ~g/mL). Ntlidixlc cid resiJtance wa defmed by an 
MJC 3~ ~glmL 
Bacterial isolation and DNA preparation 
After initial isolation. S. Typhi wa. ""red a l - iO'C in • 20% 
glycerol solution Ulleil required for furlher ",,>lysis and D, A 
t.Xtl'IIChon. To ~vive frottn orpnisOl!, M nkey and J. ylose 
Ly.ine D carboxyw. .rrn) agar pial .. " re inocubled from 'h 
gI)ttrol solution lid incubated at 37'C overnight. To .... urt 
c.CIfT'Kt i~ntiflC!lI:ion. colonies wt:r~ chechd UMI slide a.wturla 
narion with serotype sptcific antUtr:a i, ) and an D-rdeva.nt 
Ilnr15t:1"'3 a neprn.-e control ( 1) ·J'urex, 03.nford, nit~ 
Kingdom). Two mL of nutrien l broth were inocuLlIcd with ,. II! 
• T)'Pru colonies and inrubarro overnight. Ov might cultu • 
wert cenlrif" d and T)'Phi DNA was ext.r\Acltd using Wizard 
Gtnt>mje D A Purificru:' n kit (Promega, USA) rc(omnxndw 
by rhc manufacturer'. " ,id d in ... D w.u .. <>red ar -20'0 
D w.u qu~nri&d u, ing the Q.uanl·rr 1"..:oC ... n run 
R.:tg.nl nd Kit (lnvilrogtn. UK~ S. Typhi 01 cont:"ntrati ...... 
wen: ..... ju!tcd to 50 ng/mL and ~ ng r.£ ON ~ue piptued 
inlo 96-,,~ pL~ ... Each dI phte <ontalllW "'1) oolates in 
duplicate and lho sequenctd Typlu ;"'blt 10 otrOl fo r 
.... y reproducibility. 
Determination or chromosomal and plasmId haplotypes 
he cbrotnosom>l hap! typo of S YJ>!u iJoIales ,.... dol .... -
mined bued on aJIcIA!I pr ... nl :U 1.485 cltromOtlOwai NP loci 
idcnrirted previously from g .. ..,.ae-wide UI'Vq" [12.21) and liI ,ed 
in (22,23] . Inr;H1 1 plasmid hlplocypes wert detrnninw b..cd on 
tighr NP len06ed ",-.vi"",I, [22,24) Me:! .... is' . ne. g ..... 
qur.:ncu 'htrt'. iUltfTOg=Utd lJIl:ng additional oligonuckol idt 
probe. (lisIW i.. .bl< I). All loci -.-. inlermgattd using • 
GoJdt.nGalt ctUtom oligonudf'()cirl~ array acrording to tht 
rnanuraauru', stlludtud protocols (Dlu1l1iru). described previ • 
ou>ly [22.23]. A m .... imum-likclihood phy netic me based 00 
c:hromotomal "' .... coDlU'Ucted uai.ng me RAx,M.L toOwan: 
[25). 
Statistical analysis 
O iu icaJ dltta W1!re enu:n:d intO an el<ctronic dambaJe (£pi lnfo 
2001. CD • rJanl:l, US ) For oomp:u;JOf\ of pm"' dtar.lC'~ 
. . accon:Iing '0 infcering TyplU haplol)'pf'" Krudtal-WaDi 
I III w .... u",d for naI . of oontinuolll """,,bit ('ll" length of 
, oy In hospi ,nI, r.""" cil'lU'3oc. tirot) nd Iogimc I'fll't!lIOll w:u 
us.d r ca,egorical v riabltt (pr .... nc. of sympfom.). Odd$ ratios 
wt.r. adj l tM (or d ur:nion of frvu prior (0 admhs!on and ute of 
antibiolia prioe to adwitsion by includi1lg Lhe1t riabb in th 
JogUtic rtgrwion model. Wlu:re data was wi.Wng for parricuW 
paLi nl and variable. tbat pa tienl WU cxdudtd from waly,,, of 
tlull yariable (Ns35 par'"nts). wo-Illil<d p-value ...... reported; 
tltUlit:al anal)'" '" ~"'rmed using ,he R ~ (hnp: 1/ 
www .... pro,itcl arg/). 
peR amplification and sequencing of gyrA gene in S. 
Typhl 
hiOnud"otidt primtn for rhe .mplllicanon f the qmn olont 
~isr,nce dth!nnining rt£iom in tht )'phi orA ~nt wert :u 
follows [ II]' VRAIPI 5'-TG CAC A GGG C G -
3' and CY 5'- A C1' T 1\ C ·)'. 
PrtdietN R aroplicon size was 341 bp 
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for ... 5 ~conds , 
So -,phi In the Mekong Delta 
\f:U~ (u3ndard I rm3J v:uiabl~) ofl65 lhan 0; a poaiuw: cort: wa! 
iIUPrprt"ed 11 d.spt- ion ollocallo.U. 
Resuhs 
S. Typhi population st ructure 
~...,.. tly c:k\~wped ')'Ping S)'Ihttn, b.. ...... ~d 0 11 lhe lfuult-aneou! 
interrogation f 1.48~ f yphi chromooo,nai single Dude ,et. 
polymorph~j Ps) ming a CU!lom mumma lcknCa(c amy 
122.23J. wed 10 • .nal)"1< each or <he . Typloi ; ICL Tnil 
pplO: h f: fail'S lhe unequh J - 'gnmt'Ol of isolattt to 
h..,1 'YI '. all ing cJo.dy relaltd rains 10 be distinguishtd 
phyloge tiall ba.ed on ingt< nucl<olide chan '-., 01 287 
p:uienu wi lh uhurc COnfllUled r.pl id feHr recruited betwc:cn 
Janu.ry 201J.1 nd Ott.robe • .!005 (20]. 267 Typhi " ..... 
"'-:t~lb\e for. P Iypmg. Th .. t meluded S T yphl ool.ltd 
from blood cI11rurl' 3l admwion [20] OIll' rtlapst :~te 1nd two 
f,N::\! cnia~ i!ol.uN Iota! of H S. Typhi (\ 3 i$Obftd from 
i.n~ and one from Dong Th.p. randomly disonbuotd ohrou b-
Oll ' Ihe ludy riod' wcre nOI :a.vaiL>.bl< for P Iyping. 
10f>l of 26 1 Typbi "ob ... (. ) w .... of lbe common I 
h'plogroop. 1 h. nm':nmg i$Ob,.. "..... of h-,pIol)'Jl<' H I 
.- " .. 8J I ~. BJ J. 1U64). 1I 1~ floolare 8]261). H~O \1501 t 
BJq) and H~2 fl lare 1tJ3; t tigun: 2 and Table I) " ~ 
f )phi IIObI dispb.yed ,...n:..ion ... 10 ' NP loci \duaiJ<d in (23D. 
which diff.n:nci.a.~d JeVtn diJtinCl sub- H511 haplotypel. hown in 
tgll ,,. 2. Trow~· ... ~r, ?4 ~3GiI) of Ihdt: isol.:UICS be. nge to Ju.St 
Ih"" I"'tly ,yl ... d rr~8 h.plo'YJl<'. d, i .. d • £. 1 and l'.2 in 
,- ----- ~~;;)S (~)- --~ , -s"N-p----- -------H58~---_ 
o 0 (N=281): ,'--......... ~ 
~ 15 SNPs 
100 10 ~ I : I 
: '-- ./ 
I 
I 
, 
I , 
E<l2-- 9 1 
I 
I 
I 
I 
I 
Figure 1_ PIIy'Iog"" .. lc d1Jtrlbvllon of Typhl 1<01-. Gr"Y nodM 11'1"""'" control kola .os (labellod by kolab! code and haplotype group), 
un I<!d g"'Y cud. Indica ... , '"'" roo .. ~ nod<, co"",pond to n0n-HS3 S. ")phllsoknO<i In this study (labelled with kolo", cod.~ black nodos 
show HS8lsolat .. _ln"", zoom-In on the H~ hApIogro,,!\ gr.y nados "'P"''''"' control 1$01."" (labelled by 1 ... 1 ... cod. 0( haploty"" code) ...... Mod 
g~ d.d.lnd-.. .,.. 100<; colou~ elrd .. Indlc .... node«o"",pondlng to HS8 S. -yphl kolatod In th10 ~"dy, node labels .r •• , In rhe text. nod. 
colol.M1 1m s In ng~ ] - ~ node ~~J IndIC.te fhe nJmb~ of ~OIiUf'5 on the 1C.!e a~ IndKa~d by n .. mber~ Clrc~J. 
datlO-U7I .xnolpnal.OOOO'l29gOOl 
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S. Typhll" the Mekong Delta 
T.ble 1. Antimicrobial resisunce pattern of S. Typhl haplotypes. 
s. T,-phi To'" Noll rtil"." I~ of MOIl l"cHl1 pl. mid ~ .. 
H"._ (~ of ... ilOl . .. , hapl_al ' ... 01 ..... _ 1 ' ... 01 ...... -' ''10 01 ..... '_1 
HJa.C " ..... 911 117~ '021- 0l1?l'Ml ,"'-
HSa-E' l S'O!;! ' 5('_) 1Sn~ ' O(9J,.. '50000l0I 
Hsa.n 
"""'911 ,og ('000.) 21119911 '7 ('5911 1'('~ 
Ott- HSI 19(7!tI ' 6(80 ' 6184911 1&(80lII 131_ 
N_sa 6(2'1/ o ID!O) o l1IlII o (!)OO) o (OOW 
ToUI 267 257(_ ,s.~ 119 (S2l11 151 IS6'oI 
AI S. TypN w ... t IlOIIted from blood CUltufo, bC@pttwOthatW"t (dtM frOfT'l tht! stool, d two dlnwtlc. cltlien . 
.,ndudes on., ~ a"bge S. Typhl isobte. .. at • NitUclIdc. kid: OR . multici"ug ~t P~CII of 1~11 pb~id was: Inferred rr-om GOki@f~I" assay ~Ib 
(ollsola~. 
<100,1 0.' 311 l)ou",0I...,_29.\oo' 
figure 2 (number1 given in T.ble I~ TI,. &"uOO1e of S. Typbi 
strain AG3, isol:l1<d during lh. lIudy {arch 2004) from a typhoid 
ftvtr ptritnl living in An i:mg province, WlU lequrnced 
previou.1y [21 }. AG3 bolongs 10 till: I ·E2 hopl"'YP", and 'N! 
SNPI oepara,ing from hopiotypes EI and we .. origiruilly 
identifJoed by .000ys~ oftbe AG3 genowe. TlterelOre, the ability to 
differentiate witlain the cluster of 242 S. Typw iiolal<S 
dqx:ncbl\t on the inclusion of Amin 03 in [he initial ~nome 
uqnendng stUdy Il!<d '0 identify NP loci (21). 
All bot one S. yphi ilol. ted rrom the Wood cullure of p:ll'it.n 
ailiDlIted to An Ciang Provincial ho'pital (231J2g2), w U as the 
l:\o'IO ra.ccaJ . Typhi straim isolated from dlroluc carncn in An 
Ciang; belong«! '0 the S. Typhi H58 Iaplogroup. The I'"m,.;rung 
S. Typhi iJolate BJ ( e fi&u'" 2) W2.I of the H45 h_pla<ypc and 
• iJoIa.ed from .yphoid fever p 'cnt who w re.ident in 
ne.iailbouring Can Tho provio«. Ilr(: padem al An iang 
ProYindal hoIrpiw rclap.cd wi.h IDp' m. of typhoid fever and 
had S. Typhi iJolated from blood culture )1 day. an..- tile initi:>! 
' .... lment (gatifl"".cin) had ""'. c"mpl.t .... Th. moil ... of 'N! 
pallt.nr w found to ~ a chronic S. Typhi camer. L1 ,h~e: S 
Typhi strains· the pa~nt'l admission and "'''''''' blood cuiture 
iJo/O.es and the mother', flecol 1101 ",. b<Jon cd IQ •. he S. Typhi 
H~8-£2 .ubtype The pari D~' isolates " re both MDR and 
earr.<d the Iru:HJ I ST6 piasmid (ICC below), whcreu d,. modICr', 
S. Typhi ioola.e W3.! p1a.smid·lree and us«ptiblc.o U fi..., line 
antimicrobialJ at me. ci:me of itobtion. All thn!.t.. isoht.a .... ·ut al 
re" .ant but It[ ·li .. to Il"tillo.adn 11 01 9 m 1m!) ,001 
(ultut"t=S were takt.n al 1 month (9 rpaticntj), 9 monlhs «:J3o/t.) 
and 6 month. (41 % of follow.up. Chronic faecal carriage of S. 
yphi. was de.ec",d in only one tri3I pat ient This w" a MDR 
H58-C Itrain iJob •• d from Itool 6 mon.1u after treatmen' (with 
pciflox,a.cin), which ...... mdiuin",i hable • all yed loci from 
lhe patient' original blood cul.ure isob.e. Both iioldl •• were :11 
res;" ... nt bu,.e"siti.vt 10 gatiOoJ<:lCin . 1l0 0.19 wg/Ill~. 
At Dong TI."" Ptovincial II <plmJ, only 3 of tI 25 . Typhi 
isnb.,. did no • .,..Jong 10 'N! H58 hlIplogroup. Two H I' I, .. ", 
!163 and BJ64; Figure were identical "' :~I <d loci .nd 
we:re bltd on corut:culiv( days from two p:uie.nlJ ftJide.nt in 
Dong Thop. third 1\1 'lI'lIin (BJ IO~; l lgurt 4) din;, ... d from 
BJG3 and 1ij6-1 at 16 cbl'omo mal SNP loci "lid .... idated in 
Dong Th"" 14 ID ntl after th c isolaca. Two aiblillgJ from 
Dong Thap proYiuO!! we.rt stdmiul.d on con.seouN-e d'l in 2004 
2J1d were both infect d WI.h ?IDR S. Typhi of d,e hlIplotype 
1I~8-C. 
Of tile 'e" . Typw strains ilolated .lth. Ho pi.al il>rTrop' :nJ 
Disc2ses in Ho a,i Mi.nh it)·, eiab t ",ere mem ... of the H58 
:~: www.plcl.!ntds.olll s 
h2pJogl'oup, with patients mi~", in Ho Chi Minh City (n ~ 4), 
Long An (n ; I), Kien Giang (n ;2) and An Giang (n=Ol) 
provinces. rd1r..Cling Ihe: nrger c3lchrne.nr area oftht hospitttl Tht: 
remaining IWO S. Typhi we", of hlIpIOtyp<. H '2 (BJ3) nd H50 
(BJ9) nd we .. i!olo •• d from pa.;"n" living In Bmh Ho. prov inc~ 
and 110 hi Minh 'ry, rtSpCcdvcly. 
here was 00 simple ;usociation betweeo S. Typhi hapk>type 
and patient oge, length of my in hospital, fever de.nn« rime, 
vomiting, :lbdnminal pain, hepatomegaly or relap... able 
However,. upon acmimon, patit.ntl inft.c:r,...d with S. Typbi 
h2pIo'yp< I I~£ «oded 10 "'port lower frequencies of diarrhoea 
and beadaclt. nd ltigN!r f ... qu,,"~ of "'"" ipation compur<d 10 
pa.ien .. inli:cr<d wi,h oth haplotype., including H58-C ("'. 
Table 2). 
Plasmids and antimicrobial resistance 
The GoIdenGate ..... y iru:orponu:d probe • • argeting IncHl l 
pJumid sequence.. aDowing for detection of .ne presence of 
Ind-Ol plasmid wi.hln tho genomic D. extracted from e:od, S 
Typhi isoia",. Th. ....y ,nd, • d th>! ~ .otal of 139 ,~ Typhi 
ioola, , harboured .n I..,H II pl.umid. AD pl ... ,uids "e~ of the 
!.cHI! T6 ... net .yp< (24) nd.U plasmid· boaring isoIa 'd 
belongal '0 ,be . Typbi H58 h.pJogroup (_ Table I) TIl 
MDR incH I I pbumicl was more common _moog H58-C iJol.te. 
.han H58-£2 isoIat.t (~% 19 " .. e T.b1e I). Of ., .. 139 S. 
Typhi isolatel giving pc>ai.ive oigna1s lOr Inclil l NP loci, 137 
9 . ) were dusifi<d as ~mR by antimicrobial 3luc<ptibihry 
.esting oonduc •• d a. the time f itoJ"tlon. On. otha loem l · 
positive iJol.ltt tested pasili"" b kl<aCate .... y lOr the ~ne. 
,oil, 1012, 4ftAl, tMClJR, .I1MJ, ht. rwd fIJI (r .. ;'.allct gents; 
functionsoudinedinTabl SI}IUte theMDRi,;obte., uhadJo"" 
MIC for cWoramphenicol. ampicillin d lrim<thoprilu..uIr.· 
m thosa:zole. An additional S. T phi isola"" BJ5, was resistant 10 
3mpkillin and trimuhoprillHUlf.amcmoxawle: oot Knsitive to 
chlnr:unpbenicol. ThiJ w:u con';,srr:n. with Golden >te .... y 
relul", which gave pasl';". SIgnals for tN! ..pC "'plication 
in.i.tiation gtne of Ind-Dl , res~ta.nct: genes mAB, 61D, SIIU, .lUtZ, 
4ftA7, but no signal r. r .. quence. from the IJI ,e"" eocoding 
chlororophenicol r . lance. A further 17 S. Typhi i ,ea re 
rcoo"t.d. I\mR ..,cordiJ'lg ' 0 th.ir n"microbial ,.hcepribility 
pan m at .he rime of ob.tion, but did lIot ' posiri.", for lnaD I 
pb mid 100. This fikdy rdlecrw los. of the [ncHI! pJs.msid in 
cl1ltu.... CIt' Slora~ betw •• n tho time of iJoLuion and D A 
extroctio.L Tht ~mR 'Wilt ofth infectio Typbi isolate w 
n ... iated with rev .. clearance tim. (p ;0.3. , .... o·,;<I<:d T· ..... 
Or treatmea' failu ;0.18, hi' "'st~ 
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5. Typhlln the Mekong Oolta 
Tabl. :z. Selected characteri.ti" af typhoid fever patients. ba>ed on basetine pre1entation hI,tary a nd autcames. 
S. T",hl _,..12 S. TJPhI "5M2 VI .11 0$. 
varillbl_ ".11""1 5.TJPhI HSI-C 5.T,.... ( .. 110 01 
.... -
Miu,,,,data 
1'1.107 ._157 ".117 
AI. (",01 ' 1.9 ' 2.2 12.7 001. -0" (-2.0.1.0) G.al 
lime I ........ 101.,.1 , .1.9 , .l.7 II I iliff. 0.2 (-1.0.1.0) 0.74 
F.vtr dUr'aftce (1w •• 116 lIS '2, iliff.' (-12.11) 0.70 
C-odprian 'J.~ s.MOo 6.'" OR 2.6 11.1.6.1) 0.03 
,",,;...tod) OR 2.611.1,6.0) 0.03 35 
11....- ss.7'IO 1O,1" 70.1~ OR G.56 (OJ2.o.lIO) 0.02 
,""i<'.todl OR OM (0.00.1.09) 0.10 35 
ow.-.... ss.,.. 72.~ 7.1.> OR OM (O,2t.0.7Il 0.00-< 
,""juttod) OR G.56 (O,JoI,o.OJ) 0.02 
_,*n 51..,. S6.1~ 'H~ OR OJIO OJ7 
lodj.lttodl OR 0.76111A7.1.2A) 0.27 
Yo ..... ,. lSs.; ls.s~ 150110 OR I.U 0.90 
,""ju<todl OR 1.02 (0.61, .111 Q,9J 34 
--" 
....,. 12.3"'- $' .l~ 011 1..\S = 
,""juttodl OR 1.30 (G.7q.2. 1' 1 0,)0 35 
CotnJNt1sart$ of stlKlKt c.harac.t8istIU wnong 264 typhOtd !ev« pMiHtu. (iA. ~luding CMf~e .nd , @t<lpSe isoIiJtesl fOf cont""'ous \QtiJblf'S age. tim, In "mpitat 
IIId MWf d8rance, ~~ ihown •• ITW:1rU and tf'lt stMk::k. glvfln Is tht diff«8\u In n"IoNnJ {OIff .. mflll\ -'.i@ 'nr i1S1.f2 S. T)-phl- mun \'llue for l'It)fI ·kS. E2 S. 
f)'phD. OtNt VI~k'dat. fnquency of S)'ITIptorns Mf feponed 1111,..,. af idmfsiion IMd of ,.rid.., chgnosed htpitomfglty; teS stfHSl:k h odch,..rio (OR) for 
IiS8-E2 S. TypN vs nDn·HSI-E2S. T)'pht both audt CA atld Ic(U.u1!d OR; .. artpot'ted talfJUltlld for cblt~n Mh!:w.. priot to IdrNsston II'\d us, af IntSbkrdcs pr!orto 
ItPIsskln. w.kl9loGb" ragmslo • Nt c.cfr4»risons shown .,. for p.denlS .,f«ttd with HSI El S. fyphl 'IS thos.ln~ ctad wi.n oth4lf S. fyphl hapc:Jtyp6 (kldudlng 
HS8-C .,d ottws); '5~ aIIfIftdtnu .,t4IfWII, fCl) IIf« g-rvlM In bf.6.8\J. 
dot,0.13] 1i"""""",,1d.000092U)02 
A [oral of 257 S. Typhl isola, wen: rais'"nt 10 nalidixic acid 
(N AD of <hue ilOb-let bdong<d [0 the li58 baplogroup 
able 1) and aD were ccprible to p tiflox. cin. cip Ooxacin IlJld 
060_in .ccording to cu,,,nl LSI guiddin .. (17]. S. Typbi 
h""lotypel H5~, H58·EI and H58-£2 were uniformly rc,inn, 
10 al. wilh th< <plion ofa ain Ie IT~U-C bola,. which had an 
in ttnroedi.tt ~O of 28 ]lglmL (r .. !ret""e d<flllod .. MIC 
2:321lg/w . The lCquelM. .. 1 U~8-E2 ;,ola' e G3 11:" ... 
mutal10n ch.ngi", .. rine ( to phenylal:utine 0) al codon 
as ill O,e IU'A gene (GyrA eral P!.e) (2 1) , wlocb is b wn to 
confer re.isLmco to at (25] . J1\ the pmcnt nudy we seq Uti cd 
the /I1rA gcne in 223 of tbe al rt1islanl isolates (87 %) and found 
the same C,·rA·s"c83PIIi! .mlno acid , ubstitu tion in aD isola le, 
t .. 1«l 
Spatial and temporal d istributian 
'Kure . 10""" I~ . podal dtMribution of the rtsidenc .. of 160 
ryphoid p:uun3 (dus infonn.100n WllS not 3V;:UJttble (or tht. 
remairuni p>rimll). Of !he pori.n tldmitl.d at An iJ.ng 
Provinciol Ilospit:tl and Dong Thap 'nciall lospitlll, . uffleitnl 
;addro .. detai l '0 aJlow for 2SsIinm.nr ofln'irudo ond Iongiblde w 
pro~ in 6 J ~:and 73~ oft , .... spccrivcly. This rep .... """ .. 
50% 2nd 20% of.11 blood (ul",,,, confirm<d typhoid fi cr 
p>ri<nOl I An C i og Pro ' ncial Ji oop""J and n 1 h.,p 
P vincia! I lospita~ '<tp!crivdy. durin 20(H 2005 In An 
)X'mn ' hornet clu ted round Ihe- Jl Inn Provi in.} 
Hospitnl, but abo ",ound Ih. ng U . u br." h of Iht 1ekong 
river ( e f"lgure 3). ~ .. , S. yphi i lt d to nl p tier! living 
ncar Ihis poin' ill An iJ.n p .. <lVinc "'ere or Ih. H58· • 
haplotype (01'21'&1' ill Figure 3). and ,IIi. group dewon,urated 
.igT,iW:an1 clu .. in usiD near .. t-ncighbour ana.Iysis (n =37, Z· 
score = - 1 14~\' In cout >t, • T yphl of lb. h pIotype 
.~: www.pjosntds.org 
w .... ;'oI:ued rciIIclveJy r""ucntly in neighbouring province. d 
hod a mo", sporodic clustUini port m (rtd in f'lgul'f 3). \\Ibn., 
isolM from An C i:mg ProvindaJ 1· spita1al"e O\lf:rrt..pre.sentt d io 
tllis spatial analysis. the apparwt iw.-n:LI< in typboid dcnliity in An 
Ciall is cow",,,, MtIr .001l T )-phl i5oIatioD mt<!s at lhe two 
hoopital.s during I~ study period (28 * at n Giang Provincial 
Hospital and !lO u Dong ThaI' Provincial Hospital). 
The rrmpor.ll diltriburion o( S. Typbi haplOtype. over 2004 and 
200~ iJ shown in f igure 4. Typhoid rIMr ca>e p<:..udjust prior to 
the OlU" of the wtl iCa$O(\ in < h yur, lu.s been ohserv<d 
proviouiily in th is rqioo-. [1 .3] •• monthly r.UllfaD. ,oIid tint in 
.gure 4). h. 2004, H58-E2 aJld H58- were bo,h prevalent (62 C. 
red in Figur< 4; 103 ? , orange in Figurl' 4). whel'C!l5 few iJola ••• 
of I-I~a. ~ yphi were o~" ... d dunn, 2005 (~ , 4 ; ... 
I ure 4). The dedine of "\38- =y be IltiOcl I Mth .el«:tion 
["or lhe Inc l'lIl ·lOR pi mid. wh.ich much more common in 
H33- ( rable 1). f"tgIJ 4- highll II , the rna' rity of iooI lOS 
collected during the sec Id seuon were 'IDR t.nd carried the 
Inclil l phumid n . 
Discussion 
Our d ,. show the """ majoriry of S. Typhi iaohl .. (n'" 261, 
00·,,) wl:ued from the. M.mng del ... dwing tire lW.,.,oar Iludy 
p<ricld belonged 10 tl .. H~8 hoplogroup. Furthcrmocr:, 91 of 
i~ .... (n ; 2~ belonged '" • ,in Ie clonal compla d T)1JIu 
H58 (nod.. 0, 11.1, E2 hawn in FiiuI'P 2), demon<lrating 
remarb k! hom~~ity in rhl" ,.phi pa,,\1I3.tion in rhis 
10<:11;00 during tht Sbltty period. The oboer."d I.vd of do .. ", 
, minance is g<t Icr than Ihat obs.rvtd in previous hilpiolyping 
studies of local T)phi populntiOn5. Among 34 T)'Phi iJobtel 
from J .ltar .... Indon"a bem I J 973 and 2005, • total of nino 
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S. Typhl in the Mekong Dd. 
FIgure 1. Spatial dlrtribudon of S. Typhl Ioola ... by h""lotype and year. me spatial dl$trlbutlon of S. TyPhi hoplotypes surrounding M 
Giang provlno al ho1poul In ( l OCH .nd (8) 1005. EAch POInt corre,ponds to the r.,identlal 1ocotion of. typhoid fever patient; colour IndICa .. ' the 
hoplotype of the S. - yphl I<olot" (with or w~hout plasmid): d.,k orang" - H58-0 wIth MDt! p lasmid, light orange - H!>8-0 without .'.lOR pIosmid, 
dark ,ed • HS8< w~h ""OR pIa , mld, ponk. H58·C with .'.lOR plasmid, gnry • othe, S. -yphi hapiotype:s.LDcatlons of the ho1pota ls are indicated by a 
white CtoSS on a red backqrolJnd. ~kclfCtc Iodates a r~dlus of 15 km from An Giang Provindal Hospka ~ arrow indicates the SO"9 Hau branch of 
the Mekong I"'r. 
dct 1 0.13111)0umalpntd.OOO0929.g003 
h:lplntypt ,rt ( Itl~1 ltd. "llh til" d Illlll..Ul l, 115Q lu.p ty~ 
aCCQunlUlX I $3. f bou(o, tJk" n C"<1 m I lI eqllCIll 1.-:\1'10 
gtn<ticaDy cL.t:lnl from Ha9 nd c npti .. d 2 1', of isobue. 
[°1) III Kalhtn3ndu1 l tpaJ, D OOOfttion of Typll1 isolal«l from 
clo~d.,.n ho",iulU;ed "i,n t)'plo id r .... r III 200~ 2006 ~ 
d minated by tne H!>8-C haplotype (66") but the db""'l H~2 
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S. Typhl tho Mekong DeltA 
_ TOIDI rnondVy rain/lilt 
•••• Monthly max. rIIfnfaIl 
0\IIIf' Z4 hour period 
Other 
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ST8 plumld _ D _ 
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H58 lklknown 
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300 
IDO 
o 
FIgure 4. Monthly Indd..,c. of typhoid cau. by hopiotyp<l. Sor hclghts Indicate the tala I number of S. Typhllso lated coc:h month d u, ing the 
stUdy. , ccordlng .0 tho Kale given on "'cleft·hond y·,xls; co lours Indica", t he combination of S. Typhl Nplotypc .nd pre, once of IncH 11 ST6 plasmid 
os II on In tho legend. Solid block IIno ~ toul ",inlall • • eIl month reco rded in lin GIang, dashed line • ", .. I1,. .. ,m ,,1I11.n occurring In a 24 h period 
d Jring eKh monch in An G' .. ng. ,alntoll .ole .. ,ho_ o n.he rig ht·hand y-axis. 
datlO' ll71iJO .... nal pntd.DOO0920.gOO1 
haplol)'P< oIso p, ...,n •• hi II f ... qu<ncy (19'.) (231 moo 
T)"phi :un! \x,,,-(.cn 2001 m.l ~ 1n ail!. i, Kt ll)':1, 8; 
we", 1I~8, al~,Ol' h t"'O clstin ulx)'p<. (nooo n alld j , • 
tgUJ"e 2, \olio r 00-<. ubu a l eqw.Dy h.gh rr uem • .k: (>40 
, ",cell 200 I a.ud 2008 (22,.. phi 1158 1100 B IUldJ 
(cD-'{'"in;uI IJ'''' ill ~.;Lrobj' n=prC' ru di ' :OCl IUl(:;lget. e.al h 
acqwrUl umql PJ iner tilt' 1 I c{ltllm n am~or of I 8 
(r ;gu rr '" H cm"Mo't'1' Ji!)8 nock- ,, £ ! nd E), which arc ml fi r 
9 1'. of b i t'. to th' OJ m Vtt mam art IMdy rtb tro rmd 
forTnl"d • right clon-.I <ornrl'~ drto,lTn,c1Ied by JII'it " 
( ""~ 2' 'Thu, thr tnU level It d(ln.'ili<y of thr I yphl 
popularion OMlyted m th .. m ,dy wo, """"I"'rlMIy h'gh f ht 
clonal (omplex (omp<iLn 1158 :, - I.. I And -C2 w no ' d tlCcttd 
in study POPUUIioIl in r-. .pal aud Ktuy. "htrt lilt .:un< ' P 
l pin method w tAcd [_,23 .• uggc C.n it wa have ristu 
Ioully in V i<1t!.UIl. 
it~ the ntlic homo Of ;ty \oIIo( I~rvcd, 11 "",;u)abi[lyor 
wholl-"!fnomt woqUf'OCf' dJl'3 ~r " lPhl " 3- ' i b rt 
P I , ('~cttd ur.nr lh( 1tud\', , Uowtd II! to dif'ftrt n t):Hr d ~ ) 
... LUM O'i"n= ,."h'n Ill< II """I' Jus. "'0 r 'ld<nnht'd 
in a:.n (. i ubc:l \"dfd mt hnmorrnf'('I111 gmup mto rhrt'e nOOt'1 
, 1.1 .nd 12 fl.", ... ~,of .... "'h no" \ > and L ' " TIT dominrut , 
C h '. I t 1 I{>u~ ~n to til ll ~8- n \\~ rt prt: ~1tI 
a. ooruW" rotc during Ih<: "'0' of Ih tud ( ~ 00la, •• " 
200 I nd ~~ in .!OO~~ II U, itol,,<. btlon in>\, 10 lht I - '0 
node \lrcrc moo dUr.l~ .2 • :03 iwLtt 'I tt , .. rt yu'tu:illy 
undt,wtd in 2005 (3 ' Ia,cs'. his Ch:ul ill 'h h,'plOt)'PC 
d. ,ribu,;':' , . nd ,oW nu",ber or ,yphoid G-oru 2004 '0 20~ 
i .n lcirog, lid 5U ,an ,brcak " .... cd by ypm II~_ 0 
d uring 200 I. W. addiliorully fouud 'hut H58-C 51"'; , had a 
much I IIg<r , ,,,,,uJ.tion ,,0,10 tI T6 IncHII -LOR pU' ll1id 
,h.u, H · able I'. We 5p«ulatc ,ha, the p"rsisltnco or H58· 
:ltr-.uns and the cOlTcspond mg tUapprOlrance or H[)l3-E2 way be 
a :' 'tM wuh a C('ImJXtl~T phtJ'lOl')pic adv3ntlgt conftrrtd by 
the: rnd ll l ~mR plaullld t10\\otvr.r , lt is importanl lo rt~mbtr 
Ih I nodt' is 3 pr«unor of node I') and W~ I;an only 
d!fft'rt:nnart 'l from txOll~ we had whole ~nome scqlJMl(:(' 
d.II' for an lI~a·E2 tr.lin from which '0 id<nrity ' :'JP, (2 1] Thu 
.ht popuLuioll f . I )'phi 001", 'gncd '0 node C by our NP 
typlng a III y be: UlOC"t: dh.(:Ne tlun UUl a ign~d to 1L306-E.2. It 
is 0 impon anl lO nole du.l sillCt our dan. cO\.tn just two )urs, it 
is p:h ible th:3.l au y CXHll pd.itive -.lvantil(C of I U S-C trains may 
be lIort-lived and Iherr i n ew:le.llCC: fi r long«ierttl replu:c.menl 
of H.'>8·F..:!. 
\\ . id.nrifoed '" cas .. of chrome f",::oJ camag< ci . T }l'ru 
dunng th~ COUnlt' of the (rudy . on~ tn :t. p3.rienr"1 rd3.Q\.'e: and one 
in :J p:t ru-nl "fler 6 month of follow-up 1b1S underllneJ the 
Impor1'l nC't of scrunini procl"dur~ fO idtnctY c:ani.e and 
etl ec:tive treatment t.,) tlinmtate cani nd rtdutt traos lo::nl n 
The f: f 'Ph i . 01.. wcre of lhe OOtDl .Ufll H!>8· .nd 
I S·C h.plo'ype., ~'I=tivcly Ill . p, tyi ClS<-<O<llr itud 
p<rfornKd in lh" M tkonJ cRll2, close COnt:lC' w:th a pa"en, with 
J.nUAry 2011 I Volume 5 I"u. 1 I . 929 
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typllOid fever W3A $ign ifi ntty 3 . ted with dt:vtt.loping the. 
dis. e comp'll"d '0 ho",il. J con!roo (adjuSl<d odds ratio (OR) 
=52, 95~~ cOll fIden~ in,.",:U (95% J) [1.7, 15.9]) or 
community conlmb (.djusltd OR = I I 9, 95 . Cl [ .3, 60.7]) 
(28] 
We 'Ao'!:re able to col1~cl I't. identW location (L'lta from 160 
typhoid pa&nlJ (61 , ~ While typhoid pao.nlll rtpo<,il1g '0 An 
Giang Provincial Ho",ital art o ....... prtsenled in 'hi< data se' 
(50'1> of all confirmed ... VI. 20·' of all conrU11,ed CllSt, a' Dong 
Thnp H c.:RipilaJ), the: appareut elu tting i.n An Dian (fiXu l'e 3) is 
COOlistenl with the awem1J isolation rules tit 1M two ho pilo.ls i 
which during tht study period ~, more than thn"~ , inlet higher at 
An Giang I'rovin • J Ho!piw ,han .Dong n •.• p II i,'" The dut> 
.... provides roughly equal representacion of p.ti .... '" "'f<etc.! wi<h 
S. Typhi H58-C (65%) and H58·£2 (62 ), <hus 1l11y differenca in 
tpatiaJ diitribution M:~ec.n patients preknrlng at tbe diffe.rent 
h"",i,'" . hould 00< affi I lhe diffcrcncu buwero .pa<i:U 
distnbu.ioo of <hu. haplotype.. paw clu <ring of S. Typhi 
H58-£2 W2I evident pamcubriy around the ng H»,u br.anch of 
,_he ~1.c'kong river, wbile o1.ncr yphi hllplorypcl ~rc more. 
bmadly dis tributed 'aure 4). Th. pari a! dU'terin, of tl58-£2 S. 
Typhi further ,o!'Porn a Iocafued ou.bn:ak in 2004 caused by 
these isolara. In conrr.u' , .he broader ..,ariA! >nd .t1l1pornl 
diJlriburion of. yphi 11511-C durin, the . rudy lUR"tt. i. may be 
wen .. rabli!hed in !he community and Co'" penist over longer 
dis.ances and 0"'" period . 
We a1so observed tha. lOme symptom. "'POned by poti<n .. 
Infoc",d wi,h H58- S. Typhi difrered from .ho .. infected wi,h 
olher . Typhi h. plotypa abk Z). Aller ocljustin for antibiotic 
use Il1ld duration ofrtver prior to admisswn, patients infected with 
H58-E2 S. T yphi were Ul ..., likely to report dillrrhoea :>nd 
headache oowpored with O~1tt S. Typru haplorypts (OR = O.~, 
95% CI (0.34, 0.93] and OR = 0.66, 95" CI [0.40, 1.09], 
.... ptctivd ), bu. were more commonly asoocialed wi lh constip .. -
t:ou (OR =2.6,95 I [1.1, 6.0D. n Us 'uggHlS II r. may be 
JOO)e phe.notypic dift"erel e. tween H58. nd other Typhi 
with rcsJXd 10 di e e, hC1Yvl~Ver IMe were pOII l ~hoc allaJ ~1C$ tuld 
no adju tme.nb were: made lOr multiple compari3011., h nee. mes 
... ociatioru , hould be inlupre,ro wid. Clution. How er if 
rnnfirmed in ~Uh8t:qut!nl prO!ipUrlYP slUrI:,.. i i, would be of 
interest to know wht: th t r th f!1i p!lenot),pic hat tt · tic were 
l3Sociatt.d with specific mutations in H58-F..2 S. ~l>Il' The two 
Nl'I differentiating tI.. F.2 lind from EI nd C ,.,., both 
synonymous (DUmb ( -> T in ... tA (nt 315); Co> in ,. (nt 
57 ! and our carli .. anal»' of the ;\G3 "I".nc.o <bt. de .. cted 
no phage insenjom and 00 b 'l!" del nom .t." wt~ no' also 
detected in oth. r sequenced H511 itol:ues (21 ]. lIowever, we were 
unable to ""rifi> if OlMr .ingle-base in,.rtions or dele""n. wen 
pret:or, which m:ly rMuh in t;nt inactivarwn with o fTespondin 
phenotypic tffioc ... 
Pn= of .otiml biaJ reslsm.nc. of Typhi rond '0 ""ry 
marUdly be"" .. n diffi ont typhoid ndomu: I'l! om In thi! 
p resen t ,"" ork, IU in thl- recent Icudy of K )an i tes 2], thel'e 
we..., high n.t<t of MDR oc led with IncHIi 6 pbsrnids 
~mong strains of II ypIli 1-1.58 h plogroup. TW • • u III th , 
,h .. presence of til pbomid may contribute to the ,b 
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1. Typhl ln the Mokong o.b 
domin:ln. T yphi h3p pes, nd r~ ~,ul l1 of our siudy 
conooow '" ,hi! hYJ'O,heli. n .. S. Typh i 1-158· ? , ubtype (wh ich 
was 8""" .. .uy not associated wid •• pllwnid) WlLI only tran';'n" 
whili: lht H58-C subtype (wbU:b woo IDO ... commonly auociated 
wi,h the IneHll ~{oR pbmlid) W:U """",n, in 2004 and 2005 in 
,outhern lemam. In K enya, aim"" all isola, .. of the dominan, 
1I~8 haplotype. carried the MDR plasmid, while lhe plasmid-c. .. e 
H58-G ",brype W1U only detected twice [22]. All the H58 i lata 
analyotd in th. P""C'Jlt tudy rt .... iJtant to Nal, conf....,d by an 
identic 1 mut.u ion in DrA.. Thi! is consistent with previnu, h)(tiC.1 
rtpOninr ,rong wod.uion .. befWt!en thr: al raitta nce phr:no-
Iype :llld th. 11511 Illlplogroup of . Typhi [12,22,23J. 'n,t 
pmenc£ r the same mutation conferring NflI resistance in aD 
isOOtt .. of H58-C, -'£1 and -£2 IlIgg"'" Ihii mutation way to v 
risen in tI,. common ana<tor of thia cIonnl complex, perhop« in 
flbj in ,Itt I og delta rogion, and j ill Con'1nlttd presence L! 
1~1y maintained by selecti,~ pr ... urt exened by the u,. of 
OUOl'oquinolont •. 
Conclusions 
During 2004 200.), typboid inlhe Mtlwng river del .. region of 
ieln.lm w aln t exdu,ivtly cauoed by a single NaI-re.istant 
donal complex of S. Typhi. Thil rdletlll a higher Itvd of c10naliry 
than obotrwd in other loaIistd S. yphi pof'ld:uions ,.,died '0 
d'tt, ",hich rn.'y be indJcativ. of hi her trarumiuioo ruta in this 
10 non. The blgh kvel ofNa! ....atane. and (D ultidrug reslsunc<, 
frequendy in die same strains, is coocerning and mntlnucs to pose. 
probl"'" for d .. sulXu"ful t Imenl. of typhoid \her. 
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lDf«tJo 1011b SoIn/Olftlla MlMOfJ em ar Typlllisoiaies thai hav reduced ttplllllU~ Ie oloxacin (1\\1 ~ 
US Il&"mO or dpro/lolllclll _ U ~ 0.125 11".10 have bH1I ... oclaltd 1011b a d layed respome or dtnkal failure 
rouowlJlt IrI'JlWmi wtlb lbese anUmlcroll&als. These lal are not dtlet'ted res51a1l1 USIPl\ culTI'lIl disk 
, .. !IC.'<'pII>IlIty br .. lqloInIs. We «amlned 8161solaJ .. or S. Typbl froa. seven Ian rounlrles. 5a'tenlnc for nalldlldc 
Kid mislance (MIC ~ 16 11,,'aIl) klenlilil'llllJolat ,,11b an .. II<. Kin MI or ~0,2S J.l&'tnl .nib a ..sUnil)' Olf 
97:Y, (253/260) alld s pedllrll1 or 99.3'i\1 (S52/SS6). For Isolates IOtlh a f1pro/lClX/ldn MIC or ~.12S Jl.&/lUI. Ibe 
sensltll1ty.... 9"-lI'k (248/267) and spedllclly "'lIS 98. ... , (540)5-19). A lOne orlnbllllUoo or SZ8 allll arouad a 5.1'& 
...... xacin dl", del«I'" tntl ... wllh an ofIruaacln MIC or 02:0.25 I1&ItnI "lIh . . .... slllvily of 9.I.eJI, (2.&60'260) and 
spedlidlYor (524/556). zone f InhillUon or sJU mm dtlocl.'II IsOOtI .nib a clprolloxacln MIC ot~o.l.lS 
1lIfm ... IIb. msllhollyor (251(267) nil peclfidly of94.l (517~9. An olloucln n or~6.25 I1r1ml and 
a dpro/loxacin MI of ~OJ.lS 1l&In.1 dell'Clod N .5% (34 ~) ttllsOOtles .. ilh an ldenll&ed qulnolone reslsllnce. 
"", ... 1", Dllallon and 81 .5% (JJ I{.w.o or u .... .,.1 co .... on .... IIDI """>1,,,. erine-I~plK-nylal.nlne mulalloo 
al cod n tIJ In Ib gyr .. It ..... ). Scrtenlnr; ~.r II JlctJxIt tICk' mislll""" or c.mIIoXllrln and oRolQlCln d Ii Inhl>llion 
~_ art ... Ilable for del«U", • l)'Pbllsolala wllh r"'uccd ftuoroqutnolonr !K't'pClblllly. 
Hntetic f" cr ' an infection causOO by SabnoneOa en/mea 
~roV3rs Typh.i and Para1)'Phi • TIl human renrict~d 
palhogens aTe Irarl5lllil1ed by Ihe focal· rnl rollle, and enleric 
fever is common in rep,lOl1~ with poor !!Iandnrm f bygie.oa and 
samlati n. There are V mali n new enteric f<'V.r infections 
each year, of which appro imntely 200. are (ntal (16). An-
timicrobial are e~ nria l f r appropriale clinical manns.-
menl of enleric fever, bU I anlimlcrobial no ;'Iance in S. 
Typbi and S. PUlalyphi A h3" b come a plobl m in re&ions 
m y be fDund .\ hu . I c 
\0 
$201 
»il ro th y ar~ od m.i b, S. Multipt -dru - I i 18nt 
(MDR) . Typhi and S. Paratyphi A (resL" anl 10 chloram-
ph oi 01, lIimclhoprim-sulfrunelboxazol , and ampicillin 
ar parti ul rly ommon iu 80m loc3tion in in and b ve 
led to large epidemic . I MDRS. Typbi l ra;n was re pon-
sibl~ for an IIlbreak in TajilciSlM in Ihe lale 1990., call ing 
OVer 24,000 infections (39), 
The occurrence o( MDR strains limits the opllons (or 
an limicrobial th rapy or en l ric fllv r. Th curreD! wno 
guidelines "81\" llhnllb Ou roquinol nes are Ihe o",imnl 
group of nntimi robi Is (or the Ir atmeot f unc mplicated 
Iyphoid fever in adults (44). Th fIuoroquino\oo • such as 
ciprotloxacin nnd otloxncln. rll comparatively in petaivc 
and .... ell loleml d and in early randomized chnk I Inals 
... ere very effeclive. Ilowever, S. Typbi and S. Paral'yphi A 
isolal s wilh r duced ll5Ceplibility 10 tluoroqumol n • hay 
be om'} commoo in in and are incr asio&IY commoo in 
Ii a (6. 8, 13,26,32,37). [of etion .... ith S. Typhi lraitl~ 
w;lh " Ie aled Mi s to ciprofloxacin and ofio'Wcin hav" been 
335 
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assoc"iatcd with tbe failur of treatment with thes antimi-
crobial and ill , aoed dis a v rily 15, 30, 3J, 36 43). 
Iove5ligatioos of S. Typbi witb reduced susceptibility to Huo· 
roquinolon h ShO"l1 tho? • mtion of el ated M I wilh 
raJ singl -b -p3ir mutali os in th DNA &yrase gene. 
,IOT.4 , and Ibe lopoisomeras gene parC (4, b, 33,42). Fu,tb ,. 
more, e.tlensive genome sequencing and ingle nudeolide 
polymorphism (SNP) inve5lig;nion { . Typhi slrains ba\fe 
funher .!hown the dramalic imJXlcl of rains ",;tb lOT." mula-
tions on the population structure of this monophyletic organ-
ism (35), Genotypingsnldles id ntified at least IS independent 
,IO.,.A mutatioos that b8\'c OC<'Urred within a d de and S111D-
Illaled clonal c:'p:uuion in i. and Africa (6,3 ). Thcs data 
Sllgg 51 that such strains have evolved rapidly and ate main· 
tained by a strong !dective pressure. 
The lnboratol}' ddection and ideot iliCtlI ioo of ra.ins with r -
duccd susceptibility to Huoroquinoloocs Ie mponnnt (or the 
treating dinictan, but such rains at\) t~g riled as susocpllbl 
by the current interpretive guidelines Cor fluoroquillolonc disk 
SllSC ptibiity testing 3, I t. 19). The illOlales are invariably re-
sistant to oaHditic acid. and susceptibility testing with 3 oalliixic 
aad disk bas been SUgge3led lIS a Mable screening m thod for 
reduced Ho roquinolooe SIl500ptibility (ll, 19). Th Britisb Soci-
ety for AJ,limic:robi.'\I OJemother~py (B C) bas rocomm nded 
that for invasive isoIat· of SalmofleOa, an M Ie ~ r reduced sus-
ceplibililyto ftuoroquinolooes should be del nained (3). 
H r we hav e;(runiued th retail oship ben.' en 8;>,A and 
parC matation nalidixic acid re$i:slance, ollm<1c1n imd tip,a-
Ooxa in d' k inhibition ToOne sizes, od M Ie for a large numb r 
of S. Typbi clinical hol:u .. from mulliple location in Asoa "\fe, 
a l6-ycar period. We sugg I di5k 811 ptibillty bre"l1'Oinls r , 
strain with reduced susceplibdil 10 ciproOo...acil and oHo. a-
em, ""hich may p rmit the diagno tie I boratory to d ect sucb 
isolales and oid th clinical mnna8= I r enteric (ever. 
MAn:RI,w AND Alb'11 10D 
. TJPhi ... aln _ .... TK S" 1)l'bi..,.., .. _ in 1II".axty _c c ... 
priie<l of 1OQb"'" <ollocl<d _ porI ./ ~"'I indcp:ndC101 II' ",Iio, Tloe 
.tajorily of IJI""tralno (516 ("on ) "" .. <otu- f,CI' nooo",o' d oontrollcd 
".... due"'" be • tm and:OOZ in teutlle,. Vie ...... T trbt. .,,'" 
condueled l~iot ..... d:lrd prot • ~ for III It _ar "'lime'" U!Cd. 
d<scril'edlnclo:! n._htrc (5.7 • .l>,31. _ .0, ~I~O ... 'u"d"'d .. d r"" S. 
1)phl .... lno wor kotn .. pon of n. .1 .,,"lIotled 1ti.,1 (p'li .. ..,ln 
"'N" <~Iof.nlflhetoii:.1 IISR 5J25&lZ7\) . , P tin n..,,;w, Itaohooo ao ~ 
Nqn~rorlJltue::..lIIte11t"uoc:ornJ' I i..~1i,'! ealCri::(' rbctwu;d~al 20M. 
The rcntJinin& S. Typhi tuiPs (J 101<11 0(1%) R: enl led ~twQ,;:n 3)021nl1 
200J par. of popubllOa-r-'<I p"""","1ioc 81,,,,,111...,., "ud' n,o""'l<d by 
AIUll,,1e Ir.: .. ~ ia I Dna, J.odon ("I - 21). 0 b, ~",t..deA (. - 40). 
lieU, Cily, 0""3 I. Chlrl. (0 ' 5 I , 1CD1kllJ. In<li (n - 25). nl1K, ~~ 
I'il<iolan to - HJ (6) 
AoIlJl1I<tc(' ...... 000al (0-1 ;rrom 0CUlII,1-... .. 
Cbioa.ladIa. an pati;Q.) and CllIlx"Iioo 0('00 mpor><y1. TwltI_I .. koo. 
V",lIWI lid Ind.. • - J7!) ...... addIlIOa;l\ly ,., lor """""'18 10' .(, IJ, 
prC ... dp:1EIDIIIJ_ TIo<oe_ ... p • d .. Ibe""""""CJIC>I .. nri31. 
Mlenoltiokleiul ... - Tbe""bl .. ~ .. 1 .uIIe by... nl .. lIc: .. ",1 
.,... .. d >glll ... " •• ""b S._.JI .. p.e,1k .nolter. luta Di"llOOOlo. 
DJt1focct. UallN J:i.d.oca.). AJltiakrobLlllUlllttplltolltaca wen: (~d at Ulc 
ume 01 ...,,,,10. by.be lloc!lAod Daue, KIlby I!W: 01111»1 .... ethod. whh 
101C_ late'preudon _ .. CJ..SI JUldelila (9. II)" Aol1m .oIJi31 dlOb 
I<SIed were eblo, mphe.1col (CHl ) {J<! I'&l. IOl»<lIIio (AMP) (to 'aJ, 
,no.clllop<im4UItul."0",zolc lS: ( t~l:!l. 75 IV, .... rtriu.ne {CltO 
(30, • oftoul. (0 I", .. d .. lilli .... clt! (NAL) (.10 ,~). Moo.ncr-
Hln'o. OP' 'nd .n~ .. 1crobiJl 4io<o .. ete purch d ftOOl Unlp lb, Sa in 
lOt •• Vnl d tCil\!: II, 
JB!ojOTHB"R. 
!.lob ......... , Iored on Prolon boa (Probtll, O:donl, Vliled ~) .. 
- . The Ioot_ ............. bnJllW'ed, ,ad lite lI,oluoJCrol>l.1 ~I)I 
... • ....., repe'''' .0 Mueller iIJJ1lOn ,!ilI by USI ... .- lOr NAL (30 JA&). 
<\lr.I<mcia (ClP) (' "3h .04 oftaucla (Of_ I''''''~ The.tooe ollnblll".cI 3"""II loro b .. __ me_by_""'"_1tn~billdlO 
Ibo _ II of ... '"""" ..... nD ot tile otlto:t5. Tbe-." .... Itoo: recorded by Ibe 
III,.. tel.,... .... ck:ul .. ,d Tbe MJOI fot IIIc ioob ........... oIe .... mhlo:d by Ibe 
.und:ud >aM ptI~ o!IUion lIelllot! _. 10 CJ.St !Jliddi .... or by Eat 
""""nli~ 10 oIt .. to:lr.J! .............. meno!."kw (AB Biodlst, ~""'oIeft) (101. 
The .nd .. ",oobk ... u.1<tI_o CIP (0.008 ~&MI 1 1O • ""_Q. OFX (QOO8 
fA",,"11 to .. )l£I1.1). .4 AL(O.S ~l lo 512 tl&IftlO. Antimicrobial P"'" (or 
1110 S3'pt ... oIikJli .MIClI .... "'p,orc~ · f,oIlSJsn,.,V.ioedlClapllII, The 
t.U tid po.... cr. d '" .,.. ladepeot<!ettl ii, Ii3aIO.., b lIIiI III IJte 
_lOt1o:lO.m. byl oUtor. IM<.,,,lIIciea · ""'" dby_IItlE<cJo-
"lua ceI, TCC 25m an SIItM/or-«.(2U G'4N:U ATee 2!Q:1'#t-ef'C I _ 
alnlrOISlniOll (or U1CJe > TI.eraml~'" reinfetprelal. nlin&IO\''Urn:at 
USI Plit:lcli_ ... """"l.-Ie beio, vtl..,. 0( a I'NmII , n>fldhie 
.,Iiml rOC' on in. In 1 PNmI (Of q,rofto.oda. "I b~.... reti 
MORitilw r iJl3nttOC't\lor mphcnicol,trintelhopril1l8UlfanlCLb<.\'Wu 
atI'pii:illin by dillt OU><q>tlolbl)llCO'iJt&. 
PCR _tiIIeo1'" onot >eq-.:IOI: 01 "'A • ...,.'. ~.,c. -.1,.,£ _In . 
Tnotti. 0, A \rom ,Ile 'Ir'" 111" """" ""'led {or P R IlIl'hik.tian of Ibe 
IPIl .UB,pG1 -, lMpIlI'Eg,e:ftOIWMc:tlI duwllC W-ll:atdFlo.n~ 0 
llurilc3lion ku (pwcncst) $,xor.Ji", k) tile .. DulaclU r. lQ..'\)uuoendackllll, 
Bdeny, I :lUI colony WI iuocub d in 1.5 ml of Lnria- Bettadl broUI nd 
inwn..It.."d b\efOigtll 8117"C with 3k:illg II 00 'PfIl III JUdI I~ cs:u lOne 
ml of Il1e haClt:rbl atllur •• ulMfcrR:d to., nt ' "l"'"fF Ill"e nd (ell 
ttifu d In a RlEDXeOlnil al 1l. rpm (0, 2 milt. T tuperaatMt 'A 
I'C'DlO\lleC.1, a lite txJc rial pellel W I.IIC(J 'or DNA e..~, bOn. The exlracb!d 
DJ'''' W.W 10l'<d , - 2Q"C until """oiood. 
OloglllU<leoli<Jc priul<1I lor , oplill.:.tIOI d lIIe quillo ""'''' 0>."& 
de ro.ltI'l1& "PI" .. C"A. VIJ. p«,c. ",d r £ ... ,. 4 1)1*i ......... 
feu... (6): ~. OYRM't (5'·TcrrcCGAOATOOCCT G tad 
OYRNP2 (~' TA= T AT ) ( 0 hg _pet ....... 
5$'(;); ilYli. St~t (~' CAAAcrOGCOOAcroTCAOO) .nd SIl'!!1TU2 W 
TICCOO rcroA TAOA (lUI"",t... IHIpeQ"'''. 6Z'C); ;.te, 
Stmp>rCI (S' CfATOC TOT CAOAQCI"OO) .. d Stlllp>rC! "TM 
CA • OcrCOCCOTA1T) (.n .. 31Ias _"... .... ; 62"C); .. 4 ruE. 
Slmp>d!t "'·1'crcrrCCOATGAAOTOcrO) .. d Sunp>r1l2 (5 ' ATACOO 
TATAOCOO oar AO) ( Meal"', _peo", ... 6Z'C~ 
Poo.!!I'O:d PeR •• 'plkon ..... "'"' 14 IIp fnoA), >I' IIp \,».B). 1"0 IIp 
(pole). Ild::'O IIp tpa.E). PCRs ... ,." performe4U1o'.er tltt: c"a"",lnc,oo<liUOllS: 
JQ C)\!1e$ 0' tz"C tor "" s. SS"C or 6:"C ( adi" on the pri lten 'or 4" • I1d 
ICMtol l Crot l .... I.tol afillaJ onllCp '7refor2mln. 
Tile DNA quenel., ..... ioos ~ perf",. lJIln, lIIe CEO orcs Quid: 
Sun kit (Bod ... CooI",.).tt<! II It .. ito, • CEQ 8000 I ry 
1f"""''', 'Old Ute , .... ~"'l& DNA ~." .... tyzd ' .... 8 CEO 
'-n · 't,g3I"" CEQ2000 rL (B«.tllllfl Couller) . All JertUetk"U we ri 
atiSned. and nluip,bJed t..in.,& ni t aoftowarc ( hurJ.~· nabio 100U 
11l;'&;;,b"",oII,hlmO AD A,,,.B.pa<C. nd patE"""""""weoecelDpl1,,,d 
""JOIle'VA. VB, puC. adpa.e ~ .. byBlAST ... CBl'J'~ A 
"']lI<tlC. olllle .. ,ku S. 1)pIt1 ttqOl ..... ot 1YfA. B, p#lC • • ntI patE"-ere 
_ .. Ioot<A1 .. d li&Ited wi,b Ibe ptDMlCd "'Iue ....... 
D .... .., Zone Ii lnrerprtth-e criteriJ 3nd inlerpreti.e dJicrep IL"1 
..... .. b,b 4b\'1 .... l1or.. iIocImoUodd kalCtudDeIl n 
(.!7). T MIC IJr 1q><Iin 10< ,eoluilCd ........... 'biJity __ ~G.2' ...,.. .. t flit 
onilu~in and rillS Il&-tnl ror elpmfto:u..ift . ~ fDlh: ia= ~ Al~nLl '" c 
:t. lju k:c1 Uillil tbe ,"unl':'<:r or raW: .u*,..;pliNc dt.t di"l~ioo I read'': (\ ry 
m",jor dillcrqr~"") .tnd r ru-..... Ol dat ( ..... jor lei_leis) we:&' 
heW to minimum Ou I (or Ja"CPtai* repancy na 'WCfe 00 ~g 
10 !he ClSI ''''0'11 .dallooo (tZ~ Norm,11y dlsrrn. .. d I> "l:r. comrao:d 
UIling Ibo S.,,,,,,,, r ""~ nonnonft311y d"trlbu"", t .... 1\C lile M n Wltilncy 
lh: propotllOOllb\' Ibe ,111 "lUIre DL blJolJcat .. oJjH w pcrronned 
UIlIll3 1>I>ilI1(o. ~I>"D 6 (CDC. Ad ..... OA). and SJISS for \\'111<1.... ,,, •• 
to.1 (SPSS.lac.. Cbk:~ Il+ 
RES LTS 
Anllllkroblal tl>Ully I IInA or S. TypbJ Isol t • Wo 
in\fe>l;g.1Ied 816 S. Typhi isolates roll j.:(j ret"" en 1992 and 
~ rrom ven Lan counl rl.!s: Vietnam, pal. Iodoo ia. 
In din. BaJlgJadesl~ PalWlnn, nd China. Only one iJIolal lhe 
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FIG. I. Flooroquinoion. MI histogronlS for 16 S. l)phi;, lat •• from '", HistO£l1lm showing Ihe d;.rnbulion oC MIC I.ooflor.l In (0) and 
ciprQj1n."tocin (b) of R16 S. TYJ'lhi slnlln . kcllalcd tl'llill p"tienl~ ",jfll cnrcric (",,'Cr. eltCh tqo!:ue u"c.d flY nlltl~ .. was; L~I:lIed tiona nn Individwll 
enteric r",er 1'-'1' nt. The MIC'JI.rc pi ned 011 thel n.m. lid Ihe numbe" of l<;oIOi corn"I)olIdlllg "ith [tuliruinr M1Cs.re plot led on Ihey <is. 
(be \\hjtto! pro(X)rtion of 1be (,.'o i llmn~ illdicul the nnHdool: a 'd-Imsccpliblc iliOlalcs (It 563). 11lc! bl3Ck ploponion tilhe colUmns indicUf ' I b~ 
n.lld.,i. ;lcld·r""i,wnl ;.;01", n 3 2.~]) . Both hi.rogram ~how himoo., di tribllti, 'I. which I~ pnl1ly dlft'crcntiated hy nalidltic ""id r <i!:I. nro. 
slrain i';0131 d on admi sinn In Ih~ hea"h care (ucilily) from 
eacb palicn l was inchlckd for mierobi logical clUlminalion and 
analysis. 
Of Ihe 816 . Typhi is<l l.alcs Ie led.41i6 (57.1%) w<re MDR 
(rcsislnnl 10 chloramph nicol. ampi illin, nnd lrimclhoprim-
sulfaruelbCWIZo[e), wbile 303 16 (37"' ) were (ully sllSCCplible 
10 cbloramph nicol, ampicillin, and Irimelh prim- ulfaOlCtb-
oX32olc. Tw hundred fifly-thI~C of the 16 isolal (31 % ) 
were resi lanl 10 nalidixic acid (/Vile, >32 ~g!ml), and 4 i~o-
1.11cs had an MIC of 16 ILglOlI (in! rmcdialc) 10 nalidixic add 
bUI were clas ltlcd as rc L~lan t according 10 the zone sizes from 
dISk 5U...ccplibiliIY Icsting (~ 1 3 mill). or the 4(,6 MDR i~ol:lIcs, 
145 (3 1.1 %) wo:rc uddili nally r",i",JlnL tn nalidixic acid ""rn· 
pared 10 80/303 (26..1%) isol. ,,,, ,h., were fUlly SIL'lCeplible 10 
chlorumphenkol, ampicillin, and Irirnelhoprim.slllfumelhox-
37.ole (P ~ 0. 16). 
All 8111 S. Typhi L lales we..., classili d as sUS<.1:plible to 
cipruOoxn .in .ccording 10 MIC lesling (Mil 1 ~g!ml), yel 
12 gave II discl-epanl "'.<lIlt wilh dL.k lesling. These strains 
exhibited an inhibili n lOne si:w of s 20 mm and were, there-
[orc, classified as inlcrmedialc b di. k tcsting. Two of Ihe 16 
S. Typhi Slrains were gr:.ded wilh inlermedi"IIl resislanee to 
ulloxacin with an MI uf 4 ~g/ml but had Inhibililln 7..,nc sires 
uf '>16 OInt and wer •• Iherefo"" dassili I as . us',o:pliblc. 
The dislribution of the MIl' I~vels In ciprofklxacin .nd 
oll.olwcin fllr 1111111/\ S. TYI'hi isolales is presen led in Fig. l. The 
hi logram. of Ihe I",'el~ of MJr 10 eiprollo:r.ICin Hnd 00 x. in 
bOlh clem 1\Slrale a bimodal di Iribull n. Th IW.o di linci 
IP'"uJ'S are parlially divided by nuliclixic acid >I' cplihilily (Fi~. 
I, black shading denol S resiSlllnc~ I • nalidi. ie acid). 111C 563 
isolates Ihal w re susceplible 10 nalidixic a i I had an MlC 
(range) to iprofloxa in of 0.03 ~glml (O.!l( 10 O. lLg/ml) and 
0(0.06 ~g!ntl (0.0161.00.5 ,.g!ml) 10 noxa in. The 253 isolat~s 
that were resiSlaDl to ulllidiltic acid had an MIC\I() (range) 10 
ciprotloxa in o( 0.5 ,.glml (0.064 t I ~g/ml) and lootl XlI in 
.of 1.0 1I-g!11lJ (0.125 104 lLg!ml). 
Anllmlcroblal uscepl lblilly leSllnterprelhe ~a tt'gO)rles ot S. 
Typhl I" ci ,.nlHoxacin and "noxa In. The curr~nl CI_ 1 Inlcr-
mediate brcakpoinlS arc 2..,.gtml and 4 ,.g/Oll, respet1iwly, for 
clprol1oxacin and unoxacin. Only 2 of Ihe 1116 Slrains lest d had 
Ml ' levcl~ b'fl! ltler Ihan Clr e<i" l in IhOlie f the ctlrr~nl llC 
brcH~poinl5 (Fig. I). Tbe MlCs (or nalidixic acid w re com-
pared with tbose of otloxa in and ciprotlo:tllcin in sca llor plots 
(Fig. 2). The cttrren l inlerprclive break')Xlinl.'l are hown in Fig. 
l as dllrk shading in red fI r otloxacin and cip.rolloxacin an 1 in 
gray (.or nalidixic acid. The suggcsled inlerprctivc brenkpoinl 
for reduced usccptibjjjly are dcpieted by a br kCtl line wilb an 
arrow -ig. 2). As prcdicled. there was linear rclalionship 
bclwccn Ihe nalidL'<ic acid M1C and IIle (lfloxaein (Fig. 28) anll 
ciprotloxacin MJCs (Fig. 2b). 
Screenjng , 'rains USing nalidixic acid resislance (MI ,. 16 
,.!!fml) for the llclc~tion nf L,"l Ie. wllh an MY of ... 0.25 
~g/ml for olloxacin had a scnsltivily of 97.31)' (253!2!lU) and 3 
specilicily of 9IJ.J% (S52/556) (Fig. 23). The ntlm!)"r or very 
major discrepanci s w 7{2&') (2.7% ), wilh none mOre than 
Iwet dilution above Ihe brc:tkpoinl, nd th numner n( major 
discrepuIIcl"" was 4/5 6 (0.7% ), wilh none mOre Ihnn lwo cli-
1\llioM below Ihe breal')Xlinl. Screening for Ihe d~t.cljun of 
iSIII3Ic'lVilh ;, ciproll lUtein MI(, of ;",0.125 lL!!fml.llsing nali-
dixic acid r i~t aJl c (MJC of ;;,, 161Lg!ml , wa 001 asretillble as 
thai forofloxa in, as il hnd ascn ilivilyof92.9% (248 67) and 
a specineily of 98.4"" (540!S49). TIle number of v ry major 
lliscrepaJI~ics WI\.' 191267 (7.1%), ",i lh 11267 (0.4%) m{)r~ lhan 
Iwo dilu li /IS above the breakpoinl, and Ibe number o( major 
li iscrepanci"" was WS49 (I.fl% ), wilh none more Ib.1O IWO di-
lUlions be low Ibe breakpoinl. 
We explored Ihe rdmionship bclwccn Ih. diamerer of Ihe 
z nc of inhibilion and lit Ml s fll r ciproll xacin an I noxa-
cin, ILsing S-I>S di~k., (Fig. 3. 7..one of inhibilion of s 28 mm 
,Iflmnd a 5-,.g (liloxacin disk correl.lIcd wilh ttn MIC of 0.2 
~g!ml, wilh Ih 1 I number of discr panci (Fig. 3 ). Th 
number of v ry major discrcpan ics was 141200 (5.4" ). with 
nonc Ulore Ihan IWO dilution. abov the br~81.1)()inr. and rhe 
number f major discrcpru\dc was 32/55(, (5.7% ), with 14 56 
(2.5%) more than two dilulions below Ihe breakpoint. Awn.: 
of inhibilion of <2 UlOl around a 5-)I.!l otloxa in disc dell; ted 
Ira ins Wllh an olloxa in MlC of >O.25/LS1'ml. with a sensilivi!), 
of 94.6 " (24 (,0) and a spcdlkily 01' 94.2% (524 . St» . A 
lOne of inhihition O( <~J mm afOunlla S-IJ.g ciprolluxacin disk 
correluled wilh lin M Ie o( 20.125 ~g/ml_ wilh the lC(L~1 nunt. 
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II G ! con r plot! r L"ln oJla<Jdn.nd protkl.'Qcln II' '" nlli<lrnc a<i<l 11<': ror Sl6 51.n . Iypbi ,sola! 'call r plots mpri.cd 
or MJ . ~ ... [rom 16 S. r phi" IJle rll'''' cpul (II - [().I). India (n - 25). 10<1 c-ia (n - 21). Bangladc .. b (n - 40).l'ililan (n - 53). nllm 
(n - 51). 100 Vidnam (n - 516). 1'1<>1 .. 'how Ih" r"'Jlim,hip Ix",' II th MIl' 10. nali~L<ic add v ",.e') and lhe MI(, 10 uOu"dn (a) and 
ciprollcl'C3C1n {h) (x a..t~~ f'h ,"en I ilnd hm/ontalllOhJdms In • . "i\ salter pk>t Inl.h ales Ihe_current (I I recommendation'S ~ r hrcakrumts 
bci'"cen "lLUl'lIhlill) ( hUe), !fI1 rmCdlJlC (hsht gr!ly. n .lhc..Ilt.1C 11"' .. 4...1 : hGht r d. uUO"(.:I(,n .lnJ erroll ' Icl n) . and rC!iii"3ncc.:. (dMk gray. nalidil"ic 
add tlJIL. rC\.!. ofJuQ.:in "Uld drroflo."Wdn) (nJJiJitk add MIC. ~s j.Lg/ml and "'32 )J.g/ml: uiJoxa,,;in MIC, .... 2 )J.g/01I and ;. ~ J,lglml. and 
cipruOnXfk:1R MI .. - 1 J.1g. ml and -. ... ..... ~"ml) 111&: r~d hrol..cn IUl\! t."""~"POII\J In the pro p .--1..1 fl C' hn.;.<.,L.I"lint kh:ncuymg ..... rain~ \\iih T du&: ~d 
'1L""l'ubtiity In Ooo""lUlrk,lune (,,/lo'<Jan n i<o._~ J.'S/ml and ciproll,,,,,Lin MI or >: O.I25jlS'ml 
ber of diM;n:pandc (I ·ig. 3b). Til..: number o f >cry major di:.-
cr~pnnck ... w, I ~fi7 «('.orr) , wilh 4, ~('7 (1.5r~) Inure Ihan 
1\\0 diIUIII) I1> ahuve lhe hrc k lin I, an Ilh' numb-'r " f major 
dis ropande< wru 321 ~t) ( •.• "'). ","h 22{ 4q (4.1)"· ) m(>(o 
Iban '" dilull" ll Inw Ihe hn:'''r<>"ll. wne of !trowlh 
IDb,b,uoo of <. mm <10:1 cl d ,Ial", Wllh a II ronn:rucin 
11 of O. I25jl!LtOlI.\\i lha~n'ilivl l of1).1.0(' (25 1 67)3n<l 
• p,:cilicil' nr t)4. f ' ( 5 1 7/~4~). 
~cdueed ,uo.ccp lihilily ' " lIullnICluillolollc, and ~·r.4. gyrH. 
pare, nnd pur/-; mutnl ill"', 'Tn furt l ' r d ·Iint.: 1111,': s. Typhi 
repulalion wilh redu~ d ll'.' l'JlIiblhl) 1\) lIunn'<julllolnll . We 
pro<lll od PC R amph"o n and Iheo \C'lucnccd Iho qu,"ollln ,· 
r isl.ln .If I rmlning r k n In the ~)',; f, 10,8.1'" ,undJiarf: 
g 00 from a o Uectl n 01 ~75 . I 'PhI Irall1> from Vlolnam, 
C1lina. India, In,k""'''J . BnJ P"U'III1I . One hundrod "f II" e 
slr3in~ ",en: lkliiCrlhcJ in Itk.: pr\:\ k'LL' .. '("11('", unu 175 ,,"crl.! 
IIwre rc,',nl "Irallt> In'nt Idnnm and Indill. rhe tl C'rango 
of Ih, . . \lrnin, "" I I" 12 ~g/ntll" nJIiJixlc Jcid, lUX ). ' In r. 
ILSImll<) Ipro no'CI in. and 0.1131<) 12jl milO 0110 clII. l hese 
Irwll> aod UIO nmc pondlDg dJI~ lrom Ule", lralll, Jr~ tk-
scribed in the M1pp,"mcOI31 mJI<ri;u. 
Fifteen o f Ibe .\ 5 . T)1,lu "'''"0 examioc" by PCR Hnd 
c.tllcncing o r .... ')1': , ~.,.B. pll,c~ :IIlJ i',uf. hd I no mutaLion.. . in 
we quil1t"\i(' "c r ...... I ... ll" '\:--tkh. mlll1l1tl) r...:gKll\.') (r n s~nl.!, (l 
lrall\.' hMJ J mulalKlll In lh\! 4uinokH~ r\"~l"lancc·cJ":ll:rmlOlJlg 
r gll,n "I Til ,'r pari .. 1·,'>Or hlll1dr,,1 'I •• \ Ir in, h.1 1 ellller ,\ 
ingJc mUlalK.,n ur..l (.-ombinJt~.Jn t c.k)u Ie r lnplc mutations 
m Ih~ I:IT; I and IldrC genc,. 0 ,\ '"'Itlcndllll ilknllro,,(1 ".'\en 
difTer,nl amiO<l acid u lilUli( II : OS7A :\IIic Id 10 :1.· 
pa raHinc allt 1,kltl 7 in Ih . .\:.ITA g,n,,: S·~ . ..crine In Iyn illo 
al codnn 1>11111 he ,1 gene: ss,~. ",rill' III ph 'II) lalanine al 
codon :\ III the I{ITA gene: J) 7(;. id In gl 'clnc ,I 
('00011 87 in Ibe ~'rA gellc: - '3FtU 7 , rine 10 pb~n)lnlaoinc 
[II Clxlon • ~ unJ asparti acid 10 ~\arngi"" 31 rodon 87 in lhe 
lOT. genc: ~S:1I·/nS7G. ,,"C 10 pheo~1 lanilte a l CO<lc>n 3 
and a.<porli acid I gl)'Cln al CodOll \ 7 in Ihe &",;1 g ne: nnd 
'W b7G I, serine 10 phenylalanine 31 codon " nnd 
a~flarllc aCid to gJyCIIl 3t codon t In the R)'rA ' nl.! a nd nne 
to L",leucille ~ I c o n III Ibe parC gene. T he Il10';1 rom-
monly idcnliflcd a mino acid r :placem<nl was ' S3F, L'(>n."il lil . 
illil ( r:) 406/460 .Irai", wilh a mUlalioll, wllb Sh Y Ihe 
"<ond nlt)\1 <'O mm, II nmlnnl (1Il'if-) 46/460. 
e nlpared Ihe MI C 10 ftOIC3 in and ciproftoxa in of rile 
4(~) stram, with Ihc ,evo n " ,lfe renl mutation pall<ms nod Ihe 
I SlraUlS Wilh no 111ulali n del cr d (f ig. 4). Wh n rouped 
1010 slrain> " ilb and wilhoul a inglc mUlalloo in Ihe g)TA 
sen.:. Il,e .ingl . 111ulalio n group hdJ signincanlly higher MIC, 
10 oO<',acin ( Hg. 4,, ) "lid iprOne''''lc ill (!'ig. 4bl lh"" Ih,,,,,, 
without U D1 Uld tioo, I1le m()~1 l 'l'nlUlOfI amino aL"id ~ub'\ l ilU. 
lion. s.~ F, had menn MI( \ of 0.7." jlyml a nJ 0.33 IJ.!!/mllo 
ft xa 111 and ciproflo:o 111. respectively. Figure .! also sh"" 
Ibo current I brc3~polOlS and Ibe suggesled 011 ~acin 
br"ukpoinl o f 0.25 J." ml3nd Ipronm3Cin brcalqx.,inl 0[0.125 
iJ.g/ml. n Ml C oIO.25 iJ.S mlloolloxal'io a nd an Ml Co[O.12-
jlWml 10 c il'rollmllcin !.:Iccl<d 74.5'.'< (34I /MJO) or Ihe S. 
Typhi,,,ain willi an itknliti 'd f1uoro<jui no l ne re. iSlane.: DIU-
lJl~)1I and 81 ~ (3311 ) "r lit.: III I commOn S. Typhi 
mlll;)111 (. S3F) \\ ilh duccd w priblhty 10 tl llon'<juinoio ne . 
DIS :SION 
~nl ' illC rca~i l1& r\!c(~nil inll thai . Typhi i~ola l~~ \"i th r~· 
,Iuced Ml'CCpl ihitil I, ,,110 "cin allli cipmlloxa in Ulay lead 10 
Ir~ n tl11c nl fn ilure has led 10 calls ror a revision of th ir break. 
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JI3I "{"I .... lI2I 2I2l '{'I '~I '111 
ll11 2(2J 1(31 ~ 101101 12112112:1fZJ lQ'tO} 3{3} 2121 1111 
'{'I '{ 'I 2I2l '31'31~13I(3~"1"11'I"1 '1'1 '1'1 Jl21 j l!31 2[lJ '{'I 
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• 
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oftoJtICI" dilc (Svg) 10M diamlttr (mm) 
ri G. 3. ' c:lner plot rclJ llng n • in.nd Iprolk\'C\clO I ' 10 Inhibition 1 nc di.mcl r for :16 i.n Typhi isolatc . x.mer plol [or 816 
S. Typhl 1!'«)I':'lb tomp.u-ing Ihe I."hihllttln 7Ofh! dJ?",ch.;rs u. .. i llg a 5· .... g (, .. pru~oxacin Ji"C (a) am! n 5 ..... g oflo:'tucin disc (b) (.1 a.x.is) and Ihe 
cl".n;\fXmding MIC (}r L"iptntlcl\Uctn (II) ~nJ t'lh1..~aCIIi (h) (va"il"') , 1l1C number In hrncl...cl"l I'c luh: to Ihe !..t:ii nnlidixi~a.cid..r ~Irlnt '· • .n!uto.. !lIe 
vcnical red h"diQ~ in .""h \I r plol i Ihc CIlII 01 <: '1 dl« I DC ~rcakroill l for resi",,,,,c (oU :r.1cin inllibili n zon diameter. s 16 mm: 
i""'t'ln'~~-.:in inhihih()n ll)nC dllmder, < 21 mOl ). I he hlllllt'ttIiJI feU ... h,ldlllS lIi\lingui ... he .. 'h.,in.;; .... ith an MI(" lir > :2 J.lg:ml ror oflt,i'(.}Cin ur .10 
-I(C or .... l ~ml ror Cipf'tl.n"-\.~~u:1n . l1u: l!rr3), )olmdinS j ... the prup,"Cd hrcu l poinl r~)r S. Typhi i laic' \\ilh rcdu ·~d 'usceptil'ilil), (ofloucia MIC. 
c--O. 2.~ J.Lg.ml: dpwll< '(aan \11 . ~O. I25 ~l!'ml . Thl! n.."U hr,ll !.:" line "'OIl'\! l'Ulki' "ith th pm~ll bn.:ai"P',inll;! for "'lJam~ ",ilh reduc·1.l 
t1.~"Cr"hllit)' (,'1ft.,,"{J. In inhihlll('" lun Jiamcl r . """'2,' mm~ C1rn'Ut1"<::lCl n inhihitH."In l one dmmclcr. <30 mm) 
poinL .... IJr"ak[,<.inl' of"> .25 j.Lglml f,'r "n" aeln alld 1'\ ,11,'xa-
ein aDd >0.1 5 j.Lg.'ml ~)r clprotll' X:lcln lind g,l\iJ.1 .10CUI bay~ 
b~""n 11£& ·,t~d ( I, ,I~, 'l) ulid"i<: acid r~." i,ta nl . anJ di.l 
SII!;CClllihilil I~sttnll Ita,,, bn{h h\:en prnp' 'd 3' IAhor"lory 
n.:'-'I1I1l}!. m~lhl~ tn detL'd 11 h b.t"lU Ie . \vc h~ vc cxpl()rcd 
tit · I'crrl\rnmIlC~ "r lh "" m~lhods wilh a large JllImoor "r 
trains th:lI arc rcpr scnlativc of . Typhi isolate cinc-ulaLing in 
l"\\(lnlrtcS in A~ia wh~rc il i;; cnc.kmi '. 
a li"i~ic acid re<i,{ancc had a sensitivity of 96.2% and 
QI.s'1 ~nd 8 'p"cificity of 995':i and' .5'.( ~ r Ihe delccti Il 
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FIG. 4. Th rc/>lionship "r gYrA and pi11C mutnLio", and Lhe MIC. La Olk1 dn and dprolloxacin in the S. T),l'hi Lrwn isola led in Asia. Box 
plol. (boxc> ",laic to the 25Lh and 751h per""nlil.s) relaling mutaLionsin the .,TiI and the pme gene (the SSO! mul lion .. in lhe pw<: gene, and 
the rcmaindc'1' arc in Ihcg)'rA 8"J1C) 10 lhe Ml . 01 on".,.cin (:0) nd cipronolC:Kin (b) in 475 A.ian clinical i...taLes I)f S. Typhi. Th< MIlo 
"noxadn and ciproH"xJ>cin an: plotl don Lh. y ""i", Th. Ml .10 oHoxacin r.nged fmm 0.016 til 12 ~&Iml, and IheR to cipmn=cin lrom 0.008 
to 6 tJoYml. Median .;olue< lor each mulant group are indenlified by. solid line in Ihe box. Dar demonslrdle the 9S~t confidence int.",. , for lhe 
groupr. wHh suffiCient numbel's; dots corrc~n&.l tu oullic~. TIle ,r axib ill subdivided into Illt: eiGht dill'cNnl 8rou~ or . Typhi ~uains idcmitic(.) 
and ")'Cd. dlaraclcrized lIS folio.- . no mutatiun in ,\,'IrA or pare (II - 1$), 0 7A (/I g 2), W (n - 46), SIl3F (1/ - 4(6), 0870 (n a 2). 
S83FID 7 (1/ - I). S83F'ID 70 (II - I). nd S83F1D8701S801 (n - 2). The upper broken line in~iC'.tc Ih" ('\IrrclIl CLSI breakpoint 
recommenililliom lor ono.tadn and ciprofl"""dn. The lower broken lines <'Orrcspond wilh lhe propo.cd breAkpoinls for lruins with rcduoed 
susceplibililY to uno,.un <ond dprolloxacin. Slali>Ii<'alsigmfican<" .. ",calculaled oct" n Ihe nonmulant group and the single n,utanl ,roup :tnd 
het"""n the single mulant group and tho d<lubleilliplc mutant group u,ing the Siudenl'sl te .... 
of lsolal~"s Wilh reduced . USCCpllhilily In llfloxac.in and ciPIL)-
floxadn. respeclively. All mali,ely. ""jng disk sensitivity leSI-
ing, l<olalcS with reduced ,useeplibility were dcl~'Ct"d tJy an 
ofloxacin (5-~I!) di k inhibiti n wne di:tmel~r of :528 mm wilh 
a . cn,itivily of 94.6% and specificilY of 94 .2% and by 1I cipm· 
floxacin (5-~g) di~k inhibilion lone lli nMer of s 30 mm wilh 
a sellSil i"ily of 9-1,()% and I'l!CiliLily of 9.1.2"0. Therefore, bOlh 
method had ufticicnlly high sensilivily for Ihem 10 be II ed ror 
scr~ening and n plably low level. of tliMl'epanci '" ( 12). Disk 
inhibition zone siLc did, however, tlemonstrate" lightly lower 
_pccificily than nalidixic acid disk le'ting with thi, (Janel of 
lsolales. Similar data for lhe rclaliam-hip betwcen nalidi ic 
acid resi bllee and a dccrclIM!U clprono 'Iein MI huvc heen 
presenled lor S. Typhi bolale.. in the nile<! . lates (14) and 
India (23) and in non-So Typhi Salmlmrlln L 11at in Ih .. 
"iled Stat.,; ( 14) and Finland (21). For nalidixic :rcid·,u p. 
lible nnd -re~I>lant S. Typhi isolalt$ in India (23), Ihe u"crag" 
disk inhibition zone ,ttes ror cipmno u In wcre grentcr Ih n 
Ihose Ihat we observed here. The non- '. Typhi study in Finland 
proposed a ciprofl xacin (5· ... g) di k inhibition zone di m tcr 
of :537 mm a the brCllkpoinl (21). TI'e sen iti"ity of Lhi 
approach Wll IOOSl:, ),el th specificiry WtIS only 5 1,9%. 
1n some isolalc in thi srudy, the notidl i acid, oOOlln in, 
nnll eipronoxilcin MIC resull~ were di.crepanl, In thai i. 01 les 
were na lidi1ic acid susc~ptib l e bUI wllh :0 r duccd nflo.adn 
(1/ to) or Liproflo,:oc;" SlIloCCplibilily (Il - 22). Similar results 
ha"c ht..'Cn seen in other 'Iudies (13, 15, 22, 26). The elinicul 
signiHcnna. of these isolales is unclear, as there have been 
Iimiled documented C:~'ieS of infection with >neh siruin. treated 
wilh Iluoroquinolones. II is likely Ihal isolales Ihal are nalidixic 
a ill susccplihle bUI wilh redu d "noxaein and cipronoxucin 
, lIsceptibililY con lain resistana. me"hanisms other Ihan mula. 
tions in the quinolone ro ·istance.dctermining region or Ihe 
,l()'I'A gene. P""lbilities include dccrca.~d p~rmcabllily, an in· 
crcu,c in uCllv emU!(, and the presence of pla.~mid-medi3Icd 
genes, ,ueh as the qllr gene~ that ncode a prolein Ihat protecL. 
the D A gyn~ e from cil'rofi<l1wcin or auc(6')· /b·cr, an amino-
glyco,idc-modifying e nzyme with activity as'.in'! ciprol1nxucin 
(32). 
The mUllilion thaI we detecled in D gyru;,e gent$ and 
10p()isomeras~ genes were consi len I .. it h previous r POrts (4, 
6, 34,42). The mOlit common omino ucid substitution d ' teeted 
wus S83F, whi h hn been fonnd 10 be partiClt~trly associaled 
, ilh the H5 haplotype (35). Thi haplotype has become dom-
inant ill many areas of in in recent years and has also be<n 
found to have pread inlo Kenya in East Africa (24). ApprOll-
340 
VOL. .2010 
imately 20 to 25""0 of the isolate with a g)'rA mutat ion bad an 
M IC bel w the sUlll>est d breakpo,nl' (0 . .6 II-A<'ml (or on ",. 
cin and 0. 125 ILs'ml for ciprof\oxacin. Th.: effect OJ) the reo 
sponse 10 fluoroquiuolone Ircalmenl of in fection wiUl L<!olat 
with a ingle gvrA mutal i n but .. ilb an M IC below th~ '''8' 
gested breakpoml! IS not known. It IS also po ible Ulat 111a 
isolal • witlt a siogle g.',A mutBtion I>ut an MIC abO\! Ihe 
""Ue.red brellkpoinl ha.e addilionnl resi:llance mechanisms 
pr nl (32). 
The lack ofuniverilall observed guideliu for Ibe delec.1ion 
of S. Typhi ISOlales wilh reduced su'ICeplibilily has mean I thai 
slIch 00131. ore frequen tly unrecognized by microbi log)' lab· 
oratories. Continuod u of ciproHoxncin and ofiOJC:lcin for 
Ibese iofeclioTlll may be dnviog lbe m rgence of flllly IIlIoro-
quinolooe·resistan l isolat of S. 1)1'bi and S. Par:uypbJ (20. 
25, 34). Gatift lC'Icin, azilhromycin, Dnd ceftri<Ltone are hell er 
options for lrealiog such infect ions, if the is lalca also dem.oa· 
slcale resLstaucc 10 first· lm antimicrobials (7. 17. 18.29.31). 
The use of nalidix,c acid resist. nce 'IS urrogate screming 
lest is often confusing because it i n t u d for Ih t reatment 
of en Ie ric fever. Purtherm reo the emergenceornnJidL~c acid· 
susceptible isolate" with reduced oOoxacio and ciprof\oxacio 
.swcepl1bUiry may mean thai some isol, les are mWed. There. 
fore. a Slrai8blfol'V>aro solution would be 10 modify the S. 
Typhi breal;point to s~O rom and ,,;;28 mm ror c,proflo.~cin 
and oHoxucin, respectively. loterprdative breakpoints for the 
dhl.- su~ptibajty tests wilb tbe antimicrobials actually used for 
Ueatln Ilt will bener a ist dinici3ns in the choice of therapy 
ror enteri fever and will allow the collecti 11 01 accurote sur· 
veDJanre data. Our data u disk bl l-poinl of mm 
and < 28 mm for cipr nOxaeB) and oOoxncin. respectively. 
The. breaL-poinu have bigh specificity and RSllivity, permit. 
ting the detect i n of . Typbi slrnins that hav" reduc,ed SlL,· 
ceptibility to cip,oOoxacin and oflo.acin. 
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A Randomised Trial Evaluating the Safety and 
Immunogenicity of the Novel Single Oral Dose Typhoid 
Vaccine M01ZH09 in Healthy Vietnamese Children 
Tran Tinh Hlen''', Nguyen Thl Dung', Nguyen Thanh Truong', Ninh Thl Thanh Van2 , Tran Nguyen 81ch 
Chau
'
, Nguyen Van Minh Hoang2 , Tran ThlThu Nga', CaoThu Thuy', Pham Van Minh', NguyenThl Cam 
Blnh', Tran Thl Diem Ha' , Pham Van Tol' , To Song Dlep', James I. Campbell''', Elaine Stockwell"'), 
Constance SchultszU,A, Cameron P. Simmons"', Clare Glover', Winnie Lam", Filip. MarqlNls", James P. 
May', Anthony Upton", Ronald Budhram", Gordon Dougan7, Jeremy Farrar"'3, Nguyen Van Vlnh Chau"', 
Christiane Dolecek2 ..... 
1 ~ HO!Ip"" b TropiaIl:lisM Ho C)., II.lt'tt Cil.,. V..etf' 2 orOld \)~I:Wl )' a6n~ ~dllk\i1. Well e TruSl ""',or ~ ~~ TN Hospital ft.' 
Tropical Dutasofl. Ho eN ....... Oty. ~.m. l C.., t.-. for l fopKJI .Yitdk/rl. Un Sltv 0" O:tord. Odofd. Unft~ IOngdom, 4 Ac1d«nk: MedIal C..,nr. (M" ~ 
Povett),fNt@d COn'I'r"", at 0i'Sl' H. AtMt....w.f\ lh.l p., pth""t'"'eX. JI ~don, \Alitl!d I(Ingdom. 6 t:me;getlt Pfoduc.t iJf!wlopm@nt UK ltd .. Wokil wjhMn. Unit@CI 
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Abstract 
&lckground: The emergence of drug res"tant typhoid fever is a major pub"c h<!alth problem. "'pecia lly in Asia. An oral 
single dose typhoid vaccine would ha"" major advanlll9es. MOl ZH09 Is a fivc oral slngle dose candidate typhoid vaccine 
containing SoIITlOMIIa ""tmco sero""r Typhl (Ty2 oroC' noV ) lH9 w~h two Independently attenuating deletions Studies 
in heaJth)' adu demo rn.trated immunogentcity and ~n acceptable safety profile. 
obJ«tIvu:W. conducted a randomlsed placebo contro lled. single-blind tri.1 to evaluate t he safety and Immunogenlclty of 
M01ZH09 In healt hy Vietname>e children aged 5 to 14 years. 
Methods: Subjects wer randomly assigned to receive either a nomln I dose of 5 x 1 O' CFU of MOl ZH09 or placebo and 
were felowed up fer 28 days. The pnmary safety outcome was the propomon of subJ"'" with any .dverse event attnbuted 
to MOl ZH09. The primary Immunogeniclty endpoint was the proportion of subject> who ~howed a poSitive Immune 
respon>e to MOl lH09 ln the Salmoneno Typhi Upopolysaccharide (lPS) specific serum IgA and IgG EllS .... 
Prlndp6i Rndlngs: One hundred and flfty-one child, n were enrolled. 101 subjects received M01ZH09 and 50 subjects 
reCeived placebo. An intent ion to treil t analysis was conducted. The,e were no serious ad""",e events and no bacteraemias. 
In the MOl ZH09 group. 26 (26~; 950;, CI. 18 50;,: of 101 subjects experienced adverse event. compared to 11 (22%; 95% CI. 
12-36%) of SO subJoct1ln the placebo group (cldds ratio (OR) I95%CJ1 - 1.23 [0550-2.7~7t P ~ O.691) . raecal shedding of S. 
Typhl (Ty2 "roe- ssaV ) ZH9 was detected In 51 (51%; 95% Cl 41 61 "b) of 100 MOllH09 subjects. No >heddmg was 
detected beyond day 3. A posltive Immune response. dcflned as 70% Increase (1 .7 fold change) In LP5 specific serum IgG 
(day 14 or 28) ndlor SO"b Increase (1 .5 fold change) In LPS specifIC serum 19A (day 7 or 14) from baseline was detected In 98 
(9~; 951)(, cr, 92 99< ) of 101 M01 ZH09 recipient> and 8 (1 6'!b; 95 ... CI, 7 29"0) of SO placebo recipient>. Twenty-eight 
(100%; 95 .. a. 1~) of 28 VilCCln rec ipients who were evaluated In the lPS specific IgA EliSPOT assay showed a 
POSIt ive response compared to none of t he 14 placebo rec lpion" t""ted. 
Conclusion.<: This was t he fi r>t phd, e II tn I of a nov I oral candidate typhoid vaccine in ch~dren In an endemic country. 
M01 ZH09 hald an pprapnate safety profile and was Immunogenic in children. 
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M01ZHOV Vocclne In Children 
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Introduction 
yphoid f.,..r r.m.,", a major pllblle health burtKn in 
devdoping counm.. with pproocimaro/y I miUion CI«J and 
more IhM 210 000 tI worldwide per y'''' [I ). 
Drug r .. i" .... , Iyphoid "",.r h emerged ond ..,...~d globally 
lIorrowing ~te <realn nt options (2 4] TI", WOIid HeaJlb 
Organization tI .. rtfor ... colllm.ods lital COUllai ... hould con· 
si.d<r !he pr mmatic u .. of t)'llboid vaccints r. controllin 
endemic c:We2SeI and tbat tbt- immunization oftchool age and/OC" 
p.....,booI age children should be undelUl<en particularly in ...... 
w n: antibiotic r .. ist .... t Sa~"" mlnic • .. rovu Typlti (S. 
Typhi) is prenl<nl [~). 
Two lic.noM !U\d w. typhoid ,-.cdn .. ...., .""ihble. Th. oral 
bye adtnU3(m Ty21a. vattint: u modtnteJy immunogenic md 
n«eta to be admini t<red in Ihree to foor doses. Ty l a .nltric-
co: red C3l"uk. and Ty21 > liquid formulation (which is currendy 
nOf manufa.c:tured) ore lia:nttd for children above 6 re .... and 2 
). r~cri".ly. Th, lingk dose injectab~ Vi po~~accharide 
vaccine is fictns.d for child ... n .bove • yean The liquid 
fr.roll>!;ui"" of Ty I •. nd Vi v cine prrwidt about 55 to 70 
prottCrlon train CtJltut"~ confirmr.d ryphoid ~vt.r and proft:cuon 
I", • for 3 10 5 y"''' [5, . 
rom publle he .. llh perspect ive, a ingle d.,.. om! Iypl id 
acciJ.e woold h, m ~or advlnla (7 ,8]. MO 12110 ( Typhi 
)2 (IfO mV-) ZUg) it promitiulf and""'-t. of ",ch • novel 
,yphoid vaccine, il h • wellMIf.ed dual IuuU DI of 
atU:lluaUon (9] lid b<en.r. .nd imn.mogenic in a. .ingle 
rio ill W ... <nl [9 I I] and Vt<tnam. OOull volunl •• n I;"n 
TT, UDpub~ 
HislOrically, oral Ii •• v tin ollen howed reduced immuno-
gerUcity in developing < nlry popobli ru cornr ..... d to W. enl 
population (12). Ihe on: {Ol ZHO woo evaluated I t Ion early 
stale. of in devdopmnu in chlklrt.n in :m enrltmic country. 
W. duenbc be ... dJj, "' ults a mn miscd plac.bo conttolled 
lrial Ih, .. enIuated tit_ try and immunogenicil)'ofMOIZllO in 
151 healthy Vi<mlllOat children llK«i he""" .. 5 nd 14 years. 
Methods 
The. prOiorol for tbit trW and suppt.'n-ing 
a.re va':'bblc a upporting informa tionl 
hecIdiJ< I 
Study design and objectives 
The ttudy wu designed n a ranoomiscd placebo controUed 
.in • blind lrial to .. -.1u3l. the .. r. ty od immunogenicity of ,he 
n ... -e\ oral ing!<- do e lin ryphoid lI".tcrin. rOI2H09 in 
Vi .. nam .... ch~d .... n .~ 5 to 14 y ... ~nchJJive). 
The study si te and ethical approval 
1 he aioI condUCted I the Ho.pilalli>r f 
U hi Minh il)'. .,Inam. Ethico oW''''', ~ 
lrini related <locum.ntt WI\f obtrunod b lh 
Research tbi.ct OI'Ilmiue. ( , TRt. and by Ih 
Revi.w ard of L1", Muu Iry 01' U.1I!dl. HOlloi. 
trinl was conducted tn IIC""rd>.nct witb ,be ~ I' 10( He inki 
Iud i amend ntt d accotUing 10 Good 'nlcaJ Practice 
auidelinet nd was lDOIlioon:d by}.' trl., OOtract R. earcb ltd • 
• ~: PlOS 0'« I WWW.pIo!OMCrg 
K (uow NovclIa Ct:nicd\. Th. tria! w>s also nducted under Iln 
Inv ·ptional t:W Dru (IND) Iia:I 
Partldpan15 
11.~lthy iet n.'m .. ~ hiJdren aged ~ to 14 yean (mc/o,Ive) w .... 
Invited to participate in the trial. Recruinn<ot carried out by 
",ord of mouth and fl)'C Familitt who" re inter.sted in the triaJ 
wtrt: invited to alt.e:l1d one: of vera! infof1lllltiou evenings at tht 
Hoopi.", for T !"Opal Dis.ases. At ~t... JUeting> ,h. ludy ...... 
pr ... ",ed by the prindpll invu tig,uor TJ ~nd all qUO!rioo 
could be disclI5.ed and a",wered. Flmili.. who remoined 
intatsred in the fri.aJ wtre inviltd to attend the Icrt.t_ning vi.it. 
Child,..n wore e1igibl. if they"..... vaiI.bl. during Ih. trial penod 
nd at ~t One ofthe.u- JXU"t:nlJ • vt: wnut:n iofonned coll.'ilent tor 
I hei, ch~d 10 pno . pal. ner tit< ainJ proc.du.... nd pol.ntia! 
n.ks "<Ie careruUy upt;tined by th. IIJdy in""'; . 10.... AD 
childre-n ~ invhtd LOW tber JrOl to Ihe ndy tmd wr1lUn 
in.f4 nned ent wtMI obtained from bjteh Stllrl ing al th e r 
yean. AJlu inlOrm.d CO<Ual' was obWncd, ...... ning <aU wen: 
perforwcd. ChiL:lnn were scn:eocd by hiltC<)', pbyoial <nmina-
tion ("tncluding heigh~ ",.;gh, and vital .igno~ blood ""tt 
(biochemitlry, haemawlogy and fOV tell), urine dtpsricls and 
pregnancy tUl (for female wbj<u of II ye... nd hove). tool 
culto .... _re performed to heel: for the p ..... nc. of &bt....t1A 
.pecin. 
ubjccu with a htuory of typhoid fevtr, y2la y citwion in 
lbe WI 10 .. :us or an ~ler I)!iu>id voIcci ... in the wt 5 y ..... , 
"Y clinica.Dy i&1ufi "I illn t abnormaJ blood Ie r re u1 , 
iIlJIDUDt- ppre.saioD) po !.live HJV or pregnancy tHt ~re 
.xcluded. AIoo ",eluded were .ubjeclS who e body weigllt W:L~ 
un",,17 kginth.5to 10 ytuold group or und" 27 kg tnIheII 
' 0 14 year old rroop nd subjects who .,ffef'f!d &om 2.0 acure. 
rebrik iIlllOS' al lb. ume of do 'ng (lite complelt list 01 extlusion 
crn it a il:lbl III Ihe aial protOCOI). Only OIl! cbiltl r fam~y 
":l'I allowed to particip:tlt In the trial 
he. ~ult. 0( the Kftming tec..b were tn'it:wed and ,"bjtch 
who continued fa mur the inclusion air ria wert. imrired to 
continue. in .he ni2l. 
The M01ZH09 vaccine and dose 
T )'Phi Y .roe- u.l'") Z wu constructed with rational 
ttmu:u~n ! tDtelY. ~..ncd indq>enckndy Ilcnu."Uing 
delenon mutuiom wue introduced inro S. ypm y2. Dele.tion 
of.,o 1 tn('oding ("hori:!fD3U~. !yn'~ ~'t.ntJ tht blOsyndw:$iJ of 
a.romruic amino aodJ aM dtprivtl !:he live V3l"cin~ b crerium of 
c.Uc.nlial nutrients. Dele.tion or Hill p. tllCod.inJ' a structural 
cOlUpon.nt or tbe Sa/1fIJIfU/'" I"'d")genicity i nd-2 'PI-2) type 
1/1 t<Crttion '>'Stcm. prevcntt .)"emi< .prtod of S. T)"J,hi [9]. Th. 
vaccine ...as m'lwfuturtd accocding t Good M ... ufucturin 
Practice pro<ocols by u"'W'n"'" and yn 0 Rio ParUlen 
B. ; hat h number ~ 1- H r 6 was 'pped 10 VICII11ID. 
vaccine lciu ~ It red :l.l2 80:C 
Previous studies in adult volbntrtn dtmon.str:lftd rh~u a 
nomin:a.l dOM' af ~ x 10 ru o( the v.xcine. str.ain W3Il tmmuoo· 
IIi and c [9 II] . 11le Ty 1 Qral typboid "",cin¢ CllpSuI<t 
are . ' 11Ied for adul and chikll'" above 6) an u.in th. "we 
001< 1.00 immunization ochtdult and large Ty21 IkId uiali in 
dliJdn,n _d !he tam< dllo. and "'f!imen .. in adul .. [I3J. II .. 
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Lhtrtfore: dtf~rmi~d Ihal 1I\t llppropn:ue dolt for tht d \ildrt.n"a 
.tudy w:u • nomin:>l d • 01' ~ K 10 of yphi 2 moe-
n.V") Z U9. 
The vaccine (containing 5)( la' of v. cine strain plus 
excipitto ) nd d.e pI .• cWo (vocci"e ·pient. nly) w .... upplied 
as free~ed (ormuLdons in singie dose vim, ",tJich were 
I.hekd identically. conbliJling " 10 IZ H09 orallyphoid .=in. or 
placebo" but with • unique so ' ect number c ..... spouwng 10 the 
"ndomisation Ii><. The bicarbona~ lution pttpared by 
dis10lving one ell ..... "'."1 bicarbonate tablet rovidcd in the 
vaccine leil and cOOlainil1g 2.6, aodum bic:arbooa",. 1.6!i g 
ucorbic acid and 30 mg 2Spal1llme) in 150 ml of bottIi:d drinking 
wa",r (tinal roocelllnotion: l.75~ wt/vd .ndiulD bic rbonate. 
1.1 • wtI.oI ucOC'bic acid, and 0.02% ",./ vol patWD ). The 
lyophi.liJed vaccine or pl>t<bo was ....,.,nariruud in cilh.r 1.50 ml 
(foc cbi1dren bove 10 yean) or in 7~ ml Dr tI", bicarbonate 
row . 0 (the o<h .. 15 1111 ",ue dloc:udtd) ror ch.ildrtn hclow 10 
ytarS and \VilS adm.ini&ltJ.,~d lmmccbattly. 
The Sludy used "''0 S" group rpecifi . ndomi lion Ii .... 0 ... 
for lhe II to (4)e r old nd on< ~ Ihe 5 to 10 )ur old children 
'0 eNure at 1<3 t 10 ch.Udren wtre between 5 to 10 yo n old. 
Intervention 
On the day of >cci"", in" (day 0) which. .ook pile< "i.hin 28 
da or .he 1IC .... rung. inelu IOn and ",d. . on (including hiolory or 
anribioltc mtdicltion in thr I.;a I wet ) mlt-na were ~. 
Pregnancy ..... (frmal. ubjer .. of I I ..... snd above only\ unne 
dipstick ~" and 11001 a.llUm were performed. Blood mrl ror 
hmm,ology • .,; .millt')'. ELI and TJ PO • ys (only III 
clnldren I I y .... and .bo .. ) " .. r. obtamed After the subjecu had 
r""ttl ror at lets. hou (wtlh the exception of drinklnr \\'a1.1i 
the c:uullda •• typhoid , .. ccl... or pbcebo .dminist<rtd. 
ubjeru woore .uocatt.'d the lIexl 'Oup specifIC wtrlet. 
nlJOlber and the um lion pKk. bearing lhe same number WIll 
prep red and itrucd by .he pha.1Il.ci who was Olh<rwilIe " 
involved in Ih. trial. n", .u~ec .. were ",ndottlly .. signed 10 
rtteive eid>er M OI lH09, coosistin 01' ~)(IO' Cf 01' S Typhi 
y2 ..c- If 0 Jr) ZH9 or dll: pIa<:<bo n:constitulcl in 
bicubonalt: uLion, deocnbc:d .bove. 
Volunte.n wen: "",.,,'Od for at Ie"", 90 romut ... t the h"'Pita!. 
Durin, this lim< pul.'lt and blood pre. lI .... were record.d 
periodic;ally and only drinJcin water provided. 
D iary canis were io ued for all dlt \..,loot« ... and .n ;ubjert.! 
received a bu:.: hygiene kil <Onu.iniag $Gap. gI v .. lUld . p;ltub, 
for tI .. coll<ction 0( ,,001 . :uupleL The l ubjeru and th.u· pa .... n 
were Uub'UClcd to WC8:IW'C and I C- f'd the aJ (t.DlPCr.U:un: oftbc 
dWdru ..... ice dilly (wonu. .w.! evmin aud to ""cord '''y 
:ubre e eve-Uti fmc1udin uC'ad.ul:ac., fevu. n:a.u~a. \'Owitin& 
tlbdominal pain. frequency and Ol b ten oI' . too and any 
other lI)'IlIp'on ) lOr 14 d. )~. 
Follow up procedures and monitoring of adv~rs~ events 
hildru we"" rollow.d up daJiy rrom days I to 14 and .pin on 
d::ay 2Uflltr doslnl' At Ihtst: appom(mt.na diary Ct.'l.rd we~ 
checUd . nd odvtl'S< ewt1" and roncomll1ln' med!cnrioll 
rtVi.ewtd. his ry 01' th. 1M. 21 hOlln with spodaJ Mnpha.is on 
' omp<nIUre1 ,5' nd 0 nd vone ... n .. (dL'\trhoea, 
\001 of ppeti ••• vomi,,,, he he and dtills) .. obmJned. Oral 
temperaluret and \ iw ';gn' w "" re orcIed d dilldren we .... 
e mined ror s· of",lenomtply tool culturet "tee p<r/'onned 
da~y rrom day I to day 14 Blood pI .. lOr . ..mi>try and 
baematology wen: obtained on ch 7, 1\ ... d . 8; ror the LPS 
specific >Ct'WlJ I £U ' A on daY' 7 and 11, Co ~ I3C EU G" 
da)~ Ihnd 28 and lOr the LP specifi I A f"'llbody ~r.ting cdl 
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EU POT .y (only in .ubject.! .ged I I I ....... nd .bove) 
on day 7. TIlt' tOCl.l mount. of bJood tWeen during this study w 
pproxim'ldy 28 rnl fro .. ! It .5 10 JO yean old rid <14 IlII from 
.he I I to 1'1 yean old children. 
Unscheduled visits 
nbjecu and pan!.nu Wf!rt: Instruct!!d ro make :ulditioaaJ visi to 
.h. dinic, ift.he chUd relt unweD .Ddlor had "fev ... of "'385 C 
At thes~ viliu lhe: subject was uutRd nd mplel I kt.n (or 
culture c1inially indicated. Blood MtU'" 10 immgau: "r the 
Pl'CICllCt of S. Tt"w in blood ,,'Ould be btained if a fewr or 
39.0·C ..... recorded rw:"", w ... a 48 hou period, or a leV r 
re.\ r of 39.50 wa. recordL-d OflCC~ 
Definition and reporting of serious adverse l!Vl!nlS and 
definition of stopping rules 
There. was no Data at" Iy and :MoniroOng ommiuct' (or lhis 
lrial. Datil rrom all children were review.d dally and .he", w ..... 
prirm defined Slopping rules which. would trigger uspen 'on of 
.he .riBJ .. nd a ""'ty ",view (Prorocol Sl~ nou. dve ..... ven" 
were rtportcd to AKO Ltd ilChln, I • pharmacovigi1anc~ 
company wuhin 24 hOUri 
Detection or Salmonella in stool samples at the screening 
viSit and day 0 
The det<trion Gf &Im_o. spec;" at the 5tnenin, visit nd on 
day 0 w.u performed :uxordin, to microb'.ologb.l tand.'U'd 
prooed".... In brid; srooI samplea wue iDO<ulattd on.o 
lI-{acOonkey agar and ,,)10" lysin. deoxychoL"e (XLD) agor 
plot ... and In 10 ml of adenite F' broth. Plan. and broth w."" 
incubat d at 37' C .,..emigh. ond the broth w sub-culrur.d .. , 
MlIcConkey and XLD IIj\1lr plo.u:s the next wrung. bobl.S .. ere 
screened w.ing It"Ulchrd biochemical tests and &fmiswlla ~ere 
idi:ntifll!d by slidc aggIu lination wilh .peci/k antis ra (OJWid Ltd., 
K) and AP ot profiling (bi Mttieux, UK~ 
Detect ion of S. Typhlln stool samples 
IOOI....,pIes were colkclcl daily be",un days IllIld 14. 1001 
.amp1es .. re cultured din:ctl on dooxych.Cibt< citra, gar (l)CA) 
Hynes pl:.ues (direct medu.d) and in <i<nite r broth. (enriched 
mcwndl, bo.h of .. rucb were supptem.nlcl ",ith aromatic 
compouoW (DCA·"", and sdenile r·am .... spectively) to detect 
. T)phi. including the .wu>lrophic vaccine .train, in .tooIs. 
f ollowing overnight incubation at 3 C. n aliquot or the 
i_ulat.ed ocJeni,. r ·am broth WIll . ub-cultured on DCA4I"O 
Hyne. pIMa. Swpcc:ted S. yphi colonie. were inoculllfed on 
brain he n infUtion apr plates lupplemcnted with ammar.c: 
com " oW I n .arc). Oxidase nt tiw colonit$ we""" I .. :lted 
by a lutl".tion with Ild, i and 09 ti-oe", (Oxoid LId .• UK) 
and APL.?OF. profiling (bio • ux, U K) t I mples COl.caming 
isolau. thai wert! potitive 10 1ll1eut 2 out or 3 agglutinntiona and 
idelltiflcl at Typhl by APl20 Pl'OliIing were considered 10 be 
po . iv< \"" . Typhi All ilolatei were tored in 10 (v/v) glycerol 
al -30' . 
Detection of S. Typhl in blood samples 
Blond mplet "tre co""ctcd into .ith 
cul.ure bOtt (I 3 ml blood; DO. ) or D.cl<c Plu. eroblc/ F 
cui"' .... bO<de. (4 10 011 blood; 80, \ ) and ... ppI "' .ed "ith 
romalic ompoundt Blood culturtt wtrt i"cubataJ I 3~ 0 in 
Ih. 8 <, detattioo, !em and monito.'td for up to ~ d:lYL Cram 
. tain p<tiOrIDOd on aU bol triggering t positive rtaction. 
P""itive cultur ... "d aU cul.u ..... d"" were" .o.e n r ~ days 0( 
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incubation wtf"f!: ul:K:uhtu,td On XID ag.lr pla re.$. SUS'p«t-ed S 
Typhi colonia ,""err sulKuh uf"ed onlO 8HI~nro agor pla it" 
Odd; negative itol:llel wN't evalu li tied by ttggtutinadoll nd 
i\.PI20£ prof ding . 1 ~rieu K) as above. 
peR identification of S. Typhi isolates 
C.oomic DNA was itoiaeM from glycerol KOCb of S. Typhi 
isola"" using a DNmy blood and a..ue ti[ (Qjagen, UK). 
Mulr iplex PeR.! wtre performed USlDg a Taq PeR core kil 
(~n, UK). Eadl mlClion mixture COIIejned 200 11M dNTP', 
0.4 ~r ... V4 (5' ATCC CACCACTTCACCAAC 31 and 
... 7 (5' TCA ATC 3'), and 0.1 11M 
• roC.ZI W GA CTCTtT GCGTMC ') and aroC.Z3 
(~' TTACATC CTGTG C 3'), 10 ng "nomic 0 
and 1.2~ u 7.q D pcdym • .". in • toW volume of 50 fLl 
reaction buller. PCRt were performed for 25 cycltt follows: 
94°C Ii>r !lO sec, 57·C 10.. 30 tec and 72<C for 2.5 min. T he PCR 
producu were visualiled by orhidium bromide staining . nd 
rr:uuillomin>.Don ftcr dcctropho.....m on • 0.8% (w/v) TAt 
.gam", gel. T he expected si ... of tlte PeR product. were I 04 kb 
( roC) and 259 kb (11B for Typhi wild-typt SImi", ."d 0.45 kb 
(.roC) anrJ 0.70 kb (su I? for yphi y2 tuuC ss.V- ) ZH9 
Detection of antibody secreting cells producing S. Typhi 
lPS specific IgA antibodies by E1I5POT assay 
Ll POT ys [0 det t antibody _ ... dng cdlI (A ) 
prod . og . Typhl lJ'S ·tic IgA antibodies .. ere perfom,ed 
on days 0 and 7 .. deoaibed previously (lO,14J. In brief, whole 
blood was coJ1ecrcd in hcpariniled cell preparation woo 
>cuOliner CPT; BO, X) and centrifuged. Peripheral blood 
monoouduJ' ctu, 8M a) ~rt w3! tw:d, rut.I!pt.flded in (uhurt. 
medium and O<ljuslttl 10 chr« ttll onccnt ... ,ioou (I " IO'/ml, 
~x l (f/mi and 2~"IO·/n . n< hundred n~trolitr.. each 
COIlcen. r.";,:", were added 10 lJ'S coacM nd u, o.I<d weDs (Cor 
.ublractioo of non·rpc 'fie mults) of n.itroceDu e ual (outer 
plat'" ilIi""",, S .nd incubated IM'-mighl . t 31' C in a 5% 
o ncubalor. PBM ' tolJec ... d from . healthy voIunlur who 
had ... ""ived .hrt< dooc. of Ty2 1 ivori!', lkma, wilUrland) 
Vlt.r~ included as positi\.~ control and P8Me &om a non-
vac 'nar,ed person 1U negarivt control, Pbres wm, hed nd an 
albUno pbOfph_e-conju red .nt~hllrn n riA ntibody (1m-
mUII. S [em. u d., Kl was added and incub;alOd r. I' Me hour. 
Ptue. were WSlShed Mld , pots ""'ere vi£u.ot..liseJ. by the add..ition 
or >bromc>4-chlvro-!l-:ndolyl-pl pl",,,,/nitro blue t Irazoljum 
(8 11'/ B tub'rr:u~. AncibaoJy .. cret'ng cen ( en po w .... 
coonlt:d manually u ing:._" inw.rted microscope.. tfmore III n 100 
Spoil ~r wdJ wtrt prr 0 1 J the re nit W3.I ckacribt.t:1 [I " too many 
.po .. to be (ounred". posim. re OK in Ih. W . POT "'r 
on day 7 """ ~t'.ned as 4 Ig 0 specuu: lO r LI'S p" l(f 
PBMe. and n liv ..... 1'O. OJ < I liA tift for lJ'S 
pcr 10' PUMe.. Sub~cu with • day 0 m olt of 4 ASC per I (f 
PBMC were exclu~d from th EUSPOT anal is. ELl POT 
.... )'1 w .... ptnorwed the Hospital for T ropical DiIe ..... 
Analysis or s. Typhi lPS specific serum IgG and IgA by 
ELISA and definition of a positive immune response 
Quan';".m" EO f\ m thoW (or me: ring . 'phi [. 
sptcitlr ,rum IgG and I, we .... <kveloptd . nd qu.litled by 
£me~nt Product Development ' tnt u ini .. rom .. mples 
from ... Op:<n of 1011 1109 who panicipared in prior c1:rucAl 
trialt Q.mj who had 'w:n infonnecJ constnl fOC' re\ nti and U$age 
of thtir .ample •. f or the I W A. ~noru .. hid, dtmons.rnted 
mort than 4-rold incr .... e from p~e in p'"viously dC$cribcd 
.~: Pl oS ONE I www.pIolOn. ''''1I 
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end poinl .i.re .y [I I] were pooled and u",d ... f ....... e 
Standard. lbe LP: specific IgC COOCMlrtl tiQn in II stanciard 
sel'U m wru ,..., arbirnui ly a t 30000 units/ml. 'For the IgA L1S J 
.erum &om p t recipitnrt of MOl ZH09 who d.mons.mled 
positi~ response in IgA ELl POT were pooled rid uJed 
refe ... nce nndard. The lJ'S specifIC I A cooccnlr.lDon in [he 
Sbndani serum war le t arbit.rarly lU )00 unia/ruL 
t>recision WIJ evaluated .. part of the us"y qulliiflClUion 
excn:ise. V fiancc componenl :malysi.t was carried OU I (PR.t 
T rainin & Con.W13ncy Lt:d, q 10 leul:ue the I .. ><brd error 
or r:nt.a1u rtd sample mu and the. leact signifanf diO"( It.occ 
(L: 0 ) between twO .amples I tI,e 1% signitkancc level; this w 
used as the clI[-oITvalue for a pooiti~ result in [he rupeenve .. say . 
A pooitive .. rum IgG re.ponse ..... d. f .... d a 70% in= . (" ld 
change of 1.7) lU compared 10 the corresponwng baseline :l3mpie, 
.. he ...... a posi.ive , erum J~" response .. -at defined 50\4, 
increaJC (fold dl3tlge of 1.5) OJ compared to baseline. 
Serum mph! .• for mtllJU~mali wert frozt n at - 20- and 
. hipped to 'F.m~~nr_ Product Dcvd~nt " Lid for th t: 
ell onl lyse •. f or tbe lee ELl , micronler pt.1<I were coated 
with Typhi LPS, wa.!hed and lhen blocked. \ .. hini occum:d 
be",,,en each step. Calibration 5ttncbrd, .nd diluted l <S, mple, 
""IT. added, and the pia". were inOlblUcd. Bound l ew .. 
del eM using an .. " d-hulnan tgG antibody coluugated 10 
horseradish ptro';di!e (J I.RJ~ (Dako, Dewnarlc) foJJowed by the 
.ddition of 3,3',~,5' -Tetrant<thylbcnzidinc ID) lubstnte. The 
plate, ... re read . t 450 IUD within !lO a,inul<' of w>pping the 
reactions with 0.3 moJ/L sulphuric .cid. "In. standard curve was 
COlUtrUCeM by plotting the optical deNitin (ODs) of stmdanls 
Itga1m[ concentrations aDd litl<d by a 4-pas~ttr lagatic 
equation "liMa,. I'to 4.6. Mokcular Devic ... US . The 
coocenl ... iOn of LP specifre TgO in .acit sample w duermined 
rrom .he srandard cu",e. Th. Ig. quantita.ive ELlS W>J 
performed in a simila r mannu, txcr.pt using a double detection 
')'II em of bionnyb ttd anti-human T an.ibody ( outhem 
Biotech, USA) followed by otreplavidin-HRP (onj n Ie (Dako, 
Dcnm>rIt} 
Outcomes of the study 
Safety Oat.,....,_. primary safety endpoinl was .he 
proponion of lIUbjem wi.h any adv."" "".nlS attribu.ed [0 
MOIZH09. Th. """'ndary . afety endpoinl w the proponion of 
subj«ts with any knOllS r~ ted adve.rn ~w:nr.s; any rd:ued or 
unre tued adverse even .. ; persisting fa<e>.1 shLdding of S Typhi 
y2... JS4V-) ZH9:aft .. day 1; and/or had. f<v<rof38.~·C 
or greater in ,'''' 14 days JlO!' v:u;clMtion, wi .hd",,< from the tm l 
due to advtr5t ev~n l;S, inducting 1).1(r r3t.n~ nrl/or had 
clini Uy .iguiflQl\l changet in laboratory p rame:rers rthtt;d to 
the candidale. ccine. 
All ubj w1lo received a dose of the c:cine or placebo were 
analysed in the rety popubtion. Po t-vaccin:uion advtrs< """nil 
W~~ cHegorised acc.ording lO body 'Y'1~m ard prdC'..nYtf ft rm 
"'in~ tb. ledica1 ,Dictionary for R.gula.ory clivi.,.. dORA, 
mM>O 9. 1), alloc:ued before llnblinding, dvtne ~nts ""~rt 
graded by .. verity (mild, moderat. , !!<Vere) and judgpd fo r tb, 
relatedne .. '1) tho stu dy V3Ccin. (unlikdy, JlOiISibly, pmbabl by 
.he inv rig.tor. Only po ibly and probably related Advene evt'n 
~rr an riburrd to ,h~ vaccine. M-odernrt f~t.r was dt.6ned ( an 
0",1 ttmpel. ture 385'C and .. r""er II " om! 
t mpera,"re of 3 ~ Mod ... ", diofThoc d Gned 
more than <I unformed ooIs and severe diarrl.O<a _ than 6 
ull/Omoed .tools in 2<1 hour period or evidence o( . ifICan! 
denydratiool. All adve .... events wm: recorded in the Rf. and 
monitored unlit .-tlum to normal 
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Tht: numtxn and proporrioll of ,ubjtcts ~ rl in adw 
• ," we'" Ii.,ed by body "m, per .~ee"nol ~ of ad 
evt:n13 • perfonnrd t It I if:\ subjed r~ntd Ih~ sam~ a.r.iVt!rte 
event n thr'« oce ions den adwne tvtnt lly COlinttd 
once. bjccu reporting more than one ad\.'Uk C\lcnt per body 
tyJ' em wen: couDted O1~y 00<% in "' .. body 1)''' D' lOW, 
r...m ..... oaldty 0.«........ The primary immun~nicity 
CndpolO' W1I the proportion of ubj<CIJ who ~ pc<! pooitiv. 
immune respon!c to S, Typhi LI'S defined by an ill(rr ... of 70 • 
(I.i fold ch3ng.) in U'S .peci/k oerum IgG on day 14 or 28 andl 
or an iner. of 50 (I 5 r. ld ch3nge) t" LPS . pecillc .erum 19A 
on day 7 or 14 compared '0 basdiu , 
The L'OIldary imruuno nicity wdpoin "n: defined .. th 
proportion of ubjccu who ~loped • pcoitlv. immune r .. roo 
in och of ,he followin( UR§mtn : S. Typlu LPS pcculc Ig 
EU ... yon dJyJ 7 or 14. , Typl\i U'S specific IgG EUSA 
.... y on day. 14 or 28 Ind Typhi lJ'S specific Ii EU POT 
on dJy 7 pooirivc £1.I:P01' W3, d.fined o. 4 Ig nribody 
J«nting oeUJ specifIC for 1'yphi U'S ptr 10' PBM 
Sample Size 
The pla.ruu~d samplt stu. 'tn., )!(I I erb, of whom I &t ;t 
iO . , llould bc ~ 10~ ..... or YUlI" gt r. as this" the targt , "S" 
ofd,c cine. nndowised 10 tO IZH09 Or pbccbo in .2:1 ratio, 
o fomW umpl. ,;ze calcubl ' wu considtr.d ppropn..lC; 
it waa aimed to indude: a 'Ilffx:icnt umplc site. to IU.'ICSI 8!lfe.ty and 
immuno~niciry b:urd on previous ObWnt1c:lON in dull ndi~ 
.nd Immunogcuidty rot.. f UoenJtd typhoid V3cdnu in 
c\uldrtn. 
Randomisation procedures and assignment of 
Intervention (sequence generation, allocation 
concealment. implementation) 
RandomiDtion od ,"uo OIDput g n ,. d in blocU of 9 
by ."wood Lid, UK Th. vaccin. uod ,I\< plactho w."" Iabcltd 
idtnlically bu, wirh • uniqu, I .. ,*ct nllmh .. ctll'l'CSflOnding '0 
.h. rondomiJ:l tion h Th. ,,,dy I1&Cd """ ago smup opcciflC 
random' bon U .... oncfl r ,h. II to I"~arold.nd on. rorrh. ~ 
to )0 Y a.t old etuldr"tn to f:n!IlU't: :u leut 70% chUc.:Inn ~erc 
bet", ... n 5 '0 10 ) ....... old 
abj<cu w<n: alIocalCd d.. """t -group, ciIlc uJ:; ct 
nnmbtr in _riCI numtric3l ~qlXn(t from th is Un and rM. 
medication J"'Gk he ring ,I\< ..... number was pf<p3r<d by tho 
phamua.t, 
Blinding 
I\:s "Idy WI" farmoUy • Slng\< bhnd lrudy du. to hih' 
dlifereoces in t rt.. nd aroma. bt:rwt'Vl the m-almenr p","p"f"luioru 
bur it WaJ cOlldocttd lIndrr tht prin . IN ofa doubl.! blinrl tl rudy 
iO lZIl09 ,d pbccbo....,.. p gtd and I~.didtnticolly bu. 
wi,b uniquc qu.ntial numbcr Ptmi • ,ourc., of unblindiu 
cwld have bcen tbe prtpuatiou of the, in •• Iherd'on: the 
study pltMtlucu. t wu olh rwi no' im:olved in ,he trial. It. 
.ul~eco ... re askt:d to 001 reporI Ih ,,~ of Ih v 
J\iicroh' logy .... ul w.n: 001 rev' d by the in> 'pt 
.. 14 dJys afI r vacciruuion 10 "'<lid po< no.1 lInblinding 
through thl'dd::ni in nob _ Immu-n.okJey ~su11;S Wf:1'f': not rrvirwed 
by the in, ril" ' 011, • • uw:ly Ilt< rc«iv.d cod. br .. 1t .n,,.lope, 
in c;>sc an '''''''aw<r made onbfindm or a .lJIiIe I'<!iCC' 
neeOJUry. codtt " . broktn duriug tlus ",<!y, The 
unblindillg of IItttm," t aD .lilUU .ook piAtt I\or tb. trW ~d 
bcen ompleted and d~ ",I cb~ Iud be 1\ "" red and 
locUd. 
s 
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Data collection. data entry and statistical methods 
All da", w ....... cordtd in ... Record Fonru (eRF ), RF. 
wert I"e,,·ic-.«d and co11ected by the. ,'ndy monitor Dala mIry, 
data m nagemm' nd .. atiJtical analysis " n: rondllC1 d by 
flltwood, .mng • o/\ware (v .... ion 9 I). Dam were 
double .n ..... d .nd nalyl<d according to an • pMri cl<fintd 
ltatistical analYI:' plan which indudrd ltK dellnitlon of aU .ubjttt 
population. and .1\< .rW endpoln ll, < "'fcty popol: rion 
indudtd all subjf:Cf.! who rect-l\ltd tht tudy me:dk:u ion. t 
intention to Ire t population comp' iscd aD do .. d .ubjc,n 
wl\o ~d any f'O"~" imoollllogtniciry da. vail ble. Thc per 
protocOl (PI popul tion excluded major pc,otoa>l violators (fallurt 
10 wal tbe indusion/t..'(tiusion crit~ria. to comply with the rudy 
mtdlntion or uSt other cinal' Or antibiotia twO ~cb 
before unrJ 2 weeb flcr cinaJ ion, or usc of antacids or pror n· 
pump inhibuon prior to y cin.atiou and/or did not provide. 
lamples for II>< F.U I, Th. protocol .. ,ed .b:., a collfinn>Jory 
anal io of the primary immuno,""i ' ty ndpoint in Ih PP 
popul;uioo w planned if mort than 5 '. or subjcctJ ~ re 
txcluded, 
The proponion of ubJ.ct. who ~ritnc.d polt-doo •• m't • 
ev t\ wu pr ... nlcd 10 Iher wid, thclr I"'O->ided 9~% 
corwcU.' t< ill .. nooh (950;. J) Po" dOle dvc~ ."en". am 0 
eVOn comid ~ to bc rel4lCd 10 the ,':ICcinc aud dv<~ CYttIlS 
lha.toa:urrcd in more than 10 of the trial population wtrO ned 
wing a m»·sided r lSher', tlI.ICI tell to compan: l>etwctfl tl two 
smull' 
The proportioo of SU'<!iOCb who developed a "",iriv. immuo< 
.... po"'. w p ..... nled !l)v-t~r wilh ,btu Iwo-sided 95~ 
c(JtlfiliLnCL intl"rvab calculall:d by U lng an tx2d Qjnomial 
di,tribution TIlt lrr:atme.ot cliffer't:na. and -'l«iated 95~ 
con6d"" • inlLrval "'cn: pm.nted as nbovc, AU .vai).,bI. Mt:I 
frow withdrawn subj<Cl! ""5 included in the analysis. 
Results 
Partidpant flow and recruitment 
The trW waJ conduclCd bctwccn April andJuI 2007, In tom!, 
20:1 I\<lllthy i .. oan.... children bctwoen 5 IUd I ~ y ...... 
Cmdusive) were Kre<ned fur tIig:'blity. f 't/lY'Wur tbildrtn wen: 
n dig! (figure I). t most common ;uoos" u .... V3il· 
ability ror lhe whole Slud period (n = 10) and a po ' t iv •• tool 
.Itur. ~ SobtwndIa ' .. "' IItreenin (non·twhoid ~. 
n - 0 S. Typhi or S Pararn,hi w .... d""'ltd in 110015 r 
the .tcre:crung visttl 
nc hund~ nd filly-on. child ... n w ... randomistd. 10 1 
c1illdrtn .... iv.d the ndida .. ryphoid acin. \lOIZH09 nd 50 
childn:" rcccivcc:! plac.bo, All ,obj fulfilkd .h. ",elusion nd 
.,..,1, ion rircrl l serecning nd doom&,. howtvcr twO lubjecu 
'Il In th. MO IZlI09 ,",up) had din' ally .Igni/kanl tie ltd 
white blood count (163 d 18 2){ !f1L respectivcly) n doy O. 
th ullt were ooly a.vallab1e after ing 
DC ubjtt' III th. fO 12H09 sm"p V'Omlt.d afltr taking 
pproximOldy 50'\ of .he requu,.d V1tCClDt doct T .ubject 
3grr'ffl10 t.lkt ::a nothrr d O!t . but (,iIMt 10 rtt:un it Thrtt: u lbjrcts 
withdrew from th,.. s tudy. one pb.O"oo ~cip:ltnt wi,hdrr.w dut to 
non·ccmplbncc (II'r .... d '0 providc stool sampln) :an.. dJy nd 
IWI> """",.n. r<c:p,.n 1<0 'he . rudy 3f .. r day 6 (one .....,.d IQ 
wilhdraw. the 1d . ubJtct "'.nl 00 holid y) All .lIr $Objtc 
llwded ,t day 28 viti .. Th. """ .iniug 'Ubj<clS .'lCn(~ D 
trudy visiti, Tw~ lub,ieclS I\ad unschedukd ' i , On< sul!;tc\ in 
the ccin. gr p "tndtd d .. dinic on day 16 becall2 orr.""r of 
38.1· and It subjtc\ in d,. pbc.bo group n:tum.d on d 
with a tewpel'lllurt c..f 8,0· Blood culture> wore obi ; d from 
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MIl 1 ZH09 Vacdne "' Children 
He.~hy Viet""meH children egad 5 to 14 Y"'" Oncluslve) we,e ocrllned for IlIglblllty, 
n -205 
Not I ngible , n = 54 
Age under 5 years. n - I 
Fever on day 0, n : 1 
Bodyweighl bolow 27 kg (11-14 ye., 
old). n - 2 
'M1hdrewal from the atudy, n - 4 
Aboormillaboralory result, n - 8 
No stoot sample provided. n = 8 
Nol IVllllble for the dlntion of the 
slUdy, n-l 0 
Stool Ample posftlvl for Iny S. species 
alscreenlng, n - 22 
I 151 children .. ndomlsed 
-----
:--:----
101 chlldren assigned 10 M01ZH09 50 children assigned to placebo 
101 children receMld MOl ZHOO 50 children ,ecelved plecebo 
1 
1 Subject cld not take the ,equlred dose 1 SUbject wlhdrew atter day 2 
ofM01ZHOO 
2 SUbjeots took antibiotics between day 
2 Subject. withdrlw In r dlY 8 -14 Ind dlY 14 
1 Subject. took anti>iolics between day 1 SUbject hed one unachaduled vlsl on 
-141nd day 14 day 2e because offever 
1 Subjects had one uneched~ed v 'Ion 
day 16 beClUA of levar 
1 subject had unscheduled blood tests 
on day 10 boel.u. of fIver 
1 
An lOt SUbjects attended lhe day 28 vl$ft I All 50 subjects attended the day 28 visit 
l 
All 101 subjects an.lysed In lhe lIT I All 50 subjects analysed In IhI lIT 
analysis analysis 
fig"" I . flow ohub,... •• 
detla.1J71/journoLpone.oOll 778.gOOl 
bo,h . ubj t cr, and boIh GUI," ,.. w ..... ntprivt. On. (0 I ZI-I09 
.... cipien ' hod unocbtdulLd toan ptrformtd. Tht .ubjtct pn:o<n,td 
on day to with a tunptrature of 38.6' &nd ... pontd diarTh~ 
vOtniling and ftver on tht prtviou. day. The whitt blood coun, 
w tli:valZd w'Jb 14 .2)(10"/L .od the blood cultur< result .. .., 
ntga.lh·t. 
Numbers analysed 
AD 151 children who w .... r:Ulrlomi,.rl nd ... tti""rl .ithe .. 
{01ZH09 (n= 101) 01' pla bo (n-=30) constituted dl< in (oMit 
to t.real popub.' u. t:w.n tubj tI, 4 in the v:a.ccU t group 
• ",1 3 in tht placebo gaup went pro! 01 viobton (see fi . I) and 
we", ."dudtd rrom rh ptr protocol (I' alation. The lIllal}lis 
~. PLoS ONE I www.pIo"'nt.O'V 
" . . 
6 
of,he prim,ry tn<!poin" in Ihe PP populalion ""'IS pbnnt d !fmo~ 
than ~% of subjt"" ~ excludtd from ,he nT. The PP 
popul . ion comprised 9~ (1 44/151) of .ul!jtCIS ;and the .. ,fo", no 
pt .. pro I >.ouJ) is w:1t condUcted. 
All outtom" wert evaluated IDr .ru, lIT popubtlon. 
Baseline data 
he IWO I"""P' dtd no, dift'. r sil"if"",ntly at tnmlment in 
tt:rms of leX, age and laborn.tory par:unttt.rs ablt. 1). Ont 
hund ... d and seven \l1~) children ""ue '&<'<1 10 ytan or 
youn~r . 
Two sul?jcCIS in lhe (0 IZH09 ""up had clinically tigniiicanl 
ekv d wrule Wood couOt" on day 0 (_ above). w<lve IUbjecU 
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MO'Z~ V""dneln Chlldron 
T.b .. 1. Basenne cha,.cteri>llcs of the subjects on day a Omention to Treat population). 
o..act.Jstia M01ZHOt group (n_ 10" , ....... _(".501 0. .... ',..151) 
M·loy .... Hi - I., 
N..-of ....... t'W SoI.DI 
WPtgtll ., Wog',,", 21117-SJI 
Hfight In an III (97-16S) Or"'_ ..... OC lUO(lII -lH) 
H...-..ogI_glcI' 1l.J (11lS- IU) 
Ytttll:euU COtM'It. 10'AIII 72 (S-II2) 
~-.,,. , l'I6 (149 - 55.5) 
NeuttopNls, '" " .... la2- 701 
MOfIoc.yt.s. ... " S.J(23- IBl 
110 ........... ' O.l (0 0.7) 
-""" .... ,." ' .0 (o. I - I I.~ 
Plltlllttto\.f11. 1O'Il.· 195 (Ito - SOl) 
SItum -.sp..utl A,.,..oocnm~.~ AST, UJl 27(14-5;1) 
~ Alan". AIri'lonns'" .MI It. 1, UJ\. 16 (6-5~ 
er.-tnl ..... mlrNl o..o710.SJ - 1l.101 
SCM t\JIruto po<It ... (til ScIi""'_ .,.it< , 
AI dIto ... pr ___ od .. -." "'9 .... "" ~""""lPfd'Iod. 
Oar ~ an.'. ~ MId HIlMA wbjKts noc IlVaDab~ 
cIo1:IO'17 /j ....... -'OO InUlQl 
in lOIal, Ii .. in 1M pi . bo gr 'I' and It' in Ih rOlZ II09 
group (tbit included !he .ubi<'ct wbo ,'OmilLd on Iht day or dooing) 
had a positive stoOl cui ..... ror non-typhoid Stzl>mw1Ll on day 0, 
,h ...... ,,111 were only valbble an .. dO!fng. 
Protocol deviations and modifications 
11", protocol ... ted tha, 'he primary ...relJl endpoint would bt 
tho proportion nr rub';'crs ... porting .. riOIl adv..... "'<II" 
attributed to UO IZHO'). Du '0 concern. thar Ihtse numbtrs 
m:gnl be: .m:ill and would not bf! Ifficient to cktut a diJl'ert.ntt iu 
• afety betwe.n til< ."'" groups, tile primary ndpoin. w cI""'gcd 
to the pn>portion or . ubjects with any rel.,ed tJ-;"rsc cyenL IUs 
chana< W3S awle llflcr Iht complerion or.he clinic:&! phL .. bUI 
pOor tn datab3-t Jock :lM unblindin, . 
Outcomes and estimation 
Sarety o ... ~tbf!tI. Thl'fY ..... t1"e no I. am.t ~-ro l no 
bacltrnttnb and n ~ of the Iu ' cb withdrew dl .. to ad\Y~ 
evtslll in this aiaL 
imilar pn>porrion or ."bjee reponed.dvene cwnts in both 
trt<llJXl<n' groups during Ihe 28 d. rollo up, ul the .ota! 
nWIW or ",en" w Wt<her in d,e M01ZII09 group. In ti,e 
vao:cit group, 26 (26'>, 95% I, 18 35""1 Qr 101 iUbjec 
reponed 6 ~ ad roe """",. <oml",rtd 10 I I (22 ; 95%CJ, 
12 36%) nr 50 .ubjec .. on 1M pI'I"''''' ,",up "i,o rtported 17 
adverse <vena (O<ids ratio \ Rl [95% 11 I [0 550-2.14 ; 
p=0691) ble lUI'" ltd 0 CUlTtnc. p rtlctlbradw~ 
C\I'tftl in du:we tub~«.t were included in the L mlllumbc:r or6 1 
and 17 ad""", ,\enlJ, ....... • tbe G1 adverx <Yeo 
r<pO.",d by 1\11 lZH09 r<cip;'nlJ , ~ w . ... mild (8 or th ... .. crt 
coru:del'l'd ro be ... bted ro ,ho cand It ccinel, 8 mod ...... (on. 
rtl."ed) .nd 00< w .. ~ ... ~d ",law! 10 MOIZI I09 able ' 
,ho 17 adverse tvtntl in the pJ&oebo p, 12 wen: mild, 3 
ro<>del'lte nd nont Yi rtbttd. 
91S I~ 9(S-'~ 
27 (Sol) 11 
26.5 (17-661 21 (17-~ 
1l0.50 ( tOO '6S) 132 (91-165) 
lUS (1l1-17A) 3<1111 () \ .1-lUI 
114(10.9-1 5.5) 1l.J (I(I.$- 's,sl 
10 (4..- 10.7) 7.4 (4.9-1&'1 
j9.9 (21.4- 67 •• ) J'.' (14.. - Q •• , 
5O.s (IU- 71.1) 499 {lU- 71II 
5004-13.2) 5.2(1,4-111) 
0.] 10 0.7) 0,] (0 Q.7) 
3 010"-15.21 1.1 (O.I- IIA) 
311 (Ito 467) JOQ (190- SO)) 
26"4-511 27 (,4-5ll 
17 IS )) 16 (S- S8) 
O..o71J).17- 0.7l) 0..07 (1l.27- 0.73) 
5 12 
r or (4 . ) MO IZH09 recipients e~oitl .d 10 d roe t\lenU 
Ih t Wfrt rebttd to th.e ndidnte \.':lCCin~ compared to none in the-
pla tbo group fJJ = ° 302). these, a ...... mild, OUt rooderal. 
(di..-rh ) alld ooe n' of P>TcU was """'e. The mode I 
and the Rvere milted adver1C e,,'cntt oc;c.urftd in the me subject. 
Thil . ubject bad a normal 1r.mpenu.urt on day 0. bur 'he pre·dot. 
blood •• " ho"",d." eleVllttd whi,. blOQd cell count (16.3" 10~ I 
I,,). The . ubi<'c' ccpericnoed 6,,~ p<m vamnalx,n ad ....... evena 
o<cuninr on day 0, includinl fevcr or38..5 and 3. , diarrhoea, 
h dathe, abdominal pain and """rem.. The .ubject reccived 
paraa:l:lmol and ",<overed . 
imilar proponioru of u~eclJ cxperi.nc<tl f_r poIi' v>ccina· 
lion .ble 2), only one subjtct reported f<vO' rebted to 
MO IZH09 (see abo",,). 
Adw t eventS c irltd J pst ' nt~ttinaI c:bordtrs. ntNOl 
oem difordtn and invesOgalioru w<:,.. apeoitnC<d by hi&l>tr 
proportion of M O I ZHO "'npien able welYt (12 ) 
v""cine r«;pitn .. cxperi."""d pstmm'tstnaJ di.onl<,. compartd 
10 I (2 .) pbccbo <co pien' (p- 0.061). ervoua, tm duorders 
(had3cht) occurred in 9 %) v,,,:d ne rttipirn .. COtDpan'd '0 1 
(2%1 placebo n: ·pien. (p 000.1 and im<ltigatioru "' ... "'POI,ed 
by • (4 ) ccine recipient compared 10 none or tM placebo 
"'<ipie"" (JJ = 0.302). 
Ullo w the m()lll frequeooy repor.ed adv,," ."Ill, 
occurring io G (6'1) {O IZH09 rccipien .. versus 7 (14 , ) plac.bo 
. ien (p .. 0.1 24). 
n d.y ) .lter Y:'\<cin>tion, fatt31 .... dding of Typm 
lIrred In H (49"» or 5 cino r",ipirn t1; htddin w. 
de. ted by tho din.'Ct Imthod in 11 (12"-1.) bj .. Md by Ih. 
riclled mabod ofculruM II Is in 36 %) ui!jtcIJ n day 2 
f'ttr """"ina lion, flO I leddi ... de1<C\ed in 12 (12 . ) of 7 
. ub; (in I (1 ) .ub;ect by d:re" and in II (11 '11.) ubjecrs by 
enriched mtthod\ nIy One (I ~) or 98 .UbjetlS uperi.ncecl 
shtdding on D r 3 (dttt<:ted by enrichment -thod). In total, ~ 1 
(5 1 ; 9~" I, '~ I 61 ) or 100 lOl ZH09 .ubject. cJqI<oitnctd 
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M0 1ZH09 Vocd"" In Ch lldr. n 
Tabl. 2. Incld.nce of advern> events after vaccina t ion during 28 days of fo llow up (I ntention to Treat po pula t ion). 
M01ZHO' (n .,011 
_ of.ubjocto 
An, Mftf"M .... tnt 
G_~._"'("" 
rtkrrwJ 10 vttedttf 
_01"..,1'01 
"bIed ID wwront 
<MS1l_1"l 01_ . 
..- .. -
tm ... 
~fOWKt:JIttI 
Vomling 
0 ..... 4 ........ 4_""_"0' __ 
Q,iI. 
fllttgt. • 
.,..... 
_10_"""_ 
~.,.. enCII Int.t:MI .... 
¥5BI ;,..'.cion Ift_ .. _ 
Unno _ 
..... .:e bIoad eel ~t'I1 ana..std 
............ "","" .. til ....... 111' __ 
ttIattd to wet .. 
D«1'N5fd oIppIdlt 
N ...... .,....... ........... H_. 
t'IIcttfHImvlt(cjl'lf 
....... ..,._odc _ ........ "., III ........ 
eo..gh 
~" __ onnOfI 
SIUn M4 ~ • .....,. ti.eue fIl ..... 
U 
11 
• 
• 
una-lSI 
12 (a-20, 
l 
• (4-1&1 
1 ( .... 5) 
4 (1 - 101 
l(1"') 
, 
~ 
• (4-tal 
'(2-111 
, (e-,) 
, ( .... , ) 
11 
o 
o 
o 
Q 
7 
o 
22 nZ-lel 
2 (a-I1) 
Q 
10 (J-U, 
0 (0-71 
0 (0-7) 
'(0-7) 
2 (0-111 
14 (a-271 
'. 
1 (e-", 
Pot sUI;"" onalrsk of ocHers. own (urll.djo. p,,"1I>Iy and p"""'" rtfaIod to tho ,1CdntI r!pOtted dlmg 21 days of rdlow up. s.b;.cts _!d _rior,o mot. 
lhltl on_ ~ .,..1\. t.d\ Jl6.itrst IVtnt WIJ ~ (O.onUJd Met fat filCh 5Ub • .tt and systlKl\ d.u. Th .... W4M'1 56 acMt1t:.....". .. \n the MQ1lHOO gro...p and 1611\ 
!he plKlbo gnJUP.""" ftpNtedocQ,;,rW'lt"of'plr'tkuUf IWf\t" :he IiJI1lt ~ttlm wwt or!)' counted 00< .. ~ t¥Iflts tNt wn pmsilty Of ~ rtIlttd 
!D ~ . .... cdn. If. P teelln ItIlk. 
'en. WHft 1dv«se ..,t was 'tPOrtM 
doUG. 17'/j""""'.pootOO11171.tOO2 
.~ddlng on tilhor d )' I, 2 at 3 nd no lubj<a .xptrl.nctd 
.htddin on d.1.y 1 .n.. c .... COu or bier 
The p ..... nce of . Typhi w:u d.teCltd in th ooIs of 1 (2 ; 
95o('CJ, 0 11') of 50 ,"b; in the p bo oop ThiJ 
occu""d on <by 2 3IId mltf"ttd u';n, lh. tnnch<d m<thoc:l 
o ~r or :ld\"n, t'\Of'nrs "''t~ ft onit.d fOt" this lbjecr The 
finding of potiti,. 51 culture lOt r 'Plu in • pbctOO subj 
was ooIy vaiI>bl. all« uDbiindi" of In. trial. All 'ous and aD 
seqlSttl1la1 1001 culturu up 10 d 4 oflh3 .ubject " .. re Ii" • . 
;<8: Pl oS ONE 1 ~.pIo",,,..org 
Thu ' ... was idt.ntifitd OS tho '" ·n •• tn.in . Typhi y2 
.,.,c- fl. V) Zl l9 by ,ubJeq= PCR analy.is. 
" .. , (7 ) f 101 I\fO IZH09 rtcipi.n and 3 ,6") of 50 
placebo ipitn .. " re dttwtd to hav< a pOOri"" <1001 culture fot 
non·ryphoid s.tm-/JiJ bttwttn day 1 and 14 d\u """cin.rion. 
1 __ .. _ .. .,.)<'1'1 O., .... Ho 'int,>~i&h t 7~; 95% I, 
92 99") of 101 .ub,i<cts in the [0 ZH09 group nd 8 (I .0 , 
9~" I, 7 2 %) of 50 IUbjecu '" the plactbo group dtvdoptd I 
po 'Ii"" imIDune ,"lpoRi' in titha the . ypbi LPS Iptcii!c 
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I(J"UIll {gO or 19 'F'JJ A, ddine:d aJ lht! primary 
able: 3)0 TIle ditrert:1I e in prDPOI1ion of ro pond 
\':acdn~ group and Ihe pbet:bo group 81 0 5 '4 f; 63 
89""). the 10.. r limit of o.hL 9~ • CJ 0( this dilTercn« w:u greater 
tha" 50% nd fulfilled o.hL • ;rim <kilned criterion for an 
acapub1e immune r<tpOlll<. 
}.fW.i.ln basdin£ LP:, .pccilic anobody lev ... wert comp w.. 
in both groups ""'" 2~ In the MO IZB09 uP. mcclian I 
antibody Ie cch incrta.st:d from 3 (IQJt; 3 7.2) uni 1m! t bakline 
'0 91 (TQR; 19.8 15) uniD/ml and 103 QJt; 2 9 25:i.!» 
unial ml on day 7 nei 14 rcspcctiwl) . O n (L, y 7. the 88 imrnun 
IUJ"lndus in the vaccine croup bl. 3) di'PIa~'Cd. median 164 
(I R 3 75 60 2~) fold m. in ,,".1m If A :umbod;'. reI.c, .. ro 
~ ablt 1. ppltmcntl). 
In o.hL vaociru: grouP. m<d!on U'S .pc<ili IgC IlIIU'bod Ia .... 
w"'"" 66650 (IQ R; 3107~ 123900) uni 1m! and 55700 (1QJt; 
25450 1068(0) units! 101 en dJ y 14 n 28. rtlpccl"~. 
comp" .... d to med n b: ttinc ~ of 6300 Q.R 36 16560) 
uniwml. On day 14. , I>< 9 1 immun ..... 'POnd'" in tho MO IZli 09 
group (Tab 3) how.d ~n 8. 18 (I R; H7 20.68) fo Id 
incu in ocrum IgC an, ibodi<s 0-0 10 ba.oelin . 
ort}"""o OU I 0( 44 dig'l>Ie "'bj«11 provided I2mpl .. ~ th 
EU roT oy on day 7. AU b: ttint ELI POT umpU", "'e~ 
ncgui" (<krllltd ,,<:4 C pcr 10· PBM . On day 7. 8 
(100%) 0(28 fO lZHoq lubjCCII who provided u mplOi .howed a 
posiriw EUSPOT .. pon.. I rod 10 ""n" %) 0( d", 14 
ev",u hie . ubjects in the placebo group. 'ix'een (51%) of 28 
MO IZH09 recipitnll Ilisplayed resul of >100 >pOI' per lo'l 
PBMC and among the rem:sinin 12 vaa:it", .... bjec" aumben of 
IpotS I'3ngtd from 8 ' 0 123 per 10" PB 10. The mtdi ... number 
of poa in rh. MOIZH09 r .. ipima w:u >100 R 46.5->100) 
IpOIJ pcr 10' l'B~f . couorin topped abov~ 100 IpOb. this 
w • ",conI<d as " tOO many 'POlS to be counted" All ! 4 placcoo 
rcclpienu. wed < 4 'POb pcr 10" PB~I • ' h' ",con1ed 
"roo few'pem 10 be munted" 
MO .ZH09 Vocdneln Children 
T I><rt " • strotlg corrt"'uon be"" .. n th, rewl t. of Ih. IgA 
EU A .nd the I U SPOT a on d.y 7. Tw.nry~i h' 
(Hx)'~) of 28 ~'IOIZ I-I09 recip:en13 showed a potitive immun~ 
... ponse and 14 (100%) of 14 p1a<:tbo "'cipie.nu owtd a 
negativt "'lpOtue in both "'YI. 
Discussion 
Interpretation 
This is ,he f1t1l tvaluolion of a novel oral I)'phoid vaccine in 
.c:hool children in a n encic.mic: country. S. yphi y2 ar.,(; UQ 
21-19 (conl1lintd in MOI2H09) is chmcltm.d by 'wo "'tll ddined 
ckktion mutatiolll. one in n ;aromatic amino acid biocynthe . 
p;llhwa gcn<: and "'"' in Il funclioml Il"J1 ofthe Iype IIl xcrctioo 
'em encoded by PI, [ . ingle dooe 0( S _ I ~ C of Ih 
vaccine tra in w.L, well toleraled and hod I n Icctp",b1 ..rcry 
profilt . Tht.re WU'e no Strions dvt.1'K: events. no wirhdrawa1s du~ 
'0 advm. eventS and no~ of tho I\lbJcetS .xpcntnced 
b cterae.mia. 
In general, ad .... <vcnb we .. mild. imilar proportions of 
ubj..... % 6 of 10 1) in the candidate .. ccin. group and 22", 
(I J 0(50) in lho pl""tOO group n'pM<d.dvtt!t ovtnb dunnfthe 
28 ,by foUow up pcri<>d II;. 0.6Q J). The ov.rall numher orad" • .n. 
t n t.nded to be rug! r in the MO IZH09 group. tsptcially 
those cJas iIitd al gastroinltilin~ disordLn. nervous llyIltm 
diaordcn .nd iove lip-rion .. 
~r .. was one ~T'f! l"e.l:uM adverse ,. .... el t in th is trial, a h igh 
frver I')f:3 0° whO h OCCUlTed on dn 0 Otr vac ' I tioll in it 
lubj<cl who hud pr ... 1osc . Irva,ed ,.,Iute blood connl 
(18.2 x 10" d might bavc ,uif.rod from undttlying 
inf«.tion. 0"" otbu ubject vomited :UlU dnnking appl'<ll<ima.tdy 
h.If of th. vaccin. Mte, this lubj,,' w:u found to bavc • poeinv. 
,rool culrure for oon,~"hoid ~ on day O. 
Typhi was i .... ,ed from ,h. "DOh ofon pu.:.:bo recip;'nll<l 
ct..y aft r vruxinarion which w.l.l I .... idcntirtcd as .s. Tll'hi y2 
T.ble ]. Proportion. of responders to the candici;,tc typhoid vaccine M01 ZH09 (Intention to Treat pop ulation). 
M01ZHOII"IDVp,. _ 101 PI.OIIb ..... " . SO 
,_Jtiwe tff'WI'NM _ ... -
Ho. , ........ " .. ,"') l5~ a He. .. --(~ ts .. a 
Detedo4 .. ' .... BJSA _.J 
DIY 7 99 lalnl IT ... IW 09 1(7.) 0-11 0.,1. 99 219l) ~'7 49 1 0) 1)..11 
O.y1 .... .,'. 
'" 
941911 19-911 .., > (OJ 1· ' 4 
D_o4 .. 'gG WSA ._, 
DI,14 99 ,'ml 1$-97 49 a(1~ 5-ZS 
DI,2I 10 .1 00 (191 11-94 50 d ~ 5-" 
De, 14.1' 21 101 93ml 15-97 50 • (16) 7->9 
Oe1.ct. ct '" .. thet ... Of IgO EUSA • .Ha, 
DIy 7. 14.,21 10 ,.1971 92..., 50 H6) 7->9 
.,.. ... 04 .. ' .... lUSPOT-
Dey 7 ,. 1lI110C1 11-' 00 14 DID) 1)..13 
"0.. nUf'lbtr of S'Wj4!C1S 'II'IIho p'OIrtded Wiff1lIts. 
A posit" mnune rfiPOm. tn th.8JSA lUI)' WIS dtnrltd by WI 00... of sot. ( .s told chan; in LP5 speal\c wum I9A .wtfor lin ~OtWIM r:i70" 0 .7 fold 
(h "9"1 on ~ ",,,,,I( ",rum igl; ,_od to ..., .... , 
... ",bjl<tS .god 11 ~ ... 1Id -'129 ab;ocu '" !II. 10'0 ;lH1I9 g . ... p ond IS SUDJ.eu In 1M plK.,. group) w • • .. ,!bit lor "'. WSI'OT. 
A pGSIflve tllSPOf " jUIt Wil dII~-'f'd .1gA ""C~ SfiOt!CiI"Ig cf!lb: spedr.: ~.i Typhi LPS Pf' 10· PBMCs. Nc:w __ of It'le !d)~«ts "ad a ~:tVf ~ 0 8.90r 
...... 
rIoC' O'Il71rJOUNl ........ OO I177 .. tOOJ 
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MO tZH09 Va«lne In Chlldr.n 
' ...... 2. TIme ,,,,,n_ of IJ'S opecIftc ..... m I .... CAl and IvG CI) __ ody lev ... He __ to -__ ...... __ • (1_ ...... T .. 1t 
p""uIItIon~ lox ."d whl or plats showl"IJ tho distrIbutIOn of .ntJbodl", occording to tim'J"'1nt .00 VlIcclNtion groups. Tho ho<lmIltIl 5n. 
w",",n •• eh box r.pre""''' the mod"n, the lOp .00 bottom of e.och box rep' ntS the IS and 2)'" percenlile>, IMpectiYely, and the lbar 
represents the highest .00 Iowtst •• 1_ willl1n IS time< the ',te,quartlle .. nge. O",,,,,.how outliers. 
dotlQ.1l7 t/jolKnolpone.OOI17l&g002 
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T.ble 4 . Serum IgA and IgG antibody levels s!>"ciflc for S. 
Typ/1i LPS Ontentlon to Treat popl~ation). 
M01ZH.,. oroup " _ 101 
........ 
......"". IQII 
San.,. ItA antibod, WHI. lpICific for LPS 
0 •• 0 3 3-72 
0.·,1 ,.." 19.3-231 ,) 
D.". ' OJ 119-4SJ.5 
s.n..m"G Mtibod, I ...... ip4tdfic kw LPS 
Dey 0 ~ 3620-'6.160 
D.y'4 666.50" , , 07S-'Zl9OO 
D..,:. 55700 2S4S<l-l068OCl 
o.t-a Mwn ~ •• nd tw sa.:bjects mh:;<Jng. 
doI:l G., 37'1j0lJlNli1'OOl OOI1 778,!004 
Placebo group n.50 
Mod .. 
....rtl/ml IQII 
• '-7.' 
J.t" 3-1.4 
JA' 3-7,0 
6925 3950- 076l.S 
nil)" 4110-11500 
8m 44Q2S-12417 .s 
1I.e- ". ) ZH9 by PCR analy.is. In. pnviou tOOl culwr., 
and all follo"iog $1001 t-u1tur. f!his ubject up to d. 14 were 
negati ... After a dlOrougb checlc whicb included m. randomisa· 
tioo cod<s aod VlICcinacion paperworit, the poaibiliry tha t ,be 
.u'lj= received MOIZ H09 b error waJ xcIu<kd. The .u'ljea 
:abo cI!d no, d isplay an """ilive,...u1u in , he immuno~nicity 
... LY', It wu concluded that m. mOll likcly caw. for isolating S. 
Typhl 12..c- "" V") ZH9 in ,h. ttods of plocdlO recipient 
wa.s the. mWabdling or mismatch or stool tampa. 
he o.n.dida-te vaccine elicited a potitive immune rtsponK in 
97% 81101) oftbe MO l Z}109 recipien .. by £L A and in 100% 
(281 8) ofMO IZ I-I09 rccipien ... who were (V.lu.bl. by EUSPOT 
a.ss.y tn condusion MO IZ H09 waJJ sa.fc and immunormic in 
Ieln3metr' chlldrtn 
GeneralisabiHty 
The ob .. "cd sarety and imm"logcrudty p tilt: of the 
candid.~ typhoid , ccine in <hildrtn compares f •• ourably to 
that se<n in Wdttro adult voIuntt ..... MO IZH09 has been ..... d 
to fLf up to .. nominal dooe level of 5x lo' nr in nint ,U:K 
.oIuntcen (9} and 80 US volu .... e ... (10,11}, howuu"geruoty 
rtsulu from pn';ou.Jy pubU,bcd bolO I ZH09 trials used • 1 fold or 
h igber inerc ... in LP . "",cilie IgC antibody]e. li u defutilj"" of 
• positive imlDune respon in the tndpoint titre EI.J 1\ and 
l<Coconvenion ....... were 50% (811 6 .obj.ct.) [10] .nd 77.4% 
(24131 l ubjccu) [I I]. In !hi. study, aUowing for tOOe difierem cul-
olf., the magniruck of the immune ruponIC Ken in lb. children 
"' .. :opproximately 30 fold and 10 fold increut f med' n 1cveI. of 
LPS speci6c 18' and IS<: anlibodia, re'P'ttively, FUr1hennore. 
Ihe mtdian num"". of A. prod .. ing LP 'fl<' ,/ic rgA 
antiboditS, a rot U~ Glr priming of I hI!; rnU('()sa.1 immune 'y .em, 
w graler dun 100 per 10' PS:-'I in this trilll, 'h is com"..... 
fa",o ..... bty 10 an ndllllt'flC me.ln t 18 I to' PBM st:tn In 
a previous MOl ZJl I ' I In ,lui" (101 .nd •. g!()metric mt.n of 
I I CI O' PSlI! (produ in I", 31\.1 IgG) ""n tn IDtrican 
volun ... n who ''e<c,.ed 4 dooco of II,. ~O'n ed ry21 . lypl id 
v ... cine a" do .. of 2-6)(10' f'U ( I~], 
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MIl , ZH09 Vaccine In Children 
Thil i, ellcollnlging. one major cOl1ctm for lht- devdopnlCnf 
of m:my oral v.I. cir.et ron ~ltn Ih tir rtduad immunDg~n' ty 
wht.n l tskd m ~vdoping COOflll)' populatiou omp.ued 10 
Wesre.m volunte:t.rs (1 2,16]. For oral ~,cd~. a brisk colnnisatino 
of the intestine is nt;Ces ry to b«ome immuno~nic, it mighllx 
po!.1ible thClI drug resi tar .. g>mmen ab, bocttriaJ ovt:rgrowth~ 
enteric. virU5t or helm.inth! intetf~re with lhe colonia.ariou or tht: 
new vaccine (171, In this study, ~ I % (~IIIOO) of vaccine rteipienl! 
. hed . l'I'hi y .rne- f",rr) 2 H9 u, stOOls Mtr.r vnccirultion, 
one .ubject exc ... «d .he vaccine .trLin on day), but no sbcddin 
wo. obseNed OQ wy .. ;uxI beyond. In Wes,ern adult volunttm 
.bedding of S. Typhl in ,toob wa.s reponed for iligbtly longer 
duratio. and ran~d from 1 6 day and I 7 W) ' in a 5Wall 
number of volunlt<n, respectively [9,11 ]. 
Generalisation 
Typhoid fe:wr i4 still a m30j()f' health problem in ckveJopini 
tOUnlrie., with high inciduce P ,18) and high n'd of anti mlcro-
bl dn.g resi" e, esp«",Uy in Am. (4,18) 11>< Wor1d Ilcalth 
OrganlJation recomtmnd. the lmmunis>rion of school nd 
pruc.h children in endt.mic 1"e."\J, espe WIy wher-t drug 
i ... nl typhoid fever Is preva.ltnt 3. well in epickmic .illlation. 
r~,191. MOIZH09 is a p<omising oovd oral on. do .. typhoid 
v.ccine and lArge tri..Js • nee .. ary to .. lIIua", vaccine dlkacy, 
If prol«tion fro", typllOid Ie ... is demonstrated, MO I ZH 09 w.y 
f.ci1itott large v~ccination campaigns due to i ... implcr logisti<; 
and br""du :u:ceptance from children, 
Suppor1lng Informatlon 
Pro ... 001 51 T rint protocol. The 1.11\1 protocol is .. a lrue and 
correct copy of the on 'nal document (PDf version) minus 
redacted lines (penooaI infonnatioll , num.. and ttJepJlOn 
number! or aDpJoYC'CI ha.ve been l'mJOvcti to lIlainuin du:ir 
confidentiali.y). 0 part in the content of d .. trial p tocol witb 
the exception of the vaccine excipiena has been redtlCted. 
Found I: doi:10. 1371/joumoJpone,OOIl778. 001 (0 Jvrn 
PO 
Checldiol51 Co.N O RT a.edlliL 
Found at dol:IO.137I1jounulpone.0011778~002 (0.05 Mn 
00 ) 
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High-throughput sequencing provides insights into 
genome variation and evolution in Salmonella Typhi 
Kathryn E Holt l, lulial1 Pukhilll, Camila I Mazzol1i2,3, Philippe Roumagnac-1,4, Franvois-Xavier Weill5, 
Ian Goodhead l.8, Rich.rd Rancel, leph~n Bakc~ ·6, Duncan J MaskeU7, John WainJ , Christiane Dolccek6, 
Mark Achtman 2,J & Gordon Douganl 
lsolal .. of »lrnonell .. en/t'rica ..... ."..r TYI",i (TypM. a human-reslrided bacleri,,1 palhog<'n lhal cau .... IYl"'oid. show limiled 
gCfW't" varialion. We Sffi.ralt'<l whole.gMlOmc "<tum rs (or 19 TYJlI1i isol.les using 454 (Roche) and 5oltx3 (l1I.."in3) 
lechnologits. Isola'",. in luding Ihe previously 5eCJ"enced ellS and Ty2 isolale. wtre seleeled 10 represent major nod", in the 
Jlhylogen .. li tr ..... COITlIJarative ana!y. is shawi'd lilll., evidence o( IlOrifying seleclion• antigenic varialion or r...,ombination 
between isolales. R.ther. evolution In ,he TYJ"'i population s""",. 10 be characlerizl'd by ongoing 105' of gene function. con.,i,tenl 
with. small tffedive population size. The lacle of evidence for antigenic variation driven by immune sti...,tion is in contrast 10 
slrong adapliv~ ~ec1ion for mul.lioo ronferring anlibiolic resislane .. in Typhi. T .... ol~vl'd patterns o( gent'tic isolal ion and 
drift are comis!enl wilh Ihe Pmt10sed key rDlr 1)( asymJllomalic carriers of TYJlhi as lhe main reservoir of this vathogen, 
highlighting the net'rl (or idenliflClllion and lrealmenl of carriers. 
Typhoid ("' ..... along with pbgue. holerJ and smllllpul<, ion. o( Ihe 
dlsslc:U inftaious d!~s of b.umans. Th. d!s<3~. which is sp",od 
yia oral ing&K>n of rorl12miluued food r water. i au I by 
SaI,,,,,,,,,/ro ,,"ltn'" sere,"ur TypW (Typl:u) .• GI2m ~egatlvr bxterium 
dlssif.d • ~.lr of tht sp<Clts '. "",,,,",,,,1. . "'''''01 IS • brood 
ar.d promisruous . ~ with . 13 3~e lO oms gastJ'Oe"ntl.oritis in 3 
range of 3J!.iJr.alS.. incluwng hum.ms2• In ... ont.r.bl: to mO:tl the.r 
. Ct,t<.TltrI ,rro\";JJS, 1}1'ru bas . rsaken the pronllScu us lu<St ie to 
become a hUm.1.n ~stncu-d pGthoStn cnwmg w h ..cut~ l)'Sll:mic 
ir.Ic'dXlns (lyphoKl ( ..... er) and Itronk inf,'Cl' ns tllsymplon,alk 
arriers). A number of ",·olutior .. ,}, pro\.\,.,... h., t>....,n impli Illed 
in th •• doIpt3tlOn of lil'ru 1 II:u ptcia1J'" I mcb. •• 1Il(:\udlr,g lh< 
honwnbll qUisilion or sc\ rn1 Sal"JOt,.;Qa pallK)\o.O(.°llidty bl.mds 
(SPls)"" and enenslvoloss of gene rw, lion'. 
1)phi. ulGCdlt.T with ocha bwr.an patho~ such 3S }e mtlUI pesru. 
&rdddln pm>HSU and &aUm ar~hr.as, IS .. ""dcd 3$ 3 mono-
morphi organbm ... tht g.lIo", .. of ind,vidu.1 Typhi isolat'" ure 
higbl cor ... ,,-cd and donally rcllIted. A ,ceCllI study involving Ihe 
o ""1utr",mg of 199 S"'" fr'llmr"ts from po""l coDedJon of lOS 
Typlu 1>01mcs drtL"<kd only 82 ~NP>5. AJ.w ' $ of tho S~P dota 
roolved TypI:u 11llO • k'tI. fully p .. ,un r.ious phy'" ndi ITt< 
definmg 8, gmC1.:aJJy ru.tlr.rt h.",iotypcs t H 1- 1185, Suppkmcnlftry 
Fig. I O l~ inc). The avrulabmty of a robusl phylogenetic trre proved to 
b.< a usrful framework .~nst which to ID, .. stigatt the m:ent ""Iulion 
of phenotypK. tr.uts: such as the 3CC:luwtion of resh.tan e to fluor 
quinolo" ... a class of antibiotics used to trelll typhoid feverS-7• 
Becaus< Typhi sb.ows $Ucb. low levtls of gmetic vamtion. funhu 
udies require a whole-genome approach. Complet. g<r.ome 
"'-"lum"" are avai lable for two 'fyphi isolates, cns and 1Yl (refs. 
,8). IIowever. SC\-e,aJ new sequencing locb.nologi .. ttl",!! !><en devcl 
~ that n:l~e draft gmOl1!t sequeJ'l.cing simple-r attd more cost 
.lTcClh~. In order 10 .pIU", ... uiation in Typhi allh. "i lOlc·genor.'.e 
1.0\>01 ami minimize slmpli ng bias'", we sequcnC<d an additional 17 
l)1pru ,,,,Iat .. di,pastd in the phylogenetic- trtt. using a mbination 
of 454 (Roche) and 501= (UJumin.) sequencing ttchr.ologies. 
RESULTS 
Choice o( Typhi i""lal .. (or whole-!:"nomr ""lu • .'ncing 
In o rde, to cupture lIS much infoml3tion as possible aboul the 
distribution of genomic variation in the Typhi populatior.. we 
pr"1'a",d 0 from cns.. "1'2 and 17 othtr isolates for a combm, 
!Jon o( ~5~ and oba sequencing (see Methods and Tabl. I ). "wrut. 
stl ion bill as mu h as pussible. we cl\O Typhi isolat<s from r.trol 
haplolyp< d uSI"" together WIth selerud ,,,,Iates from mdial h.plot)l'e 
,.7 
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Table 1 lYphl isoille. sequenced In this study 
I~ale Haplotype 
[ 7866 1146 
[01-6750 H52 
[02·1180 2002 H4~ 
19l1.{)664 I 1155 
[911·2 llar,_, 1998 1112 
Jl85S'" 11ld:J'lCSo <s 1965 H8 5 
,1223 U '1 "~'" I q H8 
4 'Y 1rC>_ 1963 1159 
AG3 Vf!tr ." 2 1158 
E98·3 139 
'" 
1998 H50 
1!>Oi961S V /la-o 1998 1163 
8 ( IN v""'" ." 2 1 
eT I8 V~"" ll IQ<I HI 
E02-2759 I"" • 1158 
[03-<1963 lt1dor eala 1159 
t 03·9 ,. H58 
ISNll'{)71167 Y "",,0 1158 
1S?-o«l6979 Co.,,- All" ", 2 1158 
' ,2 ~.A> 
~r'ry v-lt d 0,0 .vi Ire ~I'I , . 
groups a.cd subjected th<>e 1 ~54 ><qUcr. ing ( "Prlem""lllry 
fig.. I). To .. n additional lllSlgll lU:'to P '-a.r~n amocg rt"\.-ently 
txpandmg hJPIo~ w. d SoIt:Ll StqlI.nong to gtnnat. 
3«JUm e irJl..urnauon from an lIdd ll lOll.JJ ill I.~btt".\ (: Ifl the H58 
group. "tuch b.as und<rgorJ.' rttrnt dor.:il <:Xplll'.sion in Southeast 
AiI3"', and a nd 1>01 • [rom th. 1159 group, known t be 
circuloting in Ind n<sbll . Three i lates. induding one H58 and 
ne H t bJe. wrre sequenCC" I uSIng both -4-34 nr.d leu, Ind the 
resuJ15 Wtrt comp;u-ed. 
SNPs and phylogmrlic analysi 
w. d ed high quaiJ :-;Ps bv IllJPpmg ~54 ontig:. or Sol"". 
n'3ds to th. 6.",<htd 18 S<qutna ( • Mtthods). Our anal",,. 
focused on Ih. noorq><titi,·t "'pur.enl of t il< g nome, amI we did 
nOl tlcmpt 10 .t.".tify .ir# ba>t In rtlons or dd etiollS. Rcp<tit". 
stqUte(t<, I"duebn \ . IU. n : ... t rtptats of ~ W bp, > 9'% 
Kkntical rcpalS of 50 bp and phaS" rA m>ertlOn '<"qUC'll'" (l , 
.<.COUnl fo r 7. ~ of th. eTl8 cr.om. ( uppI.menlllry Table I. 
rJlr.t). Hm'. w'" adudtd Ih d, of .... po."tlIJ , "'10m"" from 
'p anal" i) .an I ... _ ... 1 r."...1l an "i'f"'3' IlIdi>l ll.gulShabl. 
from 5. Ps. portJ ularly WIth >I..,rt "''qU cilll! "';ld. (100 250 bp fo r 
4"-1, 25 bp r 501= ), (i i) "".b1 and m ill~ of ,hort re.lds are 
u=b3b1e In rcptU"" "'S""" and ( iii) ''l",., ed reg; r.s may Ix 
. ub,..t:I to d,IT ....... l s6e<.11\t pr ur '''l11l''l1ed 10 the _ o( the 
genom •• fo , .:ample, ,""o",blMoon bttWffil rtpt.t Op,es. After 
acludong th ... qurn ..... Wt Idert.lfi..d • 1 tal of I, 4 P. in Ihe 
nonn:prtili" er.omt, app"\"'rl'~"dy I c>~ry 2~\oo bp. Dt.t ails o( these 
SNPs art gi\'u in SuppIom<lltlU' Tabl. 2 nUn •. 
W. detmruned mph,.. .Dck <bt b r 1,787 , Ps (mlSsmg dnm 
was due t low '""I! r deletion of 1\1' 1 i in n. or more 
ooI.tc» . The><! ~ t", c..t tho: or phylo&ellctit tree as pmiously 
dtfintd' ( uppItmentuy PI&- I ) but pl'<mded btu .. tsttm.t. s of 
bmnch ~pIu orA grt'uJy Incrt.ootd rt >luLlon, p rtI01 I. rl w. hm Ih. 
H anJ fU9 P (Fill- 1). 8 coUlp:orUlg " Iutt« dalS from ~5~, 
lao ar.d publo:.htd ""Iut Wt I<tt'TlTlmed It on. f"r quahty 
fJtmr.g ( IlJ'Pkmennory Fig. 2 onlm.) and t "" • • d . til!. POSIt"'. 
nlr of 2.7 and 51'.'1' J<1.«lJO • =.sIU.;o.1 01 2 99.7'lO ro, both 
9 18 
454 ""'"'" 
10.5 n.d. 
8 .16 . d. 
\ 3.1 n.d. 
10.8 n .d~ 
10.9 n.O. 
13.5 ".d. 
11.1 n.d. 
8.49 246 p8SS6 1 
10. 1 131. n.CI, 
11.1 5.40 n.d. 
8.60, n.d. 
13 I , d. 
980 pHO,l1 , pHCM 2 
65.5 ~ plteM2 
7A2. pOSSO I 
8.19 v pAKU I 
7.87 , pAKU I 
pAKU I 
I'I.d. 
5<'quer.cing plailin:u """ Methods ar.d Supplementary Table I b). 
11us appore.!ltl high fube-pos~ rate is due to t11l' cn.reme plU ity 
f true 5, I'>; tht .au.lI . rror rou. of th. S<quencir.g technolopes 1$ 
'''''1 low around 7 10 10 <TTO rs m ~A5 " 106 bo.e P'di ... &> r Sole ... 
resequencing on ens and '\)'2: see Supplcmm tary Methow onhnd. 
rJy ten SNP:. (0. ')9) did n fi t the prevlOlbIy detemojr.ed 
phylogenetic '=, two of which .. c ronfrmecl aample of convergent 
",'OIution •• si t .. unde r adaptive selection in,porA (see below). Thus, 
we have little reason to su~cr. high trror r:ltt:s among aIltJ. assign-
men~ or 10 doubt the phylogenet ic tree: structure shown in f ilure 1. 
si r.g the ",.uhing rooted ph)i ogenctic t ree, we wer able to group 
mutations InlO rtLttll" Os< groups: (il rt<enL ",uIlllions. fiuth<:>t from 
the root arod IY10g on mlr.\ hap! rypt brnnchu , (b ) inttrmtdi. t. 
Inutalion.., lying on ru.plotype-sl'orifi branches, and (iii) older 
mut1ltions. lying on brnn bes closest to the ,oot and shzlred b 
o e 
E01-t750 
SflS f~oa 
- -J1 15-4~ty ST")6 
~u~ t I q:MCllc troo _ on SNP dJlO B,.nc:h colas IOldie"" 
dlff , .. , . hne_ 01 ~P~I, ,,",""h I.ngth •• ra neas ... ed on ounbllr 01 SNPs 
Ie as Indicated. Central, 5r"'\311 blaci( cI,ck!: Indlcales the anustral roo t, 
dashed 10"" , enls SMmonoi/61" oop; "flO (51) and SP 15 I"",""" 
t • .,,,,, ... .no..,, a tong bRIne...,., pl/IV\Ids detecled I" VIC" Isola te .... 
I1d 100 101100 c los ('ncH 1 "lult oJru& ,,,,isla,,,,. plasmlds) . open 
ci los (Ct)ptk pl ...... id) and lIlted Ii ... \11".., ~ .. ",", '"''line l66 
I II ••• " .nl). 
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Table 2 Genet ic variation detected In 19'JYphl cenom .. 
leU 
~ehOI"l 
p" • MS r> 5 9 
PUlldJ 
5 Os (co",,*",,' • do ) 93 1.3"6 338 1.7&7 
-I 6\05"-1 I II (13 1"-1 (I3.0·U 227 
2 1 1226~ol 471 (35.2"-1 106(3 1.4"10) ro1 
... 61 \656",,) 66J 148 9"-1 176(52. 1~ 900 
5 (5.4 ) 39(2.~.' 12 \3.6·,,) 56 
0.98 0.46 052 0.4 
S,">( e!t:"e-edl~ 122 35 176 
-I " ",," 111 1"01 21 (1<1 7 61111 
-5,,,,"),,,,,,,, }"5~' 41 (>3 6"-1 12 \34.),-, 56 
12,63 2'!../ 57 (4 .1"-1 11\ .6~ 66 
0\0.0'\) O(Q.~' o (0.0"f0) 0 
-dNdS 12 4 0 ''-1 0 " 0.48 
cuJuple haplo<ypa. nl< w..lnbutiOIl "f NP. and " tI,rt V'.uunlS in 
""'h group w,,",, In l' ble 2 
'on 
to rnonrm NP roll dNI , is a 
mm • m IOn. A d.WdS fOlio cIosc to 1 
ir.tlk_ no sd . n "'aJr~ 1 oonsyr.or.ymou ' I'>, wh ......... dNfdS 
cio>< to 0 Indicatn strong subWzlng ldtalon. Tht mtan dl 1d - of 
• ioobJ. rompartd 10 ttl< I. I wmmon "<<>lor "':IS 0.1>1> - 0.0; 
(.d). Ind' ating dlI .. r 0 "oJ. t .. "J In lht lir.xtion or 'Iob~jzing 
sdcct.lon ,1J'.ct the llst common "(<Slor ofl)'Phi. or J OlblllQuon 
f .... 1>.II:ong ,.]<CtlOn In ",me &l'n ... nd dJ,tt'Stfying d«1l n In 
otl1m. Ai then: IS liuk e>-.J n« o( dl\""if'yin ItclIOn ill nr Typhi 
!rnes I,,,,, bdow nJ upplt"'t""'ry lioblt Ja "nlint). "cak stabiliz 
Ing sdtcUon IS m l"'tI" TIlt ", • .lIm .... o( tho Igl\.\l k>r sub~lZlng 
:K:k'(.don ol»trwd ben lila be due lO too httk time r k.~ lion to 
• a.cd/or ennlc drift JUt to low ffi I"~ pc"ul.,""n .l1t. It h .. 
btm pr .. ",mly hown llul In Io<.lv rtIottd b>..-um.lh. 1'«1"roG.l of 
cL\"/~ . or 1f(d. ... /d.\I ... m.1I«1 10 hm, !: .. mubl,OIls " I<I ltd th. 1 
when I"'pw.lI n .IL<" I~. thu .dJuor.>i .. I' was Iir., .. t but 
wh n ef'-'(1J'. I"'pul.lbon >ILl: "'... ClII!l, J;tI1ul.. dnft b<\:nm more 
n::perur.' nJ 1/(d." 'cbl reached I pI.ln ... fll, rdu nship 
o( I/(d"'fd.'i') to tDr.' 1m< U11'<1 by~' number o( 'nIt",.n;" S. ]>,,) 
for the \Irr.ted 1'fpIu ISObttS "'lIS r.or.llnear (FIg. 2.) . [nttr 
8enX' ~. P£ Kn't as .n 'ppm",m.ll11,n (II t. the art I 
li""ly 10 be under purif}ing d tK-' Ih"n Nr. In 'ng regions. 
110\\· .. · ... 1I1I.<T):tfIIc N'£ 1I'.J h3'" r~LOry r 0111 .. fund;ons tho! 
m3Y Ix ur.dcr n, a an .ltcrn."ltrvC' mraSUrt". we also 
..!cullltd cL"hlS .",emS ~l<r. ( thOr""'t reL,l", as • whim 
nfi=cd tt., ,"",. lr31,'1 ry IflK. 2b). Ie the light o( tl 
pr~usIy dtScnb<d model' • thdt !"llttms .... ,UWSU\" of gmttlc 
dnft m Typhl dot to m.n tffi I porubl"'" n. wh h ~s 
1w"lr. Tll'l" Ius n lr.own ..... fer"'ir ouuid f humans. A mall 
.0; ,'t popub"," SJtt I • - 2 I ~ 10' 1 0 ~ 10') h bern 
~bttd plnlOu<lr II r.J! BJ~'''l11 .1,yhn. pi "b on 2~, I In 
lOS TypW ..rutos. 
ARTICLES 
Poten.ial signal. of ""~Iion 
We (ound ) . ...,. l ittle evldcn e o( adaptive selection in 1)-phi sen 
which would be repr ... nted 1»' an <M!rabundaI= of nonsyn nynlous 
SNP or indtpendent changes Ie the mt or nt:1l'by .mlr.o aad 
resiclu ... Wt IOOnd chat 72% o f &"11" oonlain«! no SKi's and Ih.t the 
distribution of }IPs po- foUowW • POIS""n distribution In cru, 
range of 0-0 r. po- g<r.c (PiC' J ). Ilowt-"u. there w ..... (ew 
exceptIOn (Soppl<:.mmlary lioblt 3a). 'I'l1rtt gcr.es (j'fh u, ",E and 
511'281") coJ!l.air.f'd !'!lore Lh:m six SNPs. whic:h deviates (roC! the 
EI:",,,,,,, m cl. TY287~ is 0" exceptionally "'<go gene (3,625 bp 
rr.p.red 10 th. gm m. m r. of91O bp). whICh nup unt for the 
Inghnumberof •. HO""'\rr,ymlia ndtvtEare rnall(561.- 79bp 
and tllus W ~ "UIllba of 5:\1's =y be <Vidence of w, .... ifymS 
sclcctlon In these P"'''' tho secor.d f which IS en cd wit/un 
SP17 ar.d · m\'Ol d "ith Vi synthtsis<. Tm '1'. did not fit cru, 
ph lopmetl lr«'. ",I" h "''''y indXale eJlher reCOmbmnllOO or 
con' 'tf!ltnt ""Iuticr.. whereby the =e mutltlOO aros< Indtptn· 
dently in dilTere:nt lmeag. I rtlu~ taller planation is l rut. it would 
sul'8tst Ihe poSSibility o f alapllv .. leclion 01 cllt:SC ' it 
"Iud , In Iud MYn nymou. S. l'$ In clue< ~es . ncodll\g mem 
bl1lllt proltln! TY12().1. ;'IIdG ar.d ~.C) and two non 1lonycous 
:-'P3t In lyrA that are LcOY.'o to increase resistance to r.uoroqwn 
lones. a cLw of iU'.ubiOOC5 ~ to tr~t typbotd f"u' ,,·Il. Fifteen 
~es ront.lntd CkUltrs o( consynonymous S~Ps. wb ... eby two 
reliidu 'wl1.hin Ih' :mur.o aods were mUtlLM. which may ir.di te 
"'bpti« .ci.'<1JDn i.e 100Ilixed region. of the .eroded prOleln I UJ>' 
plemenlary Tablt al. 
f ,Itt 2b &,!"ts in which we daecttd polrntial .ir,nah o( adapu\t 
scl<'Ction. IuJf encoo.... proteins that are surflce expostd. exported 
or s kd, r .o; .ynthoi. f such proteir.s ( upplemcnwry 
TobIe 3,1. These Wtak igr.al m.y re£.<CI. ",leeth-. pressUttS "'tr.lJ1llng 
from inlcractiOf'...) with tlw human hOSlu, induding sdoction for core 
' 'Ir1lknt muUnt' or t.lI= with :tntiI:tnk vaIWlts that better .... d. the 
human immune It'ITl. nle genes ,<itntified he",osl"'lenu.Dy under 
sclection " .. rran l fUrther inns.igalion. iIlUSlr3ting the ,'3I.ue o( tills 
""proach. Ivltl h ccuJd potentiilly be od.lpttd to geneu iWOClatloo 
studltS m pa~nic 00cttn3 ,imUt to tlw..., a rritd out rolltmtly m 
rukar) I IS. Ho~\.'\ r, most @l'I"" "h""" products are> .. ttd or are 
surfa c t>:p<J><d .howtd no "ldeoce of ad""",.. e\ Iutlon. F r 
"",,,,pl •• with the tXCtption of $If.~, which tnrod... I'll .fftctor 
protein (Supplcmen.ary Tobie 3a). no other gm .. til oding l.nown 
'" rt1 I , «crl r prottiru ,hawtd !den of immur.t' selectio" 
• o~ 
02>.., 
. ..,. 
r 
00 
b 
• 
• 
reura 2 ,,. tory 01 dNdS , ..... U"".11l1S IS t'le IIC!pIOCaI 01 dNidS, 
OJ I~d cIS) (. ) "",,..; dNdS!Je1 •• 19 IIp.,I,,,'''I ... (b) dNldS 
1 SNPs I. ... rei II .. 1IJ<qn II III ", ... "",l-oldesl), ClIIcuI . .... 
Ito .... SNPs ~h tomolc.e ,11eI. dala il 19 1",1ot (ou",1e c(reb) and 
SNPs"ilh It omp1 te IUe cIoIa (ir"" "I ..... ). 
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FI&U"] DlStni>JllO'oI ",nblt 01 SNI's ... gon .. lines Incbc.,. 95" .. 
CMlkk"'" 111 101 n dltll!d'l3l undot. Pol n dlg.1 1> Ion 
hned ID t .. dBll lhQW'\ 1'1 "\. sron COUIlt on loa!C:I'-
bell • ...,. .. dcvI.Uo, 110M lhe Polsso, ""ld'1 . , hlill .umbers 01 
SNPs ?O' gena 
Recombinalion 
Olha than the tm :-0.1'5 that do r. t fitth< phytog.n<11C 11'«. which 
.... potrnt..ny. re\U of n'tlS""t "oIulJOtl. w. found 11 "",,1m. 
of rt'COntb"",uon bet en lfphl btt< ar.d very liulc C\,d~ of 
rtCOnID.r.auor. ",th 011\ r t n.t ( • ~kthoJ>, Supplemcnlary 
• Ol. and Supplement... Toble Ie orline). [mpo from mtzriaJ 
scm,"r 1\'phu:wnurn (TyPlllmurium) h.1\e 1xcJ, ttvoned .n t .. " 
Typhi bobtes tr.dudtr~ 4 • but rnnolysb of the tuSlOry of the 
OObtes a/Trcled rr..-..Ied that tl ..... Yo"e rntrodu I in th.labomtory 
durin the produ on of ara.-t· l;;n l rnulanlS a..r.cJ do n 
r",r<>tnt wild t)~ VUhllJOn. Lar e "ale recombination b ... been 
pr sed ~ttI1 1)'ptu and the hue.n restricted ~. ttlt ..... aI 
sere,,,r Pualyplu ". HO\\l:'tf, ~ll' n"",l hkd urroo before lhe 
t ludon or the rommon ar.cator of QlWll Typlti. wlu h s....-"(·m.s to be 
gtr.malIy wllttd 
IS elem...,b, phage, Jl31ho~ icil)' islands and pLHmids 
As 4 rtad, wntlong cr ugh I 3! mblN.D .r. n lOn "'C'TlU 
rol~d be mufitd Jmor.g 4"" ""llltnc:cd 1),,111 lit and 0011 
frmOO by and <apilbry scqurn ins 1><'" Mt'lhod!). !(nown ISl 
ir~ II> lD the cr l3 COOr.1 'I<'" Il\lt pr~l Qt ~, ame site:. in 
any oth .. 00131 • alth gh we do.'t I n I I d mmt at • dtfbmt 
gtr.OInK Mt. ",thin H I",latl'> '" • upplem""lary NOI.). 
eTl8 h:Irbon IC\'t"Il \\'<'. d.fu:ed pmph.S' Ukc demenu·-·I1. and 
.... h, .. .n uq.rmctd uoi.uM how,,1 n.en t IOn in moS! of lh 
some 001", harhorod n Ph>S Fig ..... I :J'OWI the <> t llr1'<11 0 of 
phage InstrUon .. nU 10 the phviogtl'.etk tree. Qnd tl numbtr 
of 11: n ""nlS occumng In h bUll" group 1$ sit n 
in T..bIc 2. The r.<'W ph> s arc dbOl further in the upple-
nlCntll')' S Ole. 
W • .t.o o/>s<n .. d ''3f1Jd n to the b-kbp ~monu IslIr.d SPI IS 
(rcf. 181. Th" R'glOn mcJudrs an '"l",rase it",e .1<11' rnt to r. ur 
h)VOthctJCII srn and,. tr. en,"" within tRN.\- ~ . , gcncr:\ling 
dll .. ct tbn\ang "'I"'" 1 he ,..pon mtd t "''' tn lhm- forms 
.mong tht ""lunad Tl'P1u (.) en ; \ .i ) II ~\I. 404ry and rOl 
4 83; and (iii) all otl"r ISOlate>. [n .ikh """'. tllt lI1>Cruon It< ""d 
dir<Ct "'PC'" "'crt identiC3l. but three distinct but rcbled alld., w .... 
P""""" for d,e inlegra« gene C95% amino id id<ntity between 
forms i and ii. 70% between all three fo=). Each of the three forr.ts 
ronu.ir.ed .. unique SC!l o( argo gf'nes. ~ fnncti n or [~ genes is 
unlrn wn, with no m.tchr. to knO\\11 prn,<in oo=tr. .. in the rfum 
da~ Cae esse<! Iuly 3. 2008). These genes merit further investi8" 
tion because of theu potcr.tW contnbution to ,iruler-ce. 
Pl1 mKb det<Ct in ""n. of lhe sequenced 1}phl tSObt (see 
'Iethods) feU irolo three dasscs (Table I and Fig. 1), which art 
dis usscd in mcre detail In the upplementary Note. 
Gmomic del .. , iom 
GenoJl'J insertions "'crt rare in the S<qucnced isol,tes. but ddruons 
were t wee 31" common Ind more ccnsen"td (Table 2). Nole. that in 
nt3D romp.mti studies. ir.senior. .. nd ddd:ion or. indistinguish-
able, but we were ablt" to separate the:.e f'\'Cnt:s by ~ng the rooted 
phyloJ;enetic tree. Th. deletions rar.j;e 10 size from 60 bp to 6.5 kbp, 
and some WIT cd to "nant region prel'iousIy ideJlI:ifed using 
DNA mX:TOIIfTllYS" (SupplemcnlJlry Table 3b). Most o f the deleted 
regions Indude protdn (ting S«fucr.as. .... "lring In partial or total 
del<ti n of 41 lfpln genes. 
Ln ad lilion. PI7, whi<h hnrbon gen required for S)T.thesi. of the 
poI)"SUCcbar:ide Vi cap", Ie'. " missing from 4041y ""d 15O(98)S. The 
isolate [-98 JIJQ saT.led to be 3 mmd popular"'n in regards to P17. 
M iu co"""'g< in both 4$.1 and Sal • • ""cIs w. - r ' thai of 
genonu co''trase (Supple.ment ... y Fig. ) online). Note that the low 
"'.ppmg co, rag in tlus rtglon " most likdy due to deletion of SP17 
"'l~ tha n r1'(J13c:nnml with. simihr island, as deltuon is l.nOI\'1l to 
occur during cultuW''O;1 and flO a1tCfl'.ao,,< lsI.:lJ1d could be assembled 
from 4 md 0 oti"r Pis wrrc Mewd from the sequ,," ed 1)'Pht. 
indi tir.g thai lhey 3rt rclativcly .table in the genom. (although we 
obsc." ,d dtrte vnmnts of the b kbp MIS. as descrilx'd ."'" ) . 
Ongoing funcl; ..... 1 genp [0 .. 
[n addition t idcrolifyir.g 42 gon"" atreaed by del ion '"''<Cu. \\.,. 
del<Cted 55 non !1St! SNl'> that had occurred sin e the last common 
anctstc r of 1)'ptu. ~ mtrcKitce stop odons into pr Itir. coding 
gene>, lhereby utting sllOn translation. Read-through of stop codoM 
ha been reponed" ; howe,..r, ~te described mecluu>JsCl applMs to 
only two of the non .. n .. SI\'PS we detocttd. Thc~ was evtden« o f 
><Iectior. all"'1l>t ""r.sc.ISC Sl\'l'>. with • lower role of oa:lurena 
than nonsyn nymous NPs. Nevertheless, man nor.s.er.se S~ wne 
f. ed. m.ktr.g up 2.9% of SNP in th. lr.lmncdi31 .nd old t .s. 
grollP. ('!abl. 2). 
18 and Tyl each eocln.!n -.00 ~'Udogt'l1es'''. defined as ger ... 
~1Jl I1fC putative I inact:i wd b tnUtlltions includin nonsense 1'.'1' .. 
frameslufts and lruncation by dd'llon or rearmng=<'11L nus 
nslltUl .. 45% of1yphi gene>, much high« th.n lh. frequmcy in 
lfptumunum (0.9'l0) or Esdt<'1'.drta coli KIl (0.7%). Hi~ pseude>-
gent frtqoenoo are ~ d with host restriction in a vanety of 
badtria ' -~Ii. presumably as «rUin gencs required for infection in a 
broad ranI!< or hosts a ... not requtrtd in the pre~ r host This is 
pot<nua.i1 also ol1I1bllt.lblt to hip, rotes of mu13uon lilOloon resulllng 
[rom a cdernted genetic drift used by e\' IUl10nary bot~.necks 
·Illl-d wi~, ho.t .dapllltioo. 
B mapping the delmon. and norurnse Np. to the ph}iOS= 
tr • w. found thnt 92 n .... psrudogenes h I" accumulaled among Ihe 
" Iuen I Typhi isolates since their last CO(;lmon ancestor (Supp['" 
mentory llable J ). whIch i If harho...d 180 psn.dog<>nest .. Mar.y 
(If th. gen f.tI] into gen. c:tlq;Dnes (m<!l1boh.m. cobabmm 
utili.lllLion. peptide or sugar tr.utspon. limbri .. ) pr",';cusiy ... oci.1<d 
VOLU E.or 
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fleU" 4 Accu1lJlatJo1 0' eone 'o8<ll'Iall'lll M.rtat lons 111)'phl II ~. 
Points torT0500nd 10 bll... """. In I"" P'l!Iog..,etl: II .. In AI\J" I . Y axl! 
shows l~ lo\ol.l numbrt 0' ee"les i h"itt d by dclchon nonsc 
nwlall::1n u, to Ihsl ~Iurt:ltkl'l E r'lline represent) the Cumulation of 
mUlations i" it partlC.Jiilf isolal ; dlffelent Ii C5 01 T)'~ .e COIClfCd as in 
fleU" 1 leA. t.ost comrN>n oncost'" 
with porud"S""'" in b05l l<>trucl plll.bogcII'" (Supple men I"'}' 
Table 3.:) . Figure 4 show. the nile of oK umulation f in.1CU ' '3tir.g 
mUL1tior. m each bnnch of the ph) Io$=et.ic tr .... N<arly . 0 of th ... 
genes ,howoo eWl<"1l C of expre.>ion in Typhi. rdlr.g to microorroy 
datll aa:n>ibJe at the l\CllI G d..wbusc l upplenlefltary Ml'lhod. 
orA SupplemmtaryT.bl. 3c). thus m ofth. non "'" Jnct deletIOn 
mutal.lOl we ob.m-ed probabl rn..tIl in lru~ inactrvatkm or pre 
viously function:ll genes. 800luse the losses hal .. ()( umd indrpro 
der.tl III dUferI'JU 1>nmg .... 1\-1'1> . i htes. t dJ{k",nt ints In the 
ph~io",r.rti IJtt b.,e varying lOmpkmcnts of runcti cal genes and 
may ha .. different p.tl~cni pot nt.~. 11ti, may ntribule to tlle 
differencts o""-nw In cl.oru >! m:miksu tlons of typhOId f.-u in 
d.i1J'erf't"J regjor..sl . f nolr.. diJTt"~J Ilnf"".tgt!l ~ l k)w ariJ.lion in the 
rdati\-"r rat of mW.Jlion of :P It_nd ir..act:iWling mutati I1S 
(tint pts in Pigure 4). Thu rna. bt mribuLJble to vwtion in 
t:::lutauon rat~ or Wftfft'r...t seleclI\~ pres U~ r or ag.slnst pseudo 
gect (om1.u.ton In partkubr liJtl."3gi.'S. 
As onl of pos<ibl. 11'>.n the Typho genome ore nOIlJOnse 
:Ps. w< npt<t only I 2 fIls< non .. r ... S :P call, ", ... mII (3 ;, of the 
eslimal<!d towl of - folse s:-w ). Th;, O,lSlltut cs ~ 2"" r gm'" 
ir.acti,-a!<d by r. rXl'.se or d. k'tion mu tJMn .. nd th ... wOldd m.~e 
hnJ dlffnm.ct to nd\u,or.J f'(g:U\:hr. lhr ronhnUt'Hu II ImuJllltOn 
ofp"",dogmes. ln ",Id.u<>n. '\0 dod nOi Lt mptlo analyz< 1T:u1'e>lu8 
nlul..Qlioru., a.s sir..gJc bose 1t\)C.'t\JOm. Qr del iOI'~:lre current! difJicuh 
to dek'tl rebJbly fro 4 .nd 1= qum datil. Ilowover, mo:.! 
of the genes idenllfoo d".,mtI..u Inac-tl' ,d betw<Cl\ ' L8 and 
1)'2 ""rr due t frnm .111ft mul .~io"" (20 fmm",h.ft, .. ISU, ~ 
r.onsense Ps arA 2 deJenonsl'A. d,u, ~ hypothesIZe th.t 1ll"".V 
more p"'udnll<" m. h ",cumubt'" m the Typhi pop"btlOn 
than tho d by r.or ... r.... :Ps or dcle\JOn Thcrdi re. although 
our iU'.alysa <kn:on,cnll.tS t1ut get I s IS ocg mg In 1I1>hi. wt most 
lIkely urA~""ot. the tent of ttus phrn men n. 
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[mrulliol15 that differ betwffi\ th. sompl'" OOI,"es. Sampling from 
one purt of the phylogenetic tree will OI..".look mud, of the variation 
presenl in the popt..l lation and collapse- an isolates Ol1uidl" the 
sequenced subpopubtion into a smgle typel°. Por ex.'mpl~ when 
SNP. det.aM b<tween 18 and Ty-2 ,..<Te typed in 3 larsu Typhi 
collt"Ction24, lnO)"t .lS01o.l CS were assigned to the S<lD1e genotype t"'VeI1 
though they w"e probably fur m ... ''3riabl. than the scheme suggeots. 
By sequencing lSol-ues from maior nodes on the previously dellmd 
ph)ioSt'tlet i IItt (Supplemcnlary Fig. 1). we expect to ha, .. OIptured 
much of lbe variation ptesel!t in lbe Typlu population. We also 
anticipale thaI the r. we ba,,, detected am ng these £<)Utn es 
will serve as gc~lotypic marker, providing phylogenetic ir.rormation at 
high resolution in fututt geno<yping studies. 
ur wbole genome an:llysis Stlpports the proposals of small popu-
btion size.nd genetic drift in Typhi. Although we detectoo sign.1.i of 
""ectin. In gyrA, we did cot detect SIgnal. of the ,ame magnitude in 
othu Typhi sen ... sugg<StiJ\j! that this 1,,-.1 of selection is ro:option:ll 
in 1}'l'hi. Furthermore. our whole-genome comparisons provide lh~ 
opportutity lo sain broad insight inlo th spectrum of genetic 
VIlriation on '!yphi. indudJng P<. Insertions. ddetJOn. ond =om 
bmations as well ... plasmid and phase conlent (alth ugh we did not 
wlillyzc inscrtiun or dck."lion of single nuclt'Oudes). TIle pnttmlS of 
genome· wlde vuriation we delfCloo d=nstral<! thlll pseudogcr.e 
formation is ongoing In Typlu (Fig. 4) and support the byp<>t.h£Sis 
tllat e,oIution in this host-reslnctoo pathogen isdominau:d by genetic 
Unrl and loss of grr.e fu.tction rather than b di",rsi/}'mg selection or 
gaJn (IimC1lOn through poinl JT:ulatior., reoombinal1on Of acquisi-
tion or new ~uences. Ahhough ~ o r fu nction seems lO bt rare, it 
nuy be occurring in a flow genes througb point mutations. 
The IJck of eVIdence for OO:tptlve seiCClJOn in gene .. 1 is In conlr.iSl 
wilh the known adaptive selection for mllt.tior .. in g)T.4 associated 
with fluoroquinolo ne resist:mcr. We ck-teacd the sign>! of selecti n in 
grrA as d usw.d. homoplasic nonsynonymow Nr. In neighboring 
co<io.1s 83 and 87. Thr •• other gtnes conlained bOCloplasic non-
.ynon)'m us SNP • on of which ·adG) .. cod tl •• membrane 
roponent of an .ffilU prol<!in in E. col,.. and 11'.:> th .. efore bt 
3led \\11th anObiOlic: resistance in "fYphi (tfflux proteins can act 
as pumps to "'move anlibiolics fro m tl •• bacterial eeD)!). However. no 
genes besides &:Y'A nillilloo multiple horeoplasi ~'NP:.. and few 
contain,d multiple noruyr.onymoll5 £.'11'. at all. consistent with the 
hypolhesi. of ger_ctic dri ll in lIle Typhi gcnOl" •. nle adaptive 
mutations evident in tl •• gyr.>\ gene highlight the >t.rong select;'" 
pressure on lh~ 1)rpht gonome a..\SOci;nffl with antibiol1C UM in the 
hum.,n l"'pulation. This " not particularly surprisir.g. a the fitness 
advanlage IlSSOClalOO with ir.crea:.cd antibiotic rolstau'e is lilcel lo be 
'~ry strong. i r '" er. th b el< of simaar eo'idence for other adapliv. 
mut.tions suggests that Typh.. i. uruler n>L,U\·dy little sdtctiv. 
pl\~ure fi'oln its host or the environment in general 
The limited cvidencr of selection in Typhi gmt >eqUetlces is 
particulariy not.bl when compar'" 10 p.~u.nu obs'T\~d am ng 
other hUlT'J111 baetmal pathogens, whid, .how a variet), of mech:m-
isnu ~ r antigerj ,mi.tion. r'OT =plt. antigenic 'miation is 
Iu~ b extensive recombin;)tion In the Hdlll>bactiT p -leri :md 
o./nmydw traD.omat" populations'''''. where:JS in M .".bacr",um 
tuberculosis. antigcric \v1ation lS associaled with dUplicntiOl! and 
diVttSlficJtlon of antlg~n-.lSSoci>ted gtnt tiu:illies-4 . In cor.trJst. od r 3 
Typhi gen. ontl1 .. cd mor th.n 6 S~I's, and 16 genes contained 
indepcndelll fI.on:.ynOilymous SNPs in the same Of n ighboring amino 
odd: lsro upplementary Thble 3a). Although th .... mo)' ropr nt 
.sn or antigmlC v:lrial1on, W Irvel ci Y.lnation is 1~ with most of 
tll< SNP. unique to a single haplotype arA thereIore Clost haplotype< 
." 
359 
ARTICLES 
shariq: 1d.,.-'lC>l ><qumc<S. hlarly. ol!houlth the", was so"'" 
.. ido: e of lInport of small ",",menu of non T)l'hi sequCIlc,," (Stt 
Supplementary Table Ie), the only ir.dkalion of possible re mbina,. 
lion bnwtrn Typhl lsollte> w...., ten NP, th.,t do nOl fit Ih. 
ph)i<>s<ntti Un ( ppkmenury Tobl. 3. ). ",hi h uld <quoJly 1>< 
due to c.'tt rot luuon. TIle pw>ity of direct sequrn <~'KIen 
for ar.tJ6"nX: naoon In 'lfplu sugpstS thost tIus pathoj;rn IS nOf. 
ur.dtr og «tj,;. p In from th. hlL"",n immune ')'SInn and 
may ir.lt1'aCt with It:. h l in a dilTt rent w • po ibly &"'ori08 lmmun< 
e'\C1SlOn cd loailization LO muuune pnvd cd silt'S HOwtWt 1l 
car.not be ruled ut tMt 1)'Phi moy poss< as )"1 unidentified 
",echams. f !rnc:mmg anugerJ d.. ny or Illat rhage gm"", 
wh.ich" re =lude\! from SKP "".al)~is n th.is srue! • may \\aYe. role. 
II "" long been sulp«'led thost hUmlln me .. pro";'l. the main 
re;eyvoir drhing the trJnsm"'IO" of Typhi J6. The terium i 
rdathd illfI.4-1.lIl to lsol l &om \o\-jlt!r a.nd the cn\fironmenl en in 
~.dtmic repons'-.l , ar:d It IS genualJ)' belie,,.d that 1)'Plli has • 
limited SlJr"'V21 lw.l OUI~W. lhe human h(.»,J J9, If human (:ume.n 
provide the main pem.lml f\ ir for lVphi, this could account for 
the pot1tTns of gtnrtlC dnlt d lack f recomb",,,l,,,n or gffi 
3C<joisi n .. .., o~'td. tho hum r<W>'Oir IS likely to be sm3IJ 
and ph iol . ally . blrd' . Furtll(:rmorc, ndnplh~ !nuull.ions 
.rumg durir.,. symptollUlk I 'PIIOld Inf«lJons ma \\aft no timb' 
oovanl:l e In thr: C3J'TYf' SI~le :md m:ly lh~"~ not persJM. m tI~ 
long tum 1fphi pulation. AU n < f tht lfphi pllylogcr.ctic tr« 
silO'! II III upplmlClllary fill~ 1 wcrt Jcte<t<d among 0 .. 1. of 
approXlmaldy ~<;() at.tl'J Typhl I :st"l. ~I~ung lhnt th. Typhi 
populauon " not shared by clonal r'1J\aGm'<nl. TI, ... !"'"mu ar. 
wd! dcscnocd b tht SOU"'NiI'.k modd of e>'lIutionory dynamics. 
" 'lud> dJSl1I!guish p'nl'.a •. ~'tl '>OW'«" nd trons",nt ' ink' populJ 
lior.> am:! p",di WI wpm. rnul:lllon ari1ing in the ·r.\. 
(indhidual "idl Itl'ho.l) "'.IV > .hort hwd in Ihe populollon if 
they provxi. no (mat benefit In 1M I ng urrn soUJCe (='" of 
1)1,hl)". imll ... dyn;.mu lila 1>< <Xrumng in 0111 r humnn-
mlrictcd erial populatio" 
An undmt.u:din or !he t\oluuor.;l1V dyn;unlcs of the lfphi 
populao n h II':: JW'.t ''''PUCllIO", r. the control of <)1'001<1. 
The > '1' IYPlllS of mdi>i.lu;l\ lfphi ""lal into dbtino gel Iype 
Clay I...d to 1Jt'.pro.ru mcil lOr tracldn! the spr<Ud of 'lfpbi 
bdwttn hum3n hosts I, \'.'C'~,nBtlon r.~lIy bt J cruoJI long tum 
stralrgy Cor d tor.uol.:s It ouId not orJ n..~uu~ tl 1C\'('1 of 
typhoiJ IrJeclior.s bul ab<ltht Ie> I c>f.uvmpt lllolli< T l'hi arri~c in 
the populao n. a Lry ........ OIT of""oo.d In "'It' . 
METHODS 
lIoctcrial Inlm. 0rt.IU> of ~'PI~ \old UO<\l ., Ihi> SlUdy .r< I' OI'WcU in 
T.bt. 1 OOl.It .......... J"'Mded the ",,1 nl'''''''''1' Qinia) Roc Uni, 
( CT:S. J!~ I AGJt B. lIo1rr<1 .. the ,->.o,w ColI<noon oIl\'p< 1= 
( M22.1~ the, .... .< Tnu1 ~ hutllul( It)', 1';11; .nd p·XW (.iiI 
oloha btls ). 
Intcf'tion 
~nnn ltC p tJC\.I U\ 
SupplCllleDlary Tobl. , d. PCR Jone in • 25 )Il ",lun:, using PCR 
Supcnni1 Taq PIIl YIll&''''''' (Invitrogen) .. >.1 C)ocW on o.n MI R.s.m:l, 1IIcrma\ 
cycler. Products 'We1'C du:cked an ~ 0.8% :lgwoJe gd .:rond purified wing 
QlAquid PCR rurific.uion Kot (Q!AGE~I). 
('\timid idoa lification. In ordo:r "' vcnfy the prcoencc and .. loe of pi .. """ 
~,,'~on 1';phl ""I;"",. we P"'Pared pbsmiJ 0 ~ from 1'ypbi isol.u:s. as 
cbcribe.J UI Supplcm<nlary ,... tllOds. AI pbsmids dL""""J UI thl. way ~ere 
Iq>res~nla.l to me scqueru:e d~t;a for Lbtir host isolates and "'o.c identi1ied 
PU'll to known pi - niJ 5CqlLmCc'::l wlnK bbstn br <\.54 ceq. anJ Aouq 
,0.6.0 "If Sol ... r ). 
SNP dttcctioa (rom seq\KnClt data. We olSScmbltd 15 ... r~s .k 110.'0 ink) 
Q)nt.i~ (tha i l4, "''11hour rtkrence to any othO' Stqlaenct:) mint ~ (vl.1~ 
Roch,). w. wed MUM",,, (v3.t9. nuan<r a1gotilhm)<1 10 alosn conuS' 10 the 
finuhed en 8 .sequence and to g~~( primary SNP c.allJ. Sakn reads W(:rC: 
100 ,shan LO bt UJar...bltJ dleawdy using CllIl'tnl JOttwarc and thw were 
I. pped Ji ... aly 10 tl1t CTtS ",li:ml« U<D<C lISin, Moq .j),6.O, ~hich ..... 
abo wc,'J to genenk' prin_ry calls We" filtereJ NP calls aaording 10 
qual,ty ... nlcria JaCnlUJ1N by ooruparison or data (rum rcuitiplC!: sequencing 
platfonus. .. d",rib<.J in upplclll .. ''''y Mcthnd.s. W. COl 'n«! Ut<re<t 
",II, iUlo, in&k'tis! of SNP 1 i.nd ddcnnineJ th, a1\de . , tach 10<: in ea<h 
of the 19 Typhi "'Iurom .... d aJdilio,w s. "JUT", SCfOI'iVS (usi nG ~I.:J 
larch for 454 conti or tinbho:l teq~ae.s. .lnd Maq CDf\KnSU.S sc a1ls for 
Solen daul. Th,,'-ed re<DI-cryof"""" ' P.th", we ... innUlIy I'C)CCICd In 
ooe 001". hea,,,. of \ow conlidc:na: but detcOed wtlh high confideD« in • 
"",nJ UuI .. ~ unJCtU< SNP. W<f< verified by manually intp«ting rnWlipic 
aligrtnl<tl1J of aD .s4 and SoIcn rcads "'"PPlns 10 <0 no"""", NP Iocw. 
E>Iiaa ...... of souil.i_iIy ud sp<ci6dty of SoW con.. , ... attmaleJ SNJ> 
dcteoi n t ,o.·uracy an..I ~Iti\'\ty for 4 and SoIeta comptrina I't$uh.j from 
thrt'e i.$O.l:u s uen\.-a! using both pbtfonns. at dtsai in SurrlemcntlWY 
~f,Qthods. Addllionlll ~.na((:I fo r SoI~ d:ua wt:re dttamint..1 by comparing 
ku dJt 3 from 0"18 and"..2 10 lhr pu h..~,1 Je(JUmaJ (itt Supplanca-
•• ry MClbods\ 
1'byic>s<:,,'1c anal" ... SNl's ~'1lG willi on rtrombined ~ons (see below) or 
~ithln r<p<at rrgwnl "ere acludoo [rom 1IIIlIlyti, Ic:tVutg 1,964 SNP calh. w. 
chc<,1,oJ aDd >gaUlSt an in.kpcndClll whol",ll"l1OIC< multiple aligrucmt of all 
• • nJ puh1ilihal 1';p1u ""IU<"~ gcnml<d usi"ll KoJon (Arri lCd ~ulh ). 
AI\cI", coolJ be ",nfInoed " all 'Uneual 1';pbi isoIiIl<S (or !J87 (110". ~ 
Thcs< .uppon a .ingk auuimwn piltSimony Il«. dctcm:ined IIStnl: the Illl1 
a\j;ontlu. ill the PlIYLlP p~e (Fis- I). romi,,,,,, willi the nf=n", 
phyIosM~k U'et (SuppleMCJliury F" I). 
d.~/£ c:aLculations. \.\'t: ~kuJ.n.a1 d.'l/ds:3Cmrding to w brmtLb lNl,. U(SlJ:. 
""~, -e- Slon of nonsytwmyrcow NPs. fI -- nor'lS)llony~ou SlIes in 
nUr\r"q"Cuti~c: rrotc:tn lang KqUc:nc:.., - sum of nOOI1)"Q'lOUJ S~ PI. 
~ r,1tonymou! SltCS in rorvq>etll..l¥e protclO~lng 1Ol1lel1(ZS. The mC!:"dn 
dNJJS ...... the IaSI """"'0" ..... or was <.kulatol by .. <Ig\lting d.\IIdS by 
112 Co< MS. iJobl('$, In (or IDa UoI.ld and 1 for all 0Iber ""Lues •• o th;ol <.u. 
haplolyp< is r<prcotDled equally. The <nur r<panal (0.05') is •• d. of thU 
wtlghro.1 mOln. 
Octioa of ' «:Om jn. rton cvu.Ii. Wt ~ , Xl> calls (rom caJl1'YPhi 
I.te fi r NP ciU5ltl1 (,tdillal >J •• ithul 1,000 bpI nd .til,...""" 
thc:te ~oru apn'" the ll.M.8L dJi1.~ using b~ n Ul roer to idermry 
pottnllal rcaomb ... u"" ......,IS \ uppt......,...." Note). 
l llt1L ~uq, hllp·!tmaq.JOUr«fO<gt.J\tl; PHYUP ht1p:/I(luution.Aencti 
~"Hhlngton.edulphyip.hlml: fCappN UJ<Scl>I"" of all 45. anJ Sol ... J .... 
U. htlp://www ang .. "",tdJProI<\:u/S_typlli· 4 and Sol= «ad. dna. 
ftI"J1ft ,,,·r .. tbi .IkIERAOOOOO1: EnttriliJ d strain PT4 5al1lC!1~. hn1"11 
\\WW ",tor 3 PrIljt...1 "Saim(lndia. 
,"""'....... cod..... EDI Whole G<n •• SboIj;\U\ d,,,.b,,,c: r.JW so:qucu« 
cbu ( d.t. ,10\.., I mbJod c.onll~) are lI\'.uJahk ",,"\dt accession coda 
Q-<:AAZ. 1lt1"'J.'C>" 500" Roo Jdln'''' Solen and 454 re.dL 
FRAOOOOOI. G<nOIllit: 1tl'hi "{';Un cn ALS 13.J82; 1tJ>hi Itt>in 1';~ 
~'2------------------------------------------------ VOtU 
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Abstract 
S.ck~: Drug res sr. t IYPnoid eve, I •• major cUnlco1 problem globally. Many of the flnt ne antibiotics, neludlng the 
aide< generatIOn ftuO<Oqu,nolone>. Clprofloucln and afloxldl\ are f.alng. 
otJi«tlvti: We performed a .. ndomlSed cont,oled 11;"1 to comp.,e the "fflcacy and >afC!) of gatifloxacin (10 mg/kg/day) 
""r>us hrom)'Cl'1 0 mgIIcgld y) 'a once dally 01.1 do", fo, 7 day. fo, the t",atmcnt of uncomplicated typhood feve, In 
ct"ldren ond oIdulh In Vi mom 
M«hoth: An open-l.1bcl multkentre ,.ncIoml><!d trbl with pre-spccJfied per protOCol analysis and intention to treat analy5ls 
was conducted The prlINI)' ourc _ lOa. fever c~ran~ ri_, the secondal)' outcome was overall treatment failure IcllnlQl 
or mlCrob.oIogKJI fJ~urc. developmenl of typhoid f ve,-n.>I;! t"d e mphcallon>. rclapse or faecal carriage of S. ryphi). 
PrlndpM FindlngJ:W nrolled 358 c Ild ren and ;>dullS With suspected typhoid feve r. There was no death in the .tudy 287 
pat.,nt, had blood cu '" confirmed typhOtd te ... r, 1.5 p tlent. recelll<!d gotlfloxacin and 142 pat"'"" receIVed 
U hromycin. T median Fa W3' 106 hours In both treatment arms (95'!1. ( onfld nee Interval [(I); 94 118 hour> for 
gat flo~.Cln .... "'" 38 112 hour> 0' aznhromycln). (logrank test p 0.984. H R 195"0 01 - 1.0 [0.80 1.261). Overall treatment 
( lure occurred In 1 145 ( pall;>n~ In the gatlfloxacin g'oup and H/l40 (9.3"4» patient. in the az~hromyCin group, 
(Iog,.n t st p -(111)4 HR l'J5 (11-0.9J (OAJ 2.Q) . 96 .. (2S4126J) of the SoimoMiIo """'rICo ..,roya, Typhl ;sola ro. were 
reutant to nalld xlc lIC.d .nd 58 (1531263) were multldrug re>isranr. 
ConcIuJion 801t! .ntlbiOl 'Q .hawed.n "",Ilent efflcacy and ,afety plOfi Both gatlfloucin and azithromycin can be 
recommended fa< the rre.rment of typhoid fl.'YCr particularly in ,egion> ",th high ra"" of multidrug and naUdixie acid =istancc. 
The cost of • 7-dly,", me<lt tourse of g.udloxacm " approxllMtely one thlld of the cOst of oz,mromYCln In Voetnam. 
Tri.J1 R"9,Wiltion.:Controlk.'Cl-Tn I •. com ISRCTN67946944 
CiU bWlt DoIf"'"~ C. pt Il. " ftlri" fIt.,,0t' 'I "'*' H. f( II (1001+" ~ ... Ia.·<<<t~ ~~ (#otr~f!d 1~ of ~"'ftQtQdn ~s Adt .... DfnY"J" .h. 
I". IftH' I rJ fItd I r~" If\: M d AdJI1 -' ~Ifll'\)m. PloS E 11.5:: el l88. cb '0 H711Jl'l".f'r".t.por"eOOO2188 
,It;....: 
~"" tit ... ~~ k til DP"~ t ..... , I If" d'inl:h,.', ~ lH'I<M the ms of tt'f' c.e'~I\"" Commor~ A<1llbullOrt h::f!iI"'ISf' """'.ctl f')@f"*S 
t.nr ICt USf'. I~ .ny ~ p'~d \ f' Iii"" .... tt>Of MId W)..rCe.f (r@(l ttl'd 
Fwnd.", : TtI • .u.dyWIII~bytf't.Wtt on"t lf'\.n.ut. lhrtvcir'g JCNftt dnotp lnyroIrtlrl tt- t ~r,(onduc:t.lf'~sOfp.blation oftf'l.swdy. 
Cofnpetlnl 1me.t'ti1:s. 
·£r'\"Iat~c"~at'G 
Introduction 
TI "" "' 1~ mlttf\; ' 1 ml.D.U n n f f)'ph d ft"'wFT 
lnnually, w.lh ""'" dun '10 I~l Ih II I lb, f'ITlt tnet of 
1I 
Mll.mK. ;.a.I dru lilt. :n ~la m!mI. .. 
""In os a ru Ijo< probkw particuJ.uiy in 
Imhan sub-COllUnenl nd ctullc.n SOUr currcnt l:JJKnlopti 
12 I). I I r< is ne<d fi r 1 draCo • e and aJlOr<bble oml 
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lre:3lm~nr , p3tt:icoia.I'ly lit r'tgmcu with a high proportion of both 
muJtidrug and na.lidixlc acid resiw.lnl !J'I1k 
In Vi~..,.m, IXIultida"Ug resi tam IDR) bola,cs of S. 'Jilti 
(ruisllln' to alllpi.cillin, t hloratnplumit:ol and ui mctboprilll-
.wmethoxazol) fi t .ppean:d in 1993 (5]. From this tim e t~ 
OuoroquinoJoncs btcamc ,~ .... ,tmcru of choicc for typhoid &:ver 
(4], .nd _..., limultan<Ouily sold widely ovu- the coun« ... o " . 
(over ofvariOUI aedolo,i .... The t><<<Mi antibiotic pn:mtre lad 
to the .. Icc ion of ingIL poin' mu""ion. In the 0 A ('~ A of S 
IJPJu, cousing .... 1 tance to naJldjxi<: .d d (.he prototype quinolont) 
and reduced ,w ept ibili,y to tloe flu oqulnolonts (bu' ("r",aIIy 
theK isolates ... ,till wi,hin the Clinical Laboratory tandanl 
Institu" (Cr..s btnlqIoints (or . """ptibility) r . T bis resulted in 
l poor c.lin£aI response to truuntlll with the. olde.r generatiou 
Ouoroquinolones, oOoxlIcin or ciprollox3cin (7,s]. 
T~ World H Ith O rpni .,ion recommends ,h. fluo"",",n -
olon<. or ceflXime for 'he ..... tm. n' of ~mR ryphoid ("""r and 
n i,hromycin, the third"f"l\t11l ' n u phalOllporinl, or a 10 14 d,y 
coonr. of hlgh-d~ olde.r F nenuion Ouomquinolones (e.g:. 
oftoxacin or ciproOo~ocin) for tbe .. eatmon. of nalidixic .cid 
.... is .. n. 1)1'hoid rover [9) . 
Azltnromycin, an azalid antibiotics, b.u achi ... d ""edlent 
din.ial rcsliu i.n the: trulm~nr or tOR and nalidix.ic acid 
utant typhoid b ... (7,sJ- Ilowev r uitbromy . 1 i. ""pens;""'. 
eCoome .... recently failed in d,e tt",uoent of nalidixic acid 
res' 'an' typhoid f ...... in Nepal (th ... data we", nO!. aV2il:l.ble at 
,he ...... of 'his triaJ) (10). 
rttrnl trial from uthtm il!mam uSld otloxadn at f~ 
nwdmum ... commended do .. of mg/kg/d.,y ~r 7 days for the 
,=rmen' of MDR and nmhdiJdc acid .... i • nt !)'ph id fever ond 
.bowed high clinical failure r . ... (36~), high immedia.e pos.-
, ..... lmtn. fi cal rriJl (19 '1\)."",' l may l. d.ol ...... nlssionin 
,h. omrnunity all ... di>charge r. til hospi,al, and prolon ed mea" 
f".r cbnnc-e time of 0,2 day. 5.. , 7.2 9 2 da ) [8) . 
T~ n:tuh. underline wt ,heldu generation Ouoroquino-
Ion .. ore c1urly faUlng In ,h. rrutmtn, of Mlidi>cic .cid re.i mn' 
typhoid f,,'u, 
Of the newer Iluoroquinolona, gati!loxacin ;. .,aiJabk and 
a/IOrd.bk in uth....... outh Eas, . including Vitln:un [10). 
or nll 'he Uuoroquinolone.. :triOoxncin howed tl", low .. , 
min imuro in/u'bi, ry c IlCUlu'wiooo , t iC.) ror nalidixic .cid 
r ;'t;w. . !Jt.1ti fi m epal [111 and VietnllIU and II rapid 
b,ctericidal t !Teet in ,~-Id ll expcrimen involving S. tJfIIa isola,,,, 
wi.h .ingle and do"b~ mu.a,ions in the !Ur,i of . tIfJu (6). 
Wt conducted randomisert eonrrolltd mal comparin .he 
ttrocy of tiOoxadn 10 3zimrom)'c.:in in soulhtm )ttnam, ru\ 
Ire ch.r3cteriKd by • \try high propareon of MDR (88%) ""d 
n>lidwe Id .... istant 3~) S "". 1JOIa ... l 
Methods 
T~ pro.ocol fOr "'IS trial nd mpponinlr NSO It: c~c:kfur 
are .,..nable as lupporting inform.non; lee Chtddlst 1 and 
Pro.ocol I. 
Study design and objectives 
The rudy dt3igned .. multictnt r. open-Iabd rondo-
mised con.roIIed trial to rnmpa ... the tfticncy and ",r.'Y of 
polloxaon ,'tn" • .zrhromyc:n r, the rrurm.nt of unoompli-
C'3t.t.d ryphoid kve:r in child"n <and "duh in1)-'Hientt in lOuth,.m 
it tnam 
'f~ ""e..n ol:!jective of ,I., Jludy "'''' to i "!ify.,, .fticacio~., 
• e vail btl: and Ilffordable on! lrtalm.nt for MDR and 
naJidwc a.,jd resist'''' typhoid r. r. 
1 
TI'@.tment d Typl'\oid f ever 
Partidpants 
Patien lll wU'C eligible to ~ included in ,h. udy if t~ had. 
clull oy .wp<crzd or culrure COf,flnIted uncomplicat d typhoid 
fever .and if fully informed ", .. rinm COOMn' had bun obtainr.d. ror 
children) consent w:u obtained from the JX'rtnr. Exclllsion aittria. 
wert. prtgnaocy, a~ nndtr 6 monrtu. hiory of hypersensi riviry ro 
either of the trW drug!, any signs or severe typboid fi:ver (.hock, 
deep jatmdice, encephaJop .. hy, couvulsions, bleeding, sulpicio!\ or 
c"ick:oc~ of gut perforation)) or previous rqJOrtc:d treatment with a 
Ouoroquinolon antibiotics. a. lruTd gl:nuation cephaJ~-porine. or 
macrolide antt"biotk W;lrun one ",uk prior 10 h05piw admission. 
The study si tes and ethical approval 
ludy was conducted. at thru horpiw t in the louth of 
ic.mam. 
dull and paedlauic patien'! were recruited " he rr"'pital for 
Trop:cal Disease. in 110 Chi Minh City, a' the Dong TI",p 
Provi, '01 hospital in CaD Lonb. Dong Thap province and III tit 
An Giang Pl-ovillciol hospi,al in Long X.yen, An Giang province. 
The " .. ely WlI. apprt",ed by the Ethical and Scientific 
ommm .. of .b. Hospital tOr Tropical DiK .... in nQ bi Minh 
Ciry and .ht 0 fOrd mvtnity Tropical a .... rch Ethics 
orumi" .. (OXTRECj, K r. aD thtu study Utes. ~ clini.caJ 
and micn,bioJogical data frml tht Cmt 40 paticn .. recrui,ed to 
earo arm of the study we ... sent to tbe independent D.tt1l. .rely 
.nd Moni,oring ornmittu fO r their advice. ... 'g: .... ling th. 
continuation of the study. The .rudy was nO! stopped. 
In letllerttion 
According fO th.eir randomita.tion number pa ri~nts were 
iro<d ' 0 oral tT'Catmenr with ei.her 20 mr!l:c uithrOf1l)cin 
(Zirhrom~ mspcn ion. Pf17.er, ; 200 mr/5 ml or Zithro-
m - tablett, Pfix r, U A; ~ mg;/tnbkt) or 10 ma/k '"tmox-
a " equin-, 8risto~Myen qwbb, A; 4()O rug/tabltt) once 
dUly fo .. 7 d.ys. T ablets w e ut to oblAin 'he appropriate study 
doDge and lIdminis, d wilh m..... I""vit1l.bly, tile dose 
admini tered was an esrimate of 10 IDg/kg/day of '"tiSo in 
or 20 mg/kg/day r nirhromycin (num~r of ",bI... or 
propon'OllI of ",bltts w .... d"""mented in .he C R .) G3riSoxacin 
W3.J only avaibble :u t3b5t.rs , which were. cut 10 obrain tht 
appropria •• dosage and crushed if ntcUSll ry for children, 
l ' he mllXimum dose of .zihromycin was I g per day. All drugs 
wert purchutd commerciaJJ • 
Procedures 
b.-Jlll lic:at proeed"""". On admission to tht bospi,al the 
p3tient's fun hi>,ory was tilin, a slllI,dtml clini.caJ t.""",inatiou 
, ... performed and axillary tern ratll"" weight and he' ,were 
roe:lsuru:L IIefore treatment, fun blood counts induding white 
blnod differr.ntial counU t K rum atpanarc IraN mina.~ , 
,<nun alarune t","",minaJe «(; and bilirubin were cbec.kt;d and 
blnod CIllnn'" wue obtained. for adult P.,Dentt, creatinine. blood 
urea nitrogtn (8 U and alUt05e levtb wert ddi,ioaally 
measurtd. In me pa.ciC.tlts bone marrow cu1lUru wert 
obtained Urina w<:re chtcktd with dip.tid: and pt .. -lrt.tment 
stool cullU we .. e obtained. Ote" . ...... y .nd alxlonr in:>l 
ullr:L!OllUd w<:re perforlIled and repc:lteti as clinically indicated. 
R:mdom' , rion . nd inin. cion of tht ropy too~ pIal:. tith .. 
immtdi • • ely on admil$ion '" hoopital or patients ....... obsc:.wd 
until rtl"lu of blood ..... includin, blood culru .... w .... ,vl.lbble 
alld lhen nndowiJtd Vita! signs including measurement of 
axillary leruptrnruret wt·r' m ured and recorded ev.ry 6 houn 
(. , 6, 12. 18.nd 24 h un,i1 ' ch~. Patient. were .xamined 
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daily unta d.iscturge from phal, wi,h pam ul3r I'dtrt:nce to 
clinical mp,ocn!lJ FCT, lidt tlTtc ta of the orug and any 
complic:ltion or che dittue. AddlllonaUy htborn lory lest3 Wel'e 
scheduled if e1ini JIy indiuled. All eM evtntS were rtcordtd. 
On day 7 10 9 r UI ..... rt of U' ttl Ol full blood cou" • r .. 
funclion 1<$ • blood and .1001 cuI'ur .. were check.d. In c 3C of 
imufficient responx to tbe-rapy, development of compUcati or 
drug-u ' ~ advent ~cnu, the: initial lrcatroent 
SU!p<nded and partnt raI ttllriaxone (2 g per day) in two 
divided doses was u .. d aJ ... rue treatmenl foc 10 days 
FoUow-.p ,re~ecl.r... ut-patient follow-up appoin tfTKnq 
we.. sch<!duled at I month. 3 months and 6 monlhs .ft .. 
discharge from hot!pilal lo seek evidence fOr map •• (I month vuit) 
ond check for chronic Iyphoid c:l[n.i" (aU vi~IS) , I. th..., 
a.ppoinrmena a, fun hisrory '\\"21 13m, ft'le~t ex.,·urunMion! 
perfOl'TlW'd and ,tOOl rulrur .. obtlined. Blood 1)1' bone murow 
culnl .... were only obtained if clinical symptoms " .... indie&rive of 
:lOll< infection, If I' tkn.. did no t "nend their follow "I' 
appointme.nr, they were rt.mindtd by Wfru or memtHor of the. 
"u~ team visiled Ibeir bome, If .lOOl lamples ""r. 1101 .vaiIabIt. 
• rtcllll swab WaJ obtLined. 
Patierus wi lh coo le!cenr tool carriage of S, !Yf!I!ior S, PlIIlI!JPIti 
A were re.trcated according 10 the KlUilh,iry of the isolare and were 
further fu"",,-.d up, ' ,",Ollml WII rfonned 10 ""dud biliary 
or k:itln 00(1 ir rna was IXrthue.nl. 
Microbiology 
rIVe to 8 mL Qf blood W3I ro l.kcted !rom adul .. and inoculAted 
inm Butee Plu. erobic Blood bottla. &!ld 3 10 5 lOt of blood 
from children wa.t inocullltt'.d into Bacttc Pem 1'1< culru~ bottle. 
(BeclOn D:ckiruon. ow Jersey. ). The bon'" _Ie inclllwed 
It 37' C in the B CTEC 9050 ulom: ted analyser f()< 7 days and 
.ulKulrured according 10 lI.ndaJd methods "ilen ,be machine 
lodiCaJed pocitivo . ignal. 01: incub&ted at 3'-C in .mndard 
Iabor:ltory incubaJor (An C ng hospito1) .nd uamilled cbily. 
StOOl sampks or r< tal swabs were inoculaled onlO MacConlcty 
agar.nd ylos I. in. De rbo.xyl • W l 'lf.!r phil,,, .lId in 
10 roL of selenile f bn,d\, Plale, and broth ",ere incuba,ed . , 
3rC overnigllt and Ihe broth w sui>-<:uJlUred on M.cConkty 
and XLD agar pia leI tbe next momin • . 
lares wert: screc.ntd usin, randard biochemical ruu and 
tfPIrJ .nd S poror;'P.' .. ue identifitd u,;" PI20E (b' ( erim", 
Paris, France) &nd $Iult Igglutiruuion with <pU.6c nrisen 
ura. fJ:utfOrd. J...,. 
ntimicrobiaJ sUS<qllibility "ing p<rformed by cfuc 
diffusion """'riling '0 O i,, ' oJ LaboralOry I2ndards III"ilule 
(CLS guidelin [l2J. u · g CLSI bre:tltpoin (13J. Amimicro-
biaJ ' t,rerI- tUltd were: ll.mpicillin. ddor.unpbenicol l IriDldho· 
prim-culf-amelooxaxol, n~,,{lc acid, Of'LoXaci~1 ,dproOo~n. and 
cefiri:u:one (O.oid, S. .. ,nll' tok.. MlIllmum Inhibilory 
on,..nlr:ltion. _ '" .) for 3IlooJciciltin. duoramph.rurol. n:\Iidixic 
"cid~ 000_ acin, ciproOox:u;:in , liOo. in , ttOriuon and nith· 
mycin were d .. m nined by f.-t .. , (AB Bind' Ie, In.. ~n). 
( uh idrug reoi !llJlce DR) ofisoL" ...... do-6 n.d as ~ :metlO 
t hlornmpbenJcoI . I 32 IIr/m L), nmpicillin ne 32 I'gl 
m nd trirnethol"'im-oulfiom<tho ,7.0'" n :>:811~ I.glm 
alic(xic acid re ' mne. w I d.nntd I an M.I 32 Ilg/mL Th 
LSI be ,lq>o!nu rl)l' 000u. 'n nd (iflo cin we... 2 I' Im L 
iU9Cq>tiblt OIld 8 Ilg/mL re isl nt. for ciproI1ox.tin I Ilglm L 
.u~ptible..,d 4 jlglmt .... bWlt Md lOr cellri .... on 8 jlgi 
mL iU ",ptiblt nd 64 1'@;!roL r.,iSlanL l1 .. re " .. tlO LSI 
t.{1 breakpoints for uiOorom)'Cin fl3] conlrol strrun. u.ed 
for all susceptibi1ity ttO" " ... £. ",It 25922. 1'u",l_ 
'm(pO'''' A C 278~. ~.... , ..,..., ATCC 29213 . 
. ~: PloS ONE I www.plo",ne.org 
All cultu ..... identi6 lion of !JIpiri and S. pm.!YJl. ... A nd cfuc 
diffi ion ""trt: perfonnt:d at the Ihrf:t 5Ou_ly !i,,.,s, AU ilol:Ltet ~rt 
.t.nt '0 lbe Hoopitru fOr T ropical D" ....... Ho Chi Minh City, lor 
confirmation of iden,ity. sU""'P'ibilily ''''ting and flC , •• ring 
Outcomes of the study 
TM prim!try endpoint or lhe ,nldy W:U ,M resolution of "".r 
(fever deru-ance time, , wh' h W3J dtflned t the dm~ from 
Ihe start of the ntibWlIM; treatment 10 when tht xillary 
ltrnperatu~ fin l fell s37 , ~·C and remain.d lbe ... ror al I .. " 
18 hoon. COI\dary endpoin "e.. Ih. ", .. ran f.liJUI.. to 
Ir. t=n~ which was MOIled a priori as any of the following: 
clinical fai.lure (persiJtence of fever nd symptoms twO days fter 
the end of UU-tment l i.e. Oll day IO) or Ui:ed rOC" re-treatment due 
10 i",uffic;"nt' lUIetll .... pon.. judged by the lreacin 
physician ; mio 'obia1o[licaJ failw'e (po it ive blood culture on day 7 
'09 .nerthe """ of ' reatIDent): the dcvclopmetll of,ypboid fev ..... 
related complications du ring hospiral-st.ay. the O«IlITCncc: or 
rclap'" (symptom. and .igns .u8I, .... ri.ve of typhoid f"""r) wi,hin 1 
mon'n no- completion f treatmenl or the deleoi n of faecal 
carriage of S. I1fJIri. .. t the foUoW>1Jp .. ie at I, 3 and 6 mon,h (10 
fx.clu(~ faecal carriage a minimum of two ( on cutt~ follow-up 
visiu had to be. attended). 
Sample Size 
The prinuty outcome mu,u", for the .rudy was the ""er 
clearance. time ( 
P .. vitM stud ies lb. t U d :rz l~lrocnycin to ueal typlloid "-ver 
pa'ielllS, reported. mean fever clearance lime of 130 houn (7] 
and 139 houn [8]. For gatiJ1 cill. clinical ob<ervationt from a 
.mill number of typhoid f.,.or P1UtnlS we ... avalbble and 
indicated • mtlln of 76 hours. \ e caJculated 0131 139 
patieDlS with culrure-confirmed typhoid ltv .. would be nteded in 
e.cb treatment ann to detect. BUiI.I:d IUtio of UQ with '''''" 
.idedaJpbaofO .~ lid power of 0,80 [14]. 11\erofore ...... w.n a 
median ftv .. cIearan~ lime of 130 boo ... for azithromycin. the 
.amplc sitt of 140 patie .. " with cukure-confinDed typhoid fever in 
each arm wouW giv. power of at leasl 0.80 10 deIJ:ct a difference 
between treaunen if the fever clearance time. in th.e gatifloxacin 
STOuP W3I 9~ hours or I . 
Randomization procedures and aSSignment of 
intervention (sequence generation, allocation 
concealment. implementalion) 
n admini«n:l r independent from lbe u udy iJ'!nerated tb~ 
random number leque.na in Excel usint RAND funatQn. The t 
randomist:d codes we.re bJoeUd in t\ size of ~O. Treatme.nt 
ignmw " 'ere folded and kep' In opaque, sealed. oequenti.11y 
numh<rod .n'~lopcs :all three study sita D"e to logi.oric ..... on. 
rand m' don Wtl.S n stratified by ctnrre. 
Al1:.er all inclusion and <XdusiOIl criteria were checktd. and 
informed consenl 'ven, Ule tu~ doctor opened the euve10pe 10 
dctennint. which treaunent the l ubject would I't'crive, The sealed 
envelopes wue opened in trier numeric aequenc:e.. 
Blinding 
This , 'udy ,va, conducted as an open ludy, 
Slat is tical methods 
Binary ul mes (d inicaJ failu. . miaobiol '111 railu",. 
t)'lll id fever-rei ( d complications) were compared betw u Ih 
lwo tre1lluxnt groups using Fi or's .. "'ct lest, .. suming the wOr'" 
cue scenario (all loll to IOUow up trtated U failures). Th. un-
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adjusted OddJ Rolie ( R) lid omli.id', 9~ Ct>llfidenco 
intaval [1~] ... ,. "kill"td 10 how Ih. ,~I .tiv. ri<k rdevdoping 
ind ividual 8ot.condary outcomes (d inicru , tnit-robiological fauI1rt1 
ryphoid f<ver-rd.ted compllcat' no) in 'h, ga.iflo,..cin group 
compa~ 10 the IlJ:'.iJhromycm group. 
r ever d ....... time, time to re"poe and tim. 10 overall failure 
were ual)'lCd wing survival IUciliocb. l 11c time to OVc.rall failw'~ 
equaled the earliest time individual f~ilure wu recorded. K.pian-
A • J' estimaJ:tJ of proba.bi1iCe1 of each event 'W't.re calculated 
UIY timt-pOint, and they we... compared between Lbc two 
trCltment groupo win the Iog-nnk 'eo<. 0. ... of pacicna "ilO 
w .... loot '" lOllow-up we ... a:nson:d a' the time of the Wt 
recorded ou<come. The Huard Ratio ..... de';v.d &om Cox 
proponional hazard modd [16] . 
AD J»ri~n~ wilh poilrive blood or bone m:vTO'W Qllrurc (or S. 
fJPIo .nd S. fJilrtItJIIIu (per protocol nalylis) and separately all 
randomiw:l parients (inun,;"n '0 ,ru, an: I.) wu< :uW,...d. 
AD dara wert ... corded prosp<cti,~ in lO individual ea.c 
LUcord Forms (CRf) and .nt .... d into . n dectroulc da",ba", (Epi 
Info 2003, CDC, Atlw.lta, U IUId double-<:h.cked. 
Analys;' w:u pt'rl"onned "!linr \'en ioll 8.0 ( 12'. 
Cotpo<alion, T CXlI , ) .... ;.tical aoOwan pmgnm. 
Results 
Partkipant flow and recruitment 
Ourin tbt study period, 460 patitnu ...... re cd foc 
digibility 19ure I ~ On" hundred and lwo patients w~ ... oon-
eligible, llx ma:n r< OIl w;u !hi: reporttd previous ute of 
OUOl"'lXluiuoloncr 01 crolid or third gc:ncratiun cepha.bporin 
:mtibiotia (41 patit.UI.) in the week bef"ure hospiulislooo. 
Berwcen pril 20().+ and ugust. 2005, 358 p ..... n .. with 
lu"""Cled typhoid f ... r ,,~.. randomi5<'d 10 ... ",iv. tilher 
garille«aCln or :azithromycio. Two bund ... d .igbty-<.ight of th • 
pa""" had blood or bollJ! marrow confirmed typhoid r.ver .~d 
70 p"NenU ....... roI.u,.. n.g;lU~ ~ !JPIa. 0", cultun PQlllnv, 
patitnu wu .,.dud.d from , .... ptr protOc I .nat is , bcr>u , 
h. had ... ~ived ciprollox.lcin btfor •• n.ry 10 Ih. ,ri"l The PP 
&""'1' ClllUmed r 7. pati.n , 146 in the. gnt~lo an grour and 
14 In the ;ui,hromyan group All 1'1' pa"enll, ouT' two m .h, 
azithn)1n)o n rmup, fi h~d (hI fuD course trr. rrrN"J1t. 
TIle" tota l numbt.r p tients~' bin f 1b000·up' 1 month \Of< 
275 out of 281 l, . , 3 n",nW '8 Otl' 4 7 (93%), t 6 
UIOnthl 128 OUI of 287 (VI 1 pal Nene. 
Numbers analysed 
AD 3~ raodornXd polItn, "'.,,.. n"IY8(d in !hi: in.ention '0 
treat (IT1) nal ,i, Two hllndr«l and eighlY"'Mvtn p cltots with 
cul.u ... confirm.d Iyphold Ihtr, 146 . ,.. ltd whh , iQo • .cn nd 
142 with azilhrom}cIo, _n: analyacd in the pre-.pecifitd PP 
aoalyslJ. 
Basel ine Data 
Th/: m<:di:.ln age of patie", m:ruil.d in this trW w-.... [ I y...n 
(mngr 1 41) In .he PP group 
he lnselint ch:tl'3l'Tffil r me p:ati~n wt'f'e SlmiLv in rht 
"'" tre:u:m~nl ",,"po nd 111 the n,hu", n.p'~ parimts able 1) 
.... tien .. wllh to'p<Cted nd wlture confllTlltd typboid 
fo> r.. eliiiblt for 'htJ trW In.he PI' group, the mod;'n dd>y 
in time ~e h p.r."21 adu,. ion nd ndomit don was 3 da 
( ,ttrqUIlrIlle range 1 4) in Ih tifloxacin up nd 3 da ' 
\inltlqullrl1le mOgle 2 4) it. the wlb.-oOl)cin group In tl'" 
group the median dcby in time Ixl eo ho piw admmion and 
rancL>:ro...tioo waJ 2 da) (In u.rtiIc" 0 4) in til 
.~: PloS O-.E I www.pIo"' .... .org 
T~.tment ~ Typhoid f f'Wf' 
ptiOox d n group d 3 d.ys (In'''''lu rtil. rang< I 4) in ,h. 
aZlIhromycin ~rollp 
Protocol deviations and modifications 
A, one .. tidy lilt, the An Ciang Provmcial Hoapilru , ,h. fonow-
up vi it al 6 monlhl wal nol potiible (or Josittr ~AJOnJ rr W1I!J 
Ihertttrc agr .. d '" ta"Y ou' ...... " rollow-up vis;" l i nd 3 
month. and '0 ",hedole ddillOmJ (emsHCCtion>l) follow-up & 1 .. 
." invi.e U ma ny patim" as po";bl< on third follow-up vilit 
rom .he PP popula.ion, 22 on. of91 paOLn" in .he pntloxarin 
""" and 17 Oil' or 87 patients in Ihe u:ichromycin urn " ' tnded 
'he 'hird visi,. 
Outcomes and estimation 
Pri ... ry OQlee.u. 1l1ere \\'U [10 signioc nt dilTtrtoa: in 
lhe relOluLion of fever bttwten the t \oW) trtalDlenl roups 
( f abi< 2) 
By PP analysiJ, 'he median r wu 106 boon in both 
' reatmen' anna (9~% Conftdenct Inttrval [Cl]: 94 118 hom. ror 
prillOlC.1Cin _ 86 112 hours for a.zitbromycinl, OOgT3l\k Ie 
p ~ 0984, HR [%% CI) '" 1 0 [0.80 I. -D. The K'pL",-M.ier 
JUrvlVal curve fur lhe tiNer c1taD.nce time it Ibown in roe. 2. AI 
day 7, fe .. r clearance .... ,. Wolf 8211% (9~% cr: 76.2% 118.4··.) in 
the galilloucin group .nd 80.5 ~% CI; 73 6 116.6 ~) in the 
uithroruycin group. 
In ,hi: ITT population, Ihe median FeT w • 100 houn in both 
trca.men t arm 5% I; 92 10 bonrs ror ptilloxaon "'trof 88 
112 boun r. r .u,b.-om in), (logrank 'm ;"'0.914, ffR r~'I4t 
=1.0 1 [011 I ) ]). td'y7,l<verclnn"erl W 81.2% 
(9) ' 1; i8.5% 89~) in th ptiflox.cin group nd 8 ~ 
(, 765 87 ') ill the ""ithromycin I'" p (Figure 3~ 
Set ..... ..,. oat......... 11 ..... w" no de Ih ill !hi: Ilucly. 
aere w nO aignlfi r\t diffi:: ... ~:llCc in over:ill fa.ilure 10 
lreau,",,,t helWttn th. two groups able 2). 
By PP .naly '1, "'" nllmber of patNen .. Ih .. lhowed o\'l:n ll 
failu""(1 treatmenl WU 13/145 ) in tht garilloxacin grollP d 
13/140 (9.3%) in Ihr azi.hrom)cin 1"'''1' ~"",,"k rur ,,"'0 OM, 
HR [9!>% "'0 ~3 (043 2.0]), or -.+tcn .... ,minitiw' wonrc < 
r<noM, thll' . 11 droppcd-<>u' patien.. "".. f.ulUrtl, 15/ 142 
(106%) failu .... in the azi' hromycin ,",up II"nk ,m,b"'O 570, 
HR [9!> '" a 81 (0.38 1.7)). 'lI" re 4 sh""" thl: proportion nf 
patitnlS f.llinr throuJll tim •• fier .he .. an of rrunnenL 
In the uilhrowycin ffil t more. than ODe failure evtnl occurrtd 
in individual patients able 2). Clinical failure occurttd ill 6/ [46 
(4.3") p"tien" in lbc ptilloucin group and in 6/140 (U ... ) in 
lhe azilbrom}cin group Ii = 1.000, OR [95% C = 0.96 [0.23 
~. 7]). 11.... p1litnlS in. It study arm were , e-treated with 
cdlriaxot , the otber p ..... n" ~ved tIWr symplOCO within 
24 hours. 
Microbiologi I failure Ittn in 2 001 of 145 pOI;en .. in th 
g-dtiOOlmCin .nn (1.4%) and in 3 out of 140 . '» in ,h. 
azilhrom)-cln arm (;., 0.680, OR (95% C '" 0.64 [0.05 5,7)). 
Two of lh~ :lZht& rom~ n rKipienl howed additionally sigru of 
elini I f.Uure 
rt w ... no typhoid f.vrr-rebl<d complication. in .he 146 
. nO(lltlltin pori.n <ompared 10 8 OIIt of 1<10 (5 7 ) I»' ...... in 
Ihe 2i.hromycinaml{.&=0003,OR[951;, =O rO 0. 1])- Two 
uhrom)-cln "'cipi"" de->eIoped sign. bYe. filOCt!on 
~ Ie, ted ' T nd [; , d«-penin of jOllndicr\ In !Id<lioon '" 
clinic1ll I.Uore. rudy t,uallenl Conlinued nd 
symptom rived b the .im~ of disch:u:g~ . Four pa,i." .. , tb 
children aud Olle &dull, ulfered from scroinlestin:ll bleeding on 
dly 3, d.y ~ (2 c os) and day 7 of treatmenl mpectivdy, tl:=e 
p>tien.. a:ived blood transfu · 0IlS. One of m... patients 
MaylOO8 I Volume 3 I bsue 5 \ 021118 
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AdJIt. and children WIth clinicaDy IUSpeded t)!lIlOid fffYer assessed fa eligibility 
clJring tlal period. ~60 
Not ellgille. n-102 
Previous antillotics, n=41 
Canpllc:atcd typhoid f~. 11"'8 
-+ 
Age \.rIde,6 months. n>6 
Refused CXlMElnl. n=16 
Study doctor absent. n=3O Allerve reaction to antibiotics. na l 
Intantlon to treat I 358 Palleru rardomised I analysis 
------
~
186 Pabents random/sed kl ga61lo1CQoo. 172 Palenl. ,andomised to azlthraTr)Cln. 
II MCeived gstiflOl<8dn aD reca..ed az;ilhran)Cin 
[--1' Patient excluded duo 10 p'&-lJeatmoot 
~ 
145 Patients v.lth culture 41 Patients 142 Pallenl. YAth 29 Pa~ents 
carlirmed t~hOId kMIr clllure cutture oonfirmed culm 
(S.Iy}ili. 11"'144. n"!jstill8 typhoidf""'" nego~'" 
s.p;ratyphI A. n=l) (S.tWll/. n=138. 
S.pantyphl A. n=4) 
! 
145 analysed In the pe' prolocc4 a/\lllysis 142 analysed In the per prolDce4 lnaIysls 
All patients canpleted treatmenl 2 did not complete trealmOnl 
13 P.-ients with ovemlllrlt8tmMt failunl 13 Patients with overal treatMnl hillle 
t model3le _8 advIIrse event 
132 Patients successfully treeled 126 Pa6ent& IIUOCIISSfutly real8d 
! 
FoIow-up; Follow-uP: 
Al 1 month. 138 of 145 palJents AI 1 month. 137 ol1-42 patlerts 
Al3 months. 137 of 145 patJants Al3montha.131 oll42 p"tientB 
Al6 months. 65 of 145 patients AI 6 months. 63 01 142 patients 
Flguro , . Prallt. of tho Trial. 
dolO t O. t 171lJoumli.pon • .IlOO2 t 88.g001 
deve1oped.rock t rc.opond<t! to intn.venou. fluids aDd 
rupponi"" autmtnt. T=tment was discontinued immediately 
in aD the pariulu and l'O'IrealJnent with tcftrla.one was iniIiated. 
Two adult potlents developed pnewnona during IlUtmenL 
Rdaple was ev.ruated only in patients that wee initWly 
calcioriJed as .ua:eafully auted, !Wien .. wilh clinical f;aj]=. 
mi<:n>biologicll failure ar compliatiOOl were not evaluated. Four 
pllllen .. out of 137 (2.9%) relapood in the gati1J"ncin pup 
compared to 0/127 in the uithromycin group (losrani. ~st 
p=O.o52. HR. (95 CIJ = not estimable c!ue to tao obcezvalioru 
in one group), (Figure 5). These reJapsu with oymplorn. wggestive 
of typhoid fever ",,,,ned on day 7, II, 13 and 15 reJpectivdy. 
after completion of treatment, three patients wae eonfumed 
culture potitivt far S. !!pili. One patient developed acute 
lelPiratoty distres. tyndrome (ARDS) and nuded ""ntih.tion. 
The patient was trea~d wilh cdlrinone and periloucine and 
suboequently made ,. compleJe recovery. 
Chronic. beca] c:arrlage was evalulIled in patients who lIltended 
at leU! two foDaw·~ "!'{>Ointments, IS7 in the gatiflOlUcin group 
and 13 1 in the uithrornycin group. Only one I"'tCl11 with chronk 
M.y20OS I Vo~ 3 lis .... S 102188 
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Tobie 1. Baseline characteristics of culture confirmed patients (pP ~n. lysl~l and culture negative patients. 
a..-1Kt.-ittkt Cu .... '. IbIIftff~d p .. , .... " • .e.ct .nth 
ClMHleDdA. .. - ,., 
Aotf!lC5.., tge in Jelf} &'~) 11 (2-1Q 
......,. of d.-. dt""od IS 1111 "dor 'S I'll 109 (75.2J 
N~offNll8~ 71 !I'll 
""d., ~gtlt WI ".'" (,..~fl) 2S IU-SS) 
............. tJon or'"- boo"" __ ,. d.,s ~.'901 , (2- ]0) 
Nwnbw of .. t .... a who ""fJttfd ptf! M8'11~· 21 ( ' 4.5) 
tdlWI ttrmpetl.b.lrt .1 ~siotI ., "C ""9') )907~Sl 
Hc!!p.~. nl6W\"ofp liff"tt("-l 69 ,,7.6l 
~,""-oIp.:IofI1S1!I/ 1701 .1) A_" ""In. .. .- of P'"'''''' 1111 IQ (l6.S) 
WttIg~t klu numb ... of pat~tt ("ij 69~7.6l 
Yon'Iiting. r"~ of p;ttMl!nts f'W Q tl2AI 
OY_~ ~ 01 poI .... u I'll ts /6S.Sl 
Mid ~cIc .. runb. 01 pMionlS I'W 124&ll 
tJf!d., hHm «,it In ,. (r'-SfOl l4.l 11 9.1-SU) 
11« .. " ..... ,al ((Lit\. 10'A ~ 6.9 (2-17.2) 
,,_ pbI .... coun~ 10'1\. (')SOlo C~ 001)0) In !l4-SOO) 
II"" AST, U,UIr\9fII IS (16.9-773) 
".«1", ALT, VI\. hrgo) 6''''1OJ-Z76) 
_. 01 S.",I>iISpor."pN A lJoIa:od lam blood , .. , ..... loWl 
11/124 (1.9) 
AST. -. .. Aspoomt. An""." .. .,,... AST ., .. "., oq., 1-30 U/U. 
AU. $Mom AI.,.. .... Am"'OO~."H AU Inofmil r1lf'!g& IJ.-40 UIU 
"rftt,:mtnt wuh arnorkll.n. Of cot~. prior 10 hoipital tdmiUlClf'l. 
dotl o. 371/joumat.poN.000l ' ... :OO 
Table 2. 
Azi" __ ~ ,, _ 142 
11 (1"') 
10' (71." 
160l.Sl 
24.5 (U-S7) 
, (2-3Ol 
'I (127) 
J'I(l1..1-4l1 
61 (4«) 
14 \7.1) 
760Ul 
71 (SO) 
S4 (JI) 
12 07.7) 
20(14 ') 
34.6 (2O.7-Q).S) 
7 OS (2A-1Ul 
1723 IOS-571) 
72 (17 ... 1190) 
.59.4 ('1G.2-~ 
lW< 
611 • (5.1) 
Trdbfteftt ... (n _ ~1) 
r .... ., O!.-art. nnw In hours (t\~ Ol 
<MR! ~_ Wur .. ou-.. of pd"," I!Ol 
Old not cornpl'!t. ""I t(e~ (ours.. " I'W 
~,"kil .. klrt,,,j 
''''crolJlologIQl r ...... . "") 
1yp/'od _ .... d <0mp6codofl. n I'll 
~tr "~~ blHldlnO __ u 
u- cIyWna"'" 
IW.lpw ,,~ ""Nn;' r ..... ".~.I, • (!O) 
.,.,.- d pllonu ... " , ..... Q'rI>G' ., f .. "" 14>. n "'I 
·P.tief'!rt GIl f it ., fMf~ tt- M. ~bw"901Y 
.... Iaad .... . 1U Adhr..,.". .. . 141. 
106 (90-1111 106(""2) 
')Il4S I9l 131140111.3\' 
0 2 
6114S (4.3) 6/140~ 
lil0 ~ OJ 1I14D (2.2) 
01145 (0) 1/1«1 (5.7) 
• 
0 
411)7 Q'Il 11127t>J 
11m (07) IIi'll 101 
'0- "' ..... "'so "... ; UI1 42 1 1 ~') Jho .......... 11 ... ,....01 fa .... "' tN nliIwomydn g""'p, k"l .... 1<>t p - D.570. 
"Thep""'t.eb~on dvlog. sL 
.r". p y.~. \1 bm«l 0(1 filM'" uxt tesL 
\: -.d '" pMlM-ti who .r.«N»d r te_ two Wow '4l "'.t'\. 
doclo. ' 3111l ....... .pono 000l' _!002 
.ood "., .... negllll .. 
patMnt4 ,, - 70 
912-0;!l 
S611O) 
29 lOll 
,lj (10.1-53) 
71.1-301 
'6Q2." 
lR7S 01-00) 
301S'A) 
2 (2.9) 
~, lOlA) 
21 (:lO) 
,. (l7 ' ) 
49 (71)) 
1 (t Al 
34J 124-." 
7.25 Q"-l1.n 
20001_ 
SQ.l (1 1-5)3) 
44 ' (10-J", 
0 
~V_ 
098. 
0.1" 
1.000' 
0"",,' 
0,003" 
0052 
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• 10 12 ,. 
l1ME AFTER rTAltT Of TREATMENT 1OAY8l 
Numbers. ~.k 
AzithtCmyc:on 1.2 133 71 42 17 1 
GalJlloxadn 145 132 92 43 18 3 
ng~r. 2. "--'on of cultur. "..,,.. .... d potlentl ttli febrll .. K.plloHo1~"r ,urvivll OJM! stlowing .h. p.epotticn of cukur~ "","'mod 
patient. (pP .. olysio) still febrile through time by I",obnent g.oup. 
dol; 1 0.1 311I)curNI.~ .oo021aa.g002 
f~ <.mage w .. detected after 6 months (An Ciang ""ely silt), 
the ~tienI had recdvcd gl1il1oucin. 
In the lIT a.wy,is (all 358 nndomilCd Iien,,),..,cnll 
trca1mUI' failure "'OJ reponed in 13 oul at 185 (7%) in the 
gatilloncin group <ornpared 10 I + out of 168 (8 ... %) in th. 
0.00 
a 
uiu.romydn grOllp QOS"w .est 1=0.615, HR. (95% 01) = 0.82 
[0.39-\.76]). On. cuJrure nega.ive patient in the .. itIlromydn 
gro.., hod a poeitiv. blood culture on day- 7 after ,tan of 
lIUtment. 'There W<Ie no clinical hilures CD' typhoid fe...r-related 
complications ill the culture negative potients_ 
10 12 14 
l1ME AlTER START OF TREA'NEHl' (DAYS, 
No.mbtra • tlak 
AzIII1Iomycin 112 ,ST 8& 4, 18 1 
G.ifIo .... n 186 ISII 91 49 18 3 
flgu •• S. I'rcIpar1iOft of I II rand_l. ed ""tient> .liIllebrll .. Kilplan-Meier survival cu"'" showing the proponion '" all .. ndomised patients 
(m on.lysls) .. II f.b"l. th.ough ti'll. by ~ .. tm.nt group. 
doo;IO.1l711jolJm l.pon~.oo02'I8.g00] 
:~: PlcS ONE I _ .plo",necrg 
.. 
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0.15 
II) ; 
... 
~ 
... 
~ 0.10 ATlTIIROIIYOH 
= 
-' 
---------------~ 
~ GAnFLOXAO N 
~ om 
a 
.. I ~ J 
... 
0 0 
'" ... 0 20 .0 6G 80 tOO 120 140 
TIM AFTER START OF TREATMENT (DAYS) 
Numb." 01 risk 
Aztthromvcin 142 
GoUOI<8cln 1~ 
12" 
130 
121 
128 
119 
128 
11& 
127 
~1 
GO 
49 
58 
47 
52 
Flgur. 04. PropCll'tlon of plltlents with ovenl falur. In t he cUtur. confirmed populltlon. Koplan-Mel .. 1U1V ....... curve ,howlng the 
,",oportlCn d pot",nll with overall (a,lu", In Ihe cultur. conformed population (I'P . nalysil;) by t ... tmen! group. 
dOl: 1 O.1371I)oum.l.pon • .oo02188.gOll4 
Adverse ellenls 
Both tre.=11 wen: well toleraled. One &dversc event related 
10 azithramycin Will reported, a maclllop,pular rash ~t occurred 
aftu the ftnt cIooe of treatment. Asilhromycin was dioconlinucd 
imn:I.edi>Wy ;and the patient ..... II ate<! with ceftrWcone. 
Gastroint(ltirl2l side-dfects (change: in consist=y ;and frequen-
cy of 'lOalt) ~t were p-obobJy typhoid feV'CT ,~ted were 
relatively frequenl in both trcalmcnl arml al the ctart of treatment. 
In the gatiIloucin group, one: patient oxpcriellced "",mili~ on d>y 
2 and day 3 ;and one patient diarrhoea (~ cpioode$l'day) on day ~ 
and. day 5 of treotmenL 1'h.e$e <pi.od .. ..,c • ..li.limiting and did 
not require the intCTTUption of thcapy. 
The median IevdJ of JCI'UIIl AS T and AL T fell in both 8"""1" 
aftu 7 days of thaapy. Tn the PP group, the median poet. 
trea1mU1t AST -.. ~6.35 u/L (range 12.8-217.5) in the 
gotiiloucin ann. and ~5 U/L (range: 5-358) in the atithromycin 
arm. The median pM tre.tment ALT fell to t6.S U/L (range 
7.4-278) ;and ~.g (1.1-~i), ... pcc.tivcly. In the cullUTe-neptive 
p .. iLnlJ, the ~ p<lIl-tre.atrneClt AST was H.S U/L (rona' 
12-65~) and ALT was ~ UlL Me I <H2H). 
Antimicrobial su ceplibililies of S. typhi and S. poraryphi 
A isolales 
From the PP popWalion, 282 (93%) S. /l'PAi ;and 5 (n.) s. 
P<m!1PAi A strain .... ce ilolllt.d. 'TWo hundred .nd .ixty three S. 
!JPIU;and 5 .£ jXUl1IJIIU A were received II the Hoopit..! for'I'ropical 
DiJcaIa for anlimicrobial IUsceptibDily IC$Ung. 
FIft)I-eight percent of the S. l)I>!ti. isolates were MDR and 96% 
were rI2lidixic acid resimnl and ,howed reduced sU5eeptibility 10 
the older generation Duoroquinoloncs (I'ohle 3~ However 
te<hni.cally, using current CLSY breUpoint., all isolate. rcnained 
IUsceptible in vim> 10 elpl'Olloxacin and oJIoucin. The MIa.. of 
gatiiloucin woo the lowest of oJ] the fluoroquinolone. te.ted .t 
:~: PLoS ONE J _.p/osone.org 
0.19 flS/mL (range O.OO4-0.5} All isolat .. were 1U6C<ptble to 
ceftrWcone. 
The 5 S. p4 .. !JIfti. A straW were fully susceplible 10 all the 
antimiaobiaJ.lested. 
Discussion 
Interpretation 
The ,esults of this trW show that both antlbiOticl worked wdl 
for the tratrnent of MDR. and nalidixic acid resistanl typhoid 
fi:,.oer in Vietnam. A leven day or.al coune of gotifk>xa.cin had 
similar efficacy and lafety .... """n day coune of uithromycin. 
which is rec.ommended for the troattnent of MDR. and nalidixic 
acid ~islanl typhoid fe .. , f7 ,9) . 
However, utthromycin is not available throughout much of the 
de\ltloping world and it u expenlive. The cost. of a ' -day 
treatment coune of gatiDoxacin (at 10 mglltg/day) for an odult 
po.ti.cnl in Vietnam ore appro:<imately 25 USI , the co,l, of 
.. ithromycin (at 20 mglkg/day) are more run 90 Un 
The resulu far gatiiloucin in this trial ore comparable 10 the 
e:s:cenent clinicAl (IIltcomes achieved with otlcttatin in Vietnam in 
the early 19900. when S. !7JIID isolata were .tiD susceptble 10 
nalidixic. acid [\7-19) . 
CatiJloxacin /ta •• higher affinity to GyrA and is len inhibited 
by the common mutatiolll in the 0rA gme [20). The gatilloxacin 
MIC~ o( the StUdy ilolate. was 0.19 jJ.g/mL compared 10 the 
o:dloucin. MIC,. of 0.15 IIgImL. We would not recommend the 
continued use of the oldc generation lIuoroquinolone. (ofloxacin 
and ciprot1oxacin) in regien. with high rate. of nalidixic acid 
TCWtant typhoid fevc for f .... of ..lecting further mutationJ in 
tpA (2 l). 'Th4 could put II ris~ the potential eliniaJ benefit of the 
newer JJuoroqUinoJollC'. includin& gatillo:&acin. 
There have been sev.:ral Cale report. of gatilloJw:in-a&SOciated 
dy1gJyccmia in patientS with type n diabetes mellitus, ove.tWcight 
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T,..tm..,t efTyPhoid f~r 
0.05 
~ 
... 
!i 
~ 
on 
~ 
-' 
... 0.112:1 GATlfLOXAON 
'" ... 0 
z 
0 
ii 
f 
~ 
~ 
AlITHROMVCIN 
0 
u ~ ~ ~ ~ 
liME AFTER COMPLEllON OF TREATMENT (DAys) 
127 
137 
1~ 
134 
123 
129 
122 
128 
122 
126 
121 
126 
110 
lIS 
52 
57 
,.,IIf. S. , ... ,,,.,,,"" of potlt"" with r.p .. III the <u.ur • ....".",-.1 ........ lotIon. K • .,..r>M .... "'MYII curv. showllg the pr()j)Ortion of 
"",lent. witII ",lop ... In 1M <ulnHe confirmed peputnbn (PP lnaly<ts) by tnoiltml!<lt greup. 
dOl:l 0.1 J71f",urNl.pooe.ooOZIlS,gOOS 
or with oW:r com.orbidity Cl2- 2+J. Rec ~~y there ha,.. bun 
concuns abo t the \lit of II"titlce<acln, .ncr a rettospecti .... cue 
contrOl SIIldy in 1.+ million individuoJ. 0"" the age of 66 yUrt 
(plein 18" 77 yun) in C."..u "' .. JNblished (25J. 
IU our ttW was completed before publicallon of tIus report, "" 
did no' systemat' y monitor for h)VD- and hypcrglywniL 
8loodgluCOlc Ievds ui n as p>T1 of the routine ClJ'e~ oomW. 
All parientl """ l'IWUOl:<d. .. inl'.ui.cnu and poten i.lI oymPC(llt\S 
of Irypo- and lIypetJlytemi;a would ha .... been noted by the study 
physiciNta. No dyltjlyeemn even" were reporttd during .he in· 
pllitnt period 0: durItIg the follow penod cI , to 6 months. 
The p .. ",n,. in OW' trial wac hulthy, }'<lung .nd non·obete 
individllals. A triAl in 861 chadron with otitis me~ with sluCCle 
monitoring and one you foDOW"\Ip Cl6), .. well as a r=. 
enteric (typhoid and para oi<O fe"", trw in Nepal used 
g>tdloucin and <fid not rcpon ony d 1ycc:mia (10). To our 
sellin( and in 0\Il' paticAl population ptinaucin waJ highly 
effective ~~e ""'Y . h r let of dru retiftiU\ .. and WIt well 
IOla.ted. 
Other ocwa geocnnon lhle><oqlllooloacs, l.. arulIoucio and 
moxi1loucin have shown low MIC, for nalldW: . resistant S. 
ptAi and I"a# A ( II J. uofOnuOllely Cle drug< = not 
.vailablG in "trW'I\ and they arc considerably ~ ""Penlive. 
The in vilro ruulu JCC n with thc.c othrx newer generation 
lhloroquin.o1Dnu should be evw..,ed in clWal ti 
Genera Zilblnty 
The aoergenu cI.w1dW: acid resistant S IJIIIu and S. ~Itl 
A with Teduced ru~pn'bmty '0 the fluoTOQuinolonet is • 
w¥ltJpread problem throughout La and therefore OW' study is 
relevanl o.lIt. whole reJion (2.6] Many ease reporu and """e 
randomiKd eontroDed trw. halll: described the ........ ~ clinical 
re..oponse til cip'ofioucin and o1loxa= (8.27,78J. 
::fj.: PleS ONE I wwwplo.,ne.crg 
. . 
The ocuch for e.Jfective antibiotia to tTelII typhoid fC\leJ' it 
impaonvt. 
TypicaJly trw. in typhoid ft:ver are limited by mWI sample 
.l .... a recen' Cochrone Rcpon has streued the nw:! for large 
weII·designed trials in enteric fova (29). The evidence from our 
trial ia otreogthenc.d by .. sample sile of 287 patien" with culture 
eonfumed 1yphoid fever (356 p .. ient. raodcmised), which we 
believe is .0 far the largest RCT penonned in ryphoid feva. 
Both an.ibiotQ al worked ~I for the patic.ots with OC8'l1ive 
blood cultures. This it ." impanant finding bCCil\lte the seruitivity 
of bJood culture for the diagnosi! d typhoid feva is only 
.PI"""lmarely 50 '0 80% (9). 
Llmitilt ions of the study 
The randomisation sequence WlS genaoted WM a large bloclc 
.i.e of So, whiclt resuherl in uneven nUJTtben in the two nu.tmt.nt 
gro..,. (186 venu. 172 patients in the lIT populalion~ 
0"" pOi sible limitAtion"," the lownle ef.tool Clll.llJ'CI positive 
for S. !J1I.i Faee.al urrioge is UluoJIy c.haracterited by interminent 
shedding .nd the stool eulture for S. !1#u ia not ""'Y I(.",itive. 
When comparing our data with otha .rum.. that dcmon.lnle 
that :l2ithromycio it highly elfu:aciou. fer.he nu.tmGnt of typhon 
fever .... e find similar low rates of faeW carriage at fonow·up 
p .SO). I. could be hypothesised that antibioria thaI ohow high 
IIltra<dluJar concentrations and &ood tissue pe.nUration like 
.. ,thromyt'" and the fiucroquinolonel. achieve rapid bacteri>l 
lWIing and elimination throughOUl the body, whiclt re.ducea far:caI 
...,.,.. 
The dose of gatiflo::ucio >.Cd uithromyein UbletJ III ... prefW'ed 
by urdul c:utting of the tabletl (p<oponion. of. the table" 
admin"tued were rcearned in lhe CRF.~ Inevitably, it w .. 
thudol'O 11\ estimation of the <Del dOle, hence we cannot 
gu3J"a/ltee that each p;llieot received <D~y 10 mglkgl d~y of 
tifloucin or 20 mg/kg/.uy cI uithromycin. 
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... lIMnt of Typhoid F""", 
Table J. Antimicrobial susceptibilities and minimum Inhibitory concentrations [MIQ of 263 So typhl isolate. 
~ct'4 Ndlurc. rtun"O.i 
... KId""~~., N 
AmoIdd .. _____ _ 
c;.,,'~"""",.,'_ ____ _ 
MlCSO 0J9IWII) 
MlCtoO>g.'mO 
, gt"qIMIl 
MIC so 0J9IWII) 
MlCto~ 
W"'" 
MIl: so IPgtml) 
MIC to mil 
, .. gt~1 
so I\Ig/mI) 
MIl: to mil 
'''91 l1Vlmf) 
MIC so "q/"'" 
MIl: to gimO 
".,.'mI1 
MlC so "glmIl 
MlCto gimO 
WMil 
MIC so "qIMIl 
MIC to 0IgImII 
,rqo"giInIl 
so 0IgImII 
MIC to "9ImO 
,_"""'" 
AlII ....... 
"_21.1 
ISJ GIl 
U4(9U) 
2.141 
> 2.141 
0.11510 >256 
>)54 
'ZS6 
OJI to ;o,2Sd 
>2.141 
> 2.141 
1$ to >1.S4 
0~5 
IJ 
0.023-2 
CUI 
OJ 
0004-0.75 
0.125 
0.19 
D.OO4-C.S 
o.lIS 
o.ln 
0.Q04.42S 
11 
1.5-16 
T,tlllnent with G_ 
ADIIw_1n 
"_1$7 "-11. 
11 "lSI "t>U) 
132196..1) 121 196) 
>256 »56 
>254 > 2.141 
OS to >2Sfi 012$ tel >25& 
»56 > 2.141 
>256 >256 
lto >256 Q.l8 to >2$6 
> 254 >2.54 
> 2.56 > 2.141 
t.S to >256 1.5 10 > 256 
.. '" 
, .5 1.1 
0.0.11-2 .. 023-2 
G..lI O.ll 
O.S OJ 
o OM-O.75 • ......, 18 
0.125 0.125 
0," 0.19 
O.~ O~J 
0 115 OJlS 
0 125 0.19 
0.06404.19 o.-.us 
12 12 
I,S-I. 4-16 
of • Df9I"kmc ~Ivl!tv .,~ ..... bt.t MOM Is dPftrrMId ~ ""ods"CI! to ctI~hMk:ci, ampki.n a.,d 
.~ sA"" CUI I'IC "' ....... I0I0 .... '" c/IIo(,""","""oI. amplclbn ",d NI<Il<ic Kid , .... ..,(0 '2 PII''mL; _In "nd g.ij~ ... dn 
5 2 PSi"'L ,_III. rd &II. ... ,_~ dpoIoXKln • I _l""'OIItlbio and pgIml """_ aftt1I>Icr>. s a ~ lUl<optlll •• nd ~ pgiMl 
~...,t. tt.n MWftOf'"e'Of_~ 
doI;lo. )71" ........ _OOCUI .. :OO.I 
10 
Ihe indep<nd,nt 0:110 and Safety {onitoring mmitttt I 
re.ul, die pooo' clinicAIl'dp"" in dl< paUtnll randomisl:d to 
Ctr.ximt. 
W. boli.ve Oll' 00.;' of tlu .nd o,he. "'<Lotly publi>.hed 
1ri3.J.s, thar rruitloxttcin or uithromyon re now the tnanmnb of 
choict r tn' ric r. r in .ea of MDR nd naJidi'lic 
rt$isbA. e [7,8,10]. liowevtr it is important to 1I!e tl~l. 
ant imicrobial ge.nu cautioldty bc.c:aUIC incfucriminatc we would 
inevinobly indue< funhe. n:mtance. 
Supporting Information 
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BJ STUDY NOTES 
.'\ ' E RE RD FORM ED FOR THE GATlFLOXAClN J,'l."'R$US 
AZITrmOMYCTN TypnOID FEVER TRfAL DESCRIDED IN CHAPTER 2 
I, P \TlE"" DET IV 
P TI ' M ' 
.' TIlER :\IE: (If palltnl thUd) 
;\IOTtTF.R 11"..: 
(if pIIll nl chIld) 
()J , unv 0: 
DATE OF ITRYTO 
~"'UD\': 
U 'P1TAL 1JlER: 
' 1£:: ': tALE I FEMALE 
CE: YEARS. 
--
• TJO : 
ADD •. 0 ITAl Flo number: Telephone number: 
Rood 
To\\nJ II) . Mobile number: 
OlSnct 'Province: 
.\Don Of:TAIT 110 'nwnber' 
Telephone nllmber: 
Rood 
To, Ili 1\ ' 
Mobile number: 
On 'Provtnce. 
llJ IT D\, 
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INFORMATION SHEET 
OXTREC No: BJ 
lU ___ _ 
An open randomized compMi on of Azithromycin versus Gatilloxacin for the treatment of 
uncomplicated coteric fever 
Introduction to Ih ludy 
ou (or) ur child) are being. ked to be in a re earch study on typhoid fever. Typhoid fever is II 
serious infection and in i t am i now becoming very difficult 10 treat. This study i~ de igned to see 
if, e n improve the treatment of typhoid fever. 
Blood Test : 
\Vbcther or not '0 11 take p.1rt in the study you wiU be given the S30le standard of care for your 
illn . If ou wi h to take p:u1 in the rudy we will randomize the treatment you receive to one of two 
altemativl: . We d notl'llow, hi h one you, ill receive or which is the best treatment. We believe 
both Irea1men to be ctfective. We \ ill k to take blood and stool amples during your stay in hospital 
and fOl' th nC,'d 6 month after u arc discharged from hospital to ensure that you have cleared the 
in1i ti n. This is va)' imp ant to ensure th t our family and friends arc not at ri k of infection. We 
will tudy the cell in the bl d that protect you against infection and also your genes to try and 
und tand wh u gol i ' . TIl bl will be tored in II freezer at the Hospital for Tropical Di II 
in Ito i [inh ity. Funher test on thClie stored samplCli rna be undertaken in the future to further 
the understanding oflhi disc c. 
nfidmtlaJlty 
Wc ill keep the inform tion \\ c get from ou lUI pri ate. Your nanle; will nol be on your 1m results-
we will usc a number instcad of our Mmc. 111 results of your blood tests will be told only to your 
doc r. Thcs resul ,in be under tit Duthonl and upervi ion of U doctor responsible for your 
inp.1ti nl can:. Your doctor, ill di cus Ul e rcsulm with ·ou. All this information will be kept 
confidential in . ur medical ree Your name will not be mentioned in any papers or speeches abolll 
the Iud . 
R1 
BJSTI.OY 
in our study. 11th drug being used in this study lIrc 
n edl wiU hurt for a moment, and rM 1 ve a bruise. 
about Uu; stud pl1;4 e l tile doctor on the ward or Ute doclorl named 
diJ . PIe e k any nurse or doctor who will help you) 
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COl SeNT FORM: 
BJ ____ _ 
OXTRRC No: BJ: 
,\n open r:sndomil.ed IlOmpari on of .\zithromy in ver us Gatiiloxa in for the treatment of 
uncompli at d ent ric fever 
Con I (rom p t" nl: 
I ha\ heera full. infonned fthe possibl risks and benefits ofWdng part in this stud)' and 
<I roc I:Ik p.ut. I SI'OC t/ul th ampl may be slored and tllal further lests may be underuken 
on tht:s mpl in the futun: 10 further tho: understanding of this dise3Se. 
e ofpati t 
Sigml D3Ie: ________ _ 
:\ m of ph i ian 
SigtUturc: __ Dah:: ________ _ 
nl In I p ,.1 In Ihe Irial bul i unable to ign, Ihe physician can 
. 'arne f ph i Uln: ______________ Si~3w 
DIe: 
\ erN I ~t: 
cd when the palient is unable to give consent because the patient 
I ha\C full inJbnn f th~ ld beraclirs of this ludy. I gree that my rebtive 
1Il.1 • 131..o part in III Iud . 
. '~ bti, : ______________________________________ _ 
RcbliOinhip \lith P II nl: ________________________________ _ 
D te: _________ _ 
• '~e fplt . un: 
igrulUN: DIe: ________ _ 
BJ IT [)\ 3 
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PLEA ENOTE,THE PATlENT AN ONLY ENTER THE STUDY IF THE ON ENT 
FORM HAS BEEN SIGNED 
2 mSTORY BJ 
RCllJlons for coming to ho pit al: Duration of illness (days): 
Duration ofsymploms (record days. 0 - nol reported) 
Fever: Cough: Const ip~tion: 
HeacL,chc: Di3JThoc:.'l: Vomiting: 
Weight loss: Abdominal pain: Convulsions: 
Anyolller ignifiCOlnt ymptom. : 
Past History 
Previous typhoid: Y / N Diabetes: Y I N 
Date ifY : DllteifYcs: 
Family mt'mller with typhoid : Y I N TB: Y I N 
Dille ifYc : DllteifYes: 
Typhoid vaccination : Y I N Hepatitis: : Y I N 
D~te ifYe ': Date if Yes: 
Drug addict: Y / N Any daily medication necessary: Y I N 
Ifyt. 
Drug 
Allergy 10 drugs: Y I . I 01 known Dose 
rr yes: Dr u g: omll tV I t m, 
Treatmenl in the IlL,1 2 weeks 
Y / N / Not known 
DateifYe: 
Antibiotics (drug and do. e): 
Other treatment (drug and dose): 
Wbere: 
J. EX liN \ TION 
Mental tate: normal / agitated / confus d Jaundice: None / Mild I Mod / Severe 
GCS(GI gow Coma Score): Hepatomegaly: Y IN 
--
ItS If yes: __ cm 
T mperature: Splenomegaly: Y IN 
___ OC If)' : __ em 
Blood prcs.~ure: mmHg Rosooille: Y I N 
Pulse: I min StilT neck: Y I N 
BJ STUDY . DIeS 4 
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Respiratory rate: ___ !min Enlarged lymph nodes: Y I N 
Weight : 
--kg Abdominal tenderness: Y I N 
Height: 
---
em Any other : 
4. LTURI!: 
Blood culture Date: __ (0 --> Date: __ OJ--> Date: __ (0--> 
Result 
I Blood wll"" 
Result 
lllil. --OJ Illire _ OJ I~<_OJ 
I Stool roll"" 
Result 
Illi< __ OJ llli. ' - CO 10"0_ CO 
I Stool roll"" 
Rt.'!Iult 
llliro --(D Illi" -_co-r~--(D 
Bone marrow Date: _ (0--> Date: __ (D_ ) Oat :_ CO--> 
culture 
Result 
s. ITIDlOCRAM 
Bacteria isolated: S·lJpJri S.JNUllI)-pbi other (specify): 
From bloodl bone marrow! stool (pleo.ladkau) Date: 
Scns Nal acid Ollox Cipm Gati Ann Chlor Amp 
RorS 
~DC 
BJ STUDY • ot~s 5 
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6. BLOOD TESTS BJ 
Date: Result Date: Results Date Result 
Ullematocnt Ihematocrit I:lauu.tocrlt 
wue wue WBC 
Nrutropblh Ntutropblh Nrutrophlls 
Lymphoc)1H Lynlphoc)1u Lymphocytu 
Monoc)1es M.olMK)'ln Monocytu 
Eoslnopblh Eoslnopbih Eosinophil 
PIlItrlds J'lnlrlrts Plulrlels 
Sodium Sodium Sodium 
Crn'lnine CNlltlnlne Crutlnlne 
ASf/SGOT ASf/SC..oT ASf/SGOT 
ALT/SGPT ALT/SGPT ALT/SGPT 
Bilirubin rr Bilirubin Tr Bilirubin IT 
Bilirubin GT Bilirubin GT BUirublnGT 
BUN DUN BUN 
Glucose Glucose Glucose 
Dale: RI.' ull 011.11.': Results Date Result 
Sodium Sodlum Sodium 
Creatinine, Cnutlnlnr CNllllnint 
ASf/SGOT AST/SGOT ASf/SGOT 
ALT/SGPT Af,TfSGPT ALT/SGPT 
Uilirubin IT Bilirubin IT .Bilirubin IT 
Uilirubln GT Bilirubin GT BilirublnGT 
BUN BUN BUN 
Glucose Glucose Glucose 
BJSTUDYN~s 6 
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7. CHEST X-RAY (please ummarize most important lin ding) 
ChtMX-RlIy Date: __ (0-> Datc: __ (O-> Date: __ (0-> 
Rrsult 
8. OTHER TESTS 
F:.cG, kerp with notrs Date: __ ro-> Date: __ (D-> Dnte: __ (0-> 
Rr~u1t 
Date: __ (0-> Date: __ (0-> Datc: __ (0-> 
9. MANAGEME T 
Diagnosis: 
GencralllSSt'SSmclIl: Severe I Average I Mild 
Treatment prescribed: 
Start of treatment: date dose 
Complication: Yes I No 
COMPLICA TlONS Date Duration, level oflllncss, mlillagemmt 
GI bleeding 
Intestinal perforation 
Hepatitis/Cholecystitis 
Shock 
OCher 
10. HAND WRITTEN UMh'lAR' 
BJ STUDY . otes 7 
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STUDY OTES 8.J ___ _ 
o rd " ate 0 It mlSJlOn: 
Day I Day 2 Day 3 Day-4 
Date: Date: Date: Date: 
Antibiotic 
Dose (polimliv) 
Hours since tart 
treatmmt 
Time 6 12 18 24 6 12 18 U 6 12 18 2-4 6 12 18 24 
-40.0 
39.0 
Fever 
·C 38.0 
37.0 
36.0 
Pul.e rate 
Blood pressure 
Rl'Spiratory rate 
GCS 
Hepatomegaly 
Splenomegaly 
Diarrhoea 
Melaena 
RoseolaI.' 
BJ STUDY , otes 8 
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STUDY NOTES n.f ___ _ 
Date or admission ' 
DayS Day 6 Day 7 Day 8 
Date: Date: Dat.e: Date: 
Antibiotic 
Dose (polimliv) 
Hours since start 
trutment 
Time 6 12 18 24 6 12 18 ~ 6 12 18 2 .. 6 12 18 2 .. 
40.0 
39.0 
Fenr 
'c 3&0 
37.0 
36.0 
Pul e rate 
Blood pressure 
Rrspiratory rate 
GCS 
Hepatomegaly 
Splenomegaly 
Diarrhoea 
Melaena 
Roseohae 
BJ STUDY . ot.:s 9 
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STIJDY NOTES B.J ___ ---'-
Dale or admission· 
Day 9 Day 10 Day 11 Day 12 
Dale: Dale: Dale: Dale: 
Antibiotic 
Dose (polimliv) 
Hours since start 
Ireatmenl 
Time 6 12 18 24 6 12 18 24 6 12 .18 24 6 12 18 24 
40.0 
39.0 
Fe~·er 
'e 38.0 
37.0 
36.0 
Pulse r ate 
Blood preMure 
R piratory raIl' 
GCS 
Hepatomegaly 
Spl nomega/y 
Diarrhoea 
Melaena 
Roseolac 
BJ STUDY . Ole! 10 
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ADl\lISSION OurCOME J)J, _ _ _ _ 
Uncompli ated recovery? Y I N Fever c1earanc:c time: (Timefrom Ih~ start of 
/reatmmt /lntil tllil temp.fall3 beloll' 37.YC and 
II' 0, describe: Nmains at or below 37. 5" f or at leasl48 hOl/r. ~ 
-
hours 
Duration ohntibiotic treatment: (days) 
Treatment failure: Clin ical (fb\'Cf after 7 days of treatment) Yes/No 
l\licrobiological (positive stool culture on dny 9) 
YcslNo 
Date of death: 
Date of discharge: 
SIDE· EFFECTS OF STIJDY DR GS 
SIDE-EFFECTS Yes! Nfl 
SIDE E}' FECTS Date Duration, lev I of illness, management 
Allergic react ion 
Nausea 
Vomiting 
Headache 
Others 
BJ STUDY, otes II 
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FOLLOW-UP 
Follow-up I after I MONTH 
Date:, _______ _ 
Time since fin.ished treatment : _______ (days) 
Compla int : _________________________ _ 
Clinical c::.umination:, ______________________ _ 
Temperature : _____ _ 
Other symptom 
Relap. e: Yes/No 
COmments: _________________________ _ 
Stool culture (I sampl ) : ____ _ 
Faecal carriage: Yes/ 0 
Name ofdoc1or _______________ -'Dale: ______ _ 
Follow-up 2 after 3 MONTH 
Dale:, _______ _ 
Tune sincc fini hed treatment : ________ (days) 
COmp~in t : ________________________ _ 
Clinical cxamination: ___ _ 
Temperature : _____ 0 C 
Other symptom 
Relapse: Yes/No 
Comments : 
Stool culture (1 samplc) : _ ___ _ 
Faecal carriage: esll 0 
Name ordoc1or ________________ Date: ______ _ 
BJ STUDY , <XeS 12 
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Follow-up 3 afttT 6MO ITH 
D3te :, _______ _ 
Time sinee fini hed treatment : ________ (days) 
omplaint : _________________________ __ 
lini~l~min3ti n:, ______________________ _ 
Temperature : ____ _ 
Other symptoms : _______________________ _ 
Relapse: Yes/No 
Comment. : ________________________ _ 
Stool culture ( I ample) : ____ _ 
Faccal carriage: Yc:sINo 
~ame ofdoctor ________________ Dale: ______ _ 
BJ STUDY , ole! \3 
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Antimicr bial Drug Re i tance of almonella em'ri (f S 
Asia and M I cular Mechani m 
t the Flu 
Vol. ~ I • • I~ 
r var Typhi in 
ptibility 
q 
!{ 
4316 CH lIT AI~ 
tant to n:iliditic acid (the prototype quinolooe, ",:hich is used 
r r in ilro screening t ~ ... ) and sbOIKed duoed SllICepllbUby 
to the tluoroquioolou have been reponed sub uently in a 
lIumber oC CQunt n (25). ictrl3fll alld part icula,f) tll 
M"kong Dell:! region of Vietnam !aced 3 ri..:s oC t}llh id 
[ever epidemics over I be 13~1 de de, unpo d on :I bock· 
round of end"mic d''-!UC, Ibal ,.:OeC! d dtan ' tu re . 
Lance pallCrru and pOinled 10 " seriouo probl m of dIU 
re~l!!tance (24). MDR ",a'!lOCillU~d .. illl a tran ftr:abl.,pln • 
mid (36), whue reduced 1IU.Icept.bil.ty I the OuoroqUIDOI • 
nes in serovar Typbi is usually anocialed ""tb polOI mula-
Ii 110 in the batlennl larget gene, encooin& D 1\ 
aDd/or DNA topoL50m~raJe IV. 
Th" study de croo lM magnitude and pattem of druS 
resistance in 1.393 ser 'at TypIu stLaios oowted (rom IWl to 
200S in Viclo.1m and (rom a CroSHec1lOlllIl sample or 81 
fOV31 Typhl runins oolated in :nl2 to 2 in l8ht AsI3Q 
counlr' (Il1ngJadc5b. (bina. India. IlIdcoc-Sla. Lao • pal. 
Paki$lan, and cenlral Vielnam). Th e munln.".,.., bom 10 
more lbnn 80'" of Ihe world'5 l)"boJd fe.er ~ (II). e 
dermed the m lecula, mecb;.nism of nalidL'ri<: acid r L,hnaJ 
IIDd performed in vitro bacterial time-kill rim 01 .. -itb 
, I lea thaI haro red Ihe Ct'mmon mutatwos U1 tht' ".'1 sen . 
The timc,1dll perimcnll aDo .. -cd us to model the impact of 
the &\,,,11 mulnliom on the lune course of the 'IIltumcr(lbw 
eft< ctJ DC older (oHoxacia) and De1''er-genCf tioa .rllauclo) 
fluo r.oqu inolonu 
(1'hi5 I100rt wu presented in part al th American!.1 llll$. 
of Hygi DC and Tropical M dicmc, 1an18. G Dcoctnbcr 
200S.) 
I 
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51 21' :an to I2t IlJ ,. J1 I. 
" 
11 .. ., a ToIII(lm) 
1- OMDR 
-
o NlIIlIio 1Gt11'HIoIatc 
-
-
I --40% 
-
-10'16 
n 0'16 :l J b 
tJtl 19904 1m I'" tJt1 an I'" 2001 2001 JCI02 lGOI _ 300$ FlO. 1. J\Jltimjcrobial drug rtsWan« of ="''''" TypIlJ strains lfOIat<d during clitua1l studle. in "",111= V'OlDlItIl from 1993 to. ~. 
PtrccDJagcs of MDR aDd oalid1.tic ncid.rcs,Sl.nt serovnr Typhi isolatcs. The number uI isolates from eacb ycnr .. "'~'''' on top of III ""',. 
to obuin 8 1( .~ )( , 2x. and 1x MIC. The gtowth coouol (.Ofltlined ooootibiotk. 
Tile (..'uttureswere inruba~4 1l lS to Ire for h. Viable ooualJwe:re ma..Jred 
mlme<1i3Jely prior 10 the addition Dr tbe amblaclc and at 30 rain and 1,1,",6, 
8. Ind24 h after t.he addiljon o(the antibiotk. ViJbbcounuwreJepcrformed by 
uslJ, We Mb and Miua t«blUque 011 outtieOI . ,at ptuel rouowio& actial 
kJllo. iI1 muxirnuIU' '''''ClweIY diluellb (Oxoid, U.ited Klogdolll). be loWer 
bmil 0( de''''lIOn .... ' 10' CFU/ml. 
udl'!Ofi,je JetjUMC':t aC'tH •• n numbt ... .t. The panial 0 A te<pJeRCes o( ,he 
".A aeae of .,"'''''' 'l}"",i AO 152 and ur 18 b,,,, be<o IO&iIre .. d in Ill< 
G< .. ll3nk nucloouli>""lue ...... datll>3:icun r U""""""/on numlle" EF6Sil160 
Old BF6Ii0461, """""th~ly. 
RESUL.TS 
Antlmlaoblal susceptibility teslin«. (I) Serour Typhl Iso 
bled In southern Vietnam from 1993 to 2005. Between 1993 
and 2005, 1, 93 isolates of serovar Typhi were co llected (Fig. 
I). The proportion of MDR serovar Typhi ""Ill 63.2% (36/57 
/'RiM) in 1993 and increased to more than 80% in the late 
19903 and e:u1y 2000 . .During the same period, there WM a 
dramatic increa.,e in nalld~ic acid resistance. In t99", 2 out of 
57 (3.5~) serovar Typhi isolat~ from patients in southern 
~ NalidiXIC acid · MIC 01 ciproftoxa<in (,.gill) C""nlty reshunt i&oIalC:lJl' R .. !lO S~ 
Cblna 4.8 (1/21) 0.~.25 0.015 0.03 0 
!noon ..... 0(0/17) 0.()()?--O.n3 0.015 0.0 1.3 Q 
Laos 0(0150) 0.006-0.023 0.012 0.016 0 
B"ngladub 40 (16140) 0.006-0.38 0.025 0.38 0 
Iodla 47.S (ll!23) 0.006-0.25 0.094 0.25 0 
Vietnam were nalidixic acid rcsistllnt (r p.:ctivl 
Iloxacin, 0.250 and O. L25 ILg/ml) (l7). IIlidi,ic acid fc..'; Ian 
snrged to 88.6% (109/123) in I 98. It h !'tmain I hJ8h 
levels since then, with 97% (196/202) of ~ Int sin • Sin 
1998, a hi8h proporti II of trains 1m .... the combuUlllull of 
MDR and nalidixic acid resistance (Fig. I). 
The antimicrobial susceptibility data of 202 Mrovar Typhl 
isola led in 2004 in ~ut.hem V,etuam are :w()\\n 111 m n ... deluU 
in Table 2. 
(II) Suovar Typbl stralDS Isolated In "lIbt Asia" ~ounllies 
lu 2002 1o 2004. The autiImcrobial su ephbilitie of 3 J 
var Typb.i uolate. collected in 2002 to 2 4 from eight n 
countri" .. 'ere analy'led (T8bl' 2). There \\(rc varioWl rut·~ r 
MDR aero&! the il rtlnging from 16% (lYSO) of ' ute 
from Laos to :'17.5% ( 15/40) from B:mglad h. Chin nd In-
donesia were exceptioos, with no MDR erovar Typhl identi-
fied . 
Tho pafcenUl&e of nalidixic acid-re i!t nt r 'or Typhl 
isolates ranged from (j<'f, in Indonesia Md Laos nd 4.8'" 
(1/21) in China to 51% (76/14Q) in Nepal (Table 2). Th 
o (MIl 
0(0/17 
1819i$0) 
40 16/40) 
Nepol 1 (76J~ 0.002 32 0.125 O . . 4 (6/149) . 6 ~6,':l3) 19 l40) 
Palu$l(UI 38.3 (1 ) O. - 0.25 0.012 0.25 0 26. (9i34) U lQ.'3~ ) 
oJrai Vietnam lO (23/47) 0.006-0.5 0.023 0.38 0 2 1.3( tO/47) l l.3 (10i~7) 
(M) 
lIlhem Vietnam 97 (1 Q6f2(2) 0.0Q8...j).7 0.38 O. O.00IHl.2S0 0.1 0.19 ~O( IOI.n1) ~O (101J'2(C) 
(HTI» 
.. ParcnU.eUa."31 RU II~ lndK:ate no. or t~lSbD I iJolalCSfoo. WItted 
• ~ not "'1Ii1ab~ 
3 8 
~1S CHAU ET L. IIDIOTlIll1l. 
TABLE 3. ReouIl> 01 of ilJllJmlcrobl:\l 3 .,,1> for 5S scI.tt.d 
VI or ('",,"ryo, MlCoIdNS(~IIJ) 
""' .. iutl:ulon pnw~ '" NoJad< Clproftolt>Cl. Oftogcia G:1I1ftG.'UIC-in acid 
043' SSlY >~6 0.25 O.S 0. 19 
Bill' SSlY M ., >256 .25 O.S 0.19 
ES6' WI' M ., ", >156 0..25 0..5 0. 19 
A 1_ Y .. , 
'" 
.. t >256 ..25 0..5 9 
C 152' Y \\' WI wt 0 >256 0..25 O.S 19 
CT 19' I~ • 31' ", .. 1. \\1. Yes 156 0..5 I {I.()9.I 
CT61' I~ WI' ", ", wt Ves 2S6 0.125 1 0.06-1 
IW' t02' 199 I' ", ", \\1 Ve.< L"'8 o.m I 0.1)9.1 
nar 104· 1995 I' ", ", \\1 V .. 256 0.25 I O. I~ 
II.tt 10i' 1995 I' 
'" 
.. , \\1 V 256 0..25 1 (tl1S 
nat I IQQS F Wl ", .., No 256 0.25 I O.US 
.p12f' 19'1 DS7 .. , .. , \\1 No 256 0..25 ~ 0.115 
oar2S 1996 F wt ", \\1 Ve 256 0-' 1 0.19 
03145 1996 WI' M \\1 .. , V.s ~6 0..5 O.S o.t2S 
.3146 1996 DS7 \\' .. , \\1 Yes ~ OM O.S .032 
.31 so 1996 31' \\' ", \\1 Ves 156 0..5 1 0.1)9.1 
nuSI 1996 ~lF .., ,,"t wt Ve 156 0 I 0. I" I Ipt 32 1997 I' W1 ", \\' Ve 256 0 1 0.l2S 
Ipt :t.l IQQ7 til' .. , ,., \\'\ V .. 156 0.5 O. o.l2S l CT II ' 200 1 F wt .. , wt Yes >156 O. I 0.094 
CT 142' ::0<1 1 ~F .. , ., .. , >156 0 1 0."" n 
CTI~' 2001 DS70 ", .. , W1 >256 0..25 I 0.094 .. 
CT 14 ' 1 F Wl .., .. , ~ 0-'6 O • .094 $ 
DT2' ;,)02 I' ", ... , .. , >~6 O. 2 n. l25 : 
DT3' 20~ F .. , .. , wt >256 0 2 0.()9.I n ;, 
DT 200~ 31' WI ~ .. , >256 0..5 2 0.25 ~ 
DT 
-
2 F \\1 
'" 
", >256 0. 1 O. ~ DT 18 2O<C S&3F and \\1 ", .., >2~6 0.5 2 0..25 
0870 :[ 
DT 37 2002 31' », lOt .., :>2!6 0..5 1 O.m 9 
DT40 z002 S&31' ", .. t .., >256 O.3S O.S O.US .... 
DT~2 2001 SS31' \\1 '" 
.., :>256 0.5 1 0.l2S ! 
DT47' 2002 WI' \\1 ... t .. , 128 0.5 1 O.ill c 
DT 2002 P .. , 10' \\1 :>2S6 0.5 1 O.l2S ~ 
DT 49 F WI 1\' w, >256 0..5 1 0.125 J.II 
DT 2002 I' \\1 ,., \\1 >156 0.5 1 O.US ~ DT6Il 2iJIl1 I' \\1 ., .., > 256 G.2S I O.l2S 
03 2004 F WI ,., \\1 ' 0 >256 0. 2 0..25 
0 2001 :11' WI .. , wt Y >156 0..5 1 0..2S 
A06 20().1 F ", ., \\1 >256 0.5 I 0.19 
AO 7 SS3F .., .. , w, :>256 0.5 1.5 0.19 
AO 2004 SSlI' \\' "' .., :>156 0..5 U 0.19 AO IS 2004 S83F \\' "t wt >156 0.5 U O.U 
AO 16 2004 I' wI ,,' ", >156 0.38 U O..u 
AO 1 31' WI , wt >156 0.5 U 0. 19 
AO IS::' 2005 Faod .... , \\1 >156 3 0.25 
OS7N 
AO 168 200S ~F .... , .. , ", Yes 1 0.1 
0169 200S 31' .., WI .., No 1 0.13 
AG 176 200' P WI WI \\1 V 0,7S 0.09 
AO Ha 20().1 SS3F WI ~1 wt 0 1 O.U 
0'" , ~ P \\1 .., .., No I 0.10 
0159' ~ I' WI ~, WI 1 0 1.5 0.13 
fm) 798 2003 F .. , ~, WI Yes I 0. l3 
8L21 I' 2l~ F WI .., .., O. 0. 19 
8L 2109S' 2004 F WI _1 WI .5 0.10 
Bt.. 376Q' 20().1 10' M WI 0.5 0.19 
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bination of MDR and oalidruc acid resistance was found in 
4.3% ( ~7) of rovar Typtli lale from oenlral Vietnam, 
8.7"'_ (2!23) of isolat from India. 23.5" ( 140) of isolates 
[rom Pakistan, aod JO<1 12140) or isolate. from Bangladesh. 
In Nepal. IB.l"'o (27/14Q) of scrovnr lYPbi isolates "'~ro resis-
laol to chlor:unph nleol lind nalidroc acid. 
Ho'" r, milg CIlTTcot CLSI br~ai-points, aU isol t es re-
mained susuptibJc in vitro to ciprollo:mcin nnd ofla:tllcin. witb 
lbe e"<ceptioo of ne is late Crom ulhem Vieloam, AG 1 2, 
with inteoncdi3tc susceptibility (MIC. 3.0 l1g/mJ 10 OflOx.1cin 
(Table 3) and L. isoble.< 4"") [rom .. pal lhal ... ere cJpro-
f1o:mcin resistant. The highest MICs of galifloxacin at which 
SOcr. and ~ o( ... rovar Typhi is lales were inhibiled "'ere 
0.12 JJ.lIml and O. ~ ~,Llml, l'lI5pectively (Tabl 2).1\11 isolates 
were UlICeptible 10 ceCtriaxone. 
DNA n'lu'JJ<e allal sis or QRDR or DNA JY1"l e alld DNA 
topOisoruera e IV alld ~ftct or Oluta tJolIs 00 Duoroqulnolone 
susceptllUIIy. One hundred twenty- yeo oalidixic add-rem -
tant serovar Typbi oolat~s (118 Crom lIOuthenl Vielnam, 5 
from [ndia, and 4 from Pakl tao) with reduced susceptibilities 
to Ihe f1uoroquin I o. MI oC floxadn r:lnging Crom 0.5 
l1g/mJ to 3 l1£1mJ) were lectC(!! r molecular analysis of tbe 
qUlOoIone re islance del rmining region (QRDR) ofgyrA. ix 
ditTeTen! types Qr mUlnti OS" re detected. '!be mas! prevalent 
amino:l id ubstituli 0 r83 Pb (TC .'fTC) in 1171 
127 (92.J%) strains. F ur oololes (3. 1"'0) bad an olterati nat 
codoo 83 chansin.@ Ser to 'JYr (TeC T AC). T,,·o isolates 
showed the Asp87--<Jly (GAC-4(}GC ubstitution, od two 
isolal s th" pS7 AI (OA C) substitution. Two er-
ovar Typbl isoIat bad doubl",amilo-add !IIlbstilulion in 
GyrA: isolate DT 1B ( r83 Pb" and AspS7 Iy) and AD 
152 S r83- ·Pbe and p87 ' I). as shown in Tabl 3. 
Pifty-ftVC of tbe slrains \\ re analyzed f r mulnti os in the 
QRDR (g)-rB purC, and p~rE (13, 20); no DluM.l005 w re 
delected (rable 3). Twenty-five isoime.s (indicated with an 
terisk in Table 3) 01 re ere ned for tb presence of tb 
pla5mid-medulled quinolone re ist:mee genes qll '-" od IjIIrS 
(15); none werc detected in tbe • isolates. 
In vitro Hili. till ao.,ly Is. One oolatc! repres<llltl1lg e:\ch 
mutoti.oa group W3 · !.eC,JOO for in vitro dOlc-tUI experiment : 
CT 76. " ,ld-type strain (M1Cs, 0.Q64 ~sfml Cor oBoxacin and 
O. B v.g/ml ~ r galil1oxacin); JITt> 79 (er83-+Ph; M I ~ 
1.0 11g/nll for l,nO:<aci.n and 0.J311g/m1 for gnliflosacin); CT 144 
(AspS7 Iy; MICs. I 11 ml f r oftoxaOn and 0.094 J.Lg/ml f~r 
&<1tifi . ein); and DT 18 ( r83 Ph and AspS? G~; MI 
2.0 v.g/inl for olloxncin ond 0.25 ~.glml for gntiJIolQcm). The 
mean changd in logl. CF /ml are presented in Fig_ 2. OBoxa-
cin sho\\ed I'3pid killing of wild-type stl'3in CT 76 (Fig. 2aj; 
viable counts C ."rOVar 1)ophl £lTD 1Q8 audCT 144 d«r<>ased 
aft~r 4 h at 4 M Ie. but complete killing could not be achi cd 
(Fig. 2b and ). 0 bactericidal activity ",-as achieved agninst 
rovar Typbi DT 18 (Fig. 2d). GatiOoxocin at 4>< MI de-
creased Ul b3Cleri31 plpulati 0 of CT 76. [lTD 798, ami CT 
144 (Fig. 2e, f, and g) in Ihe first 30 min nnd show~1 complete 
IciIlinS atl~r 6 h. Viable COUll t of scrovar Typhl DT 18 de-
C"'ruleel all r 4 h, ~ Uowed by regrowlh; higher col)centralions 
( or 16" i IC) howed a more pronounced bactericidal 
etT,,(;I ag.~insl Ihis double mutanl (Fig. 211). 
DISCUSSION 
Thistudy describe the lrends in antimICrobial drug res13-
lance of ""rova r Typhi in Vi toam bet" en 1993 and 2005 and 
across Asia in 2002 to 2004. 
In J9Q3, during the Utitial outbreak of MDR sorovar Typhi in 
Ki D Giang province in tbe south of VlCtOom, th fluoroquin-
Diona an libiolics .. ere illtroduc d fo r th treatment ofryphoid 
fever (22). Since 1993, the proportion of MDR serovar Typhi 
h •• remained al high lev,,~ and there ha., been 3 dmmatic 
i1cre.,e in nalid'lic add r""istflllte. In 1998, 5 yeal'lJ aft.r 
oOonenl and ClproOOL1cin become widely :Ivailable ill an un-
contr 11 market 87% oC Ihe L'IOlate. were resiSfnnl 10 nali-
dixic acid; tbis increased to 97% by 2004. The combination of 
MDR and nalidixic acid r""istance io • particular problem in 
Vi tnam, because it severely restricts the therapeutic options 
for patienls witb I)'phoid fCllo!r. 
Patients inf~ctoo with nalidixic acid-resistant &erovar 'I)'Pbi 
sh w poor clinical response. high failure rale (up 10 36%). aod 
prolonged fecnJ carriage when treated witb an older-genem-
tion Huoroquinolone, such 115 oOosacin (8, 26)_ The antimicro-
bial r sistance data fJom south III Vietnam arc complemented 
by U, results of a cro -sectIOnal ludy from e~bt Asian ('Ouo-
tries: Banglade.,h, Olioa, llldi;~ Indonesia, 1..:105, epal. Paki-
stan, alld Vielnam_ These untri are h m to appro..imalely 
80% oCthe world's typhoid {ever ca<e.< (11 ). 
WhUe in SQUib m Vietnam th MDR ph ootype of serovar 
Typhl ba., remnined , t higll level over fhe last 13 year, there 
bave beeD repo n of a retu rn 10 chloramphenicol oensitivity in 
lOme regions (12, 21)_ H wever. in our studytbe prevalenc~ of 
chlo rampbenX:oI resistance remained high in many Asian 
countries (18% in Laos, lOt:!> in pal, 26% in [ndia and 
Pak.istan, and 40% in Bangladesh), with Ihe ceplion oralina 
and [nOOne i:l. 
[n 2002 to 2004, alJ countries in Ihe region. \\;Ih the e.=p-
lion or a,ina and Lao Caced a problem or oalidili acid 
resistance, with southern Vietn m as a particular hoI. spol. 
R um,gnae et aI. re oily ugg led Ihal fluoroquin lone lise 
bas driven tbe clonal expansion of a nalidixic acid-r istant 
rovar Typb i bapl typc, H58, in outb Sf Asia (29). The 
emergence of resislance oC serovar 1'ypIli to ciprofloxacin (61 
149 io lat~; 4% ) in ep.'Il, t get her witb reports fbish-I el 
ciproOox:oein re L"ance in Iodin lind Bangladesh (14, 28, 30), 
might be the prelude 10 a WOT ning drug r is! ance problem io 
Asio. 
In tbis st\Idy carried oul aeros ia. mnlation n.ssociated 
.. lth nalidixic acid resistance and reduced susceptibility 10 fluo-
roqumolones for rovar Typbi lI'!re d fined only in gyrA , as 
single-amino- cid substitutiom at eilberco<lon 83 o r 87 (6, IS, 
31, 7, wilh Ibeeneption of two isolnt s CTom lelnam. which 
had double-am.mo-add sub rilutionJl. There have ~en t\\O re-
cenl report or 3erova r ryphi with tb.e Ser83Pbe and Asp87Gly 
double alt mti n in high-Ie\'el-cipr Iloxacin-re iSlant 5erovar 
yphi (28, 30). 10 our study. I.b. isolate, witb double mutations 
in gyrA w r I ullCeptibl to the Huoroquin I(lne. and thi' 
phenotype may become more wid pr ad in tho futur if con-
tinued drug pr sur is applied. This is 3 IXllticuJar pTobl m in 
many part of Asia, where antibiotics ar~ readily available in an 
UllreguJalcd m3rkelpla and inadequate do and dumtion 
of antlbiot ie. are ol\en """d. 
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Our tim -kill experimeats '"lIS that the eboic of the 
fluoroquinol ne aad the do ' used forth treatm nt ofscrovat 
Typbi may be critical and UJld~rlio that clearly not aD the 
f1uoroquinolon ate .usceplibl to these commoo muta-
11011"_ onllau~d us of th ol~r-gel1 ralion tluoroquiuolonea 
(ot1oxacin and c'proft lC3cio) IllllY olIIcourage tbe persistcn of 
re ,stant i~atea and lead to tbe development of new muta-
tiom wtlleb might comprom~ the ftlcacy of the n ", r g n-
emtion_ W,lh lower MI. and belter responses in the time-kill 
lJ"'rim u ,is po .,bI thaI galill 'acia (and pol nlially 
other newer- enerntion lluoroquinolone ) .. auld p "" n bel-
t~r choice for use in Iyphold rev r. Tb ' pr id a d at mtio-
nnl (or Ihe clinical n. se91ment {,f Ihese drugs in rnndomized 
conlroUed trials in Iyphoid fev r_ If the", in vil ro dala are 
'it,pported by clmienl reoull Ihen Ihis nev.er gen<r3tion of 
fluoroquin Ion should b recomm oded for tb.e t~atmcnl of 
typhoid fever in!!lead of ciproftoxacin and oft xacin. 
to conclu ion. th m rgen and persist ate of MD R and 
nalidi'tic acid-r istlUll rOVat Typbi slraw con!!limle a major 
probl m across Asia. No drug bas ever been developed spociC-
ically for typhoid (e r. and th re ar very few potenlial targets 
in SaimoruiliJ agaimt .. hieb n drug.. could be d isned (3). 
W need to US<! our currenl drugs beller and u:oe the best and 
m(\~1 alford ble dn,gs available in order 10 prevenl further 
resistant . Kilo\\1edgc of the at al of drug rcsi lance should 
be an importanl fact r wben dLo;cu ing Ib implemenlation of 
a compreheosiv typboid vaccinotion strategy. 
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An Open Randomized Comparison of Gatifloxacin versus 
Cefixime for the Treatment of Uncomplicated Enteric 
Fever 
Anil PJndlt l~t Amit Arjy.l l ' , Jenm)' N. OIlY2.V. BuddN PludyaJ '• Sabina 0.n901\ Mw O. Zimmerman t , Shlnt Yaday' . Kasia St~l~ska'# 
JarnH I. CarT'flbe1U, Christiane OoiecetcU , Jeremy J, F1rTVt." Buddha Basnyat '.s · 
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Ob~dil. ~ . To assess th. eff'tcacy of gatiOoxadn veD US cefDdme in the t r atment of uncomplkated cultu re posit ive ent l!ric 
fever. O",, ; ... A rondomlzfll, opt!n· label, actlv. cont rol t rial with two para n I rms . • ll;.~ . Emer9"ncy Room and Outpatient 
Clinic.s in P,un HospitaL Lagankhel, Lantpur. N pal l'arlic;l"""u, Pal ients wit h clinically diagnosed uncomplicated enteric 
ffvfr r1'W. tlOg the induslon critl!'r1i1. lutrn,," ti0ft6 . Patients wt!re .lIocat@CJ to rKeive one of two drugs, Gatifloxacin or 
Cefbcl.".,. The dosage. used were Gallfloxacln 10 mg/kg. given one. dally for 7 days, or Ceflxlme 20 mg!kg/d ay given In two 
div id.d doses for 1 day . O.d~om,. l "I1I "' N' . Th. primary outcome measure WtlS fever dearance time. Th. secondary 
outcoml!' mea.surl!' was overall t rl!' tment failure (acute t rl!'atment failure and re la pse'. R ,sull.!t. Ra ndomizat ion WIJ earne d out 
In 390 patients befo,e enrollment was s" spended on the ,dvke of the Independent data .. Iely monitoring bolrd dl» to 
signifoaont dofferenc .. In both pnmAry and wcondary outcome mMsuru In the two arms and the I tta inment of a prooro 
defined endpoints. Median (95~ confidence Interval) fever clearance times were 92 hours (84-114 hou rs) for gatifloxacin 
recipient> and 138 hours (105-164 hours) for coflxime tr •• lfll patients (Huard Rat io[9S·..a)= 2.171 [1.54S-3.0511 p< 0.0001 ). 
19 out of 70 (27'<0) patients ... ho complet ed the 7 day t ria l had acute cl inical failure In the ceflxime group as compared to lout 
of 88 patients (1 ", in g.t,Oo. dn group(Odd, R tio [95 .. 0 )- 0.031 [0.004 - 0.237). P 0.001). Overall tr atment f.~ure 
pallents (relapsfll patients plus acute treat ment 'allure pat ients plus death) numbered 29. They wert determined to be (9S"," 
confidence Inte",.I) 37.6 "'" (27.14 ..... 50.2"-) in the ceflxime group and 3.S% (2.2"b-ll .5"-) in the gatifloxacln group 
(HR.9Sot.O) - 0.084 [0025..(1 .280), p ' 00001 ). Ther. w", one death In the cefixime group. (".",reOO,""" eased o n th is s tudy, 
9 tifloxadn Is a b<!ner "eal m''"t fo r uncomplkated enteric fever as compared to celixlm • . Tri.' R' ,;l lralioll . Current 
Controlled Tn.1s ISRCTN75784880 
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METHODS 
Participants 
n .. Itudy w: approved by N poI l1ea1th Rt:.tardl Council and 
Oxfonl Trapi Rcsearth £.th. Comaailk'. 1be pr tocol r. r 
thill tri:ll ""d pporting ON RT hecklist are .vailabl, as 
IUWOrting inform.uion; '" .... c\dis. S I .nd Protocol . I We 
tnrontd pantn!! who preftnted to ~ ootparitnt or emergeney 
d<:partmcnt of P tan HOI pita!. Lalitpur. epal &om J unt 5. 2005 
to ~mber 8. 2005. Potan H ita! if 318 bed h"'!'ita! 
Ioa«d in the Wtpur d' tnet in Kamnundu aII<:y. Patien" were 
d ; .blt: 10 ~nlt!r It\!( udy it the had clinically di.agnot1if:d tn.toc 
fe\o(~.r nd Ihtir ruwen It wa witilln pproxUm~)' . ~ km radlU! 
rrom the h OlpiH,1 O,h,.,. indu ion cril . were Ihal p licnts mu 
be .gd between 2 nd 65 ) an •• ble to talu: oral aaediatioou, 
noo-pt'Cgnant nd I ~lactating, without at· lOry of scuW"CI, able 
10 stay in the dty for the dunrlon of the. rl"eUmtnl, not blown (0 
h :\'e conO":lindica.tionJ to t.irhu aphaJOfPOrlns or fiuoroquino-
1oot:s QJld willing to ' YC infon:oed "'Tllten conxnt to t:llJ;;;e part in 
the: tutly. For children (nrolled into the slu dy, wriUOI infunncd 
c,,">enl wa. talu:n trnm p,\ ... nt. Patten" wen: ",eluded from the 
.rudy .f they had ~ny "i'" 01 complicated typhoid dd'm.d lhe 
pr<:J'-"re of J undice. p'ltrninl<";noJ bl<tdlO" ~rilOn'.'m. 1 ....... 1e, 
cnccpbalopatJlY, nvulJiocu,o) oca.rditis or arryuWJia at tilt time 
of enrollmen'. P ,ienlJ who had r«.iv.d third gwer:o.tion 
(tp rill, Ouoroqumolone: r ma.cmlldc in the week. prior fO 
~r.tlion 10 our rUnic wtrt aliIo lxdudtd. 
Interventions 
On p"e.tcnwion ro Pac. " o",i.aI all patl<nll wilh f ...... withoot 
lin ~qOll focu wt.~ rdLlTtd 10 rh, tnltric rtvu .lJdy clinic, 
wb.tre ~ wece leen by ~'" study pbyician. PaUnlJ wOO fulfilled 
the inc1u ' " ai luia we.re nlIldoUll)' lAS igned to receive Cali· 
Iloxaein rouIbanrl'n.,. VIIrtu G 8: I. Switz rlam!) 10 mgl 
kg/da.rJI ), in l .ingle dtJ8. onoUy for 7 MYS or CtfLxim< 
(CifI'X • hi" ·co';o. Cypnnl 0 mg/kg/Lhy (I in two 
divided rJooes orolly tOr 7 <by,. Ilotb dnJ8t wert administered in 
tablet form, cut a.nd we.ighed in a sellsitive scrue to e.nSiurt that 
under<lc\ling did not occur. To rhildrm who v.,.r __ apprth n.llwe or 
.wallowing ,h. ttbltt. the do.g embedrlcd in ~ banana nd 
p m D p:ltttnt. ~ .. .sired rn l'Amlow lluo: . rudy dntg unrtf!r 
dirKI obte:rvarion dur.nj tlch villt 
Eao:h pati<nt had hatma.rocrir. toW It.uc:ocy.., count with 
di/l'....,."w. IUIlm creltinint. total bilirubin, abnine aminotnn-
fe~L nd a~.ml~ lUninO~Jf;oM\~I:{ rnf!. un"1i, nd 
blood nd ,,001 cullu w ... also ~rforU1od before ,Ive tar! of'M 
stud mltnttntlOn 
The c:nct loc:ltion of ~'" patient', borne W1U record<:d and the 
ftnl doK of dn., admin' lend a' Ihe clinic. \ e employed six 
ommunity 11-1.' • wcliariu ( lA ",ho Md aU receivtd at 
Ie , I ~ mon,h. of prior IOnnoi prim:>.ry heal'h c .... ",orker 
lraining nd betn rep red ill a govtrmm:nl recognized in· 
ulut ion. TIle V\J visited p ai.cntl twice daily at thelr h m to 
pt-rfonn a trnplt c.lin lcnJ M-Wllmt..nr , mL"1UU1'e the orAl kmptJ'lI· 
" .. ~ and give directly oblt",ed 'herapy with t"" st"dy drugs. The 
MA vlSltod the p"i,nt" home evtry 12 houl1. morning nd 
e\<ning, uobl <by 10 thllowing . ,u'OlImeot or compl.te """utioll 
of illn •• whic~r me later. ornl "'~rall"" of the 
p>u..nr w ... rtrOrdod twino. very d.lY by tbe lA and a nole w ' 
m.u!c of ~ nrnm, and doo"K"S of act"""mophen inmkt. Tht 
quality of p>tien' -Y1J!lj w.. en",rod by "'lI"l:1r unpl"nnod 
,uptrvUory checks in ~ the Iludy docu>r accompanied the 
MA durin ~'" ,isi to patiLn"" hom •• 
. ~: Pla50'« I WWW.p/olOnt!.O 'g 
Tvphold T'''I"",ol T~. I 
fAs \I\,~ Mud to Ie:nd patientS imm~dl3tdy 10 tht: hospital 
on encounll"ring any !Je'\'cre symptonu, and the patimtJ abo wen" 
knlco 'l,.ndclin i.cu the hadanys v retymptofns « ny her 
lim . A aymplOm qu ... ionn>i Wli uWti daUy during tach vi il to 
monitor My ad ~rac. even Any Jnllent with any Jere :lympoom 
.... lCen by tht ltudy phyaidan. The iA.o and "udy ph)'.iciaru 
held cbiIy cue confcr<.na:l at which :all the .. udy paIXn'" wen: 
ducu.Iotd 
All patienlJ regardlus CJf the. culton. results ""ue seen at bo plt.W. 
an Day 10 IOllowing .nroDmenc Blood and .. 001 culturea were 
~lIod on Day 10 in all culwre po.itive polito.. nd therull if 
th. potient a in became iD wi~. probable <nitric fevt!'. AD culture 
poJlti\'t pa.tiLnlt wen: (j Hov.T(1 up until six. mOOl.lu flu 
enrollment, ~ 001 cu\tu"" " .. ,,~ pemrmtd at the end the 
flnl, thind and sixth month. 
l\1l .... loioskal Pr ..... dar... Blood culm ... _ perform.d 
on media conttiniog trypron. soya broth and sodium po\yellw:tol 
t ulpblllute. incuba.tod at l7 and tnminc:d <b.iIy lOr growth w.r 
7 days [\ I), S.lmcttrlla t1IIonc ... retype Typbi or Paratyphi A, B or 
C ' t~d in culture wen: ide:m:iClr.d u ing tand.1n:l biochemical 
I t and ."eciC, .ntisera 'furex Biotech. OMti< d, Ell d) 
Antibio tic rusctptibiliti were de«ru.ined during itol .. ioll using 
Ih, Kirby-B.,,,« di", diffusion method in,'Olvinr Mribioric disa 
cooClininr alidll<ic .od, Oflo:Clcin, Ciprolloncin. CItIor:lmphe-
nicol. Ampicillin. Cotrimo. .. uole. Ctfiximt and tfOlUim 
\HlM~ia Laboratories, {umb";' 1ndi:t~ finimum Inlubitory 
Concentrations (MlCsjw.rc det ... mintd later for organism. ltored 
in gI)'Ccrol aerial pr ... .,..crj .. -70e. Th Ue. were 
clel<nnined by Chloramphenicol • • 'Widi<ic acid. C.riflOlQCin, 
~f",imt. dtrioxcne ... d ~ifloxacin £. t<.llJ (AB BirxIisk, 
na , ~den)# a cording 10 the rnauufacturn"'s i truclion . t 
tt:nti. ivity trsu ~"Uc in.trpnltd U!in fn ' I nd "Or'y 
tllndruth lnatiwt. critcri> for Eoterob3ctLmctat. 
Objectives 
Th. obj.etive of the "udy w.u to eompare the efficacy of 
GatiOoxacln nd Cefi:xime in the fft1tInt.nt of uft(;Ompl!C3{t;d 
culnu'e positive tnttric ftvt:r. 
Outcomes 
TI prim ry outcom .....,.. the fever dearance drne ro 
wa. ddined u time to 6",t drop in oral lelUptrarure 37.5" . 
remaini", ~ 37.5' C ror 48 hoon. 1be otcondary oulcoma 
included acute treatment &i1ure_ Acute U"U.tmcnt faiJuR W 
dtllmd. Including any VUt compllcMlQn; I.be ptrsi Ll\Ct of 
r"er (>.lIl ~ the ptrtill«nct of S)"'Plorn for 11lI)~ lhan 
7 cia antr the ltan of trt:attne.nt • rt:quirin :ldditiontll or 
resC\lC llt>lIIlCnL If .. ""lient Iud a l.mperal .... c abov. '7 .~ and 
below 38 for mon: tIwt 7 thys. bUI did n Ol necd additional or 
reacue ~ .. rapy. Wld .ubsequeo~y tlteir " or cI<:&red by day 10, 
lhar pa.ttt-nt 'Aoukl not qualify an acu te I~tmt.nl failure. 
Patitn .. who faiJ,d IIv study !.realm or wrre I', .. n rescu. 
Ircarmtn l. 
T be reSCll' do 'g was Otloxacin 20 mglkglday omUy in two 
divided dDitS ror 14 thys for the CeflW. grouP • .,rd Ccf\riaxone 
10 Ul~/kg/day IV in • fiingl< <bily doo. lOr 14 days ror the 
O.no .ucin group. For lb. CtftX!mt group ab~. if on <b 8 of 
Ircatm<!nt Ihe pal;"". un had • fever of >" 38"C. the nldy dn.g 
W3I rontinued for 10 days and ~ patient c:uegorizd """. 
.... nnenl failure If the lemperaru~ on 0 '110 " ... >37~ • • eseu. 
frnlmtnt ","U livtn. 
A rebps. wu deflOcd fo- T .. ith a po ·ti.e bbod cubure 
witbm mooth completing treatmen'. AD the relapoes ",.re 
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p.-nienu ttu.1 ~ initia.Dy c .ego.iztd a suen fuDy trt3.ted. Any 
lX'.ieOI ~~n rescue- Irf'-u lnlt:nl or prolong-ttl trealm.-nl w 
p~IUlJed (rom Ih "r~I.npii'H group 
P tienra ttgoriud "O\'U3Jl rrutmtm billlres" indude.d 
pao.nrs experiendng cutt . r."um<n' fail",.., plu. those falling 
into the relapsed Cakgo<y. plu all dtad within the trial follow up 
period. 
Sample slz.e 
The s:unple .itt was c:llculal<d ' 0 del<CI • FCT diiference of 
.PJl")Xim ely 48 houn belWttn pt:il1oxacin (u.umtd med1an 
fCT I~ hn) and ro1ximc (aswmed mtdian f 204 hnJ [1 4) 
with p = O.~ and power = eo~. 1". .cC'U.l! tim. lOr recruiunent 
was .",ulned to .... 70 clays, and that the I.,. pa.ien • ...,uld be. 
followed up mllu 8 claya after rocruilmtnL Therefore, we 
tmrmttd the minimum mple.itt 3' 235 p.'lrticipanl1 lIndh&, 
.10 to 1000ow-up of ~~. the . amp!< in was calculated 125 
blood cultu« positi"" patient> in tach rm. 
Bero .... he .. """mmended mple siu had be.en rtachtd. Dna 
16 blood CI~ III"" positi"" pa.lents h:od been enrolled, the 
inde.pend.t.nl d: t:\ ufery momtoring committee {D"'~{ 3dvised 
I.he lTind pal Invesligaton to stOp l"UMli.rm~nr 10 the Dial b.'wed on 
• priori ddined dilfere"ce (p<0.0 1) bttween the '''0 lctabD<n' 
arms in ,be primary endpoints of the study. 
Randomization-Sequence generation 
p nenl.l ~r~ randomiud in blOC"ks of 100 frt)m 3 c:ompule.r 
nernt<d r nd mizo .ion 1i..~ by n love tigator no' inYOlwd in 
p2Utnl rtcru.itmt.nt or a.sitiWIeD.L 
Randomization-Allocation cOf1Culment 
The. randomi1..1rio l1 leqlltOU and bJnck ,i7..e was ronCt:lJed fmm 
t.he physician. allocating U'e.. tnltnl and nlanaging jht pa tlbl I 
priOi' 10 patitnl e.nrolb:nen t. Trelli lmenl aUocu,' 1 ""'ere kepr In 
taIed oP"'luc envelopes. whi<h were opened only on enrollmenl 
or tbe pa.ienl to Ihe Itudy wr all incIUJion and txdwirln aile r'.. 
had been chccktd. 
Randomization-Implementation 
Plll'udpant. ~re enrolled by lht .tudy ph idol'lI\ in the , lune 
order in whid. Ihey p<ntnttrl to the study clinic. 11,. Ita led 
tnvdopet were opened in .rict numeric sequence. 
Blinding 
Blinding was nor rea>i blc in .h~ ,rial due to 10gUticai ... """.,.. 
Statistical methods 
AD data wert enl<t'td in.o an dectronic d,u;lbooe dicrosoO 
Ol\ice cess Vtrsion 2003. \ :ute. U ~ and ;malYIt! w 
peno"ned wing &am. 9 ( tal. OI'P LP; T • OSAt ). 
ominuuu, covarialts '" n: compllred belween groups Or patleJl 
using the hbnn·"Wh.ilnty rear, and au~gorical covariatr:s wc.rt 
comp:>rtd u 'ng the ctri"'luar< tt or 'uher', U2C' ~. ",h ... 
,pf'l'Oprille Fe tr c)(oraru:. ~o! and nme to I'I'lap~ w .... 
.n~)"Zcd Wiing Kapl;ul Me;'r ",,,,ivaI curves and compared 
belWt n the two groups Uliing .he logni.nk It • . Binary au om .. 
(clinical r",11lI' ) wert oomportd bet",,,",,, .m two ' .... tmenl 
groupe usinlt f'i er's txJKt "" Analysis was done in all 
mndomiuod panen" (intenrion 10 ITt .... rr ud o<p.r:lIely in 
pari<nto witb positi pretrtalmtn' cullure (per pro<oco~ P and 
nega.ti •• pretl't2.tm ... t culture . 
. ~: p~s ONE I www.plosono..org 
RESULTS 
Participant flow 
Typhoid T,,,'monl Tnl l 
or <be 482 patient. li'om .m .tudy ..... who _re clinically 
diagnosed witb coleric fever. 390 palieJlI1 wue enrolled into lbe 
study and randowiltd 92 pltients wert ineligible. the- main 
re son (49 pill ienll) being • ru.IOry of alteody having Wttll 
illlib'.otlct (Ouoroquinoloot. macrolide. or durd generation 
cc:phalosporin) witlun on< .... k prior '0 IlUdy mtry (F''l!Ure I). 
Among all randomized p"ritn , 187 parlen .. wert igncd.o 
receive ,""ime and 203 '" g.UUlOlCOCin. 77 p."i,,,!! assigned '0 
recm~ a.1ix:im,. W~re blood OlIn.IU posit" 'e (or ~n' rric r~e:r ,vhilsr 
92 of .hoce igntd .o receive g:uiflox;rcin ""rt culmre posiriw 
.Thtre we:~ un~qtal nll~r ofpOllri\."e p."ltimts in nch ofthr uudy 
arms. One pocsib1e reuon for the. cti.1f~nCl! in numbt.r of culrurt. 
po51live p:.timu berwee.n $bldy ~nn ic m:n cum.res were dmwn a.net 
elllm ... resultS obtai""d an!!r randomil:ltittn had b.tn done. 
Recruitment 
\,,"c curolle.d patiCUtl ""ho prcK.nrro to t.ht o utpa.rie.nt or 
emergency department or P •• ",. Hospital, Lali'plIr. epal from 
June ~. 2OO~ .0 pI ember 8. 200~. All enrolled p.tients Wert 
follo .. ed up fo r at 1 .... 10 days an .. reauitmrnl. P:tri nb with 
a. poiitive prell'f:amll!.nl blood cuhurr. ~re fob d up fo r 
6 momhs afi(r t:nroUmt.nl. 
A. the poinl tha •• he DSMC .. Iced to enmine the trial d3lll for 
the primary outcome measure in positive: pre .. rrearmt.nl p3rienu, 
the medi..'\o fev r d I"'3nce ti me W3.1 92 hQurs ~~ e l, 84 
11 4 hout"!) for.ht tiJloxacin trea .~dp,ritnuand 138 hOln (M% 
' . 10) 164 hou ) for c.rlXim< • ..., •• td p<>tieJlts Th dilrerence 
bel"""" the .wo trea.ment anns .... , hout"! (p<O.OOO I). 
Baseline data 
AdmiJ,;"n ch. rnereri";a are hown ~ d ITT pui .. n ll .ble I) 
and for all PP patients .ble . The median age of pati ..... 
enroned in lO the trW was 17 with a ranI!"' of 2 64 yean, There 
~re no ba.adine ditTt~n.ctl in the: culture. poIirive and aurure 
ntgatNe groups, othtr th:m t rt:1JXT ru~ ar pttltnl:3.rion, AST Mld 
LT whith w.re hightr and plateletS .ru1 'ocU \\Ill which wert 
Io~r in th~ cuhure POsltiW p.."1tlt..nt! a.s comparl'd 10 the culture •. 
negative p:>t ' n .. Among.U 1'1' I"'oeo .. , .bert wert no differentt 
in ~ elint cb.a.ra.d t..,..na btl~t.n rDt twO trt:a tmt.nt groups. 
T here \\.'e.re 40 patio!:nts. J ~ in the garlOoxacin W'm and .2~ in the 
Ctrrx.il"D~ 3nn) "o\'ho had lilin amOX)ciD.in up 10 Ihe: wtek be(Q~ 
. rudy f'nlry. Of Ihese 4 and 7 were o .il rure-- ' tN~ respectiW'ty. 
Numbers ,lnalyzed 
Analys~ w.u done in :all 390 randonilied patients and 
.c:paralely in 169 p tienll with potitive pre-treatment culture 
AD endpoint> w<.'" analysed in .he nd PP population ••• port 
from rtlapse whicb woo l)llly analyocd in Ihe PP population. 
Outcomes and estimation 
prtmary "uW .. n e Tn aU TTT p.1ri.n • m<d;"n 5 conrJdenr.. 
inttrval) r_r d.arance rime ""u 102 (90 117) hOll ... for the 
cer",ime group and 72 (62 80) houl'l fo r the gaIiOol«,cin group, 
Iognnk 'ellt 1'<0.0001 , H ozard Rn .io(95 ~Confiden~ l nttrval} -= 
1.821 [1.466 .26l)' The proportion of a U p.ofn" fnitin, .hrough 
time to dear feve.r is ,tto",,, in curt 2. t day 7 f""t.r r:it:3r.'lnre 
rate was 73. ~ 7.0% OO.S"OJ in cefixime &"oup :1I\d 94. 'Ii. 
0.2% 96 .9%) in pri!lox>.cin "Dup. 
In the PP grouP. median (M% !ever cle ..... nce time w 
92 hOt'" (84 111 hours) ror ptilloxacin <tripleDt> and 138 hoUt"l 
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l I05-16~ hC>\ln) for tcf"dme·tre~ted patients (HR[95%Cl] = 
2.171 ( l.5~5-S.05I). p<o.OOO I~ The proportion failing to tie.,. 
feva for eac.h study drug through lime afta trcwru:nl is ahown 
(Figure 3). At day 7 the feva clearance nte was 62.1'fo (95 % 
Cl = 51.5'!W-73.8%) in the c~ grC>\lp and 9l.8% (95 % 
Cl = 64.8%- 96.+%) In the gatiJloncin group. 
In the gro"" with negative blood culture but clinically diag-
nooed emer" fever (Ag I), the FCT woo 82 houra (95% CJ = H-
94 houn) for the ce/i:J:iIM group ;and 39 houn (95%CI = 2So-
54 houn) for the galiJl"",cin group (HR[9.5%CI) = I.HO (l. 309-
2.312). P <0.000 I logrank test). 
S ...... duy O ...... mn In the lIT group. ovcnlI. 30 out of 
167 (18%) in the cdlxime group and 2 out of 190 (10/.) in the 
gatitlaucin group were acute cl"mial failum. OR[95 %CJ) = 
0.049 [O.()ll ~. 207) . p<O.OO I. FIsher'. =<t test. 
In the PPgroup, 19 C>\l.t of70(27'!WJ~tienuwhoc.ompletedthe7. 
doy trW lud >.CUte clinial failure in the cdlxime rccipi<:n,. .. 
comparod to I C>\l.t of 88 (I %) in the gatiflaucin =ipicnt. (Odds 
lUtio [95%Cl) = 0.031 (O.~ - 0.237). p<O.OOI~ Conidering an 
porien,. 10 be failura who drqlped OUI of the .Ndy before 
ccmpletion of the seven day IlUttnenl coune, 26 out of 77 (WA) 
:*: Pl05 ON[ I www.plosone.org 
. , 
failed in the c:.eiOOmt group .. carnpored to 5 C>\l.t of 92 (5%) in the 
gatiJlaxacin group (OR[95%0I) = 0.1 12 (0.041- 0.312). p<O. O()!~ 
138 ~~l1fl were evalu Ie for rel..,.e; 20 had &alit tr~=t 
fuilurc and I I withdrew from the .tudy before day 7. Tn lotal. eight 
relapses (Flgure I) wen observed. Relapse rates ~ IH% (6/51) 
in the cefutime group and H% (2/87) in gatlllOl< in group 
(HR(95%CI) = 0.185 (O.037-'l.9151. P '" 0.0199). The Kaplan· 
Mrla pta,. far the time of rclapse are >hawn in f igure 4. 
OvoraD fail\D'e. (ac.UIe treattntnt failure plus relapse pIu. death} 
wo:<e 29 in n\Jl!\bCT lFigure 1). Overall f>.iJure rate at I month "'at 
cstimateda. n.s% (95% CJ=27. 1'i% - 50.2%) in the ccfutirnc 
gro.., nd 3.50/. ( 95% CJ = 2.2%-11.5%) in the GatiJloxacin 
gro.., (HR(9~%CI] = O.084[ 0.025-0.280). p <O.oOOl) (Figure 5~ 
From patiatu with negative culture<, II had ",-ule tlinieal 
tailura, 10 (out 01'97.10%) in CcfWme group and I (ou t of 103, 
1%) in the Gatiflo:ucin group, OR(95%CI] = O.OOS (0.011-
0.686). p = 0.004. F"W='. axt lest. 
Similarly. 1r~ting drOP·OUt as treatnwlt f.ilures. we had 50 OUt 
ofl87 (27%) in. tlle CdlxirMgroup and 15 C>\l t 01'203 (7%) in the 
C.tillo:ucin group acute treatmcm foiJurcs, OR(95%ClJ = 0.2 19 
[O.llIHU051, p <O.OOl, FIsher'. exact teat 
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~ Table 1. Baseline charaCl1!,..tio oil patient>. 
... ...................................... ......................................................................................................... 
: PATIENT OIAAACTUISTlC! 
;"'GCf~ t:J,"",~ 
~ Ag.~ 
: ~_Agod <l.~ ".) 
~ W.'S~1 
~ 0\.""" 01 " ...... betot. tr~1 (diiys) 
: ~f!di.., Of. t ll!!ll'lP'fatUf(I! M Pf6!t't_don(9W O. ,"V.) (ir'I df!gr~ Q 
~ H.-.. _ """ lIN _cion _ ldoyoIl 
~ An~. ~IJ,,",* Wit" ~ n 4lfM.M kJ,yiJ) 
: _II "'" ~_ wkh 1'0) toodIon cUa1I"" IdoV'l) 
~ Cougl\~...m.r whh 1'1011 ...... '" cli.tliool ldo,on 
~ OIl"""' .. """,bw wilh 1"'11_' d .... 1lm ~.n 
~ _Ing,lwmbor wilh 1!Ol_ cUoII"" rdo,oJ 
: A.,..,...,II._ ... lnl'loll) 
~ Splorolmogoly ( n N 
; HIII!P.~y ("l~ 
~ H.."oloal. '"'"' 
: 'M-h Cefl (,owl, 4n "C 000 p .. miaolkr.) 
~ PlanI", Count ., , 1000 Pl'mlc",bol 
~ 'AlTI~UA ) 
: - ASTI"'UA) 
~ fon' B.",,*, I In ";lei.) 
c.tture •• ,.\ho. Ql1. 
116171 
" 12~) 
79(J7.1) 
.. .,Oo«l) 
"11-21) 
lA.7U.6-~~7) 
200 1957) f4l 
160 1711) 
81"".311~ 
OJ mOil]) 
4S 121.111]) 
lO11~1 I 
1211s'11 
181Ul 
12 1S.7IJI 
«J 127-11) 
7.2 tU-:Z4.2) 
192{66-~ 
lOC 1-24Ct 
4l11()ol.5oO) 
0.810.17-3.61 
C~Uf'I podtJ\fe t16~) 
111/5& 
1712.7S-SO) 
60 IU.s) 
461111-73) 
512-2]) 
]9I1U-192. 1U ... ,) 
164197 (1)15) 
129(7~ 141 
10 147.3) 
54 .) I 
41 124.]) ) 
2706.0) III 
2J 11l.6] 
11 00,6] 
91>1) 
40 129-5(f 
.., 0.0-20'" 
110 (65-]1IOl 
]102-200) 
52121-169) 
~ 81~. ~aosk'" <irI aI..,d labou tOf)' '.,.u..~ .t Pf'ftMl.UOrt 0( II itlltmioo to trer. p"tiMt5 Utowing.~ I0I'l btttwllM (l.Ik\.l(, positw.,d wit ... ,.. 
: neoaWt oroups. 
: !"-T (SI!NI'II .....,. _",sf ... ",) """""' ...,go 5-JO UI\.. 
: AST """"...,.,.... _"""",!or ... )"","", rano<t 5-l4 UA 
: A' doto ",_lOCI .. .-.., _g<>l ""' ... _loti. 
: doI:lD.m'~""""'.pono.OOOOS4l.1OO 
Ancillary analyses 
Among U (:1~rHre poaU1\-"e p3lVnt in th~ c,.fOOl'not: &"O up, O~ 
p1~ (1170, 1%) h.d Pu oyphi culru...d from h .. blood on 
d.ly IO,OOt ~ were no (0188, 0'. ) po,itive blood cullure 
grD\" tI in tl ptilIoxacln group 0" day 10. 
No patient iOwul to be a pen;. nt am.r of S. Typbi or 
PU'1l}pbl A in lhLir.toOI. A posit" 11001 cult .... fOl' S. Typhi w 
_0 r. on. p1u.nt on day 10 IUId for noth« on do: 30-
ubtt.quc.nl culturu were neptive for Ih patie.nts. We wttt blt 
,oobain 001 o"ltu .... &-om 147 (87 ), 141 (83 . ), and 130 (77 , ) 
pre:treatmtnt blood ('ulrur,. potitive p.'~nIJ at OM:, Ihrtf:, and ux 
montho ... ".cnv.ly. 
Mi ..... W.ln!y Antibionc If'lUlth'ity It:aUng rt.\"( td rhal a.U 
srra.:ns Wf!(f: It.1 Kr..'t to puAo in, d'txinw; ctO ont: or 
mitloudn. llie llrain wu I'tll emt 10 "h..-.rampheni.cd, ')"d 
1:l6 (63%) oI',h, p.", .... tmtn. "ohm ....... ","\lith. acid .tsUtan. 
Ira: . .i\ RS . Minimum inhlbil .')' concr.n tr.uion 11 
dt:tennin.-d for J 1 of tilt. prltlrealml"nt blood culture isola td. 1(. 
median (ran&l') Ml ft.,r each. ntiLjotl.c wue J faUo,,", ' garino"'I(~ 
.an 0 12,s 006 05) 1' I mL,«rtxim 0300(00 1 2.0) f1 gltnL. 
n1lLdixie >~b (1,s.>2.s6)l!g/mL, ehk>nmpb.n I 8.0 (I.~. 
>2~ )1 ImL, etftri n. 0. 12,s (0 ()'I7 O~) l'g/mL IlI1d 
gomilhucin 0 12~ (0 O()<I O~) f1 ImL. 
Adverse evenU 
Amon, an pali.nI. who received ccCucillle, th.re W1U one de th, 
whid. "'igh' h . be.n due to the d.vtlopm<n' of elise •• ·related 
ComplicaliOM during tmen~ TIl it patient W1U nrolled On tb.. 
;®. PIJ>5 ONE I www.pIo .... no.o.ll 
fOU,t<:" •• "h day of hia iBn ... 0" day 6 of tmllm<nt the patient 
COlllpiruntd of reddISh "001 nd p"":chia. and w:u immedia.dy 
dmittw 10. h !,a1 wh .... ~ .. d loped..... thrombocytopenia 
a~ ga.""wl •• bn,,1 bk.ding. tie. developed ",UI. iratOry 
~~ .yndro.m and mecluuUc~ veml1atcd tic d<:vdapcd 
iCm:natcd 1Illnvaocuiar c ... guIation and succumbed to his 
il1n ... 00 day 21 of entry inlo the trial. His pretreatment blood 
culture grew S. Puatypbi which W' lI<IIIiti. 10 cdlxim with 
IUl ~UC of 0 38 f1 l UlL. O ne paCcn' dc-dopc:d ery,hematow skin 
rasb whicb n «kd two ch ... of or.llllllribistsmine. 
Amon~ all 1'31i"'l$ who rettiverl prillo_in there ",,'" 
p.,\l~ntl .with. exc~sr.ve vomiting, which requir~d intrav~nQtl 
anllemenc. and Cnids and obocrvarion in .he hospital <mtf1:en 
room f,!" DpfO 6 hou : lb.re ......... an addition.'\I 23 p1Dt.01l who 
~omJH;ain~d of f.:.'ICUl!1\,'t: n1UK3. 3_nd oc:::Q.$1onaJ vomiting flu 
mgosnon oflhL druS' Of,htt., _ .. «led oral nricmttlc· in tht 
rt.ma.inin I pantn no Intt..rvenlioo was re:qutttd. ' 
DISCUSSION 
Interpretation 
In this .tudy m n r~' .. r C A'" _ttnen. 
r, ~ure ~d r apse .. indic tot. t"at. nl.m cy, tit" ,h. 
r .. ulll "U •• doubu the llsefulnts. of c<1btim. 
gntillOXllcin is. potent choic. for .he It't men. 
enleric reo.: . 
F.brile illu is one of d.e •• 0 t COmmOn realIQ , for 
P~S<:DtlltioQ to bosp:t:W in many developing countriet. In pari nil 
ith fo""r, very common dinic.ll diognDli. joWl ric ICv r, aad S. 
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Tab'" 2. 8a .. 11ne c"',actt!,istio at p,.,..,nlOtion of cultu,e positive patients. 
................................................................................................................................................... 
'ATIE"T CHAAACTERISlIO 
Hool""*""lool""",*, 
Aile (lot>! 
~Agrd <1 4y,," N 
w.l!/ht 
!Motion 01 fo __ • ,_"""" (doys) 
~iIIfl (Ifill te1"Pt.a!UI~ II pteellGtionttS .. a rangt) In degrees 0 
"'._, .... mbor .... h IN 1_"'" d ... *'n Id'Y'l1 
AnOlt'.MJit. Nu.nbct WIth AtlI lnedLln dunl'oon ldiys}) 
_I "In, ""mil .. wilh "" .. edl .. d .. lIion [dlyoD 
Cough, ...... ..., wlm N _" eIL ... Ion Id.,..]) 
Di,,,"'_, ... _ .. "h "" "edlon .... -1dI¥.j) 
\IomIting. ~"",bot .. I'" ( ) I ... dlon eI." .. "", IdOYS!I 
AbdonNI l'I'd nru t n r-. } 
SplMc>mOCJlll ( n Nl 
MtpJltC)lll'\egaAv t n ('II) 
H!m.toalt~ 
wt-M Cell COliflt (WI )t 000 pet mo ... ) 
Placdrt Cot.f'II (in )( 1000 Pt. mc:rofItr,.) 
'ALT lin U,t) 
"AST I .. un. I 
To1>l liI.uIIIn lin mg/dl ) 
""' .... 
crfb6m •• IN. 
·~T ~~fft Unlne 1fNr0000000llerlsrt noun. '.M"IIge S·]4 UA 
-,-.sf tHrum ~atc iiIII'r'UlOtramh:liIS~) nOfmilll rJf'ge ,..,.. U/L 
AI dal:. prHtflted • • m«Iian ( ~) untr.'W 'fIKiled. 
doI:I0,1111I1ou",al __ 42.1OO2 
...tni<.J aerotype Typhl or Pararyphl A ""' the two mOlt commonly 
Isolated p;>thogtns from the blood In febrile palicntl in our hospital 
[15] . Bcfo~ the Il<h-enl of multl-drug·rcsillllnt {DR) S. Typ/I~ 
hlornmphenicol, lIlllPiti1lin or colrimoXlUole wen: ,ucCCSllUJly 
.. cd as the r .. , line drus' in thl; tn:aDnen' of enteric fe~ •. After 
the emergence of MDR .trai .... auoroqu; ooe. and third-
gtnerarion cephalosporins have en ""~,,,d and uaed u 
1.00 
~ 
~ O.ao 
~ 0.50 
S 
! O.CO I 0.2IJ 
10 12 14 Ii 18 20 
o.YSUI(ftStAMJ Orlft£A ... , 
f',gun 2. Proportion 01 .. polion .. Itll robrilt. I<oflI.ln ·Moi .. "',,"v'" 
CLOVt! show4ng "'. proportion d 1111 pMfomsOm $111 f1!brilo "'rough 
rim .. 
dot 1 0.1371 /jOOfnal.pcne.OOOO~gOO2 
Ilns 
II (2.75 
21 (29') 
49110-70) 
5.2 
39 01.9- '1.2; Jl.5-4I,o) 
.m.l'lI)(S) 
,.. ",.,..) 1<) 
a 146.l'lI)(~ 
37140h) (3) 
21 (ll .... )U) 
'7 (l1.s1ij (l) 
•• (15.201» 
'0 (10 ...... ) 
• !SA"" 
., 13D- SC) 
LnO-tl} 
IIO(6S-:!6n 
)6 ("-.10) 
53 (~H5S) 
IUS (O.11-1J) 
919.10\) 
CEFDOME(n·m 
44/33 
513-50) 
331<3"" 
42 (11-71) 
SA 
!9 BU-192; 16.1-40.5) 
76191.~ CO) 
16 173"" 14) 
4O(S21i.) H) 
U (29),) B) 
>0 Il6IIO B) 
10 11!"" 11.ll 
. ~~) 
• (10,"" 
• I"') 
40 12 50) 
0.1 11 1-20) 
116 (1)0-.) 
19(' ~OQ 
49121-1 691 
0.0(0.) >3) 
SB .... ) 
alternative antimicrobial. [16,13] . H.,...,ver the =triCn", and 
.pread ofpointm ,.doN in theD"i gtnc o(rhc bo.ctcrial CIlOlnC 
[11] hOI conferred n:USl>JlCC to nalidixic acid and reduced 
.UKcpribiliry '0 me commonly uaed Ouoroqulnolol1cs suth •• 
ollOXll£in, kading to a poorer clinic.! reIpOllX [18,19J. A r=n, 
study in Vic:! M ParTy, ... publiohcd) sbowed onoxll£in III 
the dose 0(20 mg/ lrg" by _s Ilble to .thieve. are mte .n only 
1.00 
I a.ao 
i a.1O 
a 
I a.co cuo 
0.00 
0 10 12 14 
" 
1. 20 
""'MIla fWOftlilUr .. , 
Flgu ... 1. PfOpartlOOl or wit ..... flOIl~"" pouon .. stil l.trio. Ka \an. 
MI'Ior 'IIVIvot <UN. <howing the prnpMlon of ruiN"' posltivo(llP) 
p!l1l.ou stli fl!brle1h'''''gh Hmo. 
deI:l O. t37t/joumal.ponI!.OOO0S42.gOOl 
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DA'f'SArT[RS1AR' Of fROlIIIOtl 
flgu,. 4. Propotll ... D' .. 11",a fnta poUln' •. K;oplar>NIei .. Rlrvival 
rorve showing the proportion ot relapse free patlents r, the OJiture 
positWe population. 
doi:IO.I l7I1journal.pono.ooOOS042.g004 
64% of pa~ntt. In our context of lUgh nal idixic acid resi>ta.nce, 
ga'ifloxacin ;, the most effecti.... and appropriate choice for 
1I'tatment of enleri<: {eva. GaliOondn (Sandos, lndia) ;, relatively 
inexpel1live (USSL2 fora 7 day lrealmwl course) and needs to be 
adminisreredjust once a day; both of the>e features an .ttractive 
in this letting. GatiJloxadn hal a different binding motif than oome 
otht:r lluroquinolont.l('lO), and thU chancteristie enables it TO 
retain aetivily agllinst Salman,U. mIt,w seravar Typhi or s"in .... lla 
mJnica serovar Puatyphi A even in the presenc.e of mared 
reduction in aensitivily 10 the old<!' Jluoroquinolones [17). 
CeIi:<i=, • third generation. cephalooporin, is widely tnllled TO 
be effective for enteric fever as fir$lline treatment, and is also used 
.. seoond line tbenpy when initial trcil1m<nt with a l1uoroquino· 
lone in a patient suspected to be enteric fever faO. [1$). The tad 
that we saw • high ovuall failure rate asoodated with eeJWme 
despite all of the stra.iru being fully sensiti .... in vitro TO the drug 
shows that the m<:chanism of action of cefixime [21,22J may not 
be suited to the en.d.ication of S. T)phi or Paratyphi A from the 
body or blood. and the poor intnceDular penetration into 
macrophages and reficulo endothellal tisrue. where the typhoid 
"'Pnisms co1onite [16) may be the cause of high failure ralea 
~ Z 1.00 
$ 
'j O.BO 
~ 060 I 040 
i :;;:~oLn~------~------'~4--------?Ir-------'~R---
I»YSlfTERSTllU Of TREa .... r 
Flgu", 5. Proportion 0( "".,.1 failure (r .. pa U.,Is. I(opIan-Mei .. 
survival cu,,", showing the p,ope,u,," ri ov .... fa",. free paUents in 
the culture positIVe POP'llation. 
doi:l0.1311/jolimol.pol1 • .oo00542.gOOS 
;'@.: PloS ONE I www.ploso •• .org 
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Typhoid Tr .. tmo.t Trill 
ThU .tudy _ lJni<[ue in that we used CMA. TO almul~te 
a hospital ,etup in the community. CMA', directly obterved 
patient> lilking the therapies, monitored fever and identified 
complication. early; thcte charaGtcTistic.s have net been used in the 
put for typhoid trW. although enteric fever in endwUc "' ... (I) is 
treated on an ou,!",tient tx.s4. A maj(lt' advantage of fonow-up 
using CMA. was that the health workers knew the exact house 
location of the patients, aruI therefore follow up even afta the 
succeuful completion of the initial ICVI:n-day drug trial w .. 
possible. In developing countries follow up of patients can be very 
diHicult becau.e of a lack of a proper address and relative 
unavailability of other me..,.. of communication, for enmple,a 
tdephone. 
tn a&fi.tion to iI. relevance to culture oonflrmed enteric fever 
another ~or strength of this louse randomized srudy is tho; 
satilloo<adn prO\led TO be more elIicacious than cefi:<ime with 
relpect to fever c.learance time and fo~ure rates, even in the 
subgroup of patients who were clinically pre.umed to have enteric 
fever but who had • negative blood cultw<. Antibi<lti<: treatment 
for typhoid in highly endemic ate3$ is urually .tarted based on the 
pr .. e~. of a "Iyndromi.c': il1nes. (acute fever for a few Wr/' ..,d 
conslJlutlDnal oyrnptom. wlth no known source of infection) before 
culture results are known. Enteric feva, whkh continue> to be 
• neglected dise .. e (23). is an important cause of morbidity and 
monality, and facilities for blood culture or other rellable methoW 
of diagnosis rarely exist in this setting. 
Generalizablllty 
De'P~t: wide'Pread re.istance to N~ acid in Kathmandu, 
and rumg MlC. to the older Ouoroquinolones, dproJloxacin and 
o11oxacin, gati110ucin h .. proven to be a potent drug for the 
1I'tatment of enteric fever. Our st1.ldy has relCIIaI\CG to South Aloia, 
as reoimnu. TO nalidixic acid is widely prevalent there. Inevitably 
there will be emergence of resutance to gatilloxadn in areas with 
bath MDR and NARST; and in thi, . ituation alternative 
ant~iatics. like uit.hmmycin may need to be used. Of interest, in 
keepmg wnll anecdotal reportS from elsewhere in South Asia, only 
one .train W1II resistant to chlorampbeniool in the present study. In 
areas of the world where chl(lt'amphenicol IUsetptibility II.., 
reemerged there may b. an argument for reasseuing chloram. 
phenicol. 
In the present study Gatiiloxacin wu .nociattd with n.usea in 
l2% of p.tien:, and it may be important to forewarn patient. of 
thU possible , ide effect. Then have been sporacli<: repons of 
dyogly~ ca"sed by gatifloxacin [2~26J, and a recent 
populatlOn·based, caoe controDed st1.ldy examining gatilloxacin 
usage amonglt elderly i n~vidual' in C •. nada (mean age 77 years) 
who developed d}'18lyccnua (27) allO raISe. possible concerns. We 
did not do any blood rugar testing to look for d)l!glycernia. 
However .in • study involving. younger age group where blood 
rugar te.ung was done the result. revealed no d~lycernia: 887 
children were treated with galillootacin (10 1TIg/kg) for otitis media 
and were followtd for • year with no signs of alteration of glucose 
harr=stasis eithe: acutely or otheno.Ue [2.8). Clearly, it would be 
prudent tD Il'tat diabetl<.S and eldulypeople suffering from enteric 
rever with an alternative antibiotic such as •• ithrom.ycin and .void 
the potential problo:rn> in thU !pecific populalion with gatillaxa.cin. 
Limiut!.a. Dr the _dy The D MC advised the Principal 
InvestigaTOn in thU ,tudy to .top rcctuitment to the trial "" .. c! on 
a priori defined clilferenc.e (p<o.OI) between the two 1I'tatment 
~ in the prim.uyeru:!poinu oftheotudy. l t it p0$4ible that if the 
trial had been continued with a larger sample size other important info~ncouldhave been gathered. In additio~ ifpaticnt. a.ndI 
or mveSl1g'tors had been blinded to treatment assignments, the 
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Itudy would. haw: been rurth~ I ll'f'..ng1ilt.nt.d j hCM'tWr ~ in n 
typho jd tri.:tk, il not pm ;blt: to do thi . due 10 lilt. dilTel't.l,u:e in 
do . tcht.dull! for Ihe two dnrgs lxing compared. Anoth"r 
Itmit300n or this IhKiy Ih.-lt ' t.mpt.ratu~ only mtil~urrd 
(wry 12 hou . I ( ~t.r, to addn:u tl.a lirmla.r ion~ and tI) a'\; ~d 
mL",sln iuO't.A in ~mp"rature. W~ dlle ktd Itmptr:& tur~J for 
10 d.~ aner f!'Il limen" or for 48 n('ul t'S a fi~1" rt:tol ... tion of r~ver, 
wh.irhe\l~r came l.Jtt.r~ in all patito . mally, 3; teleph n.e Or 
inttl1lt t ba.,W ~iltUl ol raudomization would l:w! ide.:tl, but l ueh 
• f) ml dotS I uist hert. 
Overall evidence 
\Ve have. comp3.m:t th~ Ollicomel from our tri:aJ with t.b.Ole of other 
(OOlJ>3r:lbl • • ,udi." identified from a re(tn ' Coch",n. oni.,.. [~], 
WHO l)1'hoid gtJld.~n .. (10], and I ,.>reh fedline using 
,h .. " tern ... , cd ixim., typhoid tria" Th. findln in our nxly .... 
coruist.nl wilh tho .. of 1 99~ "Oldy don. in Vi.. m whIch 
,howed lh , ttl' itlll! (20 mglkg/d.y) fI 7 d.)'I was IOr.rior '0 
olloxacin (10 Ul / lcg/day) r. r ~ d~)'I in the treatment of MDR 
typhoid f<,.er in <hlI<lnll(l4). However other .!ueli .. bave 
. uggested e<!lxime CIUl be . u«...,CuI in Ih< .... tment of enteric 
re.,.. [29 3 . Overall the", l.did. both deocripcive and 
randomized, have eXAmining the u..1e of cd"1ximc: in confinncd 
enteric rever (.otaI or!!92 patimlt) and wi,h ..... tment dun .. ion. of 
mottl 14 daY', h ve r. und Wlu ... n . .. ranging from 4% .0 23·~. 
a .. idu .he ~<ral undesinb~ity of a longer co ..... wi,h <.coome 
with increased morbidity and potsibly complications, thil drug iJ 
aha mere ""P"n ive (I 7 -<loy course cos.. $7 lue ro 
L"OOnuorie •• lndi ~ Tbe p .... en! "".dy is the brg .. t nndomiud 
controlltd trial evtr condu tt.d with c~fixime in e.ot(. · fever and 
c1enrty shows, even in a Ktting with fuUy ae:n&i tivc Irra.ins, that 
c.cairn. is a poor dn.g ror th is diJ ...... The,. findinp are oontrary 
'0 ,he recommendation by m~y lOul'Ctl(13.I) including .be 
W ld !lui'" rganiz:ltion[lO] th • Cf.flXim can be U1ed as fi 
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Evolutionary History of Salmonella Typhi 
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Abstract 
For microbial pathog ns. phylog~phic diITcrcntiation 'ems to be relauvcly common. How~ver. 
th.e neutrul population Slructun: of Salmanella mIen co serovor T}-pbi reflects the continued c,'<islencc: 
of ubiquitous haplotypes OV(t mill(Mia In controst. clinical use of fIuoroquinolones has yielded at 
leas! I Intk.>pend.:nl gyrA m utahans wIthin " decade and stimulated clonal expansion of hapl type 
H58 to 13 aru Afnca. Ye antlb,otlc-scruutlve strums and haplotypes other than H58 sull pcr lSI 
deSPlt· . 'Ieetlon for sntlh, tIC r ",i3tance cuml evolult n 111 Typhi appears to renCCI the 
os ·mptomatJe carri,,, stllle. and adaptive evolution depends on the rapid rmnsmission of phenotypIc 
chaJ'@ through cute Infectl ns 
Many bocterial tn.'CII nn be ubdivided into multiple. discrete lanai groupings (clannl 
complexe or orypcs) that have diverged and dIfferentiated as a result of lanai replacement. 
Ie ave ,weep periodic scle tlon, :md/orpopu\'lion bottlenecks (I). GL"Ogrnphic Isol3n n 
and clonal repluccm nt can also result In phylogcogmphJc di~ rene belWeen boctenal 
pathogens from diITertnl pans of the world (:). (ven within yoWl!. genel1cnlly monomorphIC 
pathogens ( ) (suf1'Oltlllg onlln~ matcnal te.'(1) so has irCOOaCllnUIIl IuMrL'IJlosi (4) and 
r~~ Inla fHstl . ( ). T)'I:ht IS genetically monomorphic 6). human,restn ted ba tCfral 
patrog n that en .• 21 million Case:! of typhoid f.:vcr and _00, deaths per year, 
prcdomin.'lntly In southern t ia, Afri ,ond South America (7). Typlu also enters a carner 
Slllti! In rarc In<hVldWlls [su h as Moltlm.r's~xample f ~. >fr. the milker~(8)1, who can shed 
hI' levels of the . bActena for de de:< III th· ab:..:ncc of chnical 'ympl ms. Genome 
sequences are nvnilnbl.: from trninsCTl (9) and Ty~ (10). but thegJobal diversity. popu1altoo 
·Prc""'l(k~ Oll)(o.';lInlh":lmc.Kin~url'ru ... PA 19106- 1 USA. 
"'To ~bom corra;pandcn c: Jlookl be .~cd. E.-mall' adllm I mpub-berltn.m~ d 
uPpontftl OnHn. M.,moJ. """" 'imccma, OIl '<oo"n~flII1I314 5S03JtJOl1OCl. (almal .nd Mtlhods. SOld Tnt. Figs. 5t 
to 54 Tabi 5110 • R facne 
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genetic structure, and evolUtIonary history of Typhi were poorly understood. It has been 
speculated thnt Typhl evolved m Indonesia, which is the exclUSive source of ISOlates With the 
z66 Ilascllar antisen (II). 
We investigatc'() the ev lutl nmy histOl)' and populatioogeneticsU\lClurc ofTyphi bymut.'lti n 
discovery ( I:!) withJn :ooge11o [rngments (- 500 00se Plirs each) from a globally r"Pf=tauve 
strom collectlon of 10 suaUlS The :WO genes tnClucled I:! I housekeeping genes, 50 gems 
encoding cell surface &rUcrures, regullllion. and pnthogeniclty; and 19 pseudogenes Size 
anat! n fa poly-T6. homopolymenc SIr tch within nc gene fragment wastnCOllSlstent 
With other phy logenetic pallcms (homoplasi,,") and this frngmenl was excluded from further 
analysIS The therl 99gcne fragmcntscover 8,739basep3lcs, orl. S',oflh<:genome.SL'tty. 
six were polymorphic AS a result of 88 al~ mative allelic sta~s [biallelic polymorphlsms 
(BIPS)], for a frequency of approxlCl1ntely no BIP per ktlobasc Five of the 88 BIPs probably 
r~pre m t three mdepcndent recombl09tl n ev nts Four seem to rellect two sinll iar Impon. 
spanning ::4 to 251.:b from S. enlmca serovne Typhimurium (ftg. S I), and a gene liugment 
wrth ix single.nucleottde polymorplusms (S. s) is Jdentic"1 the comsponding gene 
fragment m S. mreri a serovor Pamtyphi The ther 8 BiPs consi.<;ted oD 7 n nsynonymous 
SNP of whl h resulted in premature top codons; 3 syo nymous SNPs, 12 SNPs in 
p 'udogen.: • and L't1C deletlon of 4 00"" paUli 
~ e anticlpalc-d that ~k~cpJ.q; genes would exrnblt dimiJlll!hcd levels of nucleoude 
div(fslty, 1t., as a result of purif}'1l1g selectlon. and that pathogeruclty genes would exhIbit 
elevated levelsAs a result of dtverslfying selection. However, x did not differ significantly with 
gen~ categ ry (P > 0.0 , analysIs ofv8nanc~) (table S I) PunfymS selection should result Ul 
Ka:Ks (the ratIo of nonsyn nymous suhstlLUUOllS per nomynonY1l101lS sIte to synonymous 
substitutions per synonymous site) values that ore less than 10 and diversifying selection 
should resub m rotlos higher than l OA trend in this direction WAS observed (!Dble S I), rut It 
was nol prutlcularly strung We therefore con luded thaI these 88 B,Ps k"UlleJy r.llect the lack 
of strong sel tlon and arc mark"", of neutral populauon structure in Typhi It was somewhat 
surprISing that supposedly rohgate pathogen such as Typhi should possess a neutral 
populnllOll SU\lcture, ~t the population stt\Icture of severnl other bactenal species thBl 
OCC9. lonaUy cause dlSCil' e cnn also be explntned by ncut:rl1l genettc dnll (13) 
The dl rribuuon pnltem of the 8 Btl's wIthin Typhi IS hIghly unusual because It IS ful ly 
pnrsim nioll3 a nltng to ma~imum parsimony analysl (hanoplasy index - 0) The 8 Bil's 
defined 59 haplotype · thJt fonn 3 unique path wllhin a single m tnimal spunning tr". of kngtb 
88. ex epI for three h 'PO!heticol rodes (Fig 1). These observations suggest that each BiP was 
caused by uruque genetic event, either a single mutatl n (83 Btl's) or the three imports 
dC'lCnhed above ( AlPs). The tree contatn' 19 lOr. matlv B,Ps that mark the cI·olutl nary 
hlSt ry ofT plu plu 69 norunformauvc Btl's that are speCIfic to smgle haplotypes. A second. 
high! ' unusual f~3rure oftlus dam set is that the ancestrol nod", haplolypc H45, is represented 
by extant bacll:nn H4 - must be the onccstrnl - root" oodc, b.!caUSi! tt po s.!sscs the identical 
nuc I.otid". for .11 82 SNPs, as dId eisht g~non,,'S of S. ml<nca of other s.:mvars. whereas all 
oth~r haplotype rc It from one or more mUl8lJOns. The geneml appcamnce of the tree (FIg 
l)slQlests descenl from 1145 in multiple l1n~3ges, followed by chversificotion during multiple, 
Uldependent population e:<pansl ns thot resulted m radial clusters ofhaplotypes cOOOl ining the 
noomfonnotil·c fliPs F r example. one cluster conmins all seven Indonesian isolates with the 
z66 110sellor vnroml The z66 lusLer radmt.cs from a sl~lc haplotype, ind;Glting that It 11:" 
:trl en only once Hence, 766 '5010te5 cannot represcot the evolutIonary oure< of Typbt ( II ), 
because the zb6 cluster i d,!lnnt from 1145. 
n,., roplOl) pe tree 1= Q tlurd, lughly unusual feature: Mo5llml.:s between sequential 
hapl types conslS1 of stngl S'\1Ps. nnd many I ger edges, iro: I udtng one hypatheti I nod , 
Sr I,.. ,\lIIlh« "MtUb(I'tPI. IViihlble In PMC 2009 M{trdt 6 
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.. III T -phI. and Ibly to clonol ~pl3cem cnt of .xisting haplot)'pes within southern Asia 
We th.:rcf r~ pcrfomlcd mUlatlOn dl overy Wllh the -5 pol)''lIlorpluc codtng fragments on 295 
oddlt"'flul.t""". of Typltl that we« IS lawu from southern Asia between 1986 and 2004. 
Again. most $truiru were asslgII d 10 known haplotypes and ordy a f~w defined n w. peripheral 
hapl types (Ftg :!S) Ho",,,,,er. the relOlive frequencies of isolates differed from those in the 
Slo I el of I O' stroUlS (Fig. 11. be \l:>C most recenl ' lates from southern Asia, particularly 
.' III INlc bcl<'nlled tll hAplotype HS8 (Fig 28). Thus, R recent population eX'P"II"ion of 
H 'cern ' to hal'e resulted fran the general use of fiucroquinolones 
h IIlVCs\I'atc th' g~'11 d,,"""ty of a .\89-base pair fragment of the gyr.4 gene 
m I!lI; a D A gyrus subunn, ""tIun wluch nOllS)nonymous mutatlons at codons 83 and 
g7 re ul t m reSlStan e to nahdJ.'lic ACid (22) All 1:!5 straI1\S that were sensitive to nalidixic acid 
. 1\1$) lind aU other .tnuns WIth unknown resistance to naltdiXlc aci d possessed the ancestral 
!C·d· '<fU ·""c In oonl.r8.'lt .11 119 t\slR lrIIins. most of vhich were ISolated m south centntl 
or south 51 Asm (I bl. S~). ~me of si.x nO!l>-ynonymous mutalions al codons 83 and 
7 of ·r.1 (Fig ~\). and no other mutations wer< detected ing)o-r, l (or palC). We Identified 
I ~ mdepcndenl mutnu,mnl events ( through 0 in Fig. ~B) in di.<;tinct h.1plol)'(leS that also 
J1<I>SC :Jgyd' aile"'. 'umtng thaI they nllarosc between 1991 and 2004(13 years), the 
,d'n!lftcauon of '> l ~ mut:ltions tnlW codons (6 JXlirs) yiekls (I minimum frequency of 
0.19 r-<r bo pair per year. >c 5 I r:r' greater than the longt rm mut3l1on clock rate within E. 
.:ali IJ) 
hopl Iypes wllh g)'r.l mullltions. aJR stnlins we~ dct.!cted only once or twice; 
h<Me.~r. III .ntolllb of hapl..,t) pc HS' nd ils dcnvauvc haplotypcs (H34, H57. and H60 
II ) cn: 1$ bled U\ 'ietnam.lndta.. and Pakistan. and other countries in southern Asia 
(T ble~) The:s< . 311l vanan repr<sent ot leost five distincl ·r.1 mutations <K- L, /111, N. and 
O).whl haroscdunn or before the mld· I990s(Flg :!C) ThefrequencyofgyrA+and mutotion 
L tn~J 1,,,,1, n""mt stnCcthe mid- I • butH 58 IliOlales with mulallon I-: se<m to 
• mC)/\! ~omm<'llln rc nlears, panicularly In ietnam (Table",). 
c rcsJStan has probably led to clonal expansion 
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hIll'l I 'pes ,\ oordlllg to this tntcrpreUltiOn, IllS exnctly because the enVironment selects thnt 
evel) thin I ~'cl) \'~rc III Typh~ Ihw lIlverung R hotly disputed (~.:J)tenel ofmlCfoblaJ 
1"11) thllt \Oil propos -<I b)' L G \-\. B c ~lng Ul 19 4 r-s) 
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